

BreastScreen Aotearoa

Monitoring Report for women screened between 1 July 2019 and 30 June 2021

Bridget Robson, Te Rōpū Rangahau Hauora a Eru Pōmare, University of
Otago Wellington

5 December 2023



BreastScreen
Aotearoa

Contents

Contents	2
List of Tables	4
List of Figures	5
Executive Summary	8
Introduction	8
Overall Programme Performance	9
Lead Provider Variation	13
Equity Issues	16
Equity resources	17
Is BSA making a difference?	18
Introduction	20
National Indicator Overviews for Māori, Pacific, Total women	21
Lead Provider Indicator Overviews for Māori, Pacific and Total women aged 50–69 years	25
Introduction	25
BreastScreen Waitemata Northland (BSWN) Overview	26
BreastScreen Counties Manukau (BSCM) Overview	31
BreastScreen Auckland Central (BSAC) Overview	37
BreastScreen Midland (BSM) Overview	42
BreastScreen Coast to Coast (BSCC) Overview	48
BreastScreen Central (BSC) Overview	53
BreastScreen South Limited (BSSL) Overview	58
BreastScreen Otago Southland (BSOS) Overview	63
Coverage	68
1.a.1, Overall coverage of eligible women	68
1.a.2, Percentage of screens that are initial or subsequent	71
1.a.3, Screening unit type	75
1.a.4, Age specific coverage	79
1.b.3, Routine rescreening	81
Screening and Assessment	85
2.a, Screening image usage	85
2.b, Technical recall rate	89
2.c, Technical reject rate	93
2.d, Assessment rate	97
2.e, False positive rate	101
2.f, Positive predictive value	105
2.g, Benign open biopsy weight	109
2.h, Preoperative diagnosis rate	112

2.i, Specificity	115
2.m, Benign open biopsy rate	119
Breast Cancer Detection	123
3.a.1, DCIS and invasive cancer detection	123
3.a.2, Invasive breast cancer detection	127
3.a.3, Summary of assessment outcomes	131
3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)	132
3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate)	136
3.d, Nodal involvement.....	140
3.e, Ductal carcinoma in situ diagnosis.....	144
Treatment: Early detection of DCIS or invasive breast cancer	147
3.a.2.t, Detection of invasive breast cancer, women screened during the 4 years to December 2020	147
3.c.p.t, Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2020.....	149
3.d.t, Nodal involvement, women screened during the 4 years to December 2020	151
3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2020	152
4.a.1.t, Women with invasive breast cancers ≤ 30 mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to December 2020	153
4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020	156
4.e.t, DCIS having breast conserving surgery, women screened during the 4 years to December 2020.....	159
4.f.t, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2020	162
4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020	165
4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2020	168
4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2020	171
4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2020	175
Timeliness	178
5.a, Time taken for provision of screening results	178
5.b, Time taken from screening visit to first offer of an assessment	181
5.c.1, Women receiving a needle biopsy within 5 working days of assessment.....	184
5.c.2, Women having an open biopsy procedure within 20 working days.....	187
5.d, Time taken from final diagnostic biopsy to reporting assessment results.....	190
5.e.t, First surgical treatment, women screened during the 4 years to December 2020	193
Appendices	196
Technical notes	196
Indicator targets	196
Changes to indicator targets.....	196
Data source and extraction date	196
Ethnicity	196
Confidence intervals	196
Population projections.....	197

List of Tables

Table 1: 1.a.1, Coverage of eligible women.....	70
Table 2: 1.a.2, Initial and subsequent screen proportions	74
Table 3: 1.a.3, Percentages screened at fixed and mobile units	78
Table 4: 1.a.4, Age specific coverage	80
Table 5: 1.b.3, Routine rescreening within 27 months of an initial and subsequent screen	84
Table 6: 2.a, Screening image usage.....	88
Table 7: 2.b, Technical recall rate	92
Table 8: 2.c, Technical reject rate.....	96
Table 9: 2.d, Assessment rate	100
Table 10: 2.e, False positive rate	104
Table 11: 2.f, Positive predictive value	108
Table 12: 2.g, Benign open biopsy weight	111
Table 13: 2.h, Preoperative diagnosis rate	114
Table 14: 2.i, Specificity	118
Table 15: 2.m, Benign open biopsy rate	122
Table 16: 3.a.1, Breast cancer detection rates (DCIS and invasive combined).....	126
Table 17: 3.a.2, Invasive breast cancer detection	130
Table 18: 3.a.3, Summary of assessment outcomes	131
Table 19: 3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)	135
Table 20: 3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate).....	139
Table 21: 3.d, Nodal involvement.....	143
Table 22: 3.e, Ductal carcinoma in situ diagnosis	146
Table 23: 3.a.2.t, Detection of invasive cancer, women screened during the 4 years to December 2020.....	147
Table 24: 3.a.3.t, Treatment Data Completeness, women screened during the 4 years to December 2020	148
Table 25: 3.c.p.t Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2020	149
Table 26: 3.c.r.t Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000 screens), women screened during the 4 years to December 2020	150
Table 27: 3.d.t, Nodal involvement, women screened during the 4 years to December 2020.....	151
Table 28: 3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2020.....	152
Table 29: 4.a.1.t, Women with invasive breast cancers ≤ 30 mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020.....	155
Table 30: 4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020	158
Table 31: 4.e.t, DCIS ≤ 20 mm having breast conserving surgery, women screened during the 4 years to December 2020	161
Table 32: 4.f.t, Invasive cancers ≤ 20 mm having breast conserving surgery, women screened during the 4 years to December 2020.....	164
Table 33: 4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020	167
Table 34: 4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2020	170
Table 35: 4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2020.....	172
Table 36: 4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2020	176
Table 37: 5.a, Time taken for provision of screening results.....	180
Table 38: 5.b, Time taken from screening visit to first offer of an assessment	183
Table 39: 5.c.1, Women receiving a needle biopsy within 5 working days of assessment	186
Table 40: 5.c.2, Women having an open biopsy procedure within 20 working days	189
Table 41: 5.d, Time taken from final diagnostic biopsy to reporting assessment results	192
Table 42: 5.e.t, First surgical treatment, women screened during the 4 years to December 2020.....	195
Table 44: Mid-year population projections, 2020 update of the 2018 Census by ethnicity, Lead Provider, and 5-year age group.....	197

List of Figures

Figure 1: BreastScreen Aotearoa Lead Provider map.....	13
Figure 2: National Overview, Māori women, 50–69 years	22
Figure 3: National Overview, Pacific women aged 50–69 years.....	23
Figure 4: National Overview, Total women aged 50–69 years.....	24
Figure 5: BSWN Overview, Māori women aged 50–69 years.....	26
Figure 6: BSWN Overview, Pacific women aged 50 to 69 years.....	27
Figure 7: BSWN Overview, Total women aged 50 to 69 years.....	28
Figure 8: BSCM Overview, Māori women aged 50 to 69 years	31
Figure 9: BSCM Overview, Pacific women aged 50 to 69 years.....	32
Figure 10: BSCM Overview, Total women aged 50 to 69 years.....	33
Figure 11: BSAC Overview, Māori women aged 50 to 69 years	37
Figure 12: BSAC Overview, Pacific women aged 50 to 69 years.....	38
Figure 13: BSAC Overview, Total women aged 50 to 69 years.....	39
Figure 14: BSM Overview, Māori women aged 50 to 69 years	42
Figure 15: BSM Overview, Pacific women aged 50 to 69 years.....	43
Figure 16: BSM Overview, Total women aged 50 to 69 years.....	44
Figure 17: BSCC Overview, Māori women aged 50 to 69 years.....	48
Figure 18: BSCC Overview, Pacific women aged 50 to 69 years.....	49
Figure 19: BSCC Overview, Total women aged 50 to 69 years.....	50
Figure 20: BSC Overview, Māori women aged 50 to 69 years.....	53
Figure 21: BSC Overview, Pacific women aged 50 to 69 years.....	54
Figure 22: BSC Overview, Total women aged 50 to 69 years	55
Figure 23: BSSL Overview, Māori women aged 50 to 69 years	58
Figure 24: BSSL Overview, Pacific women aged 50 to 69 years.....	59
Figure 25: BSSL Overview, Total women aged 50 to 69 years.....	60
Figure 26:BSOS Overview, Māori women aged 50 to 69 years	63
Figure 27: BSOS Overview, Pacific women aged 50 to 69 years.....	64
Figure 28: BSOS Overview, Total women aged 50 to 69 years.....	65
Figure 29: 1.a.1, Coverage of eligible women, 45 to 49 and 50 to 69 years, total BSA.....	68
Figure 30: 1.a.1, Coverage of eligible women, 50 to 69, by LP.....	69
Figure 31: 1.a.2, Initial and subsequent screen proportions, 45-49 and 50 to 69	71
Figure 32:1.a.2, Initial screen proportions, 50 to 69, by LP.....	72
Figure 33: 1.a.2, Subsequent screen proportions, 50 to 69, by LP	73
Figure 34: 1.a.3, Percentage screened at fixed and mobile units, 50 to 69, total BSA.....	75
Figure 35: 1.a.3, Percentage screened at fixed units, 50 to 69, by LP	76
Figure 36: 1.a.3, Percentage screened at mobile units, 50 to 69, by LP.....	77
Figure 37: 1.b.3.1, Percentage rescreened within 27 months of an initial and subsequent screen, 50 to 67, all BSA	81
Figure 38: 1.b.3.3, Routine rescreening within 27 months of an initial screen, 50 to 67, by LP	82
Figure 39: 1.b.3.5, Routine rescreening within 27 months of a subsequent screen, 50 to 67, by LP	83
Figure 40: 2.a.1, Screening image usage, 50 to 69, fixed and mobile units	85
Figure 41: 2.a.3, Fixed, 50 to 69, Screening image usage, by LP	86
Figure 42: 2.a.5, Mobile, 50 to 69, Screening image usage, by LP	87
Figure 43: 2.b, Technical recall rate, 50 to 69, fixed and mobile units.....	89
Figure 44: 2.b, Fixed site, 50 to 69, Technical recall rate, by LP	90
Figure 45: 2.b, Mobile units, 50 to 69, Technical recall rate, by LP	91
Figure 46: 2.c, Technical reject rate, 50 to 69, fixed and mobile units.....	93
Figure 47: 2.c, Fixed sites 50 to 69, Technical reject rate, by LP	94
Figure 48: 2.c, Mobile units, 50 to 69, Technical reject rate, by LP	95
Figure 49: 2.d.1, 50 to 69, Assessment rate, initial and subsequent screens.....	97
Figure 50: 2.d.3, Initial, 50 to 69, Assessment rate, by LP	98
Figure 51: 2.d.5, Subsequent, 50 to 69, Assessment rate, by LP	99
Figure 52: 2.e, 50 to 69, False positive rate.....	101

Figure 53: 2.e, Initial, 50 to 69, False positive rate, by LP	102
Figure 54: 2.e, Subsequent, 50 to 69, False positive rate, by LP	103
Figure 55: 2.f, 50 to 69, Positive predictive value, initial and subsequent screens.....	105
Figure 56: 2.f, Initial, 50 to 69, Positive predictive value, by LP	106
Figure 57: 2.f, Subsequent, 50 to 69, Positive predictive value, by LP	107
Figure 58: 2.g, 50 to 69, Benign open biopsy weight, percentage <30g	109
Figure 59: 2.g, 50 to 69, Benign open biopsy weight, by LP	110
Figure 60: 2.h, 50 to 69, Preoperative diagnosis rate.....	112
Figure 61: 2.h, 50 to 69, Preoperative diagnosis rate, by LP	113
Figure 62: 2.i, 50 to 69, Specificity	115
Figure 63: 2.i, Initial, 50 to 69, Specificity, by LP	116
Figure 64: 2.i, Subsequent, 50 to 69, Specificity, by LP	117
Figure 65: 2.m, 50 to 69, Benign open biopsy rate, total BSA.....	119
Figure 66: 2.m, Initial, 50 to 69, Benign open biopsy rate, by LP	120
Figure 67: 2.m, Subsequent, 50 to 69, Benign open biopsy rate, by LP	121
Figure 68: 3.a.1, 50 to 69, breast cancer detection rates (DCIS and invasive combined), initial and subsequent screens	123
Figure 69: 3.a.1, Initial, 50 to 69 breast cancer detection rates (DCIS and invasive combined), by LP.....	124
Figure 70: 3.a.1, Subsequent, 50 to 69, breast cancer detection rates (DCIS and invasive combined), by LP.....	125
Figure 71: 3.a.2, 50 to 69, Invasive breast cancer detection, initial and subsequent screens	127
Figure 72: 3.a.2, Initial, 50 to 69, Invasive breast cancer detection, by LP	128
Figure 73: 3.a.2, Subsequent, 50 to 69, Invasive breast cancer detection, by LP	129
Figure 74: 3.c.p, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), initial and subsequent screens	132
Figure 75: 3.c.p, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP	133
Figure 76: 3.c.p, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP.....	134
Figure 77: 3.c.r, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000), initial and subsequent screens	136
Figure 78: 3.c.r, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP.....	137
Figure 79: 3.c.r, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP....	138
Figure 80: 3.d, 50 to 69, Nodal involvement	140
Figure 81: 3.d, Initial, 50 to 69, Nodal involvement, by LP	141
Figure 82: 3.d, Subsequent, 50 to 69, Nodal involvement, by LP	142
Figure 83: 3.e, 45 to 49 and 50 to 69, Ductal carcinoma in situ diagnosis	144
Figure 84: 3.e, 50 to 69, Ductal carcinoma in situ diagnosis, by LP	145
Figure 85: 4.a.1.t, 45 to 49 and 50 to 69, Women with invasive breast cancers ≤30mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020	153
Figure 86: 4.a.1.t, 50 to 69, Women with invasive breast cancers ≤30mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020, by LP.....	154
Figure 87: 4.b.t, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020.....	156
Figure 88: 4.b.t, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020, by LP	157
Figure 89: 4.e.t, 50 to 69, DCIS ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020.....	159
Figure 90: 4.e.t, 50 to 69, DCIS ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020, by LP	160
Figure 91: 4.f.t, 50 to 69, Invasive cancers ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020	162
Figure 92: 4.f.t, 50 to 69, Invasive cancers ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020, by LP.....	163
Figure 93: 4.g.t, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020	165

Figure 94: 4.g.t, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020, by LP.....	166
Figure 95: 4.h.t, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2020	168
Figure 96: 4.h.t, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2020, by LP	169
Figure 97: 5.a, Time taken for provision of screening results, 50 to 69 years, total BSA	178
Figure 98: 5.a, Time taken for provision of screening results, by LP	179
Figure 99: 5.b, 50 to 69, Time taken from screening visit to first offer of an assessment	181
Figure 100: 5.b, 50 to 69, Time taken from screening visit to first offer of an assessment, by LP.....	182
Figure 101: 5.c.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, total BSA	184
Figure 102: 5.c.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, by LP	185
Figure 103: 5.c.2, 50 to 69, Women having an open biopsy procedure within 20 working days	187
Figure 104: 5.c.2, 50 to 69, Women having an open biopsy procedure within 20 working days, by LP	188
Figure 105: 5.d, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results.....	190
Figure 106: 5.d, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results, by LP	191
Figure 107: 5.e.t, 50 to 69, First surgical treatment, women screened during the 4 years to December 2020	193
Figure 108: 5.e.t, 50 to 69, First surgical treatment, women screened during the 4 years to December 2020, by LP	194

Executive Summary

Introduction

This report summarises the performance of BreastScreen Aotearoa (BSA) based on quality indicators for women screened during the two-year period to June 2021. Treatment indicators are presented for women diagnosed through screening during the four-year period to 31 December 2020.

Breast cancer is the most commonly diagnosed cancer among women in Aotearoa New Zealand. Screening aims to detect cancers at an early stage when tumours are more amenable to treatment. A properly organised breast screening programme can significantly reduce illness and death from breast cancer.

BSA offers free two-yearly mammographic screening to women aged 45 to 69 years. It plays a vital role, firstly by finding breast cancer tumours at a very early and treatable stage; and secondly by systematically following up women whose cancer is found by the screening programme to ensure timely pathways through the cancer care continuum. Women screened by BSA have a third lower risk of dying from breast cancer than women who are not screened¹. Māori and Pacific mortality rates from breast cancer are disproportionately higher than those of other women² and more equitable outcomes could be achieved if more Māori and Pacific women were diagnosed at an earlier stage. For this reason, BSA prioritises screening these women.

BSA has eight Lead Provider (LP) regions. Each LP is responsible for providing or subcontracting mammography screening and assessment services in their region. Support to Screening Providers are contracted by the National Screening Unit (NSU) to support women from priority groups to screening and assessment. During this reporting period District Health Boards³ (DHBs) provided breast cancer treatment after diagnosis. Surgery was performed by DHB services and private providers, with oncology and radiation therapy provided by six Cancer Centres (or by private providers in some areas). Data on the treatment provided to women whose breast cancer was detected by BSA is collected by each LP and reported to the NSU.

The period covered by this report includes five months when screening was affected by the COVID-19 Pandemic. Breast screening paused from 25 March to 27 April 2020 in COVID Alert Level 4, with gradual recommencement of screening once in COVID Alert Level 3 from 28th April 2020. On 8 June 2020 the country moved to Alert Level 1 with no active cases in the community. On 14 August 2020 there was a return to Alert Level 3 in Auckland, moving to Alert Level 2 on 31 August and to Alert Level 1 on 8 October 2020. In 2021 Auckland moved to Alert Level 3 from 28 February to 7 March, while other areas remained at lower levels. Although breast screening continued during Alert Level 3, it is likely that screening coverage was impacted in those periods. The impact of the COVID-19 pandemic on screening coverage will also be evident in future annual reports. An international review of short-term impacts of the pandemic on breast cancer detection found an increase in the proportion of cancers that were symptomatic, and a decrease in the proportion of early-stage cancers detected⁴. The potential impact on screen-detected tumour size in Aotearoa has yet to be determined.

Other impacts during this reporting period arose from the transition of BreastScreen Auckland Limited the lead provider for the Auckland Central region, to BreastScreen Auckland Central from 1 March 2021. This involved a short period in February 2021 when no screens occurred, although assessments continued, and a delay in the new mobile service. BreastScreen Midland was also affected by a cybersecurity incident at Waikato DHB in May 2021.

Previous monitoring reports and details of the indicator measures are available [NSU's website](#).

¹ Ministry of Health. 2016. Summary of the BreastScreen Aotearoa Mortality evaluation 1999–2011. Wellington: Ministry of Health. Available on www.health.govt.nz

² Ministry of Health. 2016. Cancer: New registrations and deaths 2013. Wellington: Ministry of Health.

³ From 1 July 2022 the Pae Ora (Healthy Futures) Act 2022 established Health New Zealand known as Te Whatu Ora and the Māori Health Authority known as Te Aka Whai Ora (repealing the New Zealand Health and Disability Act 2000 and replacing DHBs)

⁴ Li T, Nickel B, Ngo P, McFadden K, Brennan M, Marinovich ML, Houssami N. A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis. *Breast*. 2023 Feb;67:78-88. doi: 10.1016/j.breast.2023.01.001. Epub 2023 Jan 5. PMID: 36646004; PMCID: PMC9813855.

Overall Programme Performance

This section examines the performance of the BSA programme at the national level. Quality indicators by Lead Provider may differ from those of the overall programme. The online data tool includes tables and graphs of trends over time for all indicators for women aged 45–49 and 50–69 years by ethnicity and Lead Provider. Apart from detection related and assessment related indicators, this section generally refers to indicators for women aged 45–69 years, unless otherwise indicated. Because underlying breast cancer incidence varies by age, detection and assessment related indicators are reported separately for the two age groups.

Coverage – decreased for all women, to 59% for Māori women, 63% for Pacific, and 67% for other women aged 45–69 years

- Biennial screening coverage continued to reduce for all groups and the 70% biennial target was not achieved.
- Māori women's coverage decreased 6.6% over the first 18 months of the pandemic, while coverage of non-Māori non-Pacific women decreased by 5.8%.
- To achieve the same coverage as non-Māori non-Pacific women, BSA needed to screen 7,585 more Māori women.
- Pacific women's coverage was most impacted by COVID, reducing by 9.7% during the first 18 months of the pandemic.
- To achieve the same coverage as non-Māori non-Pacific women, BSA needed to have screened a further 1,319 Pacific women.

BSA screened 516,073 women, 5,858 more than the previous biennium to June 2020. The total eligible population of women increased by 19,520 or 2.6%. This period includes nearly 18 months of the COVID pandemic. Since the pandemic began, total biennial coverage has decreased 6.1%, with most of that decrease occurring during the first 6 months of the pandemic, and about 1% occurring in the following 12 months.

Screening coverage of Māori women was most affected during the first 6 months of the pandemic, decreasing 6.2% to June 2020, but then remaining relatively stable with a drop of 0.4% to 59.3% at June 2021.

Pacific coverage was less affected during the first 6 months, reducing by 3.8% but more affected in the next 12 months with a further decrease of 5.9%, resulting in a 9.7% drop in coverage over the first 18 months of the pandemic to 63.5%.

Non-Māori non-Pacific women were least impacted by the pandemic, with biennial coverage decreasing 5.8% during the first 18 months of the pandemic to 66.9%.

If Māori were screened at the same rate as non-Māori non-Pacific women (66.9%), there would have been 7,585 more Māori women screened over the two years. To achieve the 70% target, BSA needed to have screened a further 10,668 Māori women aged 45–69 years. Inequitable coverage for Māori women is long-standing and Māori women remain the highest priority group for screening during the COVID-19 recovery era.

Timely rescreening – continued to decrease for all groups, shifts toward equitable rates for Māori and Pacific women with greater reductions in non-Māori non-Pacific rates

- Among women aged 45–67 years⁵, 65% of Māori, 58% of Pacific, 63% of other women were rescreened between 20 and 27 months of an initial screen (target 75% or more). After a subsequent screen, 78% of Māori, 72% of Pacific and 73% of other women had a timely rescreen (target 85% or more).
- Timely rescreening after an initial screen varied by age – higher for women having their first screen at ages 45–49 years than those who started at age 50 or above.

Women who screen regularly have a lower risk of dying from breast cancer than those who screen less regularly⁶. If there is too long an interval between screens, new cancers have a longer time to develop beyond the early stages and

⁵ This age group refers to the age of women at their screening episode prior to the rescreen. Since the upper age limit for screening with BSA is 69 years, and the screening interval is 24 months, a women must be aged 45-67 years at the time of their previous screen to be eligible to be rescreened with BSA

⁶ Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 to 2011. Wellington: Ministry of Health.

screening is less effective at preventing illness and death. BSA aims to have 75% of women rescreened between 20 and 27 months of their initial screen and 85% rescreened within 20 and 27 months of any subsequent screen.

The COVID pandemic affected rates of timely rescreens, with the total rates for women aged 45–67 years falling below target for the first time for initial (63%) and subsequent screens (74%). However, the prioritisation of Māori and Pacific women appears to be having a positive equity impact with smaller decreases among Māori and Pacific women than among non-Māori non-Pacific women.

Among women aged 45–67 years at their first screen with BSA, 65% of Māori (3.3% decrease), 58% of Pacific (8.9% decrease) and 63% of non-Māori non-Pacific women (12.8% decrease) were rescreened within 20–27 months.

Timely rescreens after a subsequent screen were higher: 78% of Māori women (3.6% decrease), 72% of Pacific women (9.4% decrease), and 73% of non-Māori non-Pacific women (12.4% decrease) were rescreened within 20 to 27 months.

Rescreen rates after an initial screen were higher among women aged 45–49 years at their first screen (65% overall) than among women aged 50–67 years (55%).

The additional numbers of women aged 45–67 who needed to be rescreened within 27 months to achieve the targets increased to 4,114 for Māori, 3,455 for Pacific women, and 49,222 for non-Māori non-Pacific women (initial and subsequent combined).

Screening quality – technical recall rates, image quality, and proportions of women having no more than four images all on track.

- Technical recall rates in mobile (0.2%) and fixed units (0.2%) remained in the target range ($\leq 0.5\%$).
- The proportions of women having no more than 4 images per screening episode were on target ($>80\%$).
- The rate of rejected images (0.8%) remained well within the target range ($<3\%$).

With all screening units using digital technology the low rate of women recalled for technical reasons has been maintained at 0.2% in both fixed and mobile units (target $< 0.5\%$). This indicator is monitored to ensure the number of women having to return to a screening unit for further images to complete their screening episode is minimal.

The $>80\%$ target for the proportions of women having no more than four images was met for Māori (82%) and non-Māori non-Pacific women (88%), and the total proportion of Pacific women (80%). For Pacific women the proportion was lower for those screened in mobile units (78%) than fixed units (80%).

Less than 1% of images were rejected (target $<3\%$).

Timely reporting of screening results – on target

- The proportion of women who received their screening results within 10 working days remained within the target range of $\geq 90\%$ at 93%.

Assessment – quality on track, timeliness outside target range

- Targets for assessment quality indicators continued to be met for all groups of women aged 50–69 years having an initial or subsequent screen.
- For women aged 45–49 years, all indicators were as expected. Positive predictive values were around half those of women aged 50–69 years.
- The proportion of women offered their first assessment appointment within 15 working days continued to decrease to 83% (target 90%).

For women aged 50–69 years having an **initial screen** the rates of referral to assessment, false positives, and positive predictive value were on target. The rate of referral for further assessment was 11.7% for Māori, (target $<10\%$), but the positive predictive value (PPV), the proportion of women referred for assessment who were found to have breast cancer) was also high at 17.5% (target $>9\%$). Similarly for Pacific women, the assessment rate was 13.4% but the PPV was 20.4%. The false positive target of $<9\%$ was met or within the confidence interval for each population (7.6% overall) and positive predictive values were well within the target range for all groups (13.5% overall). Around one in five Māori

and Pacific women, and one in seven non-Māori non-Pacific women referred for an assessment from an initial screen had a cancer detected. Specificity was below the target of >93% at 89.8%.

All assessment quality indicators for women aged 50–69 years having a **subsequent screen** were within the target ranges. Among women aged 50–69 years who had a subsequent screen, the rate of referral for assessment was 3.8% for Māori, 3.7% for Pacific women and 3.4% for other women (target <5%). False positive rates were 2.6% (target <4%). Positive predictive values were around twice the target of 9% or more at 18% overall, higher for Māori (24.2%) and for Pacific women (21.6%). Specificity was 96.6%, well within the target range of >93%.

Assessment quality indicators for women aged 45–49 years having initial screens were within the expected values of <9% assessment rate, <8% false positives, >6% PPV for initial screens and 92% for specificity. For women having subsequent screens, they were also within the expected ranges of <4.5% referred to assessment, <4% false positives, >8% positive predictive value, and >95% specificity.

To expedite diagnosis and minimise anxiety, BSA aims to have 90% of women offered their first assessment appointment within 15 working days of their screening mammogram. Among women aged 45–69 years, this indicator declined another 2% to 83% (79% for Māori, 84% for Pacific and 83% for other women).

Biopsies – most diagnosed without open surgery and on time, open biopsies less timely and benign biopsy weight remained below target

- Most women (95%) had a definitive diagnosis of breast cancer without open surgery and within 5 working days of their assessment (98%).
- Some women required open surgery to obtain a definitive diagnosis. Fewer than one per 1,000 women screened had an open biopsy that turned out to be benign. Of those women, most (84%) had a benign biopsy that weighed under 30g (target >90%).
- Only half (52%) had their open biopsy within 20 working days (target ≥90%).
- The proportion of women who received their final diagnostic biopsy results within 5 working days was 84% overall (target ≥90%).

Around 95% of women whose breast cancer was detected by BSA had a definitive diagnosis from a needle biopsy, meeting the target value of >90% for all groups of women. Most percutaneous biopsies (98%) were received within 5 working days of assessment.

The benign open biopsy rates were within the target ranges for initial (≤ 3.5 per 1000) and subsequent screens (≤ 1.6 per 1000). Two women per 1000 having an initial screen and less than one per 1000 women having a subsequent screen underwent an open biopsy for a benign condition. Among the women who had an open biopsy that turned out to be benign, just over four out of five had a biopsy weighing less than 30 grams (target >90%). This indicator relates to minimising harms from surgery that might not have occurred without screening.

The proportion of women who received their open biopsy within 20 working days of being notified that they needed it was 52% (target ≥90%) overall, 55% for non-Māori non-Pacific women, 47% for Pacific women and lowest for Māori women at 42%.

The proportion of women who received their final diagnostic biopsy results within five working days was 84% overall (target ≥90%), similar for Māori (83%) and Pacific women (85%). This indicator aims to minimise anxiety and delays in treatment planning.

Early detection – on target for all indicators for Māori, Pacific and other women aged 45–49 and 50–69 years

- Invasive breast cancer detection targets were met for all populations.
- Māori women were more likely to have an invasive breast cancer detected from an initial and from a subsequent screen than non-Māori women aged 50–69 but there was no difference in the 45–49 year age group.
- Pacific women had higher invasive cancer detection rates from initial screens than non-Māori non-Pacific women in both age groups, and higher detection rate from subsequent screens in women aged 50–69 years.
- Over half of the invasive cancers detected from initial (53%) and subsequent screens (64%) were ≤ 15 mm diameter.

- The targets for the proportions of invasive cancers without nodal involvement were met or were within the confidence interval for all population groups.
- The proportion of cancers that were DCIS (22%) was in the target range for women aged 50–69 years and higher for women aged 45–49 years (33%).

Among women aged 45–49 years having an initial screen the rate of invasive breast cancer detection was 3.6 per 1,000 overall, 4.5 per 1000 for Māori women and 7.3 per 1000 for Pacific women (target ≥ 3.8 per 1000 women screened). Small cancer detection rates ($\leq 15\text{mm}$) were also in the target range at 19.5 per 10,000 initial screens (target ≥ 19.0), 18.5 per 10,000 for Māori and 41.1.0 per 10,000 for Pacific women. The 70% target for invasive cancers without nodal involvement was within the confidence interval (67.5%).

Among women aged 45–49 years having a subsequent screen 2.5 per 1,000 had an invasive cancer detected (target ≥ 2.4), similar for Māori and Pacific women (both 2.8 per 1,000). The rate of small cancers detected was 15.3 per 10,000 women screened (target ≥ 12.0), with 13.4 per 10,000 for Māori, and 15.5 per 10,000 for Pacific women. Four fifths had no nodal involvement, meeting the $>75\%$ target.

Among women aged 50–69 years, invasive cancer detection rates were within the target ranges for all groups of women having an initial or a subsequent screen. Around half of invasive cancers detected from initial screens and nearly two-thirds of those detected from subsequent screens were 15mm or less in diameter. The rate of detection of small breast cancers per 10,000 screens was twice as high for Māori as for non-Māori having an initial screen and 62% higher for those having a subsequent screen. Small cancer detection rates for Pacific women having initial screens were over twice as high as for non-Māori non-Pacific women with no significant differences for small cancers detected from subsequent screens.

Among women aged 45–69 years, the total proportions of invasive cancers detected that had no nodal involvement were 69% for initial screens (target $>70\%$) and 81% for subsequent screens (target $>75\%$).

The proportion of breast cancers that were DCIS was 24%, within the target range of 10% to 25% for women aged 50–69 years, lower for Māori women (17%) and Pacific women (18%). Among women aged 45–49 years, the overall proportion of screen-detected cancers that were DCIS was 33%, similar for Māori (28%), but no cancers detected among Pacific women in this age group were DCIS.

Treatment – most indicators met targets with no ethnic differences, time to surgery under target and not equitable

- Among all women whose invasive cancer was detected by BSA during the four years to 31 December 2020, 54% had their first surgical treatment within 31 calendar days of receiving their final diagnosis (target 90%), 48% of Māori and 50% of Pacific women, and 55% of other women aged 45–69 years.
- Most women had breast conserving surgery.
- Among women whose invasive cancer was $\leq 30\text{mm}$, 84% had sentinel node biopsy as their first axillary procedure.
- The proportion of women who had radiation therapy with breast conserving surgery for invasive cancer was 89% (target 95% or more).
- The targets were met for other treatment indicators, for all populations.

The proportion of women who had their first surgical treatment within 31 calendar days of diagnosis for women screened during the four years to December 2020 was below the 90% target for all ethnic groups.

Among women aged 45–69 years with invasive breast cancer 30mm or less, 84% had sentinel node biopsy as their first axillary procedure. There is no target for this indicator. Sentinel lymph node biopsy is useful for staging of cancers and may help avoid more extensive lymph node surgery.


Most women (86%) had only a single excisional breast treatment procedure.

The majority of women diagnosed with DCIS or invasive cancer $\leq 20\text{mm}$ had breast conserving surgery (87% and 86% respectively).

The proportion of women who had radiation therapy with breast conserving surgery for invasive cancer was 89% (target 95% or more).

Lead Provider Variation

Figure 1: BreastScreen Aotearoa Lead Provider map



The eight BSA Lead Provider regions are shown in the figure above. Note that BreastScreen Auckland Limited was operating during the period of this report but was replaced by BreastScreen Auckland Central (BSAC) from 1 March 2021 onwards.

The following acronyms are used in this section:

- BSWN BreastScreen Waitemata Northland
- BSAL BreastScreen Auckland Limited
- BSCM BreastScreen Counties Manukau
- BSM BreastScreen Midland
- BSCC BreastScreen Coast to Coast
- BSC BreastScreen Central
- BSSL BreastScreen South Limited
- BSOS BreastScreen Otago Southland

Coverage – LPs varied in coverage and equity

- For Māori women aged 45–69 years, biennial coverage was over 60% in four LPs, highest in BSSL (67%). Others ranged from 54% to 59%. No LP met the 70% target. BSWN (63%) and BSAL/BSAC (55%) achieved equitable coverage for Māori and non-Māori.
- For Pacific women aged 45–69 years, BSCM achieved coverage of 71%. The next highest were BSWN (63%) and BSC (61%). Other LPs ranged from 55% to 59%. BSWN, BSCM and BSAL/BSAC achieved coverage higher or similar to that of non-Māori non-Pacific women.
- For total women aged 45–69 years, BSSL (75%) and BSCC (70%) achieved the target, with BSC and BSOS both achieving 69%. Others ranged from 51% to 64%.

Timely rescreening – variation between LPs, equitable rates for Māori and Pacific women in most LPs

- For total women aged 45–67 years, routine rescreens within 27 months of an initial screen ranged from 52% (BSOS) to 80% (BSCC). After a subsequent screen, rescreen rates ranged from 57% (BSOS) to 88% (BSCC).
- For Māori women aged 45–67 years, timely rescreening after an initial screen ranged from 56% (BSCM) to 82% (BSC). After a subsequent screen, rescreen rates ranged from 71% (BSCM and BSAC) to 88% with BSC, BSSL and BSOS achieving the target of 85%. Māori and non-Māori rescreen rates were similar in most LPs after initial and subsequent screens.
- For Pacific women aged 45–67 years, timely rescreens ranged from 50% (BSCM) to 90% (BSOS) after an initial screen, and from 64% (BSAC) to 87% (BSOS) after a subsequent screen. Pacific women had higher rescreening rates than non-Māori non-Pacific women for both initial and subsequent screens in five LPs.
- Rescreen rates after initial screens were higher in younger women (45–49 years) than older women (50–67 years) with the differences ranging from 7% to 15% higher. Timely rescreening rates after a subsequent screen were similar in both age groups in most LPs.

Screening quality – few differences between LPs

- Technical recall rates and technical reject rates were within the target ranges for mobile and fixed units for most LPs. Technical recall rates were just outside the target range of <0.5% for BSC and BSCC in fixed units (0.7% each).
- The target of >80% of women having four images or fewer per screening episode was met for total women by all LPs, but not for Pacific women in some LPs.

Assessment – some variation in initial screens but not in subsequent screens

- The target values for referrals to assessment, false positives, specificity, and positive predictive value for subsequent screens were met or within the confidence interval for all LPs for each group.
- For initial screens the target was met or was within the confidence interval for the assessment rate, false positive rate and positive predictive value for most LPs. Specificity was slightly below target for most LPs apart from BSCC and BSC. For BSOS the assessment rate, false positive rate, and specificity were outside the target ranges while the target was within the confidence interval for positive predictive value.

Biopsies – no significant variation between LPs

- Over 90% of women had a preoperative diagnosis of breast cancer in each LP.
- The targets for the benign open biopsy rate were met or were within the confidence interval for all LPs for initial and subsequent screens.
- The target of >90% of benign open biopsies weight <30g was met or within the confidence interval for most LPs, with BSM at 80%, BSSL at 81% and BSCC⁷ at 57% where the number of open biopsies was relatively low (17 of 30 benign open biopsies).

Early detection – no significant variation between LPs

- The targets for detection of small invasive breast cancers and node-negative invasive cancers were met or within the confidence interval for initial and subsequent screens for women aged 45–49 and 50–69 years in all LPs.

⁷ Note that the recent purchase of an intraoperative specimen x-ray machine at BSCC is expected to decrease the number of benign biopsies exceeding 30g in the future since the machine helps the surgeon in theatre to identify the correct lesion and thus often remove less tissue.

- There was no significant difference between LPs in the proportion of screen-detected cancers that were DCIS, ranging from 17% to 30% with the target range within the confidence interval for each LP.

Timeliness – some variation in most indicators

- Most LPs met the 90% target for receipt of screening results within 10 days, with BSC just under target at 87% and BSM increasing from 78% to 85%.
- Two LPs (BSAL/BSAC and BSC) achieved the 90% target for the proportion of women receiving their offer of a first assessment appointment within 15 working days. BSAL/BSAC increased significantly from 82% to 99%. There was a slow decline in most other LPs with BSCC showing indications of an increasing trend.
- All LPs were well within the target range for the receipt of needle biopsies within 5 working days of assessment (all over 95%).
- One LP (BSAL/BSAC) achieved the 90% target for receipt of open biopsies within 20 working days. BSSL achieved 82%. Others ranged from 20% to 55%.
- The 90% target for the percentage of women receiving their final diagnostic biopsy results within five working days was met or was within the confidence interval for three LPS. BSOS was lowest at 66%.

Treatment – some variation in time to surgery and in radiotherapy

- The proportion of women receiving their first treatment surgery within 31 calendar days (over four years) ranged from 42% to 62% for women aged 45–69 years. There was variation in trends over time with three LPs (BSCC, BSC, BSSL), showing a continuing slow decline over the two years while others show an initial decrease during the first period of the pandemic followed by a small increase over the next 12 months.
- There were no significant variations between LPs in the proportions of women who had: sentinel node biopsy as their first axillary procedure; single excisional procedures for invasive cancer; breast conserving surgery for DCIS or invasive cancer.
- The proportion of women with invasive cancer who had breast conserving surgery and went on to have radiotherapy was around 90% or more for five LPS, lowest in BSM (81%) and BSAL/BSAC (82%).⁸ The target is ≥95%.
- There was some variation in the proportions receiving adjuvant hormone therapy within diagnostic groups.

⁸ The [EXPERT](#) randomised clinical trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A low risk early breast cancer is ongoing and recruiting from cancer centres in BSM, BSCC, BSC and BSSL. This could result in lower proportions of women in those areas receiving BCS after breast conserving surgery, although the numbers affected are likely to be relatively small during this reporting period, as three participating regions showed the highest proportion receiving radiotherapy: BSCC (92%), BSC (94%) and BSSL (92%).

Equity Issues

BSA has a priority goal of providing equitable screening and achieving equitable outcomes for Māori, Pacific, and other populations in Aotearoa New Zealand. Equity is a fundamental component of a high-quality service. Systematic monitoring by ethnicity is a critical part of quality assurance and quality improvement, and of meeting obligations under Te Tiriti o Waitangi.

A range of tools are available to support health systems and providers to monitor for equity and implement strategies to achieve equitable outcomes. Strategies that improve equity generally benefit all populations. Equity needs to be prioritised at the system level (policy, contracting, standard setting, monitoring and responses to identified inequities), organisation level (are systems in place to identify and respond promptly to equity issues?), workforce level (e.g., composition, professional development and expectations), and at the community level.

The current monitoring report includes 18 months (January 2020–June 2021) of the COVID-19 pandemic response in Aotearoa New Zealand. During that time screening services changed consistent with the requirements of working within an Alert Level (1-4) system. Under Alert Level 4 all screening appointments were paused, while under Alert Levels 3 and 2, BSA operated with restricted capacity to ensure adequate safeguards for women and staff. Some regional Alert Level 3 periods would have particularly affected the Auckland region. Staffing issues as well as hesitancy among women to attend screening due to COVID restrictions, and/or other impacts of the COVID situation will have affected screening rates. While BSA has done all it could to minimise the impact of COVID-19 on screening services and the associated provision of diagnostic and treatment services, there is no doubt that these will have been affected.

Māori women

Māori women have higher underlying breast cancer incidence and mortality rates than other women. If more Māori women have their breast cancer detected early the disparity in breast cancer mortality and morbidity (e.g. from mastectomy and chemotherapy) can be reduced. From data in the current report, to achieve equal rates of breast screening coverage between Māori and non-Māori non-Pacific women, an additional 3,693 Māori women needed to be screened each year (an increase of 1,153 from the previous year). However, to achieve the 70% target would have required an additional 5,334 per year (an increase of 434). As is evident in this report among women aged 50–69 years, the higher incidence means that more cancers will be detected per 1,000 Māori women screened than among 1,000 non-Māori non-Pacific women (i.e. screening is more cost effective).

The proportions of cancers that were small or that had not spread to the lymph nodes were similar for Māori and non-Māori, and the rate of small cancers detected per 10,000 screens was higher for Māori than for non-Māori in this reporting period. Thus, BSA is certainly making a difference to breast cancer outcomes for Māori. Timely rescreen rates were similar or slightly higher for Māori than for non-Māori women in this period. The lower overall coverage is the key factor preventing BSA from achieving greater reductions in breast cancer mortality and morbidity among the Māori population.

A strong, ongoing commitment to prioritising Māori women is required to firstly achieve and maintain the target levels of coverage and timely rescreens, and to achieve and sustain equitable rates. However, due to the higher underlying rates of breast cancer, the non-Māori non-Pacific coverage rate may not achieve equitable outcomes for Māori women and further work may be required to investigate this.

In some regions, Māori women are also waiting longer for their first surgical treatment than non-Māori non-Pacific women. Regional differences in wait times may have been further challenged by restrictions imposed during the COVID-19 response.

For other treatment indicators, the differences between Māori and non-Māori, non-Pacific women were small in magnitude and/or not statistically significant.

Pacific women

Pacific women have a higher incidence and mortality rate of breast cancer than non-Māori non-Pacific women. The BSA Mortality Evaluation found that participating in the screening programme had a significant beneficial impact on Pacific

women’s risk of dying from breast cancer⁹. Thus, BSA is a critical component in breast cancer control for Pacific women in Aotearoa.

Over two-thirds of Pacific women in the screening age group reside in three LP regions: BreastScreen Waitemata Northland, BreastScreen Auckland Central, and BreastScreen Counties Manukau. The national rates are therefore strongly influenced by the performance of these LPs. Coverage of Pacific women was similar to, or slightly higher than, coverage of non-Māori non-Pacific women in these regions. However, in all other regions Pacific coverage was lower. Equitable coverage for Pacific women will be achieved when participation is high in all regions. Overall the participation rate dropped further for Pacific women and, for the first time, the national coverage rate was lower for Pacific than for non-Māori non-Pacific women (63% compared to 67%). BreastScreen Counties Manukau was the only LP to achieve the 70% coverage target for Pacific women. Timely rescreening rates among women aged 45–69 years were also lower for Pacific women than for non-Māori non-Pacific women after both initial and subsequent screens. There were no significant differences in other indicators at the national level.

Equity resources

A range of resources have been published recently that could support equity movement in breast screening. Taranaki District Health Board conducted a Health Equity Assessment in 2019 prior to the COVID pandemic, using the Health Equity Assessment Tool.¹⁰ The summary report includes a range of short-term and longer-term recommendations to improve equity in breast screening participation in the district, particularly for Māori women. The Council of Medical Colleges and Te Ohu Rata Aotearoa have published a cultural safety training plan¹¹ that, although developed for vocational medicine, may also be helpful for broader occupational groups. Te Arawhiti’s Māori Crown Relations capability components¹² at the individual and organisational level may also be useful.

Pro-equity invitation strategies which prioritise Māori and Pacific women having initial or subsequent screens are one strategy towards achieving equitable outcomes in screening participation and may be evident in the movement towards equitable rescreening rates in this report. Prioritisation criteria will be important when the planned population breast screening register is established in the future, which will no longer require women to “opt on” to enrol in BSA. The COVID recovery experience may also be relevant to regions experiencing other civil emergencies such as severe weather events or major earthquakes. In addition, strategies to reduce financial barriers such as the cost of transport to screening, or providing services outside of work hours, remain important.

⁹ Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999–2011. Wellington: Ministry of Health.

¹⁰ Pollard E, Leatherby R, Young M. Taranaki District Health Board. June 2019. Taranaki District Health Board Health Equity Assessment: Breast Screening Participation in Taranaki. Public Health Unit, Taranaki District Health Board. Available at https://www.tdhb.org.nz/services/public_health/documents/HEAT-Breast-Screening-Summary-Report.pdf

¹¹ Simmonds S, Carter M, Haggie H, Mills V, Lyndon M, Tipene-Leach D. A Cultural Safety Training Plan for Vocational Medicine in Aotearoa. Te ORA and the Council of Medical Colleges, January 2023. Available at <https://cmc.org.nz/media/4xmpx1dz/cultural-safety-training-plan-for-vocational-medicine-in-aotearoa.pdf>

¹² See <https://www.tearawhiti.govt.nz/tools-and-resources/public-sector-capability/>

Is BSA making a difference?

- BSA met its goals for early detection and treatment of breast cancers among screened women, but not its goals for equitable screening coverage and timely rescreening.
- Over half the invasive breast cancers detected by BSA were still small and most had no nodal involvement. These cancers have a better prognosis and reduced morbidity from treatment.
- Māori women were more likely than non-Māori to have a small cancer detected by BSA. Māori coverage decreased at the same rate as non-Māori during the first six months of the pandemic and remained around 7% lower. Prioritising Māori in scheduling and recruitment efforts thus remains critical to achieving equitable outcomes from breast cancer.
- Pacific women had similar overall coverage to non-Māori non-Pacific women prior to the pandemic, but Pacific coverage dropped below that of non-Māori non-Pacific women during the last 6 months of this reporting period. The rates of small cancers detected from subsequent screens were similar to those of non-Māori non-Pacific women, while those detected from initial screens were higher.
- Women aged 45–49 years had lower detection rates, reflecting the lower underlying incidence, but the proportions of screen-detected cancers that were small were similar to those of older women.
- Four out of five women whose cancer was small had breast conserving surgery, with most going on to have radiotherapy (89%). Chemotherapy and hormone therapy rates were similar for Māori, Pacific and other women.
- BSA aims to minimise harms by keeping false positive rates and open biopsy rates as low as possible. These indicators were within the target ranges.
- These indicators show that BSA is making a positive difference to breast cancer outcomes in Aotearoa.

BSA provides a high-quality breast cancer diagnostic service and monitors the quality of treatments received by women whose cancer is detected by BSA. This enables women in Aotearoa to receive a best practice, evidence-based pathway through the breast cancer care continuum.

The COVID-19 pandemic has challenged BSA's ability to meet the screening needs of all populations, particularly those in the northern regions who had more periods of COVID related restrictions, impacting access and availability of services. Delayed elective surgical operations, including for breast cancer, may also affect BSA's mortality outcomes.¹³ Future reports may also show the impact of severe weather events which will create further challenges in affected regions.

Maximising benefits

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability. The risk of dying from breast cancer is also reduced.

Around half of the invasive cancers detected from initial screens were small (15mm or less in diameter) as were nearly two-thirds of invasive cancers detected from subsequent screens. Over 70% of cancers had no nodal involvement. Most women were treated with breast conserving surgery, over 80% had a sentinel node biopsy as their first axillary procedure, and 86% only underwent a single excisional treatment procedure.

The move to a population breast screening register in the coming years should also support BSA's equity goals as it should reduce barriers to enrolment in the programme, as women will be invited automatically for screening rather than historically having to 'opt on'. However, algorithms that generate invitations to screening will need to prioritise Māori and Pacific women and Support to Screening Services resourced to be as effective as possible. Other equity related strategies may become more important if the programme faces ongoing challenges such as staff shortages.

¹³ Johnson BA, Waddimba AC, Ogola GO, Fleshman JW Jr, Preskitt JT. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic. *Am J Surg.* 2021;222(2):311-318. doi:10.1016/j.amjsurg.2020.12.015

Minimising harms

High quality screening programmes aim to minimise any harms from screening, since well women are invited to participate in an intervention. Possible harms include unnecessary procedures and surgery from false positive screens, or increased anxiety while waiting for assessment or biopsy results.

BSA achieved most targets relevant to harm minimisation, including low numbers of women recalled for technical reasons; false positive rates were on target; nearly all women had a definitive diagnosis without undergoing open surgery; the benign open biopsy rates were in the target ranges, as was the timely receipt of needle biopsies.

Just over half of women received their open biopsy within 31 calendar days and a similar proportion received their first surgical treatment within 31 calendar days of their final diagnosis. Waiting for biopsies or treatment can heighten anxiety levels for some women and potentially affect outcomes. Further impacts of hospital restrictions may be evident during the next reporting periods. The national rollout of vacuum assisted excisional biopsies¹⁴ over the next reporting periods may, in part, help to mitigate some of these potential harms.

The effectiveness of mammography screening depends on regular rescreening within recommended screening intervals. BSA aims to have most women rescreened within 27 months of a previous screen. During this reporting period, timely rescreening rates after a subsequent screen reduced for Pacific women and non-Māori non-Pacific women while staying steady for Māori women. This resulted in higher rescreen rates for Māori than for other women by the end of this reporting period. This indicates that Māori women were successfully prioritised in screening scheduling. Rescreening rates for Pacific women were similar to those of non-Māori non-Pacific women. However, all populations were below the target level. Gaps in timely rescreen rates after an initial screen reduced somewhat for Māori and non-Māori women but not for Pacific women, with all populations showing decreases. These trends varied between LPs. Increasing the proportion of Māori and Pacific women whose cancer is diagnosed early through breast screening is one of the most critical pathways for achieving equitable breast cancer mortality rates. Recruitment of Māori and Pacific women into the screening programme is also critical.

In summary, BSA is providing a high-quality screening service to women in Aotearoa and contributing to reduced illness and deaths from breast cancer. Most potential harms are being minimised. Since the greatest harm comes from lack of screening, catching up on backlogs of missed screens due to the pandemic and achieving equitable screening coverage remain as key challenges facing the programme.

¹⁴ BreastScreen Aotearoa. BreastScreen Protocol for the Management of B3 Breast Lesions. 20.01.2022 (FINAL)

Introduction

This report summarises the performance of BreastScreen Aotearoa (BSA) based on quality indicators for women screened during the two-year period to 30 June 2021. Treatment indicators are presented for women diagnosed through screening during the four-year period to December 2020.

Breast cancer is the most commonly diagnosed cancer among women in Aotearoa New Zealand. Screening aims to detect cancers at an early stage when tumours are more amenable to treatment. A properly organised breast screening programme can significantly reduce illness and death from breast cancer.

BSA offers free two-yearly mammographic screening to women aged 45 to 69 years. It plays a vital role, firstly by finding breast cancer tumours at a very early and treatable stage; and secondly by systematically following up women whose cancer is found by the screening programme to ensure timely pathways through the cancer care continuum. Women screened by BSA have a third lower risk of dying from breast cancer than women who are not screened¹⁵.

Māori and Pacific mortality rates from breast cancer are disproportionately higher than those of other women¹⁶ and more equitable outcomes could be achieved if more Māori and Pacific women were diagnosed at an earlier stage. For this reason, BSA prioritises screening these women and those who are unscreened or under-screened.

This report includes tables and graphs for each quality indicator. This report and the tables and graphs are also available in an online data tool on the [NSU's website](#). Previous monitoring reports and details of the indicator measures are also available online.

This report summarises the results of BSA quality indicators related to coverage, screening quality and assessment, early detection, and timeliness for women screened between 1 July 2019 and 30 June 2021. Breast cancer treatment indicators are summarised for women whose breast cancer was detected by BSA during the four-year period to 31 December 2020.

The period covered by this report includes 17 months in which Aotearoa was affected by the COVID-19 pandemic, from February 2020 to 30 June 2021. Routine breast screening was paused during Alert Level 4 from 25th March to 27th April 2020. Screening recommenced during Alert Level 3 (28th April to 13th May 2020) and Alert Level 2 (14th May to 8th June) but with reduced numbers due to the need for appropriate safeguards and other impacts of COVID. From 12th to 30th August 2020 the Auckland region moved to Alert Level 3 while the rest of the New Zealand moved to Alert Level 2. On 21 September 2020 all regions except Auckland moved to Alert Level 1. On 23rd September 2020 Auckland moved to Alert Level 2, then to Alert Level 1 on 7th October 2020. In 2021 Auckland moved to Alert Level 3 on 28 February, while the rest of the country moved to Alert Level 2. From 7th to 12th March Auckland moved to Alert Level 2 and the rest of the country to Level 1. After June 2021, there were further periods of Alert Level 4 and 3 which are not reflected in this reporting period which ends on 30 June 2021.

BSA has eight Lead Provider (LP) regions (see Figure 1). Each LP is responsible for providing or subcontracting mammography screening and assessment services in their region. BreastScreen Auckland Limited was operating during this reporting period but has since been replaced by BreastScreen Auckland Central. Support to Screening Providers are contracted by the National Screening Unit (NSU) to support women from priority groups to screening and assessment. During the period of this report, District Health Boards (DHBs) provided breast cancer treatment after diagnosis. Surgery is performed by DHB services and private providers; oncology and radiation therapy are provided by six Cancer Centres (or by private providers in some areas). Data on the treatment provided to women whose breast cancer was detected by BSA is collected by each LP and reported to the NSU.

¹⁵ Ministry of Health. 2016. Summary of the BreastScreen Aotearoa Mortality evaluation 1999–2011. Wellington: Ministry of Health. Available on www.health.govt.nz

¹⁶ Ministry of Health. 2016. Cancer: New registrations and deaths 2013. Wellington: Ministry of Health.

National Indicator Overviews for Māori, Pacific, Total women


This section provides national overview charts of how well BSA is achieving the targets and which indicators require continued focus. Charts are provided for Māori, Pacific and total women aged 50–69 years.

Data for most indicators are for the two-year time period 1 July 2019 to 30 June 2021, however some detection indicators and all treatment indicators cover the 4-year period 1 January 2017 to 30 December 2020 in order to maximise numbers and increase statistical precision.

The charts show the percentage difference of each indicator from the target value. The central line of the graph represents the target and all indicators with bars above this line achieved or exceeded the target, those below the line were outside the target value, if the confidence interval did not include the target value (central line). For some indicators the confidence intervals may be too small to be visible on the chart.


Indicators that do not have targets developed are not included in these charts.

Figure 2: National Overview, Māori women, 50–69 years




For Māori women aged 50–69 years, BSA met or exceeded the target values for: screening quality; assessment quality; invasive cancer detection (including small and node-negative cancers); preoperative diagnosis, benign open biopsy rate; timeliness of screening results and needle biopsies; and breast conserving surgery rates. Indicators outside the target range included: timeliness of first offer of assessment, first treatment surgery and open biopsies and receipt of biopsy results; benign open biopsy weight; radiotherapy for invasive cancer; coverage; and rescreening within 27 months. 10,668 additional Māori women needed to be screened to achieve the 70% coverage target.

Figure 3: National Overview, Pacific women aged 50–69 years



For Pacific women aged 50–69 years, BSA met or exceeded the target values for: screening quality; assessment quality; benign biopsy rates, benign open biopsy weight and preoperative diagnosis; invasive cancer detection; breast conserving surgery; timeliness of screening results and needle biopsies. Indicators not meeting target values included: overall coverage and routine rescreening; timeliness of first offer of assessment and reporting biopsy results; timeliness of first surgical treatment and open biopsies.

Figure 4: National Overview, Total women aged 50–69 years



For total women aged 50–69 years, BSA met or exceeded the target values for: rescreening after a subsequent screen; screening quality; assessment quality, open biopsy rate (but not weight) and preoperative diagnosis; invasive cancer detection; breast conserving surgery. Indicators not meeting the target values included: overall coverage and routine rescreens; timely first offer of assessment; timely open biopsies; benign open biopsy weight; timely reporting of biopsy results; timely first surgical treatment; and radiotherapy for invasive cancer. An additional 33,238 women needed to be screened to reach the 70% coverage target.

Lead Provider Indicator Overviews for Māori, Pacific and Total women aged 50–69 years

Introduction

This section provides an overview chart for each Lead Provider (LP) of how well they are achieving the targets and which indicators require continued focus. Charts are provided for Māori, Pacific and total women aged 50–69 years. For some LPs the relatively small number of Pacific women means there are too little data to interpret the results for some indicators.

Data for most indicators are for the two-year time period 1 July 2019 to 30 June 2021, however some detection indicators and all treatment indicators cover the 4-year period 1 January 2017 to 30 December 2020 in order to maximise numbers and increase statistical precision.

The data presented in the graphs show the percentage difference of each indicator from the target value. The central line of the graph represents the target and all indicators with bars above this line achieved or exceeded the target, those below the line were outside the target value, if the confidence interval did not include the target value (central line). For some indicators the confidence intervals may be too small to be visible on the chart.

Indicators that do not have targets developed are not included in the overview charts.

BreastScreen Waitemata Northland (BSWN) Overview

Figure 5: BSWN Overview, Māori women aged 50–69 years




Figure 6: BSWN Overview, Pacific women aged 50 to 69 years





Figure 7: BSWN Overview, Total women aged 50 to 69 years



BreastScreen Waitemata Northland (BSWN)

During the two years to 30 June 2021 BSWN screened 80,876 women aged 45–69 years (62% of the eligible population), 777 more screens than the previous biennium. These included 10,357 Māori (63%) and 3,682 Pacific women (63%). Overall, 92 breast cancers were detected from initial screens (72 invasive) and 408 from subsequent screens (320 invasive), with 96% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met, with 52% of initial and 83% of subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (60% initial and 81% subsequent).

Among BSWN women diagnosed with invasive cancer ≤ 20 mm over the 4 years to December 2020, 85% had breast conserving surgery, of whom 89% also had radiotherapy. Sentinel node biopsy was the first axillary procedure for 79%. Most women who had DCIS ≤ 20 mm detected by BSWN had breast conserving surgery (85%). 59% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

Among women aged 50–69 years, Māori women were more likely than non-Māori to have breast cancer detected from initial and subsequent screens and the proportions of small and node-negative cancers were similar in both groups. Among women aged 45–49 years, there were no significant differences in cancer detection rates between Māori and non-Māori women. 17 cancers (15 invasive) were detected from initial screens and 82 from subsequent screens (71 invasive) among Māori women aged 45–69 years. Treatment indicators were similar for Māori and non-Māori women, apart from the proportion having their first treatment surgery within 31 calendar days which was lower for Māori (38% compared to 63%).

BSWN detected 5 invasive cancers from initial screens among Pacific women aged 45–69 and 25 breast cancers from subsequent screens (21 invasive). A third of invasive cancers detected were ≤ 15 mm, and two-thirds were node negative. Treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving, cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of the invasive cancers detected by BSWN were small and three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single surgical procedure. These indicators show BSWN is making a positive difference to breast cancer mortality and morbidity in their region.

BSWN achieved most targets relevant to harm minimisation. Very low numbers of women were recalled for technical reasons; false positive rates were well within the target range; nearly all women had a definitive diagnosis without undergoing open surgery; the benign open biopsy rates were within the target ranges, as was the timely receipt of needle biopsy. The target for the percentage of benign open biopsies weighing < 30 g was within the confidence interval.

The next section relates to the BSWN overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

Most indicators for Māori women aged 50–69 years in the BSWN area were within the target range. BSWN is doing particularly well for Māori women in the areas of screening and assessment quality, breast cancer detection, treatment, and most timeliness indicators.

In a few instances, indicators fell outside the target range:

- Coverage
 - o Overall coverage for Māori women held relatively steady at 63%, down only 1% on the previous year which had seen a decrease during the first 6 months of the COVID pandemic. Coverage generally increased with age, from 62% for women aged 45–49 years to 67% for those aged 65–69 years. BSWN needed to have screened a further 891 women aged 50–69 or 1151 overall to reach the 70% biennial target.
 - o The impact of COVID was seen in rescreen rates. The proportion of women rescreened within 27 months of an initial screen (52%) was outside the target range of $\geq 75\%$, but only 52 additional women were needed to reach the target. Timely rescreening after a subsequent screen was 75% (target ≥ 85) with 725 more women needed to reach the target range. However, BSWN achieved equitable rescreening rates for Māori and non-Māori.
- Timeliness

- o The targets of $\geq 90\%$ were met or were within the confidence interval for most timeliness indicators, including screening results, needle biopsies, biopsy results.
- o The targets were not met for the receipt of open biopsies within 20 working days (31%) nor for first treatment surgery within 31 calendar days (37%). The proportion offered a first assessment within 15 working days dropped slightly to 85%.

Pacific women aged 50–69 years

Over half the indicators for Pacific women aged 50–69 years in the BSWN area were within the target range, although the pandemic has impacted coverage and rescreening rates. BSWN is doing particularly well for Pacific women in the areas of screening quality, breast cancer detection, biopsies, and most timeliness indicators.

Indicators that fell outside the target range included:

- Coverage
 - o Overall coverage decreased from 70% in the previous biennium to below target at 65%.
 - o Routine rescreens within 27 months decreased from 62% to 54% (target of $\geq 75\%$) after an initial screen and from 84% to 78% after subsequent screens (target $\geq 85\%$).
- Timeliness
 - o First surgical treatment within 31 calendar days, women screened during the 4 years to December 2020 (57%, target 90%).

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSWN area were within the target range. BSWN is doing particularly well in the areas of screening and assessment, breast cancer detection, and treatment.

Indicators fell outside the recommended range in the areas of:

- Coverage
 - o After dropping by 4% to 64% after the start of the COVID-19 pandemic, overall coverage decreased a further 2% to 62% in this reporting period, indicating ongoing impact from COVID restrictions. To achieve 70% coverage BSWN would have needed to screen a further 7,860 women over 2 years.
 - o Routine rescreening within 27 months after an initial screen decreased from 58% in the previous reporting period to 52% (target $\geq 75\%$). Routine rescreening after a subsequent screen decreased from 79% to 72% (target $\geq 85\%$).
- Timeliness
 - o The targets of $\geq 90\%$ were met or were within the confidence interval for most timeliness indicators, including screening results, needle biopsies, biopsy results. The proportion of women who were offered an assessment within 15 working days of their screen was close to target at 88%.
 - o The targets were not met for the receipt of open biopsies within 20 working days (45%) nor for first treatment surgery within 31 calendar days (59% over a four-year period, second highest of all LPs).

Focus on Equity

BSWN continued to sustain equitable coverage and routine rescreening rates for Māori, Pacific, and non-Māori non-Pacific women. Screening and assessment quality, the proportions of small and node-negative breast cancer detected, treatment indicators, and most timeliness indicators were similar for each group.

One indicator that continued to show possible inequity was time to first surgery. Waiting longer for surgery can heighten anxiety levels and potentially affect outcomes. The proportions of women having their first surgical treatment within 31 calendar days of receiving their final diagnostic results were 38% for Māori women, 57% for Pacific women, and 64% for non-Māori non-Pacific women. Wait times for surgery may have been affected by the COVID pandemic as DHBs had to manage staffing and theatre or ICU availability during lockdown periods or outbreaks.

BreastScreen Counties Manukau (BSCM) Overview

Figure 8: BSCM Overview, Māori women aged 50 to 69 years




Figure 9: BSCM Overview, Pacific women aged 50 to 69 years





Figure 10: BSCM Overview, Total women aged 50 to 69 years



BreastScreen Counties Manukau (BSCM)

During the two years to 30 June 2021 BSCM screened 52,694 women aged 45–69 years (64% of the eligible population), 1,013 fewer than the previous biennium. These included 6,302 Māori (59%) and 10,243 Pacific women (71%). Overall, 51 breast cancers were detected from initial screens (40 invasive) and 273 from subsequent screens (206 invasive), with 97% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met. A third of initial and 60% of subsequent screen-detected cancers were ≤15mm in diameter. A majority had no nodal involvement (60% initial and 79% subsequent).

Among BSCM women diagnosed with invasive cancer ≤20mm over the 4 years to December 2020, 85% had breast conserving surgery (BCS), of whom 88% also had radiotherapy. Sentinel node biopsy was the first axillary procedure for 80%. Over two-thirds of women with DCIS ≤20mm had BCS (70%). 60% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results (one of the two highest proportions).

Among women aged 50–69 years Māori women were more likely than non-Māori to have breast cancer detected from a subsequent screen, with no significant differences in detection rates among women aged 45–49 or those having an initial screen. There were no significant differences in proportions of small and node-negative cancers. Among Māori women aged 45–69 years, 7 breast cancers (4 invasive) were detected from initial screens and 49 (35 invasive) from subsequent screens. Treatment indicators were generally similar for Māori and non-Māori women.

Pacific women aged 45–49 years were more likely than non-Māori non-Pacific women to have an invasive cancer detected from an initial screen, with no significant differences in women aged 50–69 nor in those having subsequent screens in either age group. BSCM detected 16 breast cancers (15 invasive) from initial screens among Pacific women aged 45–69 years and 51 cancers (41 invasive) from subsequent screens. Over a third (39%) of initial screen-detected and just over half (54%) of subsequent screen-detected invasive cancers were ≤15mm in diameter, with three-quarters node negative. Treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Nearly two-thirds of all invasive cancers detected by BSCM were small and four-fifths had no nodal involvement. Most women (four in five) were treated with BCS and 92% underwent a single excisional procedure. These indicators show BSCM is making a positive difference to breast cancer mortality and morbidity in their region.

BSCM achieved targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were in the target ranges; nearly all women had a definitive diagnosis without undergoing open surgery; the benign biopsy rate and the percent of benign open biopsies <30g were on target, as was the timely receipt of needle biopsy.

The next sections relate to the BSCM overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well for Māori women in the areas of screening and assessment quality, breast cancer detection, and treatment.

In a few instances, indicators fell outside the target range:

- Coverage
 - Overall coverage decreased a further 2% to 59% (target >70%) compared to the previous reporting period. An additional 358 Māori women per year needed to be screened over two years to achieve the target coverage.
 - The proportion having a routine rescreen within 27 months of an initial screen was 48% (target ≥75%). Only 24 more per year needed to reach the target. Timely rescreening after a subsequent screen was 75% (target ≥85% with 128 more per year needed to be rescreened within 27 months to reach the target).
- Timeliness
 - The targets of ≥90% were met for most timeliness indicators, including receipt of screening results, needle biopsies, biopsy results.

- Other indicators included: offer of assessment within 15 working days which decreased by 10% from the previous biennium to 75%; open biopsy within 20 working days (22% of 9 women); and first surgical treatment within 31 calendar days which increased by 8% to 67%, highest of all LPs.

Another indicator which may require consideration by BSCM for Māori women include:

- Treatment
 - Among Māori women diagnosed with invasive cancer during the 4 years to December 2020 who had breast conserving surgery, 81% also had radiotherapy (target ≥95%).

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well for Pacific women in the areas of overall coverage (71%), screening and assessment quality, breast cancer detection, and treatment.

Indicators that fell outside the target range were in areas of:

- Rescreening within 27 months
 - The proportion of Pacific women rescreened within 27 months of an initial screen decreased by 16% to 33% (target ≥75%) with 73 more per year needed to reach the target. The proportion rescreened within 27 months of a subsequent screen decreased by 12% to 67% (target ≥85%) with a further 653 more per year needed to reach the target. These indicators show the impact of the COVID pandemic in the BSCM region.
- Timeliness
 - The targets of ≥90% were met for timely receipt of screening results, needle biopsies, biopsy results.
 - Indicators outside the target range included: offer of assessment within 15 working days (77%); open biopsy within 20 working days (0 of 8 women); and first surgical treatment within 31 calendar days (55% over a four-year period).

Total women aged 50–69 years

The majority of indicators for total women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well in the areas of screening and assessment, breast cancer detection, and treatment.

Where indicator targets fell outside the recommended range were in areas of:

- Coverage
 - Overall coverage and routine rescreens after initial screens both decreased in the last 12 months of the reporting period, indicating impacts of COVID restrictions
 - Coverage decreased by 5% to 63%. A further 2134 women needed to be screened per year to achieve 70%.
 - The proportion who was routinely rescreened within 27 months of an initial screen was decreased from 64% to 49% (target ≥75%). After meeting the ≥85% target for rescreens after a subsequent screen in the previous biennium, this indicator decreased to 74%.
- Timeliness
 - The targets of ≥90% were met for most timeliness indicators, including receipt of screening results, needle biopsies, biopsy results.
 - Indicators outside the target ranges were: offer of assessment within 15 working days (83%); open biopsy within 20 working days (23% of 44 women); and first surgical treatment within 31 calendar days (62% over a four-year period, one of the highest LPs).

Another indicator which may require consideration include:

- Treatment
 - 87% of women screened during the 4 years to December 2020 who had breast conserving surgery for invasive cancer also had radiotherapy (target ≥95%). This indicator increased slightly since the previous biennium.

Focus on Equity

Coverage remains a key equity focus. As the pandemic continued, coverage of women aged 45–69 years declined further for all groups, although the decrease was smallest for Māori women (dropping 1% to 59%), and largest for Pacific women

(dropping 6% to 71%), with coverage for non-Māori non-Pacific dropping 5% to 63%. To achieve an equal level of coverage as non-Māori women, BSCM needed to have screened an additional 273 Māori women over the two years.

Timely routine rescreening after an initial screen was outside the target range for all women aged 45–67 years at the first screen (60%) but was lower for Māori (56%) and Pacific women (50%) than for non-Māori non-Pacific women (64%). Similarly, for timely rescreens after a subsequent screen, Māori (71%) and Pacific women (67%) had lower levels than non-Māori non-Pacific women (76%).

Most timeliness indicators were similar for Māori, Pacific and other women. However, an equity gap opened up in the proportion of women aged 45–69 years offered their first assessment appointment within 15 working days with decreases among Māori (to 76%) and Pacific women (to 79%) while rates for non-Māori non-Pacific women remained fairly steady at 87%. This may be an indicator of differential impacts of the pandemic with the BSCM region particularly impacted. In contrast there were no significant differences between Māori, Pacific and other women in the proportions receiving their first treatment surgery within 31 calendar days of their final diagnosis.

BreastScreen Auckland Central (BSAC) Overview

Figure 11: BSAC Overview, Māori women aged 50 to 69 years




Figure 12: BSAC Overview, Pacific women aged 50 to 69 years





Figure 13: BSAC Overview, Total women aged 50 to 69 years



BreastScreen Auckland Ltd (BSAL) and BreastScreen Auckland Central (BSAC)

BSAL finished its contract with BSA in February 2021. BSAC started screening in March 2021. Thus this report includes data from the two providers which will be abbreviated as BSAL/AC for convenience.

During the two years to 30 June 2021 BSAL/AC screened 35,868 women aged 45–69 years, 10,322 fewer than the previous biennium (51% of the eligible population), including 2,736 Māori (55%) and 3,888 Pacific women (55%). Overall, 44 breast cancers were detected from initial screens (28 invasive) and 188 from subsequent screens (132 invasive), with 93% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 58% of all initial and 68% of all subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (61% initial and 81% subsequent).

Among BSAL women diagnosed with invasive cancer ≤ 20 mm over the 4 years to December 2020, 88% had breast conserving surgery (BCS). Of those who had BCS for invasive cancer, 82% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 86%. Over four-fifths of women with DCIS ≤ 20 mm had BCS. 50% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

BSAL/AC detected 28 breast cancers among Māori women (23 invasive). Māori women aged 45–49 years had similar breast cancer detection rates to Māori. Among Māori women aged 50–69 years, no breast cancers were detected from initial screens, but the rate of cancer detection from subsequent screens was twice that of non-Māori women. The proportions of small and node-negative cancers were similar in both groups. Treatment indicators were generally similar for Māori and non-Māori women.

BSAL/AC detected 5 breast cancers (all invasive) from initial screens among Pacific women aged 45–69 years and 35 cancers (28 invasive) from subsequent screens. Two-fifths of initial screen- and three-fifths of subsequent screen-detected invasive cancers were ≤ 15 mm in diameter, with 85% of all invasive cancers being node negative. Treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving, cause less long-term illness and disability, and reduce risk of dying from breast cancer. Two-thirds of the invasive cancers detected by BSAC were small and three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single surgical procedure. These indicators show BSAL/AC has made a positive difference to breast cancer mortality and morbidity.

BSAL/AC achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; over 90% had a definitive cancer diagnosis without undergoing open surgery; the targets for the benign biopsy rate and biopsies < 30 g were met as was the timely receipt of needle biopsy. The proportion of women receiving their first offer of assessment within 15 working days improved significantly to 99%. This upward trend began in December 2018 when just over half received a timely offer of assessment, showing steady increases to 98% by December 2020.

The next section relates to the BSAL/AC overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSAC area were within the target range. BSAL/AC is doing particularly well for Māori women in the areas of screening and assessment, breast cancer detection from subsequent screens and most timeliness indicators including time to open biopsy. No invasive cancers were detected from initial screens.

In a few instances, target indicators fell outside the recommended range, including:

- Coverage
 - o Overall coverage of Māori women aged 50–69 decreased by 5% to 60% since the previous reporting period, but equitable coverage was achieved.
 - o Routine rescreening within 27 months of an initial screen decreased by 11% to 44% (similar to the non-Māori rate). Routine rescreening after a subsequent screen also decreased by 12% to 70% (10% higher than the non-Māori rate).
- Timeliness

- Among women screened during the 4 years to December 2020, 48% received their first treatment surgery within 31 calendar days, an increase of 10% since the previous biennium (target $\geq 90\%$).

Another indicator which may require attention for Māori women was:

- Treatment
 - 64% of women who had breast conserving surgery for invasive cancer went on to have radiotherapy (target $\geq 95\%$) among women screened during the 4 years to December 2020.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSAC area were within the target range, although for many indicators there is a large degree of uncertainty due to the small numbers of women included in the calculation.

Indicators which may require attention for Pacific women include:

- Coverage
 - Overall coverage decreased by 14% since the previous biennium to 55%, showing the impacts of COVID.
 - Routine rescreening within 27 months of an initial screen decreased by 10% to 44%. Routine rescreening after a subsequent screen decreased by 15% to 64%.
- Timeliness
 - Most timeliness targets of 90% were met for Pacific women, including screening results, assessments, needle biopsies, open biopsies, and biopsy results. However, among women screened over four years to December 2020, 46% received their first surgical treatment within 31 calendar days, an increase of 14%.

All women aged 50–69 years

The majority of indicators for total women aged 50–69 years in the BSAC area were within the target range. BSAC is doing particularly well in the areas of screening and assessment quality, breast cancer detection, treatment, and timeliness.

Indicators that fell outside the recommended range were in areas of:

- Coverage
 - Routine rescreening within 27 months of an initial screen decreased by 20% to 47% (target $\geq 75\%$). Similarly routine rescreening after a subsequent screen decreased by 26% to 61% (target $\geq 85\%$).
- Treatment
 - Invasive cancer having radiotherapy after breast conserving surgery, women screened during the 4 years to December 2020 was 81% (target $\geq 95\%$).
- Timeliness
 - Final diagnostic biopsy results received within 5 working days was 83%.
 - First surgical treatment within 31 calendar days for women screened during the 4 years to December 2020 was 51%.

Focus on Equity

Although coverage decreased for all groups, BSAL/AC achieved equitable coverage rates in this biennium at 63% for Māori and Pacific women and 62% for other women. Similarly, equitable rescreening rates were achieved as rates dropped more steeply for non-Māori non-Pacific women than for Māori or Pacific women. Achieving the target rates will be the challenge for BSAC during the pandemic recovery phase.

There was significant movement towards equity in the proportions of women receiving their first treatment surgery within 31 calendar days, with Māori and Pacific rates increasing towards those of non-Māori non-Pacific women. All other timeliness indicators were similar for all groups.

BreastScreen Midland (BSM) Overview

Figure 14: BSM Overview, Māori women aged 50 to 69 years




Figure 15: BSM Overview, Pacific women aged 50 to 69 years





Figure 16: BSM Overview, Total women aged 50 to 69 years



BreastScreen Midland (BSM)

During the two years to 30 June 2021 BSM screened 80,845 women aged 45–69 years (63% of the eligible population), 791 more than the previous biennium. These included 14,064 Māori (54% coverage) and 1,271 Pacific women (57% coverage). Overall, 65 breast cancers were detected from initial screens (50 invasive) and 425 from subsequent screens (330 invasive), with 95% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 63% of initial and 64% of subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (76% initial and 77% subsequent).

Among BSM women diagnosed with invasive cancer ≤ 20 mm over the 4 years to 31 December 2020, 90% had breast conserving surgery (BCS). Of women who had invasive cancer ≤ 20 mm and BCS, 81% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 85%. Most women with DCIS ≤ 20 mm had breast conserving surgery (96%). 61% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

BSM detected 24 breast cancers (20 invasive) from initial screens and 105 (86 invasive) from subsequent screens among Māori women aged 45–69 years. Māori women aged 50–69 were more likely than non-Māori to have breast cancer detected and the proportions of small and node-negative cancers were similar in both groups. There were very few cancers detected among Māori women aged 45–49 and no significant differences. Four-year treatment indicators were similar for Māori and non-Māori women.

BSM detected 4 breast cancers (all invasive) from initial screens among Pacific women aged 45–69 years and 7 cancers (4 invasive) from subsequent screens. The low numbers partly reflect the relatively small population of Pacific women screened by BSM (1,271 of an estimated 2,220 eligible population). Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving, cause less long-term illness and disability, and reduce risk of dying from breast cancer. Nearly two-thirds of the cancers detected by BSM were small and three-quarters had no nodal involvement. Most women with invasive breast cancer only underwent a single surgical procedure (82%) and of those whose cancer was 20mm or less, 90% were treated with breast conserving surgery. Similarly 96% of women with DCIS 20mm or less had breast conserving surgery. These indicators show BSM is making a positive difference to breast cancer mortality and morbidity in their region.

BSM achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive cancer diagnosis without undergoing open surgery; the benign biopsy rates were on target; as was the timely receipt of needle biopsy. The percentage of benign open biopsies weighing < 30 g (80%) was slightly outside the target range ($> 90\%$), but low volumes were observed.

The next section relates to the BSM overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSM area were within the target range. BSM is doing particularly well for Māori women in the areas of screening and assessment, breast cancer detection, and treatment.

Target indicators were outside the recommended range for specific areas for:

- Coverage
 - Overall coverage of eligible women. This indicator has remained at 55%, 10% lower than coverage for non-Māori women.
 - Routine rescreening after an initial screen was 43% (6% lower than non-Māori) and 75% after a subsequent screen (3% lower than non-Māori).
- Timeliness (all targets $\geq 90\%$)
 - Time taken for provision of screening results. This indicator improved by 4% to 83%.
 - Time taken from screening visit to first offer of assessment decreased slightly to 73%.
 - Women having an open biopsy procedure within 20 working days remained at 58%.
 - Time taken from final diagnostic biopsy to reporting assessment results increased from 72% to 75%.
 - First surgical treatment within 31 calendar days among women screened during the 4 years to December 2020. This indicator increased from 53% to 60%.

- Treatment
 - Invasive cancer treated with breast conserving surgery who had radiotherapy, women screened during the 4 years to December 2020. This indicator was 75% for the four-year period but appears to be increasing (83% for the two-year period, similar to non-Māori).

Pacific women aged 50–69 years

Most indicators for Pacific women aged 50–69 years in the BSM area were within the target range. BSM is doing particularly well for Pacific women in the areas of screening and assessment, breast cancer detection and treatment.

Indicators outside the recommended target range for Pacific women included:

- Coverage
 - Overall coverage of eligible women remained relatively steady, decreasing 1% to 59%, with 151 more Pacific women needed to reach the 70% target.
 - Routine rescreening within 27 months of an initial screen decreased from 56% to 33%, with 47 more needed over 2 years to reach the 75% target. Rescreening after a subsequent screen showed a smaller decrease from 79% to 73%, with 98 additional Pacific women needed over 2 years to reach the 85% target.
- Timeliness (all targets $\geq 90\%$)
 - The provision of screening results within 10 working days increased from 72% to 81%.
 - The proportion offered a first offer of an assessment within 15 working days decreased slightly from 74% to 71% but 95% had a needle biopsy within 5 working days of assessment.
 - Among women screened during the 4 years to December 2020 10 out of 16 Pacific women aged 50–69 years (63%) received their first treatment surgery within 31 calendar days.

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSM area were within the target range. BSM is doing particularly well in the areas of screening and assessment and breast cancer detection.

Indicators outside the recommended target range for all women included:

- Coverage
 - After a number of years of being very close to reaching the coverage target, this indicator remained at 63%, indicating an impact of the COVID pandemic. A further 6,711 women needed to be screened over two years to reach 70%.
 - Routine rescreening within 27 months of an initial screen decreased further from 53% to 48% (a further 338 was needed per year to reach 75%. Rescreens after a subsequent screen decreased from 83% to 78%, with an additional 2,066 per year required to reach the 85% target.
- Assessment
 - Benign open biopsy weight <30g (target >90%). This indicator was 80% (68 of 85 biopsies).
- Treatment
 - Invasive cancer having radiotherapy after breast conserving surgery, women screened during the 4 years to December 2020 (target $\geq 95\%$). This indicator was 81%.
- Timeliness (all targets $\geq 90\%$)
 - The provision of screening results within 10 working days increased to 85%.
 - First offer of an assessment within 15 working days. This indicator decreased by 6% to 73%.
 - Open biopsy procedure within 20 working days. This indicator increased from 44% to 60%.
 - Final diagnostic biopsy reported within 5 working days increased from 80% to 85%.
 - First surgical treatment within 31 calendar days, for women screened during the 4 years to December 2020. This indicator remained increased slightly to 63% with two-year data showing a stronger upward trend.

Focus on Equity

The main focus for BSM to achieve equity in for Māori and for Pacific women is in the area of **coverage**.

Coverage

Coverage for non-Māori non-Pacific women aged 45 to 69 years remained at 65%, but 10% lower for Māori and Pacific women, both at 55%. To achieve an equal level of coverage with non-Māori non-Pacific women, BSM would have to have screened an additional 1,454 Māori women and 88 Pacific women per year. These are higher numbers than in the previous report.

Among women aged 45–67 at their initial screen, the proportions rescreened within 27 months were 55% for Māori, 53% for Pacific, and 59% for non-Māori non-Pacific women. To achieve the 75% target, BSM needed to rescreen around 200 more Māori women per year, and 27 more Pacific women per year. Rescreen rates after a subsequent screen were also lower for Māori (75%) and Pacific women (73%) than for non-Māori non-Pacific women (78%) (target 85%).

BSM serves just over a quarter (26%) of the national eligible Māori population aged 45–69 years and 24% of all Māori screened by BSA were screened by BSM. This makes BSM a key screening provider for Māori women nationally. It has the largest number of eligible Māori women out of all LPs (26,150 aged 45–69 years) and screened the largest number of Māori women (14,064 in this reporting period). If BSM achieved 70% screening of Māori women aged 45–69, the number of Māori women needed to be screened to achieve the national target would decrease by 40%. This indicates that it is unlikely the national Māori coverage target could be achieved without significant increases in Māori coverage by BSM and the necessary supports or resources to do so.

BreastScreen Coast to Coast (BSCC) Overview

Figure 17: BSCC Overview, Māori women aged 50 to 69 years




Figure 18: BSCC Overview, Pacific women aged 50 to 69 years





Figure 19: BSCC Overview, Total women aged 50 to 69 years



BreastScreen Coast to Coast (BSCC)

During the two years to 30 June 2021 BSCC screened 69,265 women aged 45–69 years (70% of the eligible population), 3,774 more women than the previous biennium. These included 11,312 Māori (58% coverage) and 1,027 Pacific women (59% coverage). Overall, 40 breast cancers were detected from initial screens (34 invasive) and 349 from subsequent screens (282 invasive), with 97% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 39% of initial and 56% of subsequent screen-detected cancers $\leq 15\text{mm}$ in diameter. A majority had no nodal involvement (71% initial and 78% subsequent).

Among BSCC women diagnosed with invasive cancer $\leq 20\text{mm}$ over the 4 years to 31 December 2020, 78% had breast conserving surgery (BCS). Among women who had invasive cancer and BCS, 92% had radiotherapy (target $\geq 95\%$). Sentinel node biopsy was the first axillary procedure for 83% (of those with breast cancers $\leq 30\text{mm}$). Most women with DCIS $\leq 20\text{mm}$ had breast conserving surgery (80%). 42% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

Among Māori women aged 45–69 years BSCC detected 11 breast cancers (all invasive) from initial screens and 81 (70 invasive) from subsequent screens. Māori women aged 50–69 years were more likely than non-Māori to have breast cancer detected from subsequent screens with no difference in detection rates from initial screens. The proportions of small and node-negative cancers were comparable in both groups. Treatment indicators were generally similar for Māori and non-Māori women, although Māori women were slightly less likely to have a sentinel node biopsy as their first axillary procedure (73% compared to 86%) and less likely to have their first treatment surgery within 31 calendar days (29% compared to 46%).

BSCC detected 1 invasive breast cancer from initial screens among Pacific women aged 45–69 years and 5 cancers (4 invasive) from subsequent screens. Four-year treatment indicators were generally similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability and reduce risk of dying from breast cancer. Just over half of invasive cancers detected by BSCC were small and three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and underwent a single excisional procedure. These indicators show BSCC is making a positive difference to breast cancer mortality and morbidity in their region.

BSCC achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were low; nearly all women had a definitive diagnosis without undergoing open surgery; the benign open biopsy rate was low; and almost all needle biopsies were received within 5 days of assessment.

The next section relates to the BSCC overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSCC area were within the target range. BSCC is doing particularly well for Māori women in the areas of screening and assessment quality and breast cancer detection.

For a few indicators, results were outside the recommended target range for Māori women, specifically:

- Coverage
 - Overall coverage of eligible women. After a dip during the first six months of the COVID pandemic, coverage increased slightly to 60%, with a further 1,464 required to have reached the 70% target (while non-Māori reached 73% showing a widening gap).
 - Routine rescreening within 27 months of an initial screen continued to decline from to 58% (while non-Māori remained within the target range at 76%). Rescreening after a subsequent screen also continued to decrease to below target at 80% (while non-Māori remained within the target range at 89%).
- Timeliness
 - Time taken from screening visit to first offer of an assessment. This indicator was 69%.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator improved to 83%.
 - First surgical treatment within 31 calendar days among women screened during the 4 years to December 2020. This indicator remains well outside the target range (90%) at 29% (below non-Māori at 49%).

Other indicators which may require attention by BSCC for Māori women include:

- Radiation therapy after breast conserving surgery for invasive cancer among women screened during the 4 years to December 2020. This indicator increased to 85%.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSCC region were within the target range, although for many indicators there is a large degree of uncertainty due to small numbers. BSCC is doing particularly well for Pacific women in the areas of screening and assessment, breast cancer detection, treatment, and timeliness. No breast cancers were detected in this age group from initial screens.

For a few indicators, results were outside the recommended target range for Pacific women, specifically:

- Coverage
 - Overall coverage remained at 61% while non-Māori non-Pacific coverage increased again after the initial dip to 73%. Only 119 more Pacific women were needed over 2 years to reach 70%.
 - Routine rescreening within 27 months of an initial screen continued to decline to 54% with only 11 more needed to reach the 75% target. Rescreens after a subsequent screen were higher at 80% with only 34 more women needed to reach 85%.
- Timeliness
 - Among women whose breast cancer was detected during the 4 years to December 2020 who had their first treatment surgery within 31 calendar days of their final diagnosis was 36%.

All women aged 50–69 years

The majority of indicators for total women aged 50–69 years in the BSCC area were within the target ranges. BSCC is doing particularly well in coverage, screening and assessment quality, breast cancer detection, and treatment. Some indicators improved from the previous biennium, and some were outside the target range. Of note:

- Coverage
 - Overall coverage of eligible women recovered after an initial decrease during the first 6 months of the pandemic to reach 71%.
 - Routine rescreening within 27 months of an initial screen remained just under target at 72%, while routine rescreening after a subsequent screen remained within the target range at 88%.
- Treatment
 - Invasive cancer having radiotherapy after breast conserving surgery, women screened during the 4 years to December 2020. This indicator was close to target ($\geq 95\%$) at 91%.
- Timeliness
 - The percentage offered their first assessment appointment within 15 working days increased to 72%.
 - Time taken from final diagnostic biopsy to reporting assessment results improved significantly to 90%.
 - Women having an open biopsy procedure within 20 working days. Of 24 women who had an open biopsy during this biennium 4 received their biopsy within 20 working days.
 - First treatment surgery within 31 calendar days, women screened during the 4 years to December 2020. This indicator remained outside the 90% target range at 42%.

Focus on Equity

The main focus for BSCC to achieve equity in for Māori and for Pacific women is in the areas of coverage and rescreening. BSCC serves the second highest number of Māori women and thus has a significant impact on equity in coverage at the national level. During this reporting period breast screening coverage of Māori and Pacific women aged 45–69 years declined (more steeply in the 45–49 age group) while coverage of non-Māori non-Pacific women increased. Targets for routine rescreens within 27 months of an initial or subsequent screen were exceeded for non-Māori non-Pacific women but not met for Māori or Pacific women. Processes for inviting women to screen during the pandemic recovery phase continue to highlight the importance of prioritising Māori and Pacific women.

BreastScreen Central (BSC) Overview

Figure 20: BSC Overview, Māori women aged 50 to 69 years




Figure 21: BSC Overview, Pacific women aged 50 to 69 years





Figure 22: BSC Overview, Total women aged 50 to 69 years



BreastScreen Central (BSC)

During the two years to 30 June 2021 BSC screened 56,348 women aged 45–69 years (69% of the eligible population), 3,699 more women than the previous biennium. These included 5,512 Māori (64%) and 2,819 Pacific women (61%). Overall, 30 breast cancers were detected from initial screens (24 invasive) and 335 from subsequent screens (286 invasive), with 95% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 44% of initial and 62% of subsequent screen-detected cancers ≤ 15 mm in diameter. The majority had no nodal involvement (79% initial and 86% subsequent).

Among BSC women diagnosed with invasive cancer ≤ 20 mm over the 4 years to 31 December 2020, 90% had breast conserving surgery. Among women who had invasive cancer and breast conserving surgery, 94% had radiotherapy (on target). Sentinel node biopsy was the first axillary procedure for 90% (of those with breast cancers ≤ 30 mm). Nearly all women with DCIS ≤ 20 mm had breast conserving surgery (94%). 54% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

Among Māori women aged 45–69 years, BSC detected 7 breast cancers (all invasive) from initial screens and 40 (38 invasive) from subsequent screens. There were no significant differences between rates of breast cancer between Māori and non-Māori women. The proportions of small and node-negative cancers were similar in both groups. Treatment indicators were similar for Māori and non-Māori women.

BSC detected 9 breast cancers (7 invasive) from initial screens among Pacific women aged 45–69 years and 21 cancers (17 invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving, cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of invasive cancers detected by BSC were small and more than four-fifths had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single excisional procedure. These indicators show BSC is making a positive difference to breast cancer mortality and morbidity in their region.

BSC achieved most targets relevant to harm minimisation. False positive rates were on target; almost all women had a definitive diagnosis without undergoing open surgery; almost all had a timely needle biopsy; the benign biopsy rate was low and most benign biopsies weighed < 30 gm (85 %). The technical recall rate for fixed sites (0.7%) was outside the $< 0.5\%$ target range but on target for mobile sites.

The next section relates to the BSC overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSC area were within the target range. BSC is doing particularly well for Māori women in the areas of coverage and rescreening, screening and assessment quality, breast cancer detection, treatment, and most timeliness indicators. For a few indicators, results were outside the recommended target range for Māori women. Of note:

- Coverage
 - Māori women's coverage remained close to the 70% target. After the pandemic started, equitable rates were achieved in the first 6 months of 2020 as non-Māori rates decreased with the lockdowns. However, during the 12 months to 30 June 2021, non-Māori coverage increased to 74% while Māori coverage while Māori coverage remained at 67%. By contrast, rescreening rates after initial or subsequent screens remained relatively steady for Māori women with the targets achieved or within the confidence interval, while non-Māori rates decreased to below the target levels.
- Timeliness
 - The proportion who received their screening results within 10 working days decreased after the start of the pandemic then increased again to 87% by 30 June 2021.
 - First surgical treatment within 31 calendar days, women screened during the 4 years to December 2020. This indicator decreased during the biennium from around 70% at the start of the pandemic to 49%.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSC area were within the target range, although for many indicators there is a large degree of uncertainty due to the small numbers of women. BSC is doing particularly well for Pacific women in the areas of coverage, screening and assessment, breast cancer detection and treatment.

In a few instances, BSC did not meet the recommended targets for Pacific women in the specific areas of:

- Coverage
 - Overall coverage of eligible Pacific women aged 50–69 years remained stable at 65% despite COVID restrictions. However, the target for rescreen rates after initial screens was within the confidence interval (72%), and the rescreen rate after subsequent screens was on target at 86%.

Other indicators which could be considered by BSC for Pacific women include:

- Screening
 - The proportion who had four or fewer images taken was outside the target range at 72% for both fixed and mobile sites.
- Timeliness
 - Similar to total women, compared to the previous biennium, the proportion of women notified of their screening results within 10 working days dropped below target to 86%, possibly impacted by COVID. However, the proportion offered an assessment within 15 working days of their screen increased to 94%, indicating positive screen results were likely reported promptly.
 - The proportion of women who received their final biopsy results within 5 working days decreased slightly to 74%.
 - Among women screened during the 4 years to December 2020, 39% (12 of 31) had their first treatment surgery within 31 calendar days of their final diagnosis.

All women aged 50–69 years

Most indicators for women of all ethnicities aged 50–69 years in the BSC area were within the target ranges. BSC is doing well in most indicators in the areas of coverage, screening and assessment, breast cancer detection, and treatment. Timeliness indicators appear to have been impacted by COVID. Of note:

- Coverage
 - Overall coverage was within the target range at 73% showing a steady increase after the initial pandemic lockdown period. Rescreen rates after initial screens decreased to 67% and to 77% after subsequent screens.
- Timeliness
 - The proportion notified of their screening results within 10 working days was just under target at 87%, but the proportion offered their first assessment appointment within 15 working days was on target at 91%.
 - The proportion of women having an open biopsy procedure within 20 working days was 35% (14 of 40 women).
 - The percentage notified of their final biopsy results within 5 working days was on target prior to COVID but decreased to 84% by the end of this reporting period.
 - First surgical treatment within 31 calendar days, women screened during the 4 years to December 2020. This indicator decreased to 54%, suggesting possible impact of COVID restrictions.

Focus on Equity

BSC achieved equitable coverage in the previous biennium for Māori, Pacific and non-Māori non-Pacific women aged 50–69 years, indicating effective prioritisation strategies. In the last year of this reporting period, Māori and Pacific women's coverage increased to reach the target but then declined to pre-pandemic levels (67% and 65% respectively), while non-Māori non-Pacific coverage continued to increase to pre-pandemic levels (75%). For women aged 45–49 years coverage of Māori and non-Māori women remained the same (54% each) while Pacific coverage stayed at 49%. Detection rates of small and node negative cancers were within the target ranges and similar for Māori, Pacific and other women. This indicates BSC is contributing to equitable breast cancer outcomes.

BreastScreen South Limited (BSSL) Overview

Figure 23: BSSL Overview, Māori women aged 50 to 69 years




Figure 24: BSSL Overview, Pacific women aged 50 to 69 years





Figure 25: BSSL Overview, Total women aged 50 to 69 years



BreastScreen South Limited (BSSL)

During the two years to 30 June 2021 BSSL screened 96,582 women aged 45–69 years (72% of the eligible population), including 5,809 Māori (67%) and 1,074 Pacific women (61%). Overall, 68 breast cancers were detected from initial screens (42 invasive) and 482 from subsequent screens (357 invasive), with 95% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met or within the confidence interval in both age groups, with 62% of initial and 66% of subsequent screen-detected cancers $\leq 15\text{mm}$ in diameter. The majority had no nodal involvement (69% initial and 83% subsequent).

Among BSSL women diagnosed with invasive cancer $\leq 20\text{mm}$ over the 4 years to 31 December 2020, 85% had breast conserving surgery. Of those who had breast conserving surgery for invasive cancer, 92% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 84% (with breast cancers $\leq 30\text{mm}$). Most women with DCIS $\leq 20\text{mm}$ had breast conserving surgery (92%). 49% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results (target 90%).

Among Māori women aged 45–69 years, BSSL detected 4 breast cancers (1 invasive) from initial screens and 40 (36 invasive) from subsequent screens. Invasive breast cancer detection rates and the proportions of small and node-negative cancers were similar for Māori and non-Māori women. Treatment indicators were also comparable.

BSSL detected 1 breast cancer (both invasive) from initial screens among Pacific women aged 45–69 years and 7 cancers (3 invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability and reduce risk of dying from breast cancer. Two-thirds of invasive breast cancers detected by BSSL were small and over four-fifths had no nodal involvement. Most women were treated with breast conserving surgery (89%) and most only underwent a single excisional procedure. These indicators show BSSL is making a positive difference to breast cancer mortality and morbidity in their region.

BSSL achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive diagnosis without undergoing open surgery; the benign biopsy rates were within the target range, as was the proportion of benign open biopsies weighing $< 30\text{g}$. The proportion of women receiving their final diagnostic biopsy results within 5 working days was under target at 82%.

The next section relates to the BSSL overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSSL area were within the target range. BSSL is doing particularly well for Māori women in the areas of coverage, screening and assessment, breast cancer detection, treatment and timeliness, other than in some specific indicators. No cancers were detected from initial screens among Māori in this age group.

- Coverage:
 - Overall coverage was just below the target range at 68%, highest coverage for Māori of all LPs but lower than non-Māori coverage which recovered after the initial impact of COVID to reach 75%.
 - Routine rescreening (initial). Although BSSL met the target of $\geq 75\%$ rescreened within 27 months of an initial screen for women aged 45–49 years at 80% (higher than non-Māori), the target was not met for Māori women aged 50–69 years at 57% (similar to non-Māori). The target was met for rescreens after a subsequent screen (87%) for both age groups with Māori higher than non-Māori, showing prioritisation was effective.
- Timeliness
 - First surgical treatment within 31 calendar days of final diagnostic results, women screened during the 4 years to December 2020. This indicator was 51% (but 73% for women aged 45–49 years).

Pacific women aged 50–69 years

Most indicators for Pacific women aged 50–69 years in the BSSL area were within the target range, although for many indicators there is a large degree of uncertainty due to small numbers. BSSL is doing particularly well for Pacific women in the areas of timely rescreening, screening and assessment quality, breast cancer detection and treatment, and timeliness.

- Coverage
 - Overall coverage remained steady at 59% (target $\geq 70\%$).
 - Rates of routine rescreening after initial screens (65%) and subsequent screens (83%) increased during this biennium and the targets were within the confidence intervals.

Another indicator which may require consideration for Pacific women includes:

- Screening
 - Screening image usage showed a small increase to 75% for mobile and fixed units (target $> 80\%$).

All women aged 50–69 years

Most indicators for women of all ethnicities aged 50–69 years in the BSSL area were within the target range. BSSL is doing well in each of the areas of coverage, screening and assessment, breast cancer detection, and treatment. Some timeliness indicators may have been affected by COVID. A few indicators were not in the target range, including:

- Coverage
 - Routine rescreening (initial). This reporting period showed a marked decline in this indicator to 66% rescreened within 27 months of an initial screen. A similar decline was seen for rescreening after subsequent screens (from 85% to 74%), indicating possible impact of COVID restrictions.
- Timeliness
 - The proportion offered their first assessment within 15 working days decreased to just below target at 86%.
 - Final biopsy results reported within 5 working days. This indicator declined from 86% to 81%.
 - First surgical treatment, women screened during the 4 years to December 2020. This indicator decreased slightly from 53% to 50%.

Focus on Equity

BSSL achieved higher rates of rescreens within 27 months for Māori and Pacific women aged 45–69 years and similar rates to non-Māori of small and node negative cancers detected from subsequent screens. This indicates BSSL is contributing to equitable breast cancer outcomes among women screened.

A challenge for BSSL is to achieve equity in biennial screening coverage of the eligible population. After showing movement towards equity in coverage the previous biennium, differences between the coverage of Māori, Pacific and non-Māori women aged 45–69 years returned to pre-pandemic levels, with non-Māori non-Pacific coverage at 76%, Māori at 67% and Pacific coverage at 60%.

BreastScreen Otago Southland (BSOS) Overview

Figure 26:BSOS Overview, Māori women aged 50 to 69 years




Figure 27: BSOS Overview, Pacific women aged 50 to 69 years





Figure 28: BSOS Overview, Total women aged 50 to 69 years



BreastScreen Otago Southland (BSOS)

During the two years to 30 June 2021 BSOS screened 37,414 women aged 45–69 years (66% of the eligible population), 2031 more than the previous biennium. These included 2,512 Māori (63% coverage) and 374 Pacific women (56% coverage). Overall, 27 breast cancers were detected from initial screens (18 invasive) and 210 from subsequent screens (165 invasive), with 97% having a pre-operative diagnosis. Invasive cancer detection rate targets were met, or within the confidence interval, in both age groups, with 69% of initial and 66% of subsequent screen-detected cancers ≤ 15 mm in diameter. The majority had no nodal involvement (67% initial and 80% subsequent).

Among BSOS women diagnosed with invasive cancer ≤ 20 mm over the 4 years to 31 December 2020, 85% had breast conserving surgery (BCS). Of women who had BCS for invasive cancer, 93% had radiotherapy. Sentinel node biopsy was the first axillary procedure for 85% (of those with breast cancers ≤ 30 mm). Most women with DCIS ≤ 20 mm had BCS (85%). 50% had their first treatment surgery within 31 calendar days of receiving their final diagnostic results.

Among Māori women aged 45–69 years, BSOS detected 4 breast cancers (2 invasive) from initial screens and 18 (11 invasive) from subsequent screens. There were no significant differences between Māori and non-Māori women in the proportions of invasive cancers that were small or node-negative cancers. Treatment indicators were also similar.

Among Pacific women aged 45–69 years BSOS detected no breast cancers from initial screens and 4 invasive cancers from subsequent screens. Four-year treatment indicators were similar to those for non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving, cause less long-term illness and disability, and reduce risk of dying from breast cancer. Two-thirds of invasive cancers detected by BSOS were small and three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single excisional procedure. These indicators show BSOS is making a positive difference to breast cancer mortality and morbidity.

BSOS achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; nearly all women had a definitive diagnosis without undergoing open surgery, and almost all had their needle biopsy within 5 days of assessment; the targets were met or within the confidence interval for benign open biopsy rates and open biopsy weight < 30 gm.

The next section relates to the BSOS overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSOS area were within the target range. BSOS is doing particularly well for Māori women in the areas of rescreening rates, screening and assessment, breast cancer detection and treatment. Targets were not met for overall coverage and some timeliness indicators.

- Coverage
 - Overall coverage of eligible women. Māori coverage remained at steady at 65% while non-Māori coverage increased to reach the 70% target. However, rescreen rates after subsequent screens remained in the target range at 87%, and the target was within the confidence interval for rescreening after an initial screen (68%), with both rates higher than those of non-Māori.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. This indicator has declined since the previous biennium to 68%.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator continued to improve to 73%.
 - First surgical treatment within 31 calendar days, women screened during the 4 years to December 2020. Around half of Māori women (46%) received their first treatment surgery within 31 calendar days of receiving their final diagnosis but there are indications of a possible upward trend.

Pacific women aged 50–69 years

Many of the indicators for Pacific women aged 50–69 years in the BSOS area were within the target range, although there is a large degree of uncertainty (as seen in the wide confidence intervals), due to the small numbers of women included in the calculation of some indicators. No breast cancers were detected from initial screens. BSOS is doing particularly well

for Pacific women in the areas of rescreening, screening and assessment, breast cancer detection and treatment, and less well in overall coverage and some timeliness indicators.

- Coverage
 - Coverage increased from 56% to 60% screened in this biennial period.
 - Routine rescreening rates after initial screens increased to 86%, well within the target range of $\geq 75\%$ and rescreens within 27 months of a subsequent screen remained on target at 85%.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. After substantial improvements in this indicator from 2016 to 2018, recent reporting periods have shown a decline followed by a small improvement with 50% (10 of 20 women) offered an assessment within 15 working days.
 - First surgical treatment, women screened during the 4 years to December 2020. Only 7 Pacific women aged 50–69 years had treatment surgery, with 2 receiving their surgery within 31 calendar days of their final diagnosis.

All women aged 50–69 years

Most indicators for total women aged 50–69 years in the BSOS area were within the target range. BSOS is doing particularly well in coverage, screening quality, breast cancer detection and treatment. Some indicators in the areas of coverage, screening and assessment, and timeliness were outside the target ranges.

- Coverage
 - Coverage increased after the initial decline at the start of the COVID pandemic to reach 69%.
 - Routine rescreening within 27 months. This indicator continued to decrease to 48% after initial screens and 57% after subsequent screens, likely affected by COVID. The increase in overall coverage indicates that some women were being rescreened after 27 months.
- Screening and assessment
 - Initial assessment rate. Assessment rates from initial screens have decreased 2018 to 14% (target $< 10\%$), and false positives decreased to 13% (target $< 9\%$), PPV at 7% with the target of $> 9\%$ within the confidence interval, and specificity increased to 86% (target $> 93\%$). These indicators were all within the target ranges for subsequent screens.
- Timeliness
 - The 90% targets were met for screening results within 10 working days, needle biopsies within 5 working days, and open biopsies within 20 working days.
 - Time taken from screening visit to first offer of an assessment. This indicator decreased to 70% offered an assessment in 15 working days.
 - Open biopsies within 31 calendar days of notification: Only 20 women aged 50–69 had an open biopsy over the two years, of whom 6 had their biopsy within 31 calendar days.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator showed a small decrease to 68% receiving their final biopsy results within 5 working days.
 - First surgical treatment, women screened during the 4 years to December 2020. Just over half of BSOS women had their first treatment surgery within 31 calendar days of their final diagnosis.

Focus on Equity

Coverage

The gap in coverage between Māori, Pacific and non-Māori non-Pacific women reduced in the previous biennium but appears to be increasing again. However, rates of timely rescreens decreased for non-Māori non-Pacific women to be below those of Māori and Pacific women whose rates remained steady.

Timeliness

BSOS achieved equity in the proportions of Māori, Pacific and non-Māori non-Pacific receiving their first surgical treatment within 31 calendar days.


Coverage

1.a.1, Overall coverage of eligible women


Description: The number of women screened as a percentage of women eligible.

Target: >70% of eligible women receive a screen within the most recent 24 month period

Figure 29: 1.a.1, Coverage of eligible women, 45 to 49 and 50 to 69 years, total BSA



Women aged 45 to 49 years



Women aged 50 to 69 years

BSA screened 66% of eligible women aged 45–69 years during the two years to 30 June 2021. This period included around 18 months of the COVID pandemic during which breast screening paused nationally at Alert Level 4 (25th March to 27th April 2020) and further national and regional periods of restriction when screening had recommenced but was slowed down due to COVID safety requirements, and workforce shortages. Overall coverage of Māori women aged 45–69 was 59%, lower than that of non-Māori (67%), while Pacific coverage was 64%.

Total coverage was highest in BSSL at 75%, an increase on the previous biennium but lower than pre-pandemic levels. BSCC achieved the 70% target while BSC and BSOS achieved coverage levels almost on target at 69%. Regions more affected by pandemic lockdowns had lower coverage although most were over 60%. BSAL/BSAC had the lowest coverage at 51% but there was a gap in screening provision during the period of transition the two LPs and some delay in the establishment of the mobile service.

Māori coverage was highest in BSSL at 67% and Pacific coverage was highest in BSCM at 71%.

Figure 30: 1.a.1, Coverage of eligible women, 50 to 69, by LP




Table 1: 1.a.1, Coverage of eligible women

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Screened	Eligible Women	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Pacific / Non-Pacific Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)
45 to 49		BSWN	2,482	4,020	61.7 (60.2, 63.2)	1.01 (0.98, 1.03)	845	1,440	58.7 (56.1, 61.2)	0.96 (0.91, 1)	15,092	24,630	61.3 (60.7, 61.9)	14,247	23,190	61.4 (60.8, 62.1)	17,574	28,650	61.3 (60.8, 61.9)
		BSCM	1,685	2,750	61.3 (59.44, 63.08)	0.94 (0.91, 0.97)	2,585	3,770	68.6 (67.1, 70)	1.07 (1.05, 1.1)	10,751	16,550	65.0 (64.2, 65.7)	8,166	12,780	63.9 (63.1, 64.7)	12,436	19,300	64.4 (63.8, 65.1)
		BSAC	742	1,230	60.3 (57.56, 63.02)	1.22 (1.16, 1.28)	892	1,600	55.8 (53.3, 58.2)	1.15 (1.1, 1.2)	7,642	15,480	49.4 (48.6, 50.2)	6,750	13,880	48.6 (47.8, 49.5)	8,384	16,710	50.2 (49.4, 50.9)
		BSM	3,114	6,390	48.7 (47.51, 49.96)	0.79 (0.76, 0.81)	315	610	51.6 (47.7, 55.6)	0.83 (0.77, 0.9)	12,755	20,570	62.0 (61.3, 62.7)	12,440	19,960	62.3 (61.7, 63)	15,869	26,960	58.9 (58.3, 59.4)
		BSCC	2,500	4,780	52.3 (50.88, 53.71)	0.74 (0.72, 0.76)	229	445	51.5 (46.8, 56.1)	0.72 (0.66, 0.79)	10,795	15,295	70.6 (69.9, 71.3)	10,566	14,850	71.2 (70.4, 71.9)	13,295	20,075	66.2 (65.6, 66.9)
		BSC	1,239	2,280	54.3 (52.29, 56.38)	1.01 (0.97, 1.05)	568	1,155	49.2 (46.3, 52.1)	0.91 (0.86, 0.97)	8,977	16,705	53.7 (53, 54.5)	8,409	15,550	54.1 (53.3, 54.9)	10,216	18,985	53.8 (53.1, 54.5)
		BSSL	1,537	2,400	64.0 (62.1, 65.94)	0.82 (0.79, 0.84)	323	530	60.9 (56.7, 65)	0.78 (0.72, 0.83)	20,839	26,640	78.2 (77.7, 78.7)	20,516	26,110	78.6 (78.1, 79.1)	22,376	29,040	77.1 (76.6, 77.5)
		BSOS	592	1,000	59.2 (56.12, 62.21)	0.89 (0.85, 0.94)	96	190	50.5 (43.5, 57.6)	0.76 (0.66, 0.87)	6,789	10,250	66.2 (65.3, 67.1)	6,693	10,060	66.5 (65.6, 67.4)	7,381	11,250	65.6 (64.7, 66.5)
		Total	13,891	24,850	55.9 (55.28, 56.52)	0.87 (0.86, 0.88)	5,853	9,740	60.1 (59.1, 61.1)	0.93 (0.92, 0.95)	93,640	146,120	64.1 (63.8, 64.3)	87,787	136,380	64.4 (64.1, 64.6)	107,531	170,970	62.9 (62.7, 63.1)
		50 to 69		BSWN	7,875	12,420	63.4 (62.55, 64.25)	1.02 (1.01, 1.04)	2,837	4,390	64.6 (63.2, 66)	1.04 (1.02, 1.07)	55,427	89,240	62.1 (61.8, 62.4)	52,590	84,850	62.0 (61.7, 62.3)	63,302
BSCM	4,617			7,870	58.7 (57.57, 59.75)	0.92 (0.9, 0.94)	7,658	10,730	71.4 (70.5, 72.2)	1.15 (1.13, 1.16)	35,641	55,740	63.9 (63.5, 64.3)	27,983	45,010	62.2 (61.7, 62.6)	40,258	63,610	63.3 (62.9, 63.7)
BSAC	1,994			3,740	53.3 (51.71, 54.91)	1.04 (1.01, 1.07)	2,996	5,410	55.4 (54.1, 56.7)	1.09 (1.07, 1.12)	25,490	49,790	51.2 (50.8, 51.6)	22,494	44,380	50.7 (50.2, 51.2)	27,484	53,530	51.3 (50.9, 51.8)
BSM	10,950			19,760	55.4 (54.72, 56.11)	0.85 (0.84, 0.86)	956	1,610	59.4 (57, 61.8)	0.91 (0.87, 0.94)	54,026	82,650	65.4 (65, 65.7)	53,070	81,040	65.5 (65.2, 65.8)	64,976	102,410	63.4 (63.2, 63.7)
BSCC	8,812			14,680	60.0 (59.23, 60.82)	0.82 (0.81, 0.83)	798	1,310	60.9 (58.2, 63.5)	0.83 (0.79, 0.87)	47,158	64,400	73.2 (72.9, 73.6)	46,360	63,090	73.5 (73.1, 73.8)	55,970	79,080	70.8 (70.5, 71.1)
BSC	4,273			6,340	67.4 (66.23, 68.54)	0.91 (0.9, 0.93)	2,251	3,475	64.8 (63.2, 66.3)	0.87 (0.85, 0.89)	41,859	56,605	73.9 (73.6, 74.3)	39,608	53,130	74.5 (74.2, 74.9)	46,132	62,945	73.3 (72.9, 73.6)
BSSL	4,608			6,810	67.7 (66.54, 68.77)	0.90 (0.88, 0.91)	857	1,445	59.3 (56.8, 61.8)	0.78 (0.75, 0.82)	75,779	100,385	75.5 (75.2, 75.8)	74,922	98,940	75.7 (75.5, 76)	80,387	107,195	75.0 (74.7, 75.2)
BSOS	1,920			2,970	64.6 (62.91, 66.35)	0.93 (0.9, 0.95)	278	460	60.4 (55.9, 64.8)	0.87 (0.8, 0.93)	28,113	40,360	69.7 (69.2, 70.1)	27,835	39,900	69.8 (69.3, 70.2)	30,033	43,330	69.3 (68.9, 69.7)
Total	45,049			74,590	60.4 (60.04, 60.75)	0.90 (0.89, 0.9)	18,631	28,830	64.6 (64.1, 65.2)	0.96 (0.95, 0.96)	363,493	539,170	67.4 (67.3, 67.5)	344,862	510,340	67.6 (67.4, 67.7)	408,542	613,760	66.6 (66.4, 66.7)
45 to 69				BSWN	10,357	16,440	63.0 (62.26, 63.73)	1.02 (1, 1.03)	3,682	5,830	63.2 (61.9, 64.4)	1.02 (1, 1.04)	70,519	113,870	61.9 (61.6, 62.2)	66,837	108,040	61.9 (61.6, 62.2)	80,876
		BSCM	6,302	10,620	59.3 (58.4, 60.27)	0.92 (0.91, 0.94)	10,243	14,500	70.6 (69.9, 71.4)	1.13 (1.12, 1.14)	46,392	72,290	64.2 (63.8, 64.5)	36,149	57,790	62.6 (62.2, 62.9)	52,694	82,910	63.6 (63.2, 63.9)
		BSAC	2,736	4,970	55.1 (53.66, 56.43)	1.08 (1.06, 1.11)	3,888	7,010	55.5 (54.3, 56.6)	1.10 (1.08, 1.13)	33,132	65,270	50.8 (50.4, 51.1)	29,244	58,260	50.2 (49.8, 50.6)	35,868	70,240	51.1 (50.7, 51.4)
		BSM	14,064	26,150	53.8 (53.18, 54.39)	0.83 (0.82, 0.84)	1,271	2,220	57.3 (55.2, 59.3)	0.88 (0.85, 0.92)	66,781	103,220	64.7 (64.4, 65)	65,510	101,000	64.9 (64.6, 65.2)	80,845	129,370	62.5 (62.2, 62.8)
		BSCC	11,312	19,460	58.1 (57.43, 58.82)	0.80 (0.79, 0.81)	1,027	1,755	58.5 (56.2, 60.8)	0.80 (0.77, 0.83)	57,953	79,695	72.7 (72.4, 73)	56,926	77,940	73.0 (72.7, 73.3)	69,265	99,155	69.9 (69.6, 70.1)
		BSC	5,512	8,620	63.9 (62.92, 64.95)	0.92 (0.91, 0.94)	2,819	4,630	60.9 (59.5, 62.3)	0.87 (0.85, 0.89)	50,836	73,310	69.3 (69, 69.7)	48,017	68,680	69.9 (69.6, 70.3)	56,348	81,930	68.8 (68.5, 69.1)
		BSSL	6,145	9,210	66.7 (65.75, 67.68)	0.88 (0.86, 0.89)	1,180	1,975	59.7 (57.6, 61.9)	0.78 (0.76, 0.81)	96,618	127,025	76.1 (75.8, 76.3)	95,438	125,050	76.3 (76.1, 76.6)	102,763	136,235	75.4 (75.2, 75.7)
		BSOS	2,512	3,970	63.3 (61.76, 64.76)	0.92 (0.9, 0.94)	374	650	57.5 (53.7, 61.3)	0.83 (0.78, 0.89)	34,902	50,610	69.0 (68.6, 69.4)	34,528	49,960	69.1 (68.7, 69.5)	37,414	54,580	68.5 (68.2, 68.9)
		Total	58,940	99,440	59.3 (58.97, 59.58)	0.89 (0.88, 0.89)	24,484	38,570	63.5 (63, 64)	0.95 (0.94, 0.96)	457,133	685,290	66.7 (66.6, 66.8)	432,649	646,720	66.9 (66.8, 67)	516,073	784,730	65.8 (65.7, 65.9)



1.a.2, Percentage of screens that are initial or subsequent

Description: The number of women who had an initial/subsequent as a percentage of the number of women screened.



Target: No target

Figure 31: 1.a.2, Initial and subsequent screen proportions, 45-49 and 50 to 69

45–49 years



50–69 years



Among women aged 45–49 years, 41% of screens were initial, compared to only 3% of those aged 50–69 years. Overall, 11% of BSA screens were initial.

Figure 32:1.a.2, Initial screen proportions, 50 to 69, by LP




Figure 33: 1.a.2, Subsequent screen proportions, 50 to 69, by LP




Table 2: 1.a.2, Initial and subsequent screen proportions


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Women Screened by Type	Women Screened	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened by Type	Women Screened	% Screened (95% CI)	Pacific / Non-Pacific Ratio	Women Screened by Type	Women Screened	% Screened (95% CI)	Women Screened by Type	Women Screened	% Screened (95% CI)	Women Screened by Type	Women Screened	% Screened (95% CI)	
45 to 49	Initial	BSWN	1,149	2,482	46.3 (44.3, 48.3)	1.02 (0.97, 1.06)	395	845	46.7 (43.3, 50.2)	1.03 (0.95, 1.10)	6,884	15,092	45.6 (44.8, 46.4)	6,489	14,247	45.5 (44.7, 46.4)	8,033	17,574	45.7 (45.0, 46.4)
		BSCM	720	1,685	42.7 (40.4, 45.1)	1.02 (0.96, 1.08)	1,232	2,585	47.7 (45.7, 49.6)	1.19 (1.13, 1.25)	4,509	10,751	41.9 (41.0, 42.9)	3,277	8,166	40.1 (39.1, 41.2)	5,229	12,436	42.0 (41.2, 42.9)
		BSAC	364	742	49.1 (45.4, 52.7)	1.11 (1.03, 1.20)	372	892	41.7 (38.4, 45.0)	0.94 (0.87, 1.02)	3,368	7,642	44.1 (43.0, 45.2)	2,996	6,750	44.4 (43.2, 45.6)	3,732	8,384	44.5 (43.4, 45.6)
		BSM	1,356	3,114	43.5 (41.8, 45.3)	1.05 (1.00, 1.09)	141	315	44.8 (39.2, 50.4)	1.08 (0.95, 1.22)	5,305	12,755	41.6 (40.7, 42.5)	5,164	12,440	41.5 (40.6, 42.4)	6,661	15,869	42.0 (41.2, 42.7)
		BSCC	1,015	2,500	40.6 (38.7, 42.6)	1.07 (1.02, 1.13)	102	229	44.5 (38.0, 51.2)	1.18 (1.02, 1.37)	4,086	10,795	37.9 (36.9, 38.8)	3,984	10,566	37.7 (36.8, 38.6)	5,101	13,295	38.4 (37.5, 39.2)
		BSC	508	1,239	41.0 (38.2, 43.8)	1.32 (1.23, 1.43)	232	568	40.8 (36.8, 45.0)	1.35 (1.22, 1.50)	2,779	8,977	31.0 (30.0, 31.9)	2,547	8,409	30.3 (29.3, 31.3)	3,287	10,216	32.2 (31.3, 33.1)
		BSSL	599	1,537	39.0 (36.5, 41.5)	0.97 (0.91, 1.04)	156	323	48.3 (42.7, 53.9)	1.21 (1.08, 1.35)	8,353	20,839	40.1 (39.4, 40.8)	8,197	20,516	40.0 (39.3, 40.6)	8,952	22,376	40.0 (39.4, 40.7)
		BSOS	221	593	37.3 (33.4, 41.3)	0.89 (0.80, 0.99)	46	96	47.9 (37.6, 58.4)	1.14 (0.93, 1.41)	2,856	6,797	42.0 (40.8, 43.2)	2,810	6,701	41.9 (40.7, 43.1)	3,077	7,390	41.6 (40.5, 42.8)
		Total	5,932	13,892	42.7 (41.9, 43.5)	1.05 (1.03, 1.07)	2,676	5,853	45.7 (44.4, 47.0)	1.13 (1.10, 1.17)	38,140	93,648	40.7 (40.4, 41.0)	35,464	87,795	40.4 (40.1, 40.7)	44,072	107,540	41.0 (40.7, 41.3)
		Subsequent	BSWN	1,333	2,482	53.7 (51.7, 55.7)	0.99 (0.95, 1.03)	450	845	53.3 (49.8, 56.7)	0.98 (0.92, 1.04)	8,208	15,092	54.4 (53.6, 55.2)	7,758	14,247	54.5 (53.6, 55.3)	9,541	17,574
	BSCM		965	1,685	57.3 (54.9, 59.6)	0.99 (0.94, 1.03)	1,353	2,585	52.3 (50.4, 54.3)	0.87 (0.84, 0.91)	6,242	10,751	58.1 (57.1, 59.0)	4,889	8,166	59.9 (58.8, 60.9)	7,207	12,436	58.0 (57.1, 58.8)
	BSAC		378	742	50.9 (47.3, 54.6)	0.91 (0.85, 0.98)	520	892	58.3 (55.0, 61.6)	1.05 (0.99, 1.11)	4,274	7,642	55.9 (54.8, 57.0)	3,754	6,750	55.6 (54.4, 56.8)	4,652	8,384	55.5 (54.4, 56.6)
	BSM		1,758	3,114	56.5 (54.7, 58.2)	0.97 (0.93, 1.00)	174	315	55.2 (49.6, 60.8)	0.94 (0.85, 1.04)	7,450	12,755	58.4 (57.5, 59.3)	7,276	12,440	58.5 (57.6, 59.4)	9,208	15,869	58.0 (57.3, 58.8)
	BSCC		1,485	2,500	59.4 (57.4, 61.3)	0.96 (0.92, 0.99)	127	229	55.5 (48.8, 62.0)	0.89 (0.79, 1.00)	6,709	10,795	62.1 (61.2, 63.1)	6,582	10,566	62.3 (61.4, 63.2)	8,194	13,295	61.6 (60.8, 62.5)
	BSC		731	1,239	59.0 (56.2, 61.8)	0.86 (0.81, 0.90)	336	568	59.2 (55.0, 63.2)	0.85 (0.79, 0.91)	6,198	8,977	69.0 (68.1, 70.0)	5,862	8,409	69.7 (68.7, 70.7)	6,929	10,216	67.8 (66.9, 68.7)
	BSSL		938	1,537	61.0 (58.5, 63.5)	1.02 (0.98, 1.06)	167	323	51.7 (46.1, 57.3)	0.86 (0.77, 0.96)	12,846	20,839	59.9 (59.2, 60.6)	12,319	20,516	60.0 (59.4, 60.7)	13,424	22,376	60.0 (59.3, 60.6)
	BSOS		372	593	62.7 (58.7, 66.6)	1.08 (1.01, 1.16)	50	96	52.1 (41.6, 62.4)	0.90 (0.74, 1.09)	3,941	6,797	58.0 (56.8, 59.2)	3,891	6,701	58.1 (56.9, 59.3)	4,313	7,390	58.4 (57.2, 59.5)
	Total		7,960	13,892	57.3 (56.5, 58.1)	0.97 (0.95, 0.98)	3,177	5,853	54.3 (53.0, 55.6)	0.91 (0.89, 0.93)	55,508	93,648	59.3 (59.0, 59.6)	52,331	87,795	59.6 (59.3, 59.9)	63,468	107,540	59.0 (58.7, 59.3)
	50 to 69		Initial	BSWN	285	7,875	3.6 (3.2, 4.1)	0.91 (0.81, 1.03)	96	2,837	3.4 (2.7, 4.1)	0.84 (0.69, 1.03)	2,206	55,427	4.0 (3.8, 4.1)	2,110	52,590	4.0 (3.8, 4.2)	2,491
BSCM		165		4,617	3.6 (3.1, 4.2)	1.08 (0.92, 1.27)	259	7,658	3.4 (3.0, 3.8)	1.03 (0.90, 1.18)	1,177	35,641	3.3 (3.1, 3.5)	918	27,983	3.3 (3.1, 3.5)	1,342	40,258	3.3 (3.2, 3.5)
BSAC		110		1,994	5.5 (4.6, 6.6)	1.20 (0.99, 1.45)	99	2,996	3.3 (2.7, 4.0)	0.69 (0.56, 0.85)	1,173	25,490	4.6 (4.3, 4.9)	1,074	22,494	4.8 (4.5, 5.1)	1,283	27,484	4.7 (4.4, 4.9)
BSM		477		10,950	4.4 (4.0, 4.8)	1.49 (1.35, 1.65)	38	956	4.0 (2.8, 5.4)	1.37 (1.00, 1.88)	1,576	54,026	2.9 (2.8, 3.1)	1,538	53,070	2.9 (2.8, 3.0)	2,053	64,976	3.2 (3.0, 3.3)
BSCC		355		8,812	4.0 (3.6, 4.5)	1.57 (1.40, 1.76)	31	798	3.9 (2.7, 5.5)	1.53 (1.08, 2.17)	1,209	47,158	2.6 (2.4, 2.7)	1,178	46,360	2.5 (2.4, 2.7)	1,564	55,970	2.8 (2.7, 2.9)
BSC		135		4,273	3.2 (2.7, 3.7)	1.51 (1.26, 1.80)	96	2,251	4.3 (3.5, 5.2)	2.17 (1.76, 2.67)	876	41,859	2.1 (2.0, 2.2)	780	39,608	2.0 (1.8, 2.1)	1,011	46,132	2.2 (2.1, 2.3)
BSSL		120		4,608	2.6 (2.2, 3.1)	1.20 (1.00, 1.44)	42	857	4.9 (3.6, 6.6)	2.29 (1.70, 3.08)	1,647	75,779	2.2 (2.1, 2.3)	1,605	74,922	2.1 (2.0, 2.2)	1,767	80,387	2.2 (2.1, 2.3)
BSOS		44		1,922	2.3 (1.7, 3.1)	1.02 (0.75, 1.37)	18	279	6.5 (3.9, 10.0)	2.91 (1.85, 4.59)	635	28,144	2.3 (2.1, 2.4)	617	27,865	2.2 (2.0, 2.4)	679	30,066	2.3 (2.1, 2.4)
Total		1,691		45,051	3.8 (3.6, 3.9)	1.30 (1.24, 1.37)	679	18,632	3.6 (3.4, 3.9)	1.28 (1.19, 1.38)	10,499	363,524	2.9 (2.8, 2.9)	9,820	344,892	2.8 (2.8, 2.9)	12,190	408,575	3.0 (2.9, 3.0)
Subsequent		BSWN		7,590	7,875	96.4 (95.9, 96.8)	1.00 (1.00, 1.01)	2,741	2,837	96.6 (95.9, 97.3)	1.01 (1.00, 1.01)	53,221	55,427	96.0 (95.9, 96.2)	50,480	52,590	96.0 (95.8, 96.2)	60,811	63,302
		BSCM	4,452	4,617	96.4 (95.8, 96.9)	1.00 (0.99, 1.00)	7,399	7,658	96.6 (96.2, 97.0)	1.00 (0.99, 1.00)	34,464	35,641	96.7 (96.5, 96.9)	27,065	27,983	96.7 (96.5, 96.9)	38,916	40,258	96.7 (96.5, 96.8)
		BSAC	1,884	1,994	94.5 (93.4, 95.4)	0.99 (0.98, 1.00)	2,897	2,996	96.7 (96.0, 97.3)	1.02 (1.01, 1.02)	24,317	25,490	95.4 (95.1, 95.7)	21,420	22,494	95.2 (94.9, 95.5)	26,201	27,484	95.3 (95.1, 95.6)
		BSM	10,473	10,950	95.6 (95.2, 96.0)	0.99 (0.98, 0.99)	918	956	96.0 (94.6, 97.2)	0.99 (0.98, 1.00)	52,450	54,026	97.1 (96.9, 97.2)	51,532	53,070	97.1 (97.0, 97.2)	62,923	64,976	96.8 (96.7, 97.0)
		BSCC	8,457	8,812	96.0 (95.5, 96.4)	0.99 (0.98, 0.99)	767	798	96.1 (94.5, 97.3)	0.99 (0.97, 1.00)	45,949	47,158	97.4 (97.3, 97.6)	45,182	46,360	97.5 (97.3, 97.6)	54,406	55,970	97.2 (97.1, 97.3)
		BSC	4,138	4,273	96.8 (96.3, 97.3)	0.99 (0.98, 0.99)	2,155	2,251	95.7 (94.8, 96.5)	0.98 (0.97, 0.98)	40,983	41,859	97.9 (97.8, 98.0)	38,828	39,608	98.0 (97.9, 98.2)	45,121	46,132	97.8 (97.7, 97.9)
		BSSL	4,488	4,608	97.4 (96.9, 97.8)	1.00 (0.99, 1.00)	815	857	95.1 (93.4, 96.4)	0.97 (0.96, 0.99)	74,132	75,779	97.8 (97.7, 97.9)	73,317	74,922	97.9 (97.8, 98.0)	78,620	80,387	97.8 (97.7, 97.9)
		BSOS	1,878	1,922	97.7 (96.9, 98.3)	1.00 (0.99, 1.01)	261	279	93.5 (90.0, 96.1)	0.96 (0.93, 0.99)	27,509	28,144	97.7 (97.6, 97.9)	27,248	27,865	97.8 (97.6, 98.0)	29,387	30,066	97.7 (97.6, 97.9)
		Total	43,360	45,051	96.2 (96.1, 96.4)	0.99 (0.99, 0.99)	17,953	18,632	96.4 (96.1, 96.6)	0.99 (0.99, 0.99)	353,025	363,524	97.1 (97.1, 97.2)	335,072	344,892	97.2 (97.1, 97.2)	396,385	408,575	97.0 (97.0, 97.1)
		45 to 69	Initial	BSWN	1,434	10,357	13.8 (13.2, 14.5)	1.07 (1.02, 1.13)	491	3,682	13.3 (12.3, 14.5)	1.04 (0.95, 1.13)	9,090	70,519	12.9 (12.6, 13.1)	8,599	66,837	12.9 (12.6, 13.1)	10,524
BSCM	885			6,302	14.0 (13.2, 14.9)	1.15 (1.07, 1.22)	1,491	10,243	14.6 (13.9, 15.3)	1.25 (1.19, 1.32)	5,686	46,392	12.3 (12.0, 12.6)	4,195	36,149	11.6 (11.3, 11.9)	6,571	52,694	12.5 (12.2, 12.8)
BSAC	474			2,736	17.3 (15.9, 18.8)	1.26 (1.16, 1.38)	471	3,888	12.1 (11.1, 13.2)	0.87 (0.80, 0.95)	4,541	33,132	13.7 (13.3, 14.1)	4,070	29,244	13.9 (13.5, 14.3)	5,015	35,868	14.0 (13.6, 14.3)
BSM	1,833			14,064	13.0 (12.5, 13.6)	1.27 (1.21, 1.33)	179	1,271	14.1 (12.2, 16.1)	1.38 (1.20, 1.58)	6,881	66,781	10.3 (10.1, 10.5)	6,702	65,510	10.2 (10.0, 10.5)	8,714	80,845	10.8 (10.6, 11.0)
BSCC	1,370			11,312	12.1 (11.5, 12.7)	1.33 (1.25, 1.40)	133	1,027	13.0 (11.0, 15.2)	1.43 (1.22, 1.68)	5,295	57,953	9.1 (8.9, 9.4)	5,162	56,926	9.1 (8.8, 9.4)	6,665	69,265	9.6 (9.4, 9.8)
BSC	643			5,512	11.7 (10.8, 12.5)	1.62 (1.50, 1.76)	328	2,819	11.6 (10.5, 12.9)	1.68 (1.51, 1.87)	3,655	50,836	7.2 (7.0, 7.4)	3,327	48,017	6.9 (6.7, 7.2)	4,298	56,348	7.6 (7.4, 7.8)
BSSL	719			6,145	11.7 (10.9, 12.5)	1.13 (1.05, 1.21)	198	1,180	16.8 (14.7, 19.0)	1.63 (1.44, 1.86)	10,000	96,618	10.4 (10.2, 10.5)	9,802	95,438	10.3 (10.1, 10.5)	10,719	102,763	10.4 (10.2, 10.6)
BSOS	265			2,515	10.5 (9.4, 11.8)	1.06 (0.94, 1.19)	64	375	17.										

1.a.3, Screening unit type

Description: The number of women who had a screen at a fixed/mobile site as a percentage of the number of women screened.

Target: No target

Figure 34: 1.a.3, Percentage screened at fixed and mobile units, 50 to 69, total BSA



Just over three-quarters of women screened by BSA were screened at a fixed unit (77%), and just over a fifth were screened at a mobile unit (22%).

Māori women (28%) were a third more likely than non-Māori women (22%) to be screened at a mobile unit, and Pacific women (24%) were 12% more likely than non-Māori non-Pacific women (21%).

Figure 35: 1.a.3, Percentage screened at fixed units, 50 to 69, by LP




Figure 36: 1.a.3, Percentage screened at mobile units, 50 to 69, by LP








Table 3: 1.a.3, Percentages screened at fixed and mobile units

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Screened at Unit	Women Screened	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened at Unit	Women Screened	% Screened (95% CI)	Pacific / Non-Pacific Ratio	Women Screened at Unit	Women Screened	% Screened (95% CI)	Women Screened at Unit	Women Screened	% Screened (95% CI)	Women Screened at Unit	Women Screened	% Screened (95% CI)
45 to 49	Fixed	BSWN	1,612	2,482	64.9 (63.0, 66.8)	0.82 (0.79, 0.84)	756	845	89.5 (87.2, 91.5)	1.14 (1.11, 1.16)	11,990	15,092	79.4 (78.8, 80.1)	11,234	14,247	78.9 (78.2, 79.5)	13,602	17,574	77.4 (76.8, 78.0)
		BSCM	1,342	1,685	79.6 (77.6, 81.5)	1.01 (0.98, 1.04)	2,123	2,585	82.1 (80.6, 83.6)	1.05 (1.03, 1.08)	8,484	10,751	78.9 (78.1, 79.7)	6,361	8,166	77.9 (77.0, 78.8)	9,826	12,436	79.0 (78.3, 79.7)
		BSAC	579	742	78.0 (74.9, 81.0)	0.98 (0.94, 1.02)	580	892	65.0 (61.8, 68.2)	0.79 (0.76, 0.83)	6,107	7,642	79.9 (79.0, 80.8)	5,527	6,750	81.9 (80.9, 82.8)	6,686	8,384	79.7 (78.9, 80.6)
		BSM	2,339	3,114	75.1 (73.6, 76.6)	0.90 (0.89, 0.92)	243	315	77.1 (72.1, 81.7)	0.93 (0.87, 0.98)	10,599	12,755	83.1 (82.4, 83.7)	10,356	12,440	83.2 (82.6, 83.9)	12,938	15,869	81.5 (80.9, 82.1)
		BSCC	1,925	2,500	77.0 (75.3, 78.6)	0.88 (0.86, 0.90)	184	229	80.3 (74.6, 85.3)	0.92 (0.86, 0.98)	9,401	10,795	87.1 (86.4, 87.7)	9,217	10,566	87.2 (86.6, 87.9)	11,326	13,295	85.2 (84.6, 85.8)
		BSC	745	1,239	60.1 (57.3, 62.9)	1.04 (0.99, 1.09)	266	568	46.8 (42.7, 51.0)	0.80 (0.73, 0.87)	5,205	8,977	58.0 (57.0, 59.0)	4,939	8,409	58.7 (57.7, 59.8)	5,950	10,216	58.2 (57.3, 59.2)
		BSSL	1,384	1,537	90.0 (88.4, 91.5)	0.97 (0.95, 0.98)	276	323	85.4 (81.1, 89.1)	0.91 (0.87, 0.96)	19,449	20,839	93.3 (93.0, 93.7)	19,173	20,516	93.5 (93.1, 93.8)	20,833	22,376	93.1 (92.8, 93.4)
		BSOS	521	593	87.9 (85.0, 90.4)	1.05 (1.02, 1.09)	89	96	92.7 (85.6, 97.0)	1.11 (1.05, 1.18)	5,673	6,797	83.5 (82.6, 84.3)	5,584	6,701	83.3 (82.4, 84.2)	6,194	7,390	83.8 (83.0, 84.6)
		Total	10,447	13,892	75.2 (74.5, 75.9)	0.92 (0.91, 0.93)	4,517	5,853	72.7 (76.1, 78.2)	0.94 (0.92, 0.95)	76,908	93,648	82.1 (81.6, 82.4)	72,391	87,795	82.5 (82.2, 82.7)	87,355	107,540	81.2 (81.0, 81.5)
		Mobile	BSWN	870	2,482	35.1 (33.2, 37.0)	1.71 (1.60, 1.81)	89	845	10.5 (8.5, 12.8)	0.50 (0.41, 0.61)	3,102	15,092	20.6 (19.9, 21.2)	3,013	14,247	21.1 (20.5, 21.8)	3,972	17,574
	BSCM		343	1,685	20.4 (18.5, 22.4)	0.97 (0.87, 1.07)	462	2,585	17.9 (16.4, 19.4)	0.81 (0.74, 0.89)	2,267	10,751	21.1 (20.3, 21.9)	1,805	8,166	22.1 (21.2, 23.0)	2,610	12,436	21.0 (20.3, 21.7)
	BSAC		163	742	22.0 (19.0, 25.1)	1.09 (0.95, 1.26)	312	892	35.0 (31.8, 38.2)	1.93 (1.74, 2.14)	1,535	7,642	20.1 (19.2, 21.0)	1,223	6,750	18.1 (17.2, 19.1)	1,698	8,384	20.3 (19.4, 21.1)
	BSM		775	3,114	24.9 (23.4, 26.4)	1.47 (1.37, 1.58)	72	315	22.9 (18.3, 27.9)	1.36 (1.11, 1.68)	2,156	12,755	16.9 (16.3, 17.6)	2,084	12,440	16.8 (16.1, 17.4)	2,931	15,869	18.5 (17.9, 19.1)
	BSCC		575	2,500	23.0 (21.4, 24.7)	1.78 (1.63, 1.94)	45	229	19.7 (14.7, 25.4)	1.54 (1.18, 2.01)	1,394	10,795	12.9 (12.3, 13.6)	1,349	10,566	12.8 (12.1, 13.4)	1,969	13,295	14.8 (14.2, 15.4)
	BSC		494	1,239	39.9 (37.4, 42.7)	0.95 (0.88, 1.02)	302	568	53.2 (49.0, 57.3)	1.29 (1.19, 1.40)	3,772	8,977	42.0 (41.0, 43.0)	3,470	8,409	41.3 (40.2, 42.3)	4,266	10,216	41.8 (40.8, 42.7)
	BSSL		153	1,537	10.0 (8.5, 11.6)	1.49 (1.27, 1.75)	47	323	14.6 (10.9, 18.9)	2.22 (1.70, 2.91)	1,390	20,839	6.7 (6.3, 7.0)	1,343	20,516	6.5 (6.2, 6.9)	1,543	22,376	6.9 (6.6, 7.2)
	BSOS		72	593	12.1 (9.6, 15.0)	0.73 (0.59, 0.92)	7	96	7.3 (3.0, 14.4)	0.44 (0.21, 0.89)	1,124	6,797	16.5 (15.7, 17.4)	1,117	6,701	16.7 (15.8, 17.6)	1,196	7,390	16.2 (15.4, 17.0)
	Total		3,445	13,892	24.8 (24.1, 25.5)	1.39 (1.34, 1.43)	1,336	5,853	22.8 (21.8, 23.9)	1.30 (1.24, 1.37)	16,740	93,648	17.9 (17.6, 18.1)	15,404	87,795	17.5 (17.3, 17.8)	20,185	107,540	18.8 (18.5, 19.0)
	50 to 69		Fixed	BSWN	4,578	7,875	58.1 (57.0, 59.2)	0.78 (0.76, 0.79)	2,567	2,837	90.5 (89.3, 91.5)	1.22 (1.21, 1.24)	41,478	55,427	74.8 (74.5, 75.2)	38,911	52,590	74.0 (73.6, 74.4)	46,056
BSCM		3,554		4,617	77.0 (75.7, 78.2)	1.00 (0.98, 1.01)	6,347	7,658	82.9 (82.0, 83.7)	1.10 (1.08, 1.11)	27,475	35,641	77.1 (76.6, 77.5)	21,128	27,983	75.5 (75.0, 76.0)	31,029	40,258	77.1 (76.7, 77.5)
BSAC		1,393		1,994	69.9 (67.8, 71.9)	0.89 (0.86, 0.92)	1,813	2,996	60.5 (58.7, 62.3)	0.75 (0.73, 0.77)	20,019	25,490	78.5 (78.0, 79.0)	18,206	22,494	80.9 (80.4, 81.4)	21,412	27,484	77.9 (77.4, 78.4)
BSM		7,879		10,950	72.0 (71.1, 72.8)	0.95 (0.94, 0.96)	696	956	72.8 (69.9, 75.6)	0.96 (0.92, 1.00)	41,004	54,026	75.9 (75.5, 76.3)	40,308	53,070	76.0 (75.6, 76.3)	48,883	64,976	75.2 (74.9, 75.6)
BSCC		6,429		8,812	73.0 (72.0, 73.9)	0.88 (0.87, 0.89)	637	798	79.8 (76.9, 82.6)	0.96 (0.93, 1.00)	39,029	47,158	82.8 (82.4, 83.1)	38,392	46,360	82.8 (82.5, 83.2)	45,458	55,970	81.2 (80.9, 81.5)
BSC		2,363		4,273	55.3 (53.8, 56.8)	0.98 (0.95, 1.01)	1,077	2,251	47.8 (45.8, 49.8)	0.84 (0.80, 0.88)	23,631	41,859	56.5 (56.0, 56.9)	22,554	39,608	56.9 (56.5, 57.4)	25,994	46,132	56.3 (55.9, 56.8)
BSSL		4,065		4,608	88.2 (87.3, 89.1)	0.97 (0.96, 0.98)	748	857	87.3 (84.9, 89.4)	0.96 (0.94, 0.98)	68,904	75,779	90.9 (90.7, 91.1)	68,156	74,922	91.0 (90.8, 91.2)	72,969	80,387	90.8 (90.6, 91.0)
BSOS		1,535		1,922	79.9 (78.0, 81.6)	1.07 (1.04, 1.09)	251	279	90.0 (85.8, 93.2)	1.20 (1.16, 1.25)	21,095	28,144	75.0 (74.7, 75.5)	20,844	27,865	74.8 (74.3, 75.3)	22,630	30,066	75.3 (74.8, 75.8)
Total		31,796		45,051	70.6 (70.2, 71.0)	0.91 (0.90, 0.91)	14,136	18,632	75.9 (75.2, 76.5)	0.98 (0.97, 0.98)	282,635	363,524	77.7 (77.6, 77.9)	268,499	344,892	77.9 (77.7, 78.0)	314,431	408,575	77.0 (76.8, 77.1)
Mobile		BSWN		3,297	7,875	41.9 (40.8, 43.0)	1.66 (1.61, 1.71)	270	2,837	9.5 (8.5, 10.7)	0.37 (0.33, 0.41)	13,949	55,427	25.2 (24.8, 25.5)	13,679	52,590	26.0 (25.6, 26.4)	17,246	63,302
		BSCM	1,063	4,617	23.0 (21.8, 24.3)	1.01 (0.95, 1.06)	1,311	7,658	17.1 (16.3, 18.0)	0.70 (0.66, 0.74)	8,166	35,641	22.9 (22.5, 23.4)	6,855	27,983	24.5 (24.0, 25.0)	9,229	40,258	22.9 (22.5, 23.3)
		BSAC	601	1,994	30.1 (28.1, 32.2)	1.40 (1.31, 1.51)	1,183	2,996	39.5 (37.7, 41.3)	2.07 (1.97, 2.18)	5,471	25,490	21.5 (21.0, 22.0)	4,288	22,494	19.1 (18.6, 19.6)	6,072	27,484	22.1 (21.6, 22.6)
		BSM	3,071	10,950	28.0 (27.2, 28.9)	1.16 (1.12, 1.20)	260	956	27.2 (24.4, 30.1)	1.13 (1.02, 1.26)	13,022	54,026	24.1 (23.7, 24.5)	12,762	53,070	24.0 (23.7, 24.4)	16,093	64,976	24.8 (24.4, 25.1)
		BSCC	2,383	8,812	27.0 (26.1, 28.0)	1.57 (1.51, 1.63)	161	798	20.2 (17.4, 23.1)	1.17 (1.02, 1.35)	8,129	47,158	17.2 (16.9, 17.6)	7,968	46,360	17.2 (16.8, 17.5)	10,512	55,970	18.8 (18.5, 19.1)
		BSC	1,910	4,273	44.7 (43.2, 46.2)	1.03 (0.99, 1.06)	1,174	2,251	52.2 (50.1, 54.2)	1.21 (1.16, 1.26)	18,228	41,859	43.5 (43.1, 44.0)	17,054	39,608	43.1 (42.6, 43.5)	20,138	46,132	43.7 (43.2, 44.1)
		BSSL	543	4,608	11.8 (10.5, 12.7)	1.30 (1.20, 1.41)	109	857	12.7 (10.6, 15.1)	1.41 (1.18, 1.68)	6,875	75,779	9.1 (8.9, 9.3)	6,766	74,922	9.0 (8.8, 9.2)	7,418	80,387	9.2 (9.0, 9.4)
		BSOS	387	1,922	20.1 (18.4, 22.0)	0.80 (0.73, 0.88)	28	279	10.0 (6.8, 14.2)	0.40 (0.28, 0.57)	7,049	28,144	25.0 (24.5, 25.6)	7,021	27,865	25.2 (24.7, 25.7)	7,436	30,066	24.7 (24.2, 25.2)
		Total	13,255	45,051	29.4 (29.0, 29.8)	1.32 (1.30, 1.34)	4,496	18,632	24.1 (23.5, 24.8)	1.09 (1.06, 1.12)	80,889	363,524	22.3 (22.1, 22.4)	76,393	344,892	22.1 (22.0, 22.3)	94,144	408,575	23.0 (22.9, 23.2)
		45 to 69	Fixed	BSWN	6,190	10,357	59.8 (58.8, 60.7)	0.79 (0.78, 0.80)	3,323	3,682	90.2 (89.2, 91.2)	1.20 (1.19, 1.22)	53,468	70,519	75.8 (75.5, 76.1)	50,145	66,837	75.0 (74.7, 75.4)	59,658
BSCM	4,896			6,302	77.7 (76.6, 78.7)	1.00 (0.99, 1.02)	8,470	10,243	82.7 (81.9, 83.4)	1.09 (1.08, 1.10)	35,959	46,392	77.5 (77.1, 77.9)	27,489	36,149	76.0 (75.6, 76.5)	40,855	52,694	77.5 (77.2, 77.9)
BSAC	1,972			2,736	72.1 (70.4, 73.8)	0.91 (0.89, 0.94)	2,393	3,888	61.5 (60.0, 63.1)	0.76 (0.74, 0.78)	26,126	33,132	78.9 (78.4, 79.3)	23,733	29,244	81.2 (80.7, 81.6)	28,098	35,868	78.3 (77.9, 78.8)
BSM	10,218			14,064	72.7 (71.9, 73.4)	0.94 (0.93, 0.95)	939	1,271	73.9 (71.4, 76.3)	0.96 (0.92, 0.99)	51,603	66,781	77.3 (77.0, 77.6)	50,664	65,510	77.3 (77.0, 77.7)	61,821	80,845	76.5 (76.2, 76.8)
BSCC	8,354			11,312	73.9 (73.0, 74.7)	0.88 (0.87, 0.89)	821	1,027	79.9 (77.4, 82.4)	0.96 (0.93, 0.99)	48,430	57,953	83.6 (83.3, 83.9)	47,609	56,926	83.6 (83.3, 83.9)	56,784	69,265	82.0 (81.7, 82.3)
BSC	3,108			5,512	56.4 (55.1, 57.7)	0.99 (0.97, 1.02)	1,343	2,819	47.6 (45.8, 49.5)	0.83 (0.80, 0.87)	28,836	50,836	56.7 (56.3, 57.2)	27,493	48,017	57.3 (56.8, 57.7)	31,944	56,348	56.7 (56.3, 57.1)
BSSL	5,449			6,145	88.7 (87.9, 89.5)	0.97 (0.96, 0.98)	1,024	1,180	86.8 (84.7, 88.7)	0.95 (0.93, 0.97)	88,353	96,6							

1.a.4, Age specific coverage

Description: The number of women screened as a percentage of women eligible by 5 year age group.

Target: No target



Coverage generally increased with age. Māori coverage was lower than that of non-Māori in each age group, with the gap widest in women aged 45–49 years. Pacific coverage generally increased with age and was lower than non-Māori non-Pacific coverage in the three younger age groups but similar to that of non-Māori non-Pacific in the two older age groups.

Table 4: 1.a.4, Age specific coverage


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Screened	Eligible Women	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)
45 to 49	none	BSWN	2,482	4,020	61.7 (60.2, 63.2)	0.99 (0.97, 1.02)	845	1,440	58.7 (56.1, 61.2)	0.96 (0.91, 1)	15,092	24,260	62.2 (61.6, 62.8)	14,247	23,190	61.4 (60.8, 62.1)	17,574	28,650	61.3 (60.8, 61.9)
		BSCM	1,685	2,750	61.3 (59.4, 63.1)	0.90 (0.87, 0.92)	2,585	3,770	68.6 (67.1, 70)	1.07 (1.05, 1.1)	10,751	15,720	68.4 (67.7, 69.1)	8,166	12,780	63.9 (63.1, 64.7)	12,436	19,300	64.4 (63.8, 65.1)
		BSAC	742	1,230	60.3 (57.6, 63)	1.20 (1.15, 1.26)	892	1,600	55.8 (53.3, 58.2)	1.15 (1.1, 1.2)	7,642	15,240	50.1 (49.4, 50.9)	6,750	13,880	48.6 (47.8, 49.5)	8,384	16,710	50.2 (49.4, 50.9)
		BSM	3,114	6,390	48.7 (47.5, 50)	0.77 (0.75, 0.79)	315	610	51.6 (47.7, 55.6)	0.83 (0.77, 0.9)	12,755	20,190	63.2 (62.5, 63.8)	12,440	19,960	62.3 (61.7, 63)	15,869	26,960	58.9 (58.3, 59.4)
		BSCC	2,500	4,780	52.3 (50.9, 53.7)	0.74 (0.72, 0.77)	229	445	51.5 (46.8, 56.1)	0.72 (0.66, 0.79)	10,795	15,370	70.2 (69.5, 71)	10,566	14,850	71.2 (70.4, 71.9)	13,295	20,075	66.2 (65.6, 66.9)
		BSC	1,239	2,280	54.3 (52.3, 56.4)	0.99 (0.95, 1.03)	568	1,155	49.2 (46.3, 52.1)	0.91 (0.86, 0.97)	8,977	16,360	54.9 (54.1, 55.6)	8,409	15,550	54.1 (53.3, 54.9)	10,216	18,985	53.8 (53.1, 54.5)
		BSSL	1,537	2,400	64.0 (62.1, 65.9)	0.80 (0.78, 0.83)	323	530	60.9 (56.7, 65)	0.78 (0.72, 0.83)	20,839	26,090	79.9 (79.4, 80.4)	20,516	26,110	78.6 (78.1, 79.1)	22,376	29,040	77.1 (76.6, 77.5)
		BSOS	592	1,000	59.2 (56.1, 62.2)	0.87 (0.82, 0.92)	96	190	50.5 (43.5, 57.6)	0.76 (0.66, 0.87)	6,789	9,950	68.2 (67.3, 69.1)	6,693	10,060	66.5 (65.6, 67.4)	7,381	11,250	65.6 (64.7, 66.5)
		Total	13,891	24,850	55.9 (55.3, 56.5)	0.85 (0.84, 0.86)	5,853	9,740	60.1 (59.1, 61.1)	0.93 (0.92, 0.95)	93,640	143,180	65.4 (65.2, 65.6)	87,787	136,360	64.4 (64.1, 64.6)	107,531	170,970	62.9 (62.7, 63.1)
50 to 54	none	BSWN	2,223	3,690	60.2 (58.7, 61.8)	0.98 (0.96, 1.01)	865	1,460	59.2 (56.7, 61.7)	1.00 (0.96, 1.04)	14,609	23,840	61.3 (60.7, 61.9)	13,744	23,160	59.3 (58.7, 60)	16,832	28,310	59.5 (58.9, 60)
		BSCM	1,501	2,640	56.9 (55, 58.7)	0.88 (0.85, 0.92)	2,402	3,730	64.4 (62.8, 65.9)	1.07 (1.05, 1.1)	9,971	15,520	64.2 (63.5, 65)	7,569	12,630	59.9 (59.1, 60.8)	11,472	19,000	60.4 (59.7, 61.1)
		BSAC	633	1,170	54.1 (51.2, 56.9)	1.02 (0.97, 1.08)	967	1,790	54.0 (51.7, 56.3)	1.07 (1.03, 1.12)	7,423	13,990	53.1 (52.2, 53.9)	6,456	12,830	50.3 (49.5, 51.2)	8,056	15,790	51.0 (50.2, 51.8)
		BSM	3,080	5,850	52.6 (51.4, 53.9)	0.83 (0.81, 0.86)	289	550	52.5 (48.4, 56.7)	0.84 (0.77, 0.91)	12,966	20,530	63.2 (62.5, 63.8)	12,677	20,220	62.7 (62, 63.4)	16,046	26,620	60.3 (59.7, 60.9)
		BSCC	2,514	4,420	56.9 (55.4, 58.3)	0.79 (0.77, 0.81)	247	415	59.5 (54.7, 64.1)	0.83 (0.76, 0.89)	11,284	15,620	72.2 (71.5, 72.9)	11,037	15,320	72.0 (71.3, 72.7)	13,798	20,155	68.5 (67.8, 69.1)
		BSC	1,400	2,050	68.3 (66.2, 70.3)	0.96 (0.93, 0.99)	717	1,150	62.3 (59.5, 65.1)	0.88 (0.85, 0.93)	11,161	15,755	70.8 (70.1, 71.5)	10,444	14,820	70.5 (69.7, 71.2)	12,561	18,020	69.7 (69, 70.4)
		BSSL	1,541	2,290	67.3 (65.3, 69.2)	0.93 (0.9, 0.96)	280	505	55.4 (51.1, 59.7)	0.77 (0.71, 0.83)	19,021	26,320	72.3 (71.7, 72.8)	18,741	26,015	72.0 (71.5, 72.6)	20,562	28,810	71.4 (70.8, 71.9)
		BSOS	635	1,000	63.5 (60.5, 66.4)	0.95 (0.9, 0.99)	106	180	58.9 (51.6, 65.8)	0.88 (0.78, 1)	6,869	10,240	67.1 (66.2, 68)	6,763	10,150	66.6 (65.7, 67.5)	7,504	11,330	66.2 (65.4, 67.1)
		Total	13,527	23,110	58.5 (57.9, 59.2)	0.89 (0.88, 0.9)	5,873	9,780	60.1 (59.1, 61)	0.93 (0.91, 0.94)	93,304	141,815	65.8 (65.5, 66)	87,431	135,145	64.7 (64.4, 64.9)	106,831	168,035	63.6 (63.3, 63.8)
55 to 59	none	BSWN	2,335	3,660	63.8 (62.2, 65.3)	1.01 (0.98, 1.04)	825	1,260	65.5 (62.8, 68.1)	1.06 (1.02, 1.1)	15,013	23,750	63.2 (62.6, 63.8)	14,188	22,970	61.8 (61.1, 62.4)	17,348	27,890	62.2 (61.6, 62.8)
		BSCM	1,317	2,340	56.3 (54.3, 58.3)	0.85 (0.82, 0.88)	2,151	3,150	68.3 (66.6, 69.9)	1.12 (1.1, 1.15)	9,710	14,650	66.3 (65.5, 67)	7,559	12,420	60.9 (60, 61.7)	11,027	17,910	61.6 (60.9, 62.3)
		BSAC	629	1,120	56.2 (53.2, 59)	1.06 (1.01, 1.12)	836	1,510	55.4 (52.8, 57.9)	1.10 (1.05, 1.16)	7,053	13,340	52.9 (52, 53.7)	6,217	12,370	50.3 (49.4, 51.1)	7,682	15,000	51.2 (50.4, 52)
		BSM	3,125	5,810	53.8 (52.5, 55.1)	0.82 (0.8, 0.84)	269	420	64.0 (59.4, 68.5)	0.98 (0.92, 1.06)	14,070	21,430	65.7 (65, 66.3)	13,801	21,200	65.1 (64.5, 65.7)	17,195	27,430	62.7 (62.1, 63.3)
		BSCC	2,578	4,290	60.1 (58.6, 61.5)	0.83 (0.81, 0.85)	217	395	54.9 (50, 59.8)	0.75 (0.69, 0.82)	12,571	17,370	72.4 (71.7, 73)	12,354	16,850	73.3 (72.6, 74)	15,149	21,535	70.3 (69.7, 71)
		BSC	1,235	1,860	66.4 (64.2, 68.5)	0.86 (0.83, 0.89)	639	945	67.6 (64.6, 70.5)	0.89 (0.85, 0.93)	11,753	15,250	77.1 (76.4, 77.7)	11,114	14,630	76.0 (75.3, 76.7)	12,988	17,435	74.5 (73.8, 75.1)
		BSSL	1,327	2,000	66.4 (64.2, 68.4)	0.86 (0.83, 0.89)	238	430	55.3 (50.6, 60)	0.72 (0.66, 0.79)	20,817	26,985	77.1 (76.6, 77.6)	20,579	26,915	76.5 (75.9, 77)	22,144	29,345	75.5 (75, 75.9)
		BSOS	601	910	66.0 (62.9, 69)	0.93 (0.89, 0.98)	72	120	60.0 (51.1, 68.3)	0.85 (0.73, 0.98)	7,760	10,960	70.8 (69.9, 71.6)	7,688	10,880	70.7 (69.8, 71.5)	8,361	11,910	70.2 (69.4, 71)
		Total	13,147	21,990	59.8 (59.1, 60.4)	0.87 (0.86, 0.88)	5,247	8,230	63.8 (62.7, 64.8)	0.94 (0.93, 0.96)	98,747	143,735	68.7 (68.5, 68.9)	93,500	138,235	67.6 (67.4, 67.9)	111,894	168,455	66.4 (66.2, 66.6)
60 to 64	none	BSWN	1,922	2,980	64.5 (62.8, 66.2)	1.02 (0.99, 1.05)	610	950	64.2 (61.1, 67.2)	1.04 (0.99, 1.09)	13,538	21,450	63.1 (62.5, 63.8)	12,928	20,910	61.8 (61.2, 62.5)	15,460	24,840	62.2 (61.6, 62.8)
		BSCM	1,041	1,670	62.3 (60, 64.6)	0.90 (0.86, 0.93)	1,757	2,240	78.4 (76.7, 80.1)	1.24 (1.21, 1.27)	8,635	12,450	69.4 (68.5, 70.2)	6,878	10,840	63.5 (62.5, 64.4)	9,676	14,750	65.6 (64.8, 66.4)
		BSAC	426	840	50.7 (47.3, 54.1)	0.97 (0.91, 1.04)	667	1,200	55.6 (52.8, 58.4)	1.11 (1.06, 1.17)	5,897	11,320	52.1 (51.2, 53)	5,230	10,460	50.0 (49, 51)	6,323	12,500	50.6 (49.7, 51.5)
		BSM	2,684	4,680	57.4 (55.9, 58.8)	0.88 (0.86, 0.91)	231	360	64.2 (59.1, 68.9)	0.98 (0.91, 1.06)	13,529	20,850	64.9 (64.2, 65.5)	13,298	20,380	65.3 (64.6, 65.9)	16,213	25,420	63.8 (63.2, 64.4)
		BSCC	2,136	3,430	62.3 (60.6, 63.9)	0.86 (0.84, 0.88)	180	290	62.1 (56.4, 67.5)	0.85 (0.77, 0.93)	12,002	16,575	72.4 (71.7, 73.1)	11,822	16,115	73.4 (72.7, 74)	14,138	19,835	71.3 (70.6, 71.9)
		BSC	1,000	1,480	67.6 (65.1, 69.9)	0.91 (0.88, 0.95)	506	770	65.7 (62.3, 69)	0.89 (0.84, 0.93)	10,006	13,530	74.0 (73.2, 74.7)	9,500	12,810	74.2 (73.4, 74.9)	11,006	15,060	73.1 (72.4, 73.8)
		BSSL	976	1,500	65.1 (62.6, 67.4)	0.89 (0.86, 0.92)	187	295	63.4 (57.8, 68.7)	0.86 (0.79, 0.93)	18,239	24,895	73.3 (72.7, 73.8)	18,052	24,390	74.0 (73.5, 74.6)	19,215	26,185	73.4 (72.8, 73.9)
		BSOS	386	610	63.3 (59.4, 67)	0.91 (0.85, 0.97)	60	100	60.0 (50.2, 69.1)	0.86 (0.73, 1.01)	7,135	10,230	69.7 (68.8, 70.6)	7,075	10,150	69.7 (68.8, 70.6)	7,521	10,860	69.3 (68.4, 70.1)
		Total	10,571	17,190	61.5 (60.8, 62.2)	0.91 (0.9, 0.92)	4,198	6,205	67.7 (66.5, 68.8)	1.01 (0.99, 1.02)	88,981	131,300	67.8 (67.5, 68)	84,783	126,055	67.3 (67, 67.5)	99,552	149,450	66.6 (66.4, 66.9)
65 to 69	none	BSWN	1,395	2,090	66.7 (64.7, 68.7)	1.01 (0.97, 1.04)	537	720	74.6 (71.3, 77.6)	1.13 (1.09, 1.18)	12,267	18,500	66.3 (65.6, 67)	11,730	17,810	65.9 (65.2, 66.6)	13,662	20,620	66.3 (65.6, 66.9)
		BSCM	758	1,220	62.1 (59.4, 64.8)	0.88 (0.84, 0.92)	1,348	1,610	83.7 (81.8, 85.4)	1.28 (1.25, 1.31)	7,325	10,400	70.4 (69.5, 71.3)	5,977	9,120	65.5 (64.6, 66.5)	8,083	11,950	67.6 (66.8, 68.5)
		BSAC	306	610	50.2 (46.2, 54.1)	0.92 (0.85, 1)	526	910	57.8 (54.6, 61)	1.10 (1.04, 1.16)	5,117	9,360	54.7 (53.7, 55.7)	4,591	8,720	52.6 (51.6, 53.7)	5,423	10,240	53.0 (52, 53.9)
		BSM	2,061	3,420	60.3 (58.6, 61.9)	0.87 (0.85, 0.9)	167	280	59.6 (53.8, 65.2)	0.86 (0.78, 0.95)	13,461	19,500	69.0 (68.4, 69.7)	13,294	19,240	69.1 (68.4, 69.7)	15,522	22,940	67.7 (67.1, 68.3)
		BSCC	1,584	2,540	62.4 (60.5, 64.2)	0.84 (0.82, 0.87)	154	210	73.3 (67, 78.9)	0.97 (0.9, 1.06)	11,301	15,255	74.1 (73.4, 74.8)	11,147	14,805	75.3 (74.6, 76)	12,885	17,555	73.4 (72.7, 74)
		BSC	638	950	67.2 (64.1, 70.1)	0.86 (0.82, 0.9)	389	610	63.8 (59.9, 67.5)	0.81 (0.76, 0.86)	8,939	11,465	78.0 (77.2, 78.7)	8,550	10,870	78.7 (77.9, 79.4)	9,577	12,430	77.0 (76.3, 77.8)
		BSSL	764	1,020	74.9 (72.2, 77.5)	0.93 (0.9, 0.97)	152	215	70.7 (64.3, 76.4)	0.87 (0.8, 0.95)	17,702	22,045	80.3 (79.8, 80.8)	17,550	21,620	81.2 (80.6, 81.7)	18,466		

1.b.3, Routine rescreening

Description: The number of women rescreened within 27 months of their previous screen as a percentage of the number of women eligible for a rescreen.

Targets: Initial: $\geq 75\%$ of women who are eligible for rescreen are re-screened within 27 months. Subsequent: $\geq 85\%$ of women who are eligible for rescreen are re-screened within 27 months.

Figure 37: 1.b.3.1, Percentage rescreened within 27 months of an initial and subsequent screen, 50 to 67, all BSA



Timely rescreening rates were affected by COVID related lockdowns in the last 18 months of this reporting period. Among women aged 45–67 years, 63% were rescreened within 27 months of their initial screen (a decrease of 12%) and 74% within 27 months of a subsequent screen (a decrease of 11%). Women aged 45–49 years at their first screen were more likely to be rescreened within 27 months (65%) than those aged 50 and above at their first screen (55%) with little difference after subsequent screens (72% compared to 74%). LPs with the highest proportions of timely rescreens were BSCC (80% after initial and 88% after subsequent) and BSC (72% after initial and 77% after subsequent screens). Note that BSAC has not been operating long enough to include rescreening trends. The data in the table applies predominantly to the previous provider, BreastScreen Auckland Ltd.

Māori women aged 45–49 years were slightly more likely than non-Māori women to have a timely rescreen after an initial screen overall (65% compared to 63%) but less likely in the older age group (52% compared to 55%). Timely rescreening rates after a subsequent screen were higher for Māori than for non-Māori (78% compared to 73%), similar in both age groups. For Pacific women aged 45–67 years, timely rescreening rates were lower than for non-Māori non-Pacific women after an initial screen (58% compared to 63%) but similar after a subsequent screen (72% compared to 73%). For women aged 45–67 years, BSWN, BSC, BSSL and BSOS achieved equitable rescreening rates for Māori and non-Māori after both initial and subsequent screens.

Figure 38: 1.b.3.3, Routine rescreening within 27 months of an initial screen, 50 to 67, by LP




Figure 39: 1.b.3.5, Routine rescreening within 27 months of a subsequent screen, 50 to 67, by LP




Table 5: 1.b.3, Routine rescreening within 27 months of an initial and subsequent screen

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Māori / Non-Māori Ratio	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Pacific / Non-Pacific Ratio	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)
45 to 49	Initial	BSWN	795	1,239	64.2 (61.4, 66.8)	1.05 (1.00, 1.10)	272	403	67.5 (62.7, 72.0)	1.11 (1.03, 1.19)	4,472	7,310	61.2 (60.0, 62.3)	4,200	6,907	60.8 (59.6, 62.0)	5,267	8,549	61.6 (60.6, 62.6)
		BSCM	546	933	58.5 (55.3, 61.7)	0.92 (0.87, 0.98)	786	1,477	53.2 (50.6, 55.8)	0.79 (0.75, 0.83)	3,524	5,548	63.5 (62.2, 64.8)	2,738	4,071	67.3 (65.8, 68.7)	4,070	6,481	62.8 (61.6, 64.0)
		BSAC	230	367	62.7 (57.5, 67.6)	1.15 (1.06, 1.25)	314	543	57.8 (53.5, 62.0)	1.07 (0.99, 1.16)	2,564	4,711	54.4 (53.0, 55.9)	2,250	4,168	54.0 (52.5, 55.5)	2,794	5,078	55.0 (53.6, 56.4)
		BSM	1,086	1,747	62.2 (59.8, 64.4)	1.00 (0.96, 1.04)	105	183	57.4 (49.9, 64.6)	0.92 (0.81, 1.05)	4,101	6,619	62.0 (60.8, 63.1)	3,996	6,436	62.1 (60.9, 63.3)	5,187	8,366	62.0 (61.0, 63.0)
		BSCC	918	1,282	71.6 (69.1, 74.1)	0.84 (0.81, 0.87)	84	118	71.2 (62.1, 79.2)	0.83 (0.74, 0.93)	4,155	4,854	85.6 (84.6, 86.6)	4,071	4,736	86.0 (84.9, 86.9)	5,073	6,136	82.7 (81.7, 83.6)
		BSC	480	564	85.1 (81.9, 87.9)	1.18 (1.14, 1.23)	258	302	85.4 (80.9, 89.2)	1.20 (1.14, 1.26)	3,584	4,978	72.0 (70.7, 73.2)	3,326	4,676	71.1 (69.8, 72.4)	4,064	5,542	73.3 (72.1, 74.5)
		BSSL	507	632	80.2 (76.9, 83.3)	1.20 (1.15, 1.25)	104	135	77.0 (69.0, 83.8)	1.16 (1.05, 1.27)	5,816	8,715	66.7 (65.7, 67.7)	5,712	8,580	66.6 (65.6, 67.6)	6,323	9,347	67.6 (66.7, 68.6)
		BSOS	225	288	78.1 (72.9, 82.8)	1.57 (1.46, 1.68)	33	36	91.7 (77.5, 98.2)	1.86 (1.67, 2.06)	1,524	3,057	49.9 (48.1, 51.6)	1,491	3,021	49.4 (47.6, 51.2)	1,749	3,345	52.3 (50.6, 54.0)
		Total	4,787	7,052	67.9 (66.8, 69.0)	1.05 (1.03, 1.06)	1,956	3,197	61.2 (59.5, 62.9)	0.94 (0.91, 0.96)	29,740	45,792	64.9 (64.5, 65.4)	27,784	42,595	65.2 (64.8, 65.7)	34,527	52,844	65.3 (64.9, 65.7)
		Subsequent	BSWN	1,028	1,386	74.2 (71.8, 76.5)	1.05 (1.02, 1.09)	391	494	79.1 (75.3, 82.6)	1.13 (1.08, 1.19)	6,572	9,325	70.5 (69.5, 71.4)	6,181	8,831	70.0 (69.0, 70.9)	7,600	10,711
	BSCM		696	981	70.9 (68.0, 73.8)	0.96 (0.92, 1.00)	1,041	1,567	66.4 (64.0, 68.8)	0.88 (0.84, 0.91)	5,264	7,134	73.8 (72.8, 74.8)	4,223	5,567	75.9 (74.7, 77.0)	5,960	8,115	73.4 (72.5, 74.4)
	BSAC		345	459	75.2 (70.9, 79.1)	1.23 (1.16, 1.30)	423	648	65.3 (61.5, 68.9)	1.07 (1.01, 1.14)	3,741	6,097	61.4 (60.1, 62.6)	3,318	5,449	60.9 (59.6, 62.2)	4,086	6,556	62.3 (61.1, 63.5)
	BSM		1,218	1,627	74.9 (72.7, 77.0)	1.02 (0.99, 1.05)	115	155	74.2 (66.6, 80.9)	1.01 (0.92, 1.11)	5,815	7,930	73.3 (72.3, 74.3)	5,700	7,775	73.3 (72.3, 74.3)	7,033	9,557	73.6 (72.7, 74.5)
	BSCC		1,122	1,414	79.3 (77.1, 81.4)	0.89 (0.86, 0.91)	100	129	77.5 (69.3, 84.4)	0.86 (0.79, 0.95)	5,900	6,577	89.7 (88.9, 90.4)	5,800	6,448	90.0 (89.2, 90.7)	7,022	7,991	87.9 (87.1, 88.6)
	BSC		667	749	89.1 (86.6, 91.2)	1.20 (1.17, 1.24)	294	345	85.2 (81.0, 88.8)	1.16 (1.10, 1.21)	4,796	6,462	74.2 (73.1, 75.3)	4,502	6,117	73.6 (72.5, 74.7)	5,463	7,211	75.8 (74.8, 76.7)
	BSSL		835	955	87.4 (85.2, 89.5)	1.25 (1.21, 1.28)	126	156	80.8 (73.7, 86.6)	1.15 (1.07, 1.24)	9,491	13,510	70.3 (69.5, 71.0)	9,365	13,354	70.1 (69.3, 70.9)	10,326	14,465	71.4 (70.6, 72.1)
	BSOS		324	376	86.2 (82.3, 89.4)	1.72 (1.63, 1.81)	52	57	91.2 (80.7, 97.1)	1.84 (1.69, 2.00)	2,134	4,252	50.2 (48.7, 51.7)	2,082	4,195	49.6 (48.1, 51.2)	2,458	4,628	53.1 (51.7, 54.6)
	Total		6,235	7,947	78.5 (77.5, 79.5)	1.10 (1.09, 1.11)	2,542	3,551	71.6 (70.1, 73.1)	1.00 (0.98, 1.03)	43,713	61,287	73.3 (71.0, 71.7)	41,171	57,736	71.3 (70.9, 71.7)	49,948	69,234	71.2 (71.8, 72.5)
	50 to 67		Initial	BSWN	123	239	51.5 (44.9, 58.0)	0.99 (0.87, 1.13)	61	114	53.5 (43.9, 62.9)	1.03 (0.87, 1.23)	1,149	2,213	51.9 (49.8, 54.0)	1,088	2,099	51.8 (49.7, 54.0)	1,272
BSCM		77		185	41.6 (34.4, 49.1)	0.83 (0.70, 0.99)	139	380	36.6 (31.7, 41.6)	0.68 (0.59, 0.78)	855	1,710	50.0 (47.6, 52.4)	716	1,330	53.8 (51.1, 56.5)	932	1,895	49.2 (46.9, 51.5)
BSAC		36		82	43.9 (33.0, 55.3)	0.93 (0.72, 1.19)	66	151	43.7 (35.7, 52.0)	0.91 (0.76, 1.10)	692	1,460	47.4 (44.8, 50.0)	626	1,309	47.8 (45.1, 50.6)	728	1,542	47.2 (44.7, 49.7)
BSM		234		542	43.2 (39.0, 47.5)	0.88 (0.79, 0.98)	22	58	37.9 (25.5, 51.6)	0.77 (0.55, 1.08)	943	1,931	48.8 (46.6, 51.1)	921	1,873	49.2 (46.9, 51.5)	1,177	2,473	47.6 (45.6, 49.6)
BSCC		221		382	57.9 (52.7, 62.9)	0.76 (0.70, 0.83)	28	52	53.8 (39.5, 67.8)	0.70 (0.54, 0.90)	985	1,298	75.9 (73.5, 78.1)	957	1,246	76.8 (74.4, 79.1)	1,206	1,680	71.8 (69.6, 73.9)
BSC		103		142	72.5 (64.4, 79.7)	1.09 (0.98, 1.22)	62	86	72.1 (61.4, 81.2)	1.09 (0.95, 1.25)	914	1,374	66.5 (64.0, 69.0)	852	1,288	66.1 (63.5, 68.7)	1,017	1,516	67.1 (64.7, 69.4)
BSSL		52		92	56.5 (45.8, 66.8)	0.99 (0.82, 1.19)	30	46	65.2 (49.8, 78.6)	1.15 (0.92, 1.42)	765	1,339	57.1 (54.4, 59.8)	735	1,293	56.8 (54.1, 59.6)	817	1,431	57.1 (54.5, 59.7)
BSOS		41		60	68.3 (55.0, 79.7)	1.48 (1.22, 1.79)	12	14	85.7 (57.2, 98.2)	1.89 (1.50, 2.39)	276	597	46.2 (42.2, 50.3)	264	583	45.3 (41.2, 49.4)	317	657	48.2 (44.4, 52.1)
Total		887		1,724	51.5 (49.1, 53.8)	0.93 (0.89, 0.98)	420	901	46.6 (43.3, 49.9)	0.83 (0.78, 0.90)	6,579	11,922	55.2 (54.2, 56.1)	6,159	11,021	55.9 (55.0, 56.8)	7,466	13,646	54.7 (53.9, 55.5)
Subsequent		BSWN		5,154	6,917	74.5 (73.5, 75.5)	1.04 (1.02, 1.06)	1,994	2,552	78.1 (76.5, 79.7)	1.10 (1.07, 1.12)	35,678	49,836	71.6 (71.2, 72.0)	33,684	47,284	71.2 (70.8, 71.6)	40,832	56,753
		BSCM	2,913	4,115	70.8 (69.4, 72.2)	0.95 (0.93, 0.97)	4,810	7,195	66.9 (65.8, 67.9)	0.87 (0.86, 0.89)	24,663	33,104	74.5 (74.0, 75.0)	19,853	25,909	76.6 (76.1, 77.1)	27,576	37,219	74.1 (73.6, 74.5)
		BSAC	1,335	1,894	70.5 (68.4, 72.5)	1.16 (1.13, 1.20)	1,993	3,121	63.9 (62.1, 65.5)	1.06 (1.03, 1.09)	17,827	29,435	60.6 (60.0, 61.1)	15,834	26,314	60.2 (59.6, 60.8)	19,162	31,329	61.2 (60.6, 61.7)
		BSM	6,818	9,041	75.4 (74.5, 76.3)	0.97 (0.95, 0.98)	573	789	72.6 (69.4, 75.7)	0.93 (0.89, 0.97)	36,965	47,329	78.1 (77.7, 78.6)	36,392	46,540	78.2 (77.3, 78.6)	43,783	56,370	77.7 (77.3, 78.0)
		BSCC	5,955	7,441	80.0 (79.1, 80.9)	0.90 (0.89, 0.91)	526	659	79.8 (76.5, 82.8)	0.90 (0.86, 0.93)	36,601	41,092	89.1 (88.8, 89.4)	36,075	40,433	89.2 (88.9, 89.5)	42,556	48,533	87.7 (87.4, 88.0)
		BSC	3,117	3,538	88.1 (87.0, 89.1)	1.16 (1.14, 1.17)	1,569	1,827	85.9 (84.2, 87.4)	1.14 (1.11, 1.16)	27,209	35,701	76.2 (75.8, 76.7)	25,640	33,874	75.7 (75.2, 76.1)	30,326	39,239	77.3 (76.9, 77.7)
		BSSL	3,161	3,698	85.5 (84.3, 86.6)	1.16 (1.15, 1.18)	530	640	82.8 (79.7, 85.7)	1.13 (1.09, 1.17)	48,870	66,548	73.4 (73.1, 73.8)	48,340	65,908	73.3 (73.0, 73.7)	52,031	70,246	74.1 (73.7, 74.4)
		BSOS	1,329	1,532	86.7 (84.9, 88.4)	1.56 (1.52, 1.59)	158	185	85.4 (79.5, 90.2)	1.54 (1.45, 1.64)	14,088	25,304	55.7 (55.1, 56.3)	13,930	25,119	55.5 (54.0, 56.1)	15,417	26,836	57.4 (56.9, 58.0)
		Total	29,782	38,176	78.0 (77.6, 78.4)	1.06 (1.05, 1.06)	12,153	16,968	71.6 (70.9, 72.3)	0.97 (0.96, 0.98)	241,901	328,349	73.7 (73.5, 73.8)	229,748	311,381	73.8 (73.6, 73.9)	271,683	366,525	74.1 (74.0, 74.3)
		45 to 69	Initial	BSWN	917	1,477	62.1 (59.6, 64.6)	1.05 (1.01, 1.10)	333	517	64.4 (60.1, 68.5)	1.10 (1.03, 1.17)	5,602	9,504	58.9 (57.9, 59.9)	5,269	8,987	58.6 (57.6, 59.6)	6,519
BSCM	622			1,117	55.7 (52.7, 58.6)	0.93 (0.88, 0.98)	922	1,854	49.7 (47.4, 52.0)	0.78 (0.74, 0.82)	4,360	7,239	60.2 (59.1, 61.4)	3,438	5,385	63.8 (62.5, 65.1)	4,982	8,356	59.6 (58.6, 60.7)
BSAC	266			449	59.2 (54.5, 63.8)	1.13 (1.04, 1.22)	380	694	54.8 (51.0, 58.5)	1.05 (0.97, 1.12)	3,245	6,160	52.7 (51.4, 53.9)	2,865	5,466	52.4 (51.9, 53.7)	3,511	6,609	53.1 (51.9, 54.3)
BSM	1,316			2,285	57.6 (55.5, 59.6)	0.98 (0.94, 1.02)	127	241	52.7 (46.2, 59.1)	0.89 (0.79, 1.01)	5,034	8,540	58.9 (57.9, 60.0)	4,907	8,299	59.1 (58.1, 60.2)	6,350	10,825	58.7 (57.7, 59.6)
BSCC	1,137			1,662	68.4 (66.1, 70.6)	0.82 (0.79, 0.85)	112	170	65.9 (58.2, 73.0)	0.78 (0.70, 0.87)	5,129	6,141	83.5 (82.6, 84.4)	5,017	5,971	84.0 (83.1, 84.9)	6,266	7,803	80.3 (79.4, 81.2)
BSC	579			702	82.5 (79.5, 85.2)	1.17 (1.12, 1.21)	317	385	82.3 (78.2, 86.0)	1.18 (1.12, 1.24)	4,495	6,349	70.8 (69.7, 71.9)	4,178	5,964	70.1 (68.9, 71.2)	5,074	7,051	72.0 (70.9, 73.0)
BSSL	557			722	77.1 (73.9, 80.2)	1.18 (1.13, 1.23)	134	181	74.0 (67.0, 80.3)	1.13 (1.04, 1.24)	6,571	10,044	65.4 (64.5, 66.2)	6,437	9,863	65.3 (64.3, 66.2)	7,128	10,766	66.2 (65.3, 67.1)
BSOS	265			347	76.4 (71.5														


Screening and Assessment

2.a, Screening image usage

Description: The percentage of women screened who have had four or fewer images taken.

Target: >80% of women screened have four or fewer images taken.

Figure 40: 2.a.1, Screening image usage, 50 to 69, fixed and mobile units



For BSA overall, the proportions of Māori women aged 45–69 years having no more than 4 images taken has increased to meet the target of >80% for fixed and mobile units. For Pacific women the target was met in fixed units (82%) and was within the confidence interval for women screened in mobile units (79%). The target was met for other women at 88% in both fixed and mobile units.

Figure 41: 2.a.3, Fixed, 50 to 69, Screening image usage, by LP




Figure 42: 2.a.5, Mobile, 50 to 69, Screening image usage, by LP




Table 6: 2.a, Screening image usage


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Māori / Non-Māori Ratio	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	
45 to 49	Fixed	BSWN	1,382	1,626	85.0 (83.2, 86.7)	0.95 (0.93, 0.97)	600	765	78.4 (75.3, 81.3)	0.87 (0.84, 0.91)	10,792	12,098	89.2 (88.6, 89.8)	10,192	11,333	89.9 (89.4, 90.5)	12,174	13,724	88.7 (88.2, 89.2)
		BSCM	1,104	1,369	80.6 (78.4, 82.7)	0.93 (0.91, 0.96)	1,801	2,128	84.6 (83.0, 86.3)	0.97 (0.95, 0.99)	7,368	8,533	86.3 (85.6, 87.1)	5,567	6,405	86.9 (86.1, 87.7)	8,472	9,902	85.6 (84.9, 86.2)
		BSAC	483	581	83.1 (79.8, 86.1)	0.96 (0.93, 1.00)	427	581	73.5 (69.7, 77.0)	0.84 (0.80, 0.88)	5,276	6,120	86.2 (85.3, 87.1)	4,849	5,539	87.5 (86.6, 88.4)	5,759	6,701	85.9 (85.1, 86.8)
		BSM	2,125	2,437	87.2 (85.8, 88.5)	0.96 (0.95, 0.98)	219	254	86.2 (81.4, 90.2)	0.95 (0.91, 1.00)	9,687	10,697	90.6 (90.0, 91.1)	9,468	10,443	90.7 (90.1, 91.2)	11,812	13,134	89.9 (89.4, 90.4)
		BSCC	1,703	1,972	86.4 (84.8, 87.8)	0.97 (0.95, 0.99)	161	189	85.2 (79.3, 89.9)	0.95 (0.90, 1.01)	8,449	9,463	89.3 (88.6, 89.9)	8,288	9,274	89.4 (88.7, 90.0)	10,152	11,435	88.8 (88.2, 89.4)
		BSC	610	772	79.0 (76.0, 81.8)	0.93 (0.90, 0.97)	200	271	73.8 (68.1, 78.9)	0.86 (0.80, 0.93)	4,476	5,268	85.0 (84.0, 85.9)	4,276	4,997	85.6 (84.6, 86.5)	5,086	6,040	84.2 (83.3, 85.1)
		BSSL	1,246	1,501	83.0 (81.0, 84.9)	0.97 (0.94, 0.99)	229	301	76.1 (70.9, 80.8)	0.88 (0.83, 0.94)	16,780	19,532	85.9 (85.4, 86.4)	16,551	19,231	86.1 (85.6, 86.6)	18,026	21,033	85.7 (85.2, 86.2)
		BSOS	464	565	82.1 (78.7, 85.2)	0.99 (0.95, 1.03)	75	96	78.1 (68.5, 85.9)	0.94 (0.85, 1.05)	4,719	5,689	82.9 (81.9, 83.9)	4,644	5,593	83.0 (82.0, 84.0)	5,183	6,254	82.9 (81.9, 83.8)
		Total	9,117	10,823	84.2 (83.5, 84.9)	0.97 (0.96, 0.97)	3,712	4,585	81.0 (79.8, 82.1)	0.92 (0.91, 0.94)	67,547	77,400	87.3 (87.0, 87.5)	63,835	72,815	87.7 (87.4, 87.9)	76,664	88,223	86.9 (86.7, 87.1)
	Mobile	BSWN	780	873	89.3 (87.1, 91.3)	0.98 (0.96, 1.01)	82	89	92.1 (84.5, 96.8)	1.01 (0.95, 1.08)	2,834	3,112	91.1 (90.0, 92.0)	2,752	3,023	91.0 (90.0, 92.0)	3,614	3,985	90.7 (89.7, 91.6)
		BSCM	291	348	83.6 (79.3, 87.4)	0.96 (0.92, 1.01)	383	466	82.2 (78.4, 85.6)	0.94 (0.89, 0.98)	2,000	2,305	86.8 (85.3, 88.1)	1,617	1,839	87.9 (86.4, 89.4)	2,291	2,653	86.4 (85.0, 87.6)
		BSAC	134	164	81.7 (74.9, 87.3)	0.96 (0.89, 1.03)	238	313	76.0 (70.9, 80.7)	0.87 (0.81, 0.93)	1,314	1,540	85.3 (83.5, 87.1)	1,076	1,227	87.7 (85.7, 89.5)	1,448	1,704	85.0 (83.2, 86.6)
		BSM	659	789	83.5 (80.7, 86.0)	0.93 (0.90, 0.96)	58	72	80.6 (69.5, 88.9)	0.90 (0.80, 1.00)	1,950	2,173	89.7 (88.4, 91.0)	1,892	2,101	90.1 (88.7, 91.3)	2,609	2,962	88.1 (86.9, 89.2)
		BSCC	474	576	82.3 (78.8, 85.3)	0.94 (0.90, 0.98)	30	45	66.7 (51.0, 80.9)	0.75 (0.61, 0.93)	1,226	1,394	87.9 (86.1, 89.6)	1,196	1,349	88.7 (86.8, 90.3)	1,700	1,970	86.6 (84.9, 87.8)
		BSC	413	509	81.1 (77.5, 84.4)	0.95 (0.91, 0.99)	235	313	75.1 (69.9, 79.8)	0.87 (0.81, 0.93)	3,297	3,850	85.6 (84.5, 86.7)	3,062	3,537	86.6 (85.4, 87.7)	3,710	4,359	85.1 (84.0, 86.2)
		BSSL	119	153	77.8 (70.4, 84.1)	0.92 (0.84, 1.00)	30	47	63.8 (48.5, 77.3)	0.75 (0.60, 0.93)	1,181	1,390	85.0 (83.0, 86.8)	1,151	1,343	85.7 (83.7, 87.5)	1,300	1,543	84.3 (82.3, 86.0)
		BSOS	60	73	82.2 (71.5, 90.2)	0.98 (0.88, 1.10)	5	7	71.4 (29.0, 96.3)	0.85 (0.53, 1.37)	938	1,123	83.5 (81.2, 85.7)	933	1,116	83.6 (81.3, 85.7)	998	1,196	83.4 (81.2, 85.5)
		Total	2,930	3,485	84.1 (82.8, 85.3)	0.96 (0.95, 0.98)	1,061	1,352	78.5 (76.2, 80.6)	0.89 (0.87, 0.92)	14,740	16,887	87.3 (86.8, 87.8)	13,679	15,335	88.1 (87.5, 88.6)	17,970	20,372	86.4 (86.3, 87.2)
		50 to 69	Fixed	BSWN	3,943	4,593	85.8 (84.8, 86.8)	0.96 (0.95, 0.97)	2,110	2,584	81.7 (80.1, 83.1)	0.91 (0.89, 0.93)	37,381	41,815	89.4 (89.1, 89.7)	35,271	39,231	89.9 (89.6, 90.2)	41,324
BSCM	2,973			3,626	82.0 (80.7, 83.2)	0.95 (0.93, 0.96)	5,420	6,370	85.1 (84.2, 86.0)	0.98 (0.97, 0.99)	23,934	27,663	86.5 (86.1, 86.9)	18,514	21,293	86.9 (86.5, 87.4)	26,907	31,289	86.0 (85.6, 86.4)
BSAC	1,171			1,398	83.8 (81.7, 85.7)	0.94 (0.92, 0.96)	1,478	1,813	81.5 (79.7, 83.3)	0.91 (0.89, 0.93)	17,830	20,053	88.9 (88.5, 89.3)	16,352	18,240	89.6 (89.2, 90.1)	19,001	21,451	88.6 (88.1, 89.0)
BSM	7,069			8,230	85.9 (85.1, 86.6)	0.94 (0.94, 0.95)	615	731	84.1 (81.3, 86.7)	0.92 (0.90, 0.95)	37,723	41,470	91.0 (90.7, 91.2)	37,108	40,739	91.1 (90.8, 91.4)	44,792	49,700	90.6 (89.9, 90.4)
BSCC	5,525			6,541	84.5 (83.6, 85.3)	0.95 (0.94, 0.96)	549	649	84.6 (81.6, 87.3)	0.95 (0.92, 0.98)	35,057	39,259	89.3 (89.0, 89.6)	34,508	38,610	89.4 (89.1, 89.7)	40,582	45,800	88.6 (88.3, 88.9)
BSC	1,875			2,444	76.7 (75.0, 78.4)	0.91 (0.89, 0.93)	790	1,102	71.7 (68.9, 74.3)	0.84 (0.81, 0.87)	20,209	23,898	84.6 (84.1, 85.0)	19,419	22,796	85.2 (84.7, 85.6)	22,084	26,342	83.8 (83.4, 84.3)
BSSL	3,538			4,342	81.5 (80.3, 82.6)	0.94 (0.93, 0.95)	609	808	75.4 (72.2, 78.3)	0.87 (0.84, 0.91)	59,926	69,271	86.5 (86.3, 86.8)	59,317	68,463	86.6 (86.4, 86.9)	63,464	73,613	86.2 (86.0, 86.5)
BSOS	1,334			1,624	82.1 (80.2, 84.0)	0.99 (0.97, 1.01)	190	260	73.1 (67.2, 78.4)	0.88 (0.82, 0.95)	17,547	21,134	83.0 (82.5, 83.5)	17,357	20,874	83.2 (82.6, 83.7)	18,881	22,758	83.0 (82.5, 83.5)
Total	27,428			32,798	83.6 (83.2, 84.0)	0.95 (0.95, 0.96)	11,761	14,317	82.1 (81.5, 82.8)	0.93 (0.93, 0.94)	249,607	284,563	87.7 (87.5, 87.8)	237,846	270,246	88.0 (87.9, 88.1)	277,035	317,361	87.3 (87.2, 87.4)
Mobile	BSWN		2,906	3,307	87.9 (86.7, 89.0)	0.97 (0.96, 0.98)	249	275	90.5 (86.5, 93.7)	1.00 (0.96, 1.04)	12,650	13,988	90.4 (89.9, 90.9)	12,401	13,713	90.4 (89.9, 90.9)	15,556	17,295	89.9 (89.5, 90.4)
	BSCM		887	1,081	82.1 (79.6, 84.3)	0.93 (0.91, 0.96)	1,098	1,319	83.2 (81.1, 85.2)	0.94 (0.91, 0.96)	7,265	8,260	88.0 (87.2, 88.6)	6,167	6,941	88.8 (88.1, 89.6)	8,152	9,341	87.3 (86.6, 87.9)
	BSAC		497	601	82.7 (79.4, 85.6)	0.93 (0.89, 0.96)	970	1,183	82.0 (79.7, 84.1)	0.90 (0.87, 0.93)	4,888	5,478	89.2 (88.4, 90.0)	3,918	4,295	91.2 (90.3, 92.1)	5,385	6,079	88.6 (87.8, 89.4)
	BSM		2,528	3,100	81.5 (80.1, 82.9)	0.91 (0.89, 0.93)	210	262	80.2 (74.8, 84.8)	0.89 (0.84, 0.95)	11,773	13,127	89.7 (89.2, 90.2)	11,563	12,865	89.9 (89.3, 90.4)	14,301	16,227	88.7 (87.6, 88.6)
	BSCC		1,936	2,387	81.1 (79.5, 82.7)	0.93 (0.91, 0.95)	118	161	73.3 (65.8, 79.9)	0.84 (0.77, 0.92)	7,072	8,142	86.9 (86.1, 87.6)	6,954	7,981	87.1 (86.4, 87.9)	9,008	10,529	85.6 (84.9, 86.2)
	BSC		1,569	1,950	80.5 (78.6, 82.2)	0.94 (0.92, 0.96)	875	1,207	72.5 (69.9, 75.0)	0.84 (0.81, 0.87)	15,868	18,538	85.6 (85.1, 86.1)	14,993	17,331	86.5 (86.0, 87.0)	17,437	20,488	85.1 (84.6, 85.6)
	BSSL		453	544	83.3 (79.9, 86.3)	0.97 (0.93, 1.01)	82	110	74.5 (65.4, 82.4)	0.87 (0.78, 0.96)	5,931	6,897	86.0 (85.2, 86.8)	5,849	6,787	86.2 (85.3, 87.0)	6,384	7,441	85.8 (85.0, 86.6)
	BSOS		318	391	81.3 (77.1, 85.1)	0.99 (0.94, 1.04)	22	28	78.6 (59.0, 97.1)	0.96 (0.79, 1.16)	5,798	7,068	82.0 (81.1, 82.9)	5,776	7,040	82.0 (81.1, 82.9)	6,116	7,459	82.0 (81.1, 82.9)
	Total		11,094	13,361	83.0 (82.4, 83.7)	0.95 (0.94, 0.96)	3,624	4,545	79.7 (78.5, 80.9)	0.91 (0.89, 0.92)	71,245	81,498	87.4 (87.2, 87.6)	67,621	76,953	87.9 (87.6, 88.1)	82,339	94,859	86.8 (86.6, 87.0)
	45 to 69		Fixed	BSWN	5,325	6,219	85.6 (84.7, 86.5)	0.96 (0.95, 0.97)	2,710	3,349	80.9 (79.5, 82.2)	0.90 (0.89, 0.92)	48,173	53,913	89.4 (89.1, 89.6)	45,463	50,564	89.9 (89.6, 90.2)	53,498
BSCM		4,077		4,995	81.6 (80.5, 82.7)	0.94 (0.93, 0.96)	7,221	8,498	85.0 (84.2, 85.7)	0.98 (0.97, 0.99)	31,302	36,196	86.5 (86.1, 86.8)	24,081	27,698	86.9 (86.5, 87.3)	35,379	41,191	85.9 (85.6, 86.2)
BSAC		1,654		1,979	83.6 (81.9, 85.2)	0.95 (0.93, 0.97)	1,905	2,394	79.6 (77.9, 81.2)	0.89 (0.87, 0.91)	23,106	26,173	88.3 (87.9, 88.7)	21,201	23,779	89.2 (88.8, 89.6)	24,760	28,152	88.0 (87.6, 88.3)
BSM		9,194		10,667	86.2 (85.5, 86.8)	0.95 (0.94, 0.96)	834	985	84.7 (82.3, 86.9)	0.93 (0.91, 0.96)	47,410	52,167	90.9 (90.6, 91.1)	46,576	51,182	91.0 (90.7, 91.2)	56,604	62,834	90.1 (89.8, 90.3)
BSCC		7,228		8,513	84.9 (84.1, 85.7)	0.95 (0.94, 0.96)	710	838	84.7 (82.1, 87.1)	0.95 (0.92, 0.98)	43,506	48,722	89.3 (89.0, 89.6)	42,796	47,884	89.4 (89.1, 89.6)	50,734	57,235	88.6 (88.4, 88.9)
BSC		2,485		3,216	77.3 (75.8, 78.7)	0.91 (0.90, 0.93)	990	1,373	72.1 (69.7, 74.5)	0.85 (0.82, 0.87)	24,685	29,166	84.6 (84.2, 85.0)	23,695	27,793	85.3 (84.8, 85.7)	27,170	32,882	83.9 (83.5, 84.3)
BSSL		4,784		5,843	81.9 (80.9, 82.9)	0.95 (0.94, 0.96)	838	1,109	75.6 (72.9, 78.2)	0.87 (0.84, 0.90)	76,706	88,803	86.4 (86.2, 86.7)	73,868	87,694				

2.b, Technical recall rate

Description: The number of women recommended for technical recall as a percentage of number of women screened.

Target: ≤0.5% of women screened

Figure 43: 2.b, Technical recall rate, 50 to 69, fixed and mobile units



For BSA overall, technical recall rates were 0.2% for both fixed sites and mobile units for women aged 45–69 years, well within the target range of 0.5% or less. BSC's rates decreased to 0.7% in fixed sites and 0.5% in mobile units. BSOS was similar at 0.7% in fixed sites and 0.6% in mobile units.

Figure 44: 2.b, Fixed site, 50 to 69, Technical recall rate, by LP




Figure 45: 2.b, Mobile units, 50 to 69, Technical recall rate, by LP




Table 7: 2.b, Technical recall rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Māori / Non-Māori Ratio	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Pacific / Non-Pacific Ratio	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)
45 to 49	Fixed	BSWN	0	1,625	0.0 (0.0, 0.2)	0.00 (0.00, 17.99)	1	765	0.1 (0.0, 0.7)	7.40 (0.67, 81.49)	3	12,083	0.0 (0.0, 0.1)	2	11,318	0.0 (0.0, 0.1)	3	13,708	0.0 (0.0, 0.1)
		BSCM	1	1,365	0.1 (0.0, 0.4)	0.21 (0.03, 1.53)	2	2,127	0.1 (0.0, 0.3)	0.22 (0.05, 0.90)	30	8,531	0.4 (0.2, 0.5)	28	6,404	0.4 (0.3, 0.6)	31	9,896	0.3 (0.2, 0.4)
		BSAC	1	581	0.2 (0.0, 1.0)	0.96 (0.12, 7.40)	3	581	0.5 (0.1, 1.5)	3.58 (0.95, 13.44)	11	6,120	0.2 (0.1, 0.3)	8	5,539	0.1 (0.1, 0.3)	12	6,701	0.2 (0.1, 0.3)
		BSM	3	2,422	0.1 (0.0, 0.4)	0.51 (0.15, 1.68)	1	251	0.4 (0.0, 2.2)	1.66 (0.23, 12.23)	26	10,687	0.2 (0.2, 0.4)	25	10,436	0.2 (0.2, 0.4)	29	13,109	0.2 (0.1, 0.3)
		BSCC	3	1,962	0.2 (0.0, 0.4)	7.23 (1.21, 43.22)	0	188	0.0 (0.0, 1.9)	0.00 (0.00, 262.38)	2	9,452	0.0 (0.0, 0.1)	2	9,264	0.0 (0.0, 0.1)	5	11,414	0.0 (0.0, 0.1)
		BSC	9	764	1.2 (0.5, 2.2)	1.05 (0.52, 2.11)	2	269	0.7 (0.1, 2.7)	0.65 (0.16, 2.65)	59	5,251	1.1 (0.9, 1.4)	57	4,982	1.1 (0.9, 1.5)	68	6,015	1.1 (0.9, 1.4)
		BSSL	2	1,471	0.1 (0.0, 0.5)	0.60 (0.15, 2.48)	1	293	0.3 (0.0, 1.9)	1.53 (0.21, 11.04)	44	19,506	0.2 (0.2, 0.3)	43	19,213	0.2 (0.2, 0.3)	46	20,977	0.2 (0.2, 0.3)
		BSOS	6	555	1.1 (0.4, 2.3)	0.99 (0.43, 2.28)	1	96	1.0 (0.0, 5.7)	0.96 (0.13, 6.82)	62	5,689	1.1 (0.8, 1.4)	61	5,593	1.1 (0.8, 1.4)	68	6,244	1.1 (0.8, 1.4)
		Total	25	10,745	0.2 (0.2, 0.3)	0.76 (0.50, 1.15)	11	4,570	0.2 (0.1, 0.4)	0.78 (0.42, 1.42)	237	77,319	0.3 (0.3, 0.3)	226	72,749	0.3 (0.3, 0.4)	262	88,064	0.3 (0.3, 0.3)
	Mobile	BSWN	0	872	0.0 (0.0, 0.4)	0.00 (0.00, 18.99)	0	89	0.0 (0.0, 4.1)	0.00 (0.00, 180.74)	2	3,110	0.1 (0.0, 0.2)	2	3,021	0.1 (0.0, 0.2)	2	3,982	0.1 (0.0, 0.2)
		BSCM	0	348	0.0 (0.0, 1.1)	0.00 (0.00, 4.60)	1	466	0.2 (0.0, 1.2)	0.66 (0.08, 5.45)	7	2,305	0.3 (0.1, 0.6)	6	1,839	0.3 (0.1, 0.7)	7	2,653	0.3 (0.1, 0.5)
		BSAC	0	164	0.0 (0.0, 2.2)	0.00 (0.00, 4.19)	3	313	1.0 (0.2, 2.8)	1.68 (0.44, 6.46)	10	1,540	0.6 (0.3, 1.2)	7	1,227	0.6 (0.2, 1.2)	10	1,704	0.6 (0.3, 1.1)
		BSM	3	787	0.4 (0.1, 1.1)	1.38 (0.35, 5.50)	1	72	1.4 (0.0, 7.5)	5.83 (0.69, 49.27)	6	2,171	0.3 (0.1, 0.6)	5	2,099	0.2 (0.1, 0.6)	9	2,958	0.3 (0.1, 0.6)
		BSCC	0	576	0.0 (0.0, 0.6)	NA (0.06, 94.23)	0	45	0.0 (0.0, 7.9)	NA (0.76, 1130.99)	0	1,394	0.0 (0.0, 0.3)	0	1,349	0.0 (0.0, 0.3)	0	1,970	0.0 (0.0, 0.2)
		BSC	7	508	1.4 (0.6, 2.8)	2.12 (0.92, 4.88)	3	311	1.0 (0.2, 2.8)	1.55 (0.47, 5.15)	25	3,846	0.7 (0.4, 1.0)	22	3,535	0.6 (0.4, 0.9)	32	4,354	0.7 (0.5, 1.0)
		BSSL	0	153	0.0 (0.0, 2.4)	0.00 (0.00, 21.98)	0	47	0.0 (0.0, 7.5)	0.00 (0.00, 69.15)	3	1,390	0.2 (0.0, 0.6)	3	1,343	0.2 (0.0, 0.7)	3	1,543	0.2 (0.0, 0.6)
		BSOS	2	73	2.7 (0.3, 9.5)	4.40 (0.93, 20.78)	0	7	0.0 (0.0, 41.0)	0.00 (0.00, 110.61)	7	1,123	0.6 (0.3, 1.3)	7	1,116	0.6 (0.3, 1.3)	9	1,196	0.8 (0.3, 1.4)
		Total	12	3,481	0.2 (0.2, 0.6)	0.97 (0.52, 1.80)	8	1,350	0.6 (0.3, 1.2)	1.77 (0.84, 3.72)	60	16,879	0.3 (0.3, 0.5)	52	15,529	0.3 (0.3, 0.4)	72	20,360	0.4 (0.3, 0.4)
		50 to 69	Fixed	BSWN	4	4,592	0.1 (0.0, 0.2)	6.06 (1.71, 21.47)	0	2,580	0.0 (0.0, 0.1)	0.00 (0.00, 12.89)	6	41,749	0.0 (0.0, 0.0)	6	39,169	0.0 (0.0, 0.0)	10
BSCM	4			3,611	0.1 (0.0, 0.3)	1.02 (0.36, 2.90)	5	6,363	0.1 (0.0, 0.2)	0.67 (0.26, 1.75)	30	27,635	0.1 (0.1, 0.2)	25	21,272	0.1 (0.1, 0.2)	34	31,246	0.1 (0.1, 0.2)
BSAC	1			1,398	0.1 (0.0, 0.4)	0.55 (0.07, 4.06)	2	1,813	0.1 (0.0, 0.4)	0.84 (0.20, 3.54)	26	20,053	0.1 (0.1, 0.2)	24	18,240	0.1 (0.1, 0.2)	27	21,451	0.1 (0.1, 0.2)
BSM	19			8,148	0.2 (0.1, 0.4)	1.42 (0.85, 2.36)	0	722	0.0 (0.0, 0.5)	0.00 (0.00, 3.14)	68	41,391	0.2 (0.1, 0.2)	68	40,669	0.2 (0.1, 0.2)	87	49,539	0.2 (0.1, 0.2)
BSCC	9			6,505	0.1 (0.1, 0.3)	3.39 (1.50, 7.67)	0	645	0.0 (0.0, 0.6)	0.00 (0.00, 15.50)	16	39,208	0.0 (0.0, 0.1)	16	38,563	0.0 (0.0, 0.1)	25	45,713	0.1 (0.0, 0.1)
BSC	17			2,414	0.7 (0.4, 1.1)	1.21 (0.73, 1.99)	8	1,092	0.7 (0.3, 1.4)	1.27 (0.62, 2.59)	139	23,814	0.6 (0.5, 0.7)	131	22,722	0.6 (0.5, 0.7)	156	26,228	0.6 (0.5, 0.7)
BSSL	15			4,250	0.4 (0.2, 0.6)	2.37 (1.38, 4.07)	2	790	0.3 (0.0, 0.9)	1.71 (0.42, 6.94)	103	69,186	0.1 (0.1, 0.2)	101	68,396	0.1 (0.1, 0.2)	118	73,436	0.2 (0.1, 0.2)
BSOS	11			1,596	0.7 (0.3, 1.2)	1.26 (0.68, 2.33)	1	258	0.4 (0.0, 2.1)	0.70 (0.10, 5.02)	116	21,126	0.5 (0.5, 0.7)	115	20,868	0.6 (0.5, 0.7)	127	22,722	0.6 (0.5, 0.7)
Total	80			32,514	0.2 (0.2, 0.3)	1.39 (1.10, 1.76)	18	14,263	0.1 (0.1, 0.2)	0.70 (0.44, 1.12)	504	284,162	0.2 (0.2, 0.2)	486	269,899	0.2 (0.2, 0.2)	584	316,676	0.2 (0.2, 0.2)
Mobile	BSWN		0	3,306	0.0 (0.0, 0.1)	0.00 (0.00, 4.62)	0	275	0.0 (0.0, 1.3)	0.00 (0.00, 54.39)	5	13,981	0.0 (0.0, 0.1)	5	13,706	0.0 (0.0, 0.1)	5	17,287	0.0 (0.0, 0.1)
	BSCM		1	1,081	0.1 (0.0, 0.5)	0.59 (0.08, 4.48)	2	1,318	0.2 (0.0, 0.5)	0.96 (0.21, 4.30)	13	8,240	0.2 (0.1, 0.3)	11	6,922	0.2 (0.1, 0.3)	14	9,321	0.2 (0.1, 0.3)
	BSAC		0	601	0.0 (0.0, 0.6)	0.00 (0.00, 6.32)	1	1,183	0.1 (0.0, 0.5)	0.61 (0.07, 5.02)	7	5,478	0.1 (0.1, 0.3)	6	4,295	0.1 (0.1, 0.3)	7	6,079	0.1 (0.0, 0.2)
	BSM		5	3,100	0.2 (0.1, 0.4)	1.63 (0.58, 4.56)	0	262	0.0 (0.0, 1.4)	0.00 (0.00, 16.09)	13	13,106	0.1 (0.1, 0.2)	13	12,844	0.1 (0.1, 0.2)	18	16,206	0.1 (0.1, 0.2)
	BSCC		0	2,387	0.0 (0.0, 0.2)	0.00 (0.00, 8.25)	0	161	0.0 (0.0, 2.3)	0.00 (0.00, 119.93)	3	8,140	0.0 (0.0, 0.1)	3	7,979	0.0 (0.0, 0.1)	3	10,527	0.0 (0.0, 0.1)
	BSC		7	1,939	0.4 (0.1, 0.7)	0.76 (0.35, 1.64)	8	1,199	0.7 (0.3, 1.3)	1.44 (0.70, 2.98)	88	18,498	0.5 (0.4, 0.6)	80	17,299	0.5 (0.4, 0.6)	95	20,437	0.5 (0.4, 0.6)
	BSSL		0	545	0.0 (0.0, 0.7)	0.00 (0.00, 10.74)	2	110	1.8 (0.2, 6.4)	30.82 (5.71, 166.53)	6	6,891	0.1 (0.0, 0.2)	4	6,781	0.1 (0.0, 0.2)	6	7,436	0.1 (0.0, 0.2)
	BSOS		2	391	0.5 (0.1, 1.8)	0.98 (0.24, 4.04)	1	28	3.6 (0.1, 18.3)	6.98 (0.99, 49.19)	37	7,068	0.5 (0.4, 0.7)	36	7,040	0.5 (0.4, 0.7)	39	7,459	0.5 (0.4, 0.7)
	Total		15	13,350	0.1 (0.1, 0.2)	0.53 (0.31, 0.90)	14	4,536	0.3 (0.2, 0.5)	1.50 (0.87, 2.59)	172	81,402	0.2 (0.2, 0.2)	158	76,866	0.2 (0.2, 0.2)	187	94,752	0.2 (0.2, 0.2)
	45 to 69		Fixed	BSWN	4	6,217	0.1 (0.0, 0.2)	3.85 (1.19, 12.49)	1	3,345	0.0 (0.0, 0.2)	1.89 (0.24, 15.08)	9	53,832	0.0 (0.0, 0.0)	8	50,487	0.0 (0.0, 0.0)	13
BSCM		5		4,976	0.1 (0.0, 0.2)	0.61 (0.24, 1.51)	7	8,490	0.1 (0.0, 0.2)	0.43 (0.20, 0.95)	60	36,166	0.2 (0.1, 0.2)	53	27,676	0.2 (0.1, 0.3)	65	41,142	0.2 (0.1, 0.2)
BSAC		2		1,979	0.1 (0.0, 0.4)	0.72 (0.17, 2.96)	5	2,394	0.2 (0.1, 0.5)	1.55 (0.60, 3.98)	37	26,173	0.1 (0.1, 0.2)	32	23,779	0.1 (0.1, 0.2)	39	28,152	0.1 (0.1, 0.2)
BSM		22		10,570	0.2 (0.1, 0.3)	1.15 (0.72, 1.83)	1	973	0.1 (0.0, 0.6)	0.57 (0.08, 4.05)	94	52,078	0.2 (0.1, 0.2)	93	51,105	0.2 (0.1, 0.2)	116	62,648	0.2 (0.2, 0.2)
BSCC		12		8,467	0.1 (0.1, 0.2)	3.83 (1.85, 7.95)	0	833	0.0 (0.0, 0.4)	0.00 (0.00, 13.06)	18	48,660	0.0 (0.0, 0.1)	18	47,827	0.0 (0.0, 0.1)	30	57,127	0.1 (0.0, 0.1)
BSC		26		3,178	0.8 (0.5, 1.2)	1.20 (0.80, 1.80)	10	1,361	0.7 (0.4, 1.3)	1.08 (0.57, 2.04)	198	29,065	0.7 (0.6, 0.8)	188	27,704	0.7 (0.6, 0.8)	224	32,243	0.7 (0.6, 0.8)
BSSL		17		5,721	0.3 (0.2, 0.5)	1.79 (1.09, 2.96)	3	1,083	0.3 (0.1, 0.8)	1.69 (0.54, 5.28)	147	88,692	0.2 (0.1, 0.2)	144	87,609	0.2 (0.1, 0.2)	164	94,413	0.2 (0.1, 0.2)
BSOS		17		2,151	0.8 (0.5, 1.3)	1.19 (0.72, 1.95)	2	354	0.6 (0.1, 2.0)	0.85 (0.21, 3.41)	178	26,815	0.7 (0.6, 0.8)	176	26,461	0.7 (0.6, 0.8)	195	28,966	0.7 (0.6, 0.8)
Total		105		43,259	0.2 (0.2, 0.3)	1.18 (0.96, 1.45)	29	18,833	0.2 (0.1, 0.2)	0.74 (0.51, 1.07)	741	361,481	0.2 (0.2, 0.2)	712	342,648	0.2 (0.2, 0.2)	846	404,740	0.2 (0.2, 0.2)
Mobile		BSWN	0	4,178	0.0 (0.0, 0.1)	0.00 (0.00, 2.84)	0	364	0.0 (0.0, 1.0)	0.00 (0.00, 31.88)	7	17,091	0.0 (0.0, 0.1)	7	16,727	0.0 (0.0, 0.1)	7	21,269	0.0 (0.0, 0.1)
		BSCM	1	1,429	0.1 (0.0, 0.4)	0.37 (0.05, 2.75)	3	1,784	0.2 (0.0, 0.5)	0.87 (0.25, 2.95)	20	10,545	0.2 (0.1, 0.3)	17	8,761	0.2 (0.1, 0.3)	21	11,974	0.2 (0.1, 0.3)
		BSAC	0	765	0.0 (0.0, 0.5)	0.00 (0.00, 2.22)	4	1,496	0.3 (0.1, 0.7)	1.14 (0.37, 3.48)	17	7,018	0.2 (0.1, 0.4)	13	5,522	0.2 (0.1, 0.4)	17		

2.c, Technical reject rate

Description: The number of images rejected as a percentage of total number of images taken, including technical recalls.

Target: ≤3% of images are rejected

Figure 46: 2.c, Technical reject rate, 50 to 69, fixed and mobile units



Technical reject rates were all well within the target range of 3% or less.

Figure 47: 2.c, Fixed sites 50 to 69, Technical reject rate, by LP




Figure 48: 2.c, Mobile units, 50 to 69, Technical reject rate, by LP




Table 8: 2.c, Technical reject rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Māori / Non-Māori Ratio	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Pacific / Non-Pacific Ratio	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)
45 to 49	Fixed	BSWN	56	6,904	0.8 (0.6, 1.1)	1.12 (0.84, 1.48)	32	3,310	1.0 (0.7, 1.4)	1.36 (0.95, 1.95)	371	51,066	0.7 (0.7, 0.8)	339	47,756	0.7 (0.6, 0.8)	427	57,970	0.7 (0.6, 0.8)
		BSCM	90	6,069	1.5 (1.2, 1.8)	0.98 (0.78, 1.22)	147	9,024	1.6 (1.4, 1.9)	1.10 (0.91, 1.32)	551	36,249	1.5 (1.4, 1.7)	404	27,225	1.5 (1.3, 1.6)	641	42,318	1.5 (1.4, 1.6)
		BSAC	2	2,500	0.1 (0.0, 0.3)	0.28 (0.07, 1.16)	10	2,567	0.4 (0.2, 0.7)	1.44 (0.74, 2.81)	73	25,895	0.3 (0.2, 0.4)	63	23,328	0.3 (0.2, 0.3)	75	28,395	0.3 (0.2, 0.3)
		BSM	103	10,578	1.0 (0.8, 1.2)	0.99 (0.80, 1.22)	13	1,118	1.2 (0.6, 2.0)	1.19 (0.69, 2.05)	443	44,959	1.0 (0.9, 1.1)	430	43,841	1.0 (0.9, 1.1)	546	55,537	1.0 (0.9, 1.1)
		BSCC	79	8,456	0.9 (0.7, 1.2)	1.07 (0.84, 1.36)	6	805	0.7 (0.3, 1.6)	0.85 (0.38, 1.90)	346	39,597	0.9 (0.8, 1.0)	340	38,792	0.9 (0.8, 1.0)	425	48,053	0.9 (0.8, 1.0)
		BSC	1	3,443	0.0 (0.0, 0.2)	0.22 (0.03, 1.59)	0	1,223	0.0 (0.0, 0.3)	0.00 (0.00, 2.27)	30	22,453	0.1 (0.1, 0.2)	30	21,230	0.1 (0.1, 0.2)	31	25,896	0.1 (0.1, 0.2)
		BSSL	53	6,961	0.8 (0.6, 1.0)	1.23 (0.93, 1.62)	8	1,399	0.6 (0.2, 1.1)	0.92 (0.46, 1.84)	515	82,908	0.6 (0.6, 0.7)	507	81,509	0.6 (0.6, 0.7)	568	89,869	0.6 (0.6, 0.7)
		BSOS	32	2,584	1.2 (0.8, 1.7)	0.75 (0.53, 1.08)	3	436	0.7 (0.1, 2.0)	0.42 (0.13, 1.29)	397	24,181	1.6 (1.5, 1.8)	394	23,745	1.7 (1.5, 1.8)	429	26,765	1.6 (1.5, 1.8)
		Total	416	47,495	0.9 (0.8, 1.0)	1.05 (0.95, 1.17)	219	19,882	1.1 (1.0, 1.3)	1.35 (1.18, 1.55)	2,726	327,308	0.8 (0.8, 0.9)	2,507	307,426	0.8 (0.8, 0.8)	3,142	374,803	0.8 (0.8, 0.9)
	Mobile	BSWN	26	3,647	0.7 (0.5, 1.0)	1.03 (0.67, 1.59)	4	373	1.1 (0.3, 2.7)	1.57 (0.58, 4.26)	90	12,964	0.7 (0.6, 0.9)	86	12,591	0.7 (0.5, 0.8)	116	16,611	0.7 (0.6, 0.8)
		BSCM	28	1,494	1.9 (1.2, 2.7)	1.08 (0.73, 1.60)	37	1,993	1.9 (1.3, 2.5)	1.09 (0.76, 1.56)	170	9,795	1.7 (1.5, 2.0)	133	7,802	1.7 (1.4, 2.0)	198	11,289	1.8 (1.5, 2.0)
		BSAC	1	700	0.1 (0.0, 0.8)	2.33 (0.26, 20.82)	2	1,377	0.1 (0.0, 0.5)	3.74 (0.53, 26.52)	4	6,526	0.1 (0.0, 0.2)	2	5,149	0.0 (0.0, 0.1)	5	7,226	0.1 (0.0, 0.2)
		BSM	48	3,372	1.4 (1.1, 1.9)	1.55 (1.09, 2.21)	4	306	1.3 (0.4, 3.3)	1.45 (0.53, 3.93)	83	9,059	0.9 (0.7, 1.1)	79	8,753	0.9 (0.7, 1.1)	131	12,431	1.1 (0.9, 1.2)
		BSCC	29	2,459	1.2 (0.8, 1.7)	0.80 (0.53, 1.22)	11	201	5.5 (2.8, 9.6)	4.13 (2.23, 7.67)	85	5,790	1.5 (1.2, 1.8)	74	5,589	1.3 (1.0, 1.7)	114	8,249	1.4 (1.1, 1.7)
		BSC	0	2,244	0.0 (0.0, 0.2)	0.00 (0.00, 6.14)	0	1,376	0.0 (0.0, 0.3)	0.00 (0.00, 9.17)	6	16,237	0.0 (0.0, 0.1)	6	14,861	0.0 (0.0, 0.1)	6	18,481	0.0 (0.0, 0.1)
		BSSL	5	671	0.7 (0.2, 1.7)	0.84 (0.34, 2.10)	3	213	1.4 (0.3, 4.1)	1.63 (0.51, 5.18)	52	5,871	0.9 (0.7, 1.2)	49	5,658	0.9 (0.6, 1.1)	57	6,542	0.9 (0.7, 1.1)
		BSOS	2	310	0.6 (0.1, 2.3)	0.60 (0.15, 2.46)	0	31	0.0 (0.0, 11.2)	0.00 (0.00, 11.45)	51	4,762	1.1 (0.8, 1.4)	51	4,731	1.1 (0.8, 1.4)	53	5,072	1.0 (0.8, 1.4)
		Total	139	14,897	0.9 (0.8, 1.1)	1.23 (1.02, 1.47)	61	5,870	1.0 (0.8, 1.3)	1.41 (1.08, 1.84)	541	71,004	0.8 (0.7, 0.8)	480	65,134	0.7 (0.7, 0.8)	680	85,901	0.8 (0.7, 0.9)
		50 to 69	Fixed	BSWN	133	19,412	0.7 (0.6, 0.8)	1.13 (0.94, 1.35)	76	11,032	0.7 (0.5, 0.9)	1.15 (0.91, 1.45)	1,064	175,452	0.6 (0.6, 0.6)	988	164,420	0.6 (0.6, 0.6)	1,197
BSCM	242			15,668	1.5 (1.4, 1.8)	1.11 (0.97, 1.26)	375	26,868	1.4 (1.3, 1.5)	1.00 (0.89, 1.12)	1,626	116,479	1.4 (1.3, 1.5)	1,251	89,611	1.4 (1.3, 1.5)	1,868	132,147	1.4 (1.4, 1.5)
BSAC	19			5,920	0.3 (0.2, 0.5)	1.42 (0.89, 2.27)	26	7,734	0.3 (0.2, 0.5)	1.56 (1.03, 2.36)	189	83,549	0.2 (0.2, 0.3)	163	75,815	0.2 (0.2, 0.3)	208	89,469	0.2 (0.2, 0.3)
BSM	379			35,946	1.1 (1.0, 1.2)	1.14 (1.02, 1.27)	40	3,204	1.2 (0.9, 1.7)	1.36 (0.99, 1.85)	1,610	173,688	0.9 (0.9, 1.0)	1,570	170,484	0.9 (0.9, 1.0)	1,989	209,634	0.9 (0.9, 1.0)
BSCC	243			28,080	0.9 (0.8, 1.0)	1.02 (0.89, 1.16)	25	2,783	0.9 (0.6, 1.3)	1.06 (0.71, 1.56)	1,396	163,739	0.9 (0.8, 0.9)	1,371	160,956	0.9 (0.8, 0.9)	1,639	191,819	0.9 (0.8, 0.9)
BSC	10			10,794	0.1 (0.0, 0.2)	1.57 (0.80, 3.06)	1	4,933	0.0 (0.0, 0.1)	0.33 (0.05, 2.40)	60	101,570	0.1 (0.0, 0.1)	59	96,637	0.1 (0.0, 0.1)	70	112,364	0.1 (0.0, 0.1)
BSSL	149			20,090	0.7 (0.6, 0.9)	1.24 (1.05, 1.46)	44	3,696	1.2 (0.9, 1.6)	2.01 (1.49, 2.71)	1,746	291,102	0.6 (0.6, 0.6)	1,702	287,406	0.6 (0.6, 0.6)	1,895	311,192	0.6 (0.6, 0.6)
BSOS	104			7,495	1.4 (1.1, 1.7)	0.86 (0.70, 1.05)	25	1,221	2.0 (1.3, 3.0)	1.27 (0.86, 1.88)	1,445	89,425	1.6 (1.5, 1.7)	1,420	88,204	1.6 (1.5, 1.7)	1,549	96,920	1.6 (1.5, 1.7)
Total	1,279			143,405	0.9 (0.8, 0.9)	1.17 (1.10, 1.24)	612	61,471	1.0 (0.9, 1.1)	1.32 (1.22, 1.44)	9,136	1,195,004	0.8 (0.7, 0.8)	8,524	1,133,533	0.8 (0.7, 0.8)	10,415	1,338,409	0.8 (0.8, 0.8)
Mobile	BSWN			116	13,826	0.8 (0.7, 1.0)	1.12 (0.92, 1.38)	6	1,136	0.5 (0.2, 1.1)	0.70 (0.32, 1.57)	434	58,102	0.7 (0.7, 0.8)	428	56,966	0.8 (0.7, 0.8)	550	71,928
	BSCM		89	4,624	1.9 (1.5, 2.4)	1.34 (1.07, 1.68)	85	5,595	1.5 (1.2, 1.9)	1.07 (0.85, 1.35)	498	34,689	1.4 (1.3, 1.6)	413	29,094	1.4 (1.3, 1.6)	587	39,313	1.5 (1.4, 1.6)
	BSAC		7	2,553	0.3 (0.1, 0.6)	2.15 (0.94, 4.90)	11	5,038	0.2 (0.1, 0.4)	2.15 (1.01, 4.54)	29	22,719	0.1 (0.1, 0.2)	18	17,681	0.1 (0.1, 0.2)	36	25,272	0.1 (0.1, 0.2)
	BSM		139	13,315	1.0 (0.9, 1.2)	1.19 (0.99, 1.44)	17	1,134	1.5 (0.9, 2.4)	1.74 (1.08, 2.81)	479	54,741	0.9 (0.8, 1.0)	462	53,607	0.9 (0.8, 0.9)	618	68,056	0.9 (0.8, 1.0)
	BSCC		158	10,143	1.6 (1.3, 1.8)	1.24 (1.03, 1.48)	12	694	1.7 (0.9, 3.0)	1.38 (0.78, 2.44)	428	33,924	1.3 (1.1, 1.4)	416	33,230	1.3 (1.1, 1.4)	586	44,067	1.3 (1.2, 1.4)
	BSC		1	8,404	0.0 (0.0, 0.1)	0.52 (0.07, 3.87)	0	5,400	0.0 (0.0, 0.1)	0.00 (0.00, 3.06)	18	78,072	0.0 (0.0, 0.0)	18	72,672	0.0 (0.0, 0.0)	19	86,476	0.0 (0.0, 0.0)
	BSSL		16	2,322	0.7 (0.4, 1.1)	0.92 (0.55, 1.52)	6	496	1.2 (0.4, 2.6)	1.63 (0.73, 3.64)	218	29,005	0.8 (0.7, 0.9)	212	28,509	0.7 (0.6, 0.9)	234	31,327	0.7 (0.7, 0.8)
	BSOS		15	1,678	0.9 (0.5, 1.5)	0.76 (0.46, 1.27)	0	120	0.0 (0.0, 3.0)	0.00 (0.00, 2.62)	352	29,955	1.2 (1.1, 1.3)	352	29,835	1.2 (1.1, 1.3)	367	31,633	1.2 (1.0, 1.3)
	Total		541	56,865	1.0 (0.9, 1.0)	1.32 (1.21, 1.45)	137	19,613	0.7 (0.6, 0.8)	0.97 (0.82, 1.15)	2,456	341,207	0.7 (0.7, 0.7)	2,319	321,594	0.7 (0.7, 0.8)	2,997	398,072	0.8 (0.7, 0.8)
45 to 69	Fixed		BSWN	189	26,316	0.7 (0.6, 0.8)	1.13 (0.97, 1.32)	108	14,342	0.8 (0.6, 0.9)	1.20 (0.99, 1.46)	1,435	226,518	0.6 (0.6, 0.7)	1,327	212,176	0.6 (0.6, 0.7)	1,624	252,834
		BSCM	332	21,737	1.5 (1.4, 1.7)	1.07 (0.95, 1.20)	522	35,892	1.5 (1.3, 1.6)	1.03 (0.93, 1.13)	2,177	152,728	1.4 (1.4, 1.5)	1,655	116,836	1.4 (1.3, 1.5)	2,509	174,465	1.4 (1.4, 1.5)
		BSAC	21	8,420	0.2 (0.2, 0.4)	1.04 (0.67, 1.62)	36	10,301	0.3 (0.2, 0.5)	1.53 (1.08, 2.18)	262	109,444	0.2 (0.2, 0.3)	226	99,143	0.2 (0.2, 0.3)	283	117,864	0.2 (0.2, 0.3)
		BSM	482	46,524	1.0 (0.9, 1.1)	1.10 (1.00, 1.22)	53	4,322	1.2 (0.9, 1.6)	1.31 (1.00, 1.72)	2,053	218,647	0.9 (0.9, 1.0)	2,000	214,325	0.9 (0.9, 1.0)	2,535	265,171	1.0 (0.9, 1.0)
		BSCC	322	36,536	0.9 (0.8, 1.0)	1.03 (0.91, 1.16)	31	3,588	0.9 (0.6, 1.2)	1.01 (0.71, 1.44)	1,742	203,336	0.9 (0.8, 0.9)	1,711	199,748	0.9 (0.8, 0.9)	2,064	239,872	0.9 (0.8, 0.9)
		BSC	11	14,237	0.1 (0.0, 0.1)	1.07 (0.57, 1.99)	1	6,156	0.0 (0.0, 0.1)	0.22 (0.03, 1.54)	90	124,023	0.1 (0.1, 0.1)	89	117,867	0.1 (0.1, 0.1)	101	138,260	0.1 (0.1, 0.1)
		BSSL	202	27,051	0.7 (0.6, 0.9)	1.24 (1.07, 1.43)	52	5,095	1.0 (0.8, 1.3)	1.70 (1.30, 2.24)	2,261	374,010	0.6 (0.6, 0.6)	2,209	368,915	0.6 (0.6, 0.6)	2,463	401,061	0.6 (0.6, 0.6)
		BSOS	136	10,079	1.3 (1.1, 1.6)	0.83 (0.70, 0.99)	28	1,657	1.7 (1.1, 2.4)	1.04 (0.72, 1.51)	1,842	113,606	1.6 (1.5, 1.7)	1,814	111,949	1.6 (1.5, 1.7)	1,978	123,685	1.6 (1.5, 1.7)
		Total	1,695	190,900	0.9 (0.8, 0.9)	1.14 (1.08, 1.20)	831	81,353	1.0 (1.0, 1.1)	1.33 (1.24, 1.43)	11,862	1,522,312	0.8 (0.8, 0.8)	11,031	1,440,959	0.8 (0.8, 0.8)	13,557	1,713,212	0.8 (0.8, 0.8)
		Mobile	BSWN	142	17,473	0.8 (0.7, 1.0)	1.10 (0.92, 1.33)	10	1,509	0.7 (0.3, 1.2)	0.90 (0.48, 1.67)	524	71,066	0.7 (0.7, 0.8)	514	69,557	0.7 (0.7, 0.8)	666	88,539
	BSCM		117</																

2.d, Assessment rate

Description: The number of women referred to assessment as a percentage of number of women screened.

Targets: Initial: expected value <10%. Subsequent: expected value <5%. (45–49 and 50–69 age group)

Figure 49: 2.d.1, 50 to 69, Assessment rate, initial and subsequent screens



There were 21,510 referrals to assessment over the two-year period, an increase of 798 from the previous biennium.

The proportion of Māori women aged 50–69 years referred for assessment from an initial screen was 12%, above the target of <10% but the positive predictive value for Māori women was high at 18.6%, indicating the higher assessment rate was appropriate. For Pacific women aged 50–69 having initial screens the assessment rate was 13.4% but the positive predictive value was also high at 20.4%. The assessment rate for non-Māori non-Pacific women aged 50–69 having initial screens was 10% with a positive predictive value of 11.8%. Among women having subsequent screens, assessment rates were within the target range of <5% for all groups at 3.8% for Māori, 3.7% for Pacific and 3.4% for non-Māori non-Pacific women.

For women aged 45–49 years, rates of referral to assessment were within the expected ranges for initial (8.3%) and subsequent screens (4.5%).

Figure 50: 2.d.3, Initial, 50 to 69, Assessment rate, by LP




Figure 51: 2.d.5, Subsequent, 50 to 69, Assessment rate, by LP




Table 9: 2.d, Assessment rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Māori / Non-Māori Ratio	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Pacific / Non-Māori Non-Pacific Ratio	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to
45 to 49	Initial	BSWN	139	1,156	12.0 (10.2, 14.0)	1.44 (1.21, 1.71)	42	398	10.6 (7.7, 14.0)	1.28 (0.95, 1.73)	583	6,969	8.4 (7.7, 9.0)	541	6,571	8.2 (7.6, 8.9)	722	8,125	8.9 (8.3, 9.5)
		BSCM	51	741	6.9 (5.2, 9.0)	0.88 (0.66, 1.17)	98	1,233	7.9 (6.5, 9.6)	1.02 (0.82, 1.28)	355	4,541	7.8 (7.1, 8.6)	257	3,308	7.8 (6.9, 8.7)	406	5,282	7.7 (7.0, 8.4)
		BSAC	48	366	13.1 (9.8, 17.0)	1.60 (1.20, 2.13)	29	372	7.8 (5.3, 11.0)	0.95 (0.66, 1.37)	276	3,373	8.2 (7.3, 9.2)	247	3,001	8.2 (7.3, 9.3)	324	3,739	8.7 (7.8, 9.6)
		BSM	157	1,422	11.0 (9.5, 12.8)	1.42 (1.20, 1.69)	15	151	9.9 (5.7, 15.9)	1.29 (0.79, 2.10)	417	5,372	7.8 (7.1, 8.5)	402	5,221	7.7 (7.0, 8.5)	574	6,794	8.4 (7.8, 9.1)
		BSCC	67	1,047	6.4 (5.0, 8.1)	1.50 (1.14, 1.97)	3	104	2.9 (0.6, 8.2)	0.67 (0.22, 2.06)	176	4,125	4.3 (3.7, 4.9)	173	4,021	4.3 (3.7, 5.0)	243	5,172	4.7 (4.1, 5.3)
		BSC	39	543	7.2 (5.2, 9.7)	1.01 (0.73, 1.40)	19	248	7.7 (4.7, 11.7)	1.09 (0.69, 1.71)	206	2,896	7.1 (6.2, 8.1)	187	2,648	7.1 (6.2, 8.1)	245	3,439	7.1 (6.3, 8.0)
		BSSL	60	683	8.8 (6.8, 11.2)	1.03 (0.80, 1.32)	12	169	7.1 (3.7, 12.1)	0.83 (0.48, 1.44)	720	8,433	8.5 (7.9, 9.2)	708	8,264	8.6 (8.0, 9.2)	780	9,116	8.6 (8.0, 9.1)
		BSOS	42	249	16.9 (12.4, 22.1)	1.34 (1.00, 1.79)	6	49	12.2 (4.6, 24.8)	0.97 (0.46, 2.06)	362	2,867	12.6 (11.4, 13.9)	356	2,818	12.6 (11.4, 13.9)	404	3,116	13.0 (11.8, 14.2)
		Total	603	6,207	9.7 (9.0, 10.5)	1.21 (1.11, 1.32)	224	2,724	8.2 (7.2, 9.3)	1.03 (0.90, 1.17)	3,095	38,576	8.0 (7.8, 8.3)	2,871	35,852	8.0 (7.7, 8.3)	3,698	44,783	8.3 (8.0, 8.5)
	Subsequent	BSWN	72	1,347	5.3 (4.2, 6.7)	1.30 (1.01, 1.66)	15	458	3.3 (1.8, 5.3)	0.79 (0.47, 1.31)	342	8,294	4.1 (3.7, 4.6)	327	7,836	4.2 (3.7, 4.6)	414	9,641	4.3 (3.9, 4.7)
		BSCM	34	989	3.4 (2.4, 4.8)	0.75 (0.53, 1.06)	59	1,361	4.3 (3.3, 5.6)	0.93 (0.70, 1.23)	289	6,310	4.6 (4.1, 5.1)	230	4,949	4.6 (4.1, 5.3)	323	7,299	4.4 (4.0, 4.9)
		BSAC	18	379	4.7 (2.8, 7.4)	1.00 (0.62, 1.60)	26	522	5.0 (3.3, 7.2)	1.05 (0.70, 1.57)	204	4,287	4.8 (4.1, 5.4)	178	3,765	4.7 (4.1, 5.5)	222	4,666	4.8 (4.2, 5.4)
		BSM	90	1,847	4.9 (3.9, 6.0)	0.98 (0.78, 1.22)	4	180	2.2 (0.6, 5.6)	0.44 (0.17, 1.16)	376	7,530	5.0 (4.5, 5.5)	372	7,350	5.1 (4.6, 5.6)	466	9,377	5.0 (4.5, 5.4)
		BSCC	34	1,519	2.2 (1.6, 3.1)	1.10 (0.76, 1.59)	2	131	1.5 (0.2, 4.4)	0.74 (0.19, 2.97)	138	6,756	2.0 (1.7, 2.4)	136	6,625	2.1 (1.7, 2.4)	172	8,275	2.1 (1.7, 2.4)
		BSC	43	757	5.7 (4.1, 7.6)	1.37 (1.00, 1.87)	15	346	4.3 (2.4, 7.0)	1.05 (0.63, 1.74)	261	6,286	4.2 (3.7, 4.7)	246	5,940	4.1 (3.6, 4.7)	304	7,043	4.3 (3.9, 4.8)
		BSSL	58	1,024	5.7 (4.3, 7.3)	1.16 (0.90, 1.51)	8	185	4.3 (1.9, 8.3)	0.89 (0.45, 1.76)	610	12,539	4.9 (4.5, 5.3)	602	12,354	4.9 (4.5, 5.3)	668	13,563	4.9 (4.6, 5.3)
		BSOS	30	411	7.3 (5.0, 10.3)	1.05 (0.73, 1.50)	4	57	7.0 (1.9, 17.0)	1.01 (0.39, 2.60)	276	3,951	7.0 (6.2, 7.8)	272	3,894	7.0 (6.2, 7.8)	306	4,362	7.0 (6.3, 7.8)
		Total	379	8,273	4.6 (4.1, 5.1)	1.03 (0.92, 1.14)	133	3,240	4.1 (3.4, 4.8)	1.01 (0.77, 1.09)	2,496	55,953	4.5 (4.3, 4.6)	2,363	52,713	4.5 (4.3, 4.7)	2,875	64,226	4.5 (4.3, 4.6)
		50 to 69	Initial	BSWN	42	290	14.5 (10.6, 19.1)	1.22 (0.90, 1.65)	19	99	19.2 (12.0, 28.3)	1.67 (1.09, 2.54)	264	2,228	11.8 (10.5, 13.3)	245	2,129	11.5 (10.2, 12.9)	306
BSCM	25			167	15.0 (9.9, 21.3)	1.35 (0.91, 2.01)	30	259	11.6 (8.0, 16.1)	1.06 (0.72, 1.56)	131	1,184	11.1 (9.3, 13.0)	101	925	10.9 (9.0, 13.1)	156	1,351	11.5 (9.9, 13.4)
BSAC	8			111	7.2 (3.2, 13.7)	0.70 (0.35, 1.40)	9	99	9.1 (4.2, 16.6)	0.88 (0.46, 1.67)	121	1,178	10.3 (8.6, 12.1)	112	1,079	10.4 (8.6, 12.4)	129	1,289	10.0 (8.4, 11.8)
BSM	69			491	14.1 (11.1, 17.4)	1.53 (1.17, 2.00)	10	40	25.0 (12.7, 41.2)	2.85 (1.63, 4.98)	147	1,600	9.2 (7.8, 10.7)	137	1,769	8.8 (7.4, 10.3)	216	2,091	10.3 (9.1, 11.7)
BSCC	33			364	9.1 (6.3, 12.5)	1.73 (1.16, 2.59)	2	31	6.5 (0.8, 21.4)	1.24 (0.32, 4.83)	64	1,220	5.2 (4.1, 6.6)	62	1,189	5.2 (4.0, 6.6)	97	1,584	6.1 (5.0, 7.4)
BSC	8			142	5.6 (2.5, 10.8)	0.74 (0.36, 1.50)	11	101	10.9 (5.6, 18.7)	1.50 (0.82, 2.77)	69	902	7.6 (6.0, 9.6)	58	801	7.2 (5.5, 9.3)	77	1,044	7.4 (5.9, 9.1)
BSSL	13			131	9.9 (5.4, 16.4)	0.96 (0.56, 1.64)	7	46	15.2 (6.3, 28.9)	1.50 (0.74, 3.01)	171	1,659	10.3 (8.9, 11.9)	164	1,613	10.2 (8.7, 11.7)	184	1,790	10.3 (8.9, 11.8)
BSOS	6			52	11.5 (4.4, 23.4)	0.79 (0.36, 1.72)	5	21	23.8 (8.2, 47.2)	1.67 (0.76, 3.67)	93	638	14.6 (11.6, 17.6)	88	617	14.3 (11.6, 17.3)	99	690	14.3 (11.6, 17.2)
Total	204			1,748	11.7 (10.2, 13.3)	1.17 (1.01, 1.34)	93	696	13.4 (10.9, 16.1)	1.37 (1.12, 1.67)	1,060	10,609	10.0 (9.4, 10.6)	967	9,913	9.8 (9.2, 10.4)	1,264	12,357	10.2 (9.7, 10.8)
Subsequent	BSWN			317	7,614	4.2 (3.7, 4.6)	1.23 (1.09, 1.38)	113	2,756	4.1 (3.4, 4.9)	1.22 (1.01, 1.47)	1,816	53,539	3.4 (3.2, 3.5)	1,703	50,783	3.4 (3.2, 3.5)	2,133	61,153
	BSCM		192	4,529	4.2 (3.7, 4.9)	1.16 (1.00, 1.35)	263	7,423	3.5 (3.1, 4.0)	0.96 (0.84, 1.10)	1,266	34,702	3.6 (3.5, 3.9)	1,003	27,279	3.7 (3.5, 3.9)	1,458	39,231	3.7 (3.5, 3.9)
	BSAC		66	1,888	3.5 (2.7, 4.4)	1.11 (0.86, 1.42)	119	2,897	4.1 (3.4, 4.9)	1.36 (1.12, 1.64)	769	24,353	3.2 (2.9, 3.4)	650	21,456	3.0 (2.8, 3.3)	835	26,241	3.2 (3.0, 3.4)
	BSM		443	10,788	4.1 (3.7, 4.5)	1.15 (1.04, 1.27)	33	947	3.5 (2.4, 4.9)	0.97 (0.69, 1.36)	1,894	52,947	3.6 (3.4, 3.7)	1,861	52,000	3.6 (3.4, 3.7)	2,337	63,735	3.7 (3.5, 3.8)
	BSCC		193	8,537	2.3 (2.0, 2.6)	1.36 (1.17, 1.59)	12	776	1.5 (0.8, 2.7)	0.93 (0.53, 1.64)	765	46,144	1.7 (1.5, 1.8)	753	45,368	1.7 (1.5, 1.8)	958	54,681	1.8 (1.6, 1.9)
	BSC		166	4,221	3.9 (3.4, 4.6)	1.05 (0.90, 1.23)	92	2,195	4.2 (3.4, 5.1)	1.13 (0.92, 1.39)	1,552	41,448	3.7 (3.6, 3.9)	1,460	39,253	3.7 (3.5, 3.9)	1,718	45,669	3.8 (3.6, 3.9)
	BSSL		207	4,710	4.4 (3.8, 5.0)	1.21 (1.05, 1.39)	28	862	3.2 (2.2, 4.7)	0.89 (0.62, 1.29)	2,705	74,449	3.6 (3.5, 3.8)	2,677	73,587	3.6 (3.5, 3.8)	2,912	79,159	3.7 (3.5, 3.8)
	BSOS		104	1,950	5.3 (4.4, 6.4)	1.21 (0.99, 1.47)	17	269	6.3 (3.7, 9.9)	1.44 (0.90, 2.28)	1,218	27,561	4.4 (4.2, 4.7)	1,201	27,292	4.4 (4.2, 4.7)	1,322	29,511	4.5 (4.2, 4.7)
	Total		1,688	44,237	3.8 (3.6, 4.0)	1.13 (1.08, 1.19)	677	18,125	3.7 (3.5, 4.0)	1.11 (1.03, 1.20)	11,985	355,143	3.4 (3.3, 3.4)	11,308	337,018	3.4 (3.3, 3.4)	13,673	399,380	3.4 (3.4, 3.5)
45 to 69	Initial		BSWN	181	1,446	12.5 (10.9, 14.3)	1.36 (1.17, 1.58)	61	497	12.3 (9.5, 15.5)	1.36 (1.06, 1.74)	847	9,197	9.2 (8.6, 9.8)	786	8,700	9.0 (8.4, 9.7)	1,028	10,643
		BSCM	76	908	8.4 (6.7, 10.4)	0.99 (0.78, 1.24)	128	1,492	8.6 (7.2, 10.1)	1.01 (0.84, 1.23)	486	5,725	8.5 (7.8, 9.2)	358	4,233	8.5 (7.8, 9.3)	562	6,633	8.5 (7.8, 9.2)
		BSAC	56	477	11.7 (9.0, 15.0)	1.35 (1.03, 1.75)	38	471	8.1 (5.8, 10.9)	0.92 (0.67, 1.26)	397	4,551	8.7 (7.9, 9.6)	359	4,080	8.8 (7.9, 9.7)	453	5,028	9.0 (8.2, 9.8)
		BSM	226	1,913	11.8 (10.4, 13.3)	1.46 (1.26, 1.69)	25	191	13.1 (8.7, 18.7)	1.65 (1.13, 2.39)	564	6,972	8.1 (7.5, 8.8)	539	6,781	7.9 (7.3, 8.6)	790	8,885	8.9 (8.3, 9.5)
		BSCC	100	1,411	7.1 (5.8, 8.6)	1.58 (1.26, 1.98)	5	135	3.7 (1.2, 8.4)	0.82 (0.34, 1.96)	240	5,345	4.5 (4.0, 5.1)	235	5,210	4.5 (4.0, 5.1)	340	6,756	5.0 (4.5, 5.6)
		BSC	47	685	6.9 (5.1, 9.0)	0.95 (0.70, 1.28)	30	349	8.6 (5.9, 12.0)	1.21 (0.84, 1.74)	275	3,798	7.2 (6.4, 8.1)	245	3,449	7.1 (6.3, 8.0)	322	4,483	7.2 (6.4, 8.0)
		BSSL	73	814	9.0 (7.1, 11.1)	1.02 (0.81, 1.27)	19	215	8.8 (5.4, 13.5)	1.00 (0.65, 1.54)	891	10,092	8.8 (8.3, 9.4)	872	9,877	8.8 (8.3, 9.4)	964	10,906	8.8 (8.3, 9.4)
		BSOS	48	301	15.9 (12.0, 20.6)	1.23 (0.94, 1.61)	11	70	15.7 (8.1, 26.4)	1.22 (0.70, 2.11)	455	3,505	13.0 (11.9, 14.1)	444	3,435	12.9 (11.8, 14.1)	503	3,806	13.2 (12.2, 14.3)
		Total	807	7,955	10.1 (9.5, 10.8)	1.20 (1.12, 1.29)	317	3,420	9.3 (8.3, 10.3)	1.11 (0.99, 1.23)	4,155	49,185	8.4 (8.2, 8.7)	3,838	45,765	8.4 (8.1, 8.6)	4,962	57,140	8.7 (8.5, 8.9)
		Subsequent	BSWN	389	8,961	4.3 (3.9, 4.8)	1.24 (1.12, 1.38)	128	3,214	4.0 (3.3, 4.7)	1.15 (0.96, 1.37)	2,158	61,833	3.5 (3.3, 3.6)	2,030	58,619	3.5 (3.3, 3.6)	2,547	70,794
	BSCM		226	5,518	4.1 (3.6, 4.7)	1.08 (0.94, 1.24)	322	8,784	3.7 (3.3, 4.1)	0.96 (0.85,									

2.e, False positive rate

Description: The number with false positive screening results as a percentage of number of women screened.

Targets: Initial: <9% false positive screens. Subsequent: <4% false positive screens (50–69 age group only)

Figure 52: 2.e, 50 to 69, False positive rate



The false positive rates for women aged 50–69 years having initial screens were within the target range of <9% for BSA overall (7.6%). In BSOS the false positive rate for initial screens was outside the target range of <9% at 13% but showed a 2% decrease from the previous biennium.

The target for subsequent screens was met by all LPs for women aged 50–69 years, with an overall rate of 2.6%.

For women aged 45–49 years, the overall false positive rates were within the expected ranges for initial (6.9%) and subsequent screens (3.9%).

Figure 53: 2.e, Initial, 50 to 69, False positive rate, by LP




Figure 54: 2.e, Subsequent, 50 to 69, False positive rate, by LP




Table 10: 2.e, False positive rate

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	Māori / Non-Māori Ratio	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	Pacific / Non-Pacific Ratio	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	
45 to 49	Initial	BSWN	80	1,156	6.9 (5.5, 8.5)	1.48 (1.17, 1.88)	32	398	8.0 (5.6, 11.2)	1.80 (1.27, 2.56)	325	6,969	4.7 (4.2, 5.2)	293	6,571	4.5 (4.0, 5.0)	405	8,125	5.0 (4.5, 5.5)	
		BSCM	45	741	6.1 (4.5, 8.0)	0.85 (0.63, 1.15)	87	1,233	7.1 (5.7, 8.6)	0.98 (0.77, 1.24)	325	4,541	7.2 (6.4, 7.9)	238	3,308	7.2 (6.3, 8.1)	370	5,282	7.0 (6.3, 7.7)	
		BSAC	39	366	10.7 (7.7, 14.3)	1.58 (1.15, 2.19)	23	372	6.2 (4.0, 9.1)	0.91 (0.60, 1.38)	227	3,373	6.7 (5.9, 7.6)	204	3,001	6.8 (5.9, 7.8)	266	3,739	7.1 (6.3, 8.0)	
		BSM	140	1,422	9.8 (8.3, 11.5)	1.36 (1.13, 1.63)	13	151	8.6 (4.7, 14.3)	1.20 (0.70, 2.03)	389	5,372	7.2 (6.6, 8.0)	376	5,221	7.2 (6.5, 7.9)	529	6,794	7.8 (7.2, 8.4)	
		BSCC	60	1,047	5.7 (4.4, 7.3)	1.51 (1.13, 2.01)	2	104	1.9 (0.2, 6.8)	0.50 (0.12, 1.99)	157	4,125	3.8 (3.2, 4.4)	155	4,021	3.9 (3.3, 4.5)	217	5,172	4.2 (3.7, 4.8)	
		BSC	34	543	6.3 (4.4, 8.6)	0.94 (0.66, 1.34)	15	248	6.0 (3.4, 9.8)	0.91 (0.54, 1.51)	192	2,896	6.6 (5.8, 7.6)	177	2,648	6.7 (5.8, 7.7)	226	3,439	6.6 (5.8, 7.5)	
		BSSL	55	683	8.1 (6.1, 10.4)	1.03 (0.79, 1.34)	12	169	7.1 (3.7, 12.1)	0.91 (0.52, 1.57)	658	8,433	7.8 (7.2, 8.4)	646	8,264	7.8 (7.2, 8.4)	713	9,116	7.8 (7.3, 8.4)	
		BSOS	39	249	15.7 (11.4, 20.8)	1.32 (0.97, 1.79)	4	49	6.2 (2.3, 19.6)	0.69 (0.27, 1.76)	340	2,867	11.9 (10.7, 13.1)	336	2,818	11.9 (10.7, 13.2)	379	3,116	12.2 (11.0, 13.4)	
		Total	492	6,207	7.9 (7.3, 8.6)	1.17 (1.07, 1.28)	188	2,724	6.9 (6.0, 7.9)	1.02 (0.88, 1.18)	2,613	38,576	6.8 (6.5, 7.0)	2,425	35,852	6.8 (6.5, 7.0)	3,105	44,783	6.9 (6.7, 7.2)	
		Subsequent	BSWN	41	1,347	3.0 (2.2, 4.1)	1.15 (0.83, 1.59)	12	458	2.6 (1.4, 4.5)	0.99 (0.56, 1.75)	220	8,294	2.7 (2.3, 3.0)	208	7,836	2.7 (2.3, 3.0)	261	9,641	2.7 (2.4, 3.1)
	BSCM		32	989	3.2 (2.2, 4.5)	0.77 (0.54, 1.11)	54	1,361	4.0 (3.0, 5.1)	0.94 (0.70, 1.25)	264	6,310	4.2 (3.7, 4.7)	210	4,949	4.2 (3.7, 4.8)	296	7,299	4.1 (3.6, 4.5)	
	BSAC		16	379	4.2 (2.4, 6.8)	1.02 (0.62, 1.68)	23	522	4.4 (2.8, 6.5)	1.07 (0.70, 1.64)	178	4,287	4.2 (3.6, 4.8)	155	3,765	4.1 (3.5, 4.8)	194	4,666	4.2 (3.6, 4.8)	
	BSM		84	1,847	4.5 (3.6, 5.6)	0.99 (0.79, 1.25)	4	180	2.2 (0.6, 5.6)	0.48 (0.18, 1.27)	345	7,530	4.6 (4.1, 5.1)	341	7,350	4.6 (4.2, 5.1)	429	9,377	4.6 (4.2, 5.0)	
	BSCC		28	1,519	1.8 (1.2, 2.7)	1.10 (0.73, 1.66)	1	131	0.8 (0.0, 4.2)	0.45 (0.06, 3.21)	113	6,756	1.7 (1.4, 2.0)	112	6,625	1.7 (1.4, 2.0)	141	8,275	1.7 (1.4, 2.0)	
	BSC		39	757	5.2 (3.7, 7.0)	1.34 (0.97, 1.87)	14	346	4.0 (2.2, 6.7)	1.06 (0.62, 1.80)	241	6,286	3.8 (3.4, 4.3)	227	5,940	3.8 (3.3, 4.3)	280	7,043	4.0 (3.5, 4.5)	
	BSSL		52	1,024	5.1 (3.8, 6.6)	1.15 (0.87, 1.52)	8	185	4.3 (1.9, 8.3)	0.98 (0.49, 1.94)	553	12,539	4.4 (4.1, 4.8)	545	12,354	4.4 (4.1, 4.8)	605	13,563	4.5 (4.1, 4.8)	
	BSOS		29	411	7.1 (4.8, 10.0)	1.08 (0.74, 1.56)	4	57	7.0 (1.9, 17.0)	1.07 (0.41, 2.78)	259	3,951	6.6 (5.8, 7.4)	255	3,894	6.5 (5.8, 7.4)	288	4,362	6.6 (5.9, 7.4)	
	Total		321	8,273	3.9 (3.5, 4.3)	1.00 (0.89, 1.12)	120	3,240	3.7 (3.1, 4.4)	0.95 (0.79, 1.14)	2,173	55,953	3.9 (3.7, 4.0)	2,053	52,713	3.9 (3.7, 4.1)	2,494	64,226	3.9 (3.7, 4.0)	
	50 to 69		Initial	BSWN	20	290	6.9 (4.3, 10.5)	1.19 (0.76, 1.88)	10	99	10.1 (5.0, 17.8)	1.81 (0.98, 3.34)	129	2,228	5.8 (4.9, 6.8)	119	2,129	5.6 (4.7, 6.7)	149	2,518
		BSCM		21	167	12.6 (8.0, 18.6)	1.37 (0.88, 2.12)	24	259	9.3 (6.0, 13.5)	1.01 (0.66, 1.55)	109	1,184	9.2 (7.6, 11.0)	85	925	9.2 (7.4, 11.2)	130	1,351	9.6 (8.1, 11.3)
BSAC		7		111	6.3 (2.6, 12.6)	0.78 (0.37, 1.64)	5	99	5.1 (1.7, 11.4)	0.61 (0.25, 1.46)	95	1,178	8.1 (6.6, 9.8)	90	1,079	8.3 (6.8, 10.2)	102	1,289	7.9 (6.5, 9.5)	
BSM		47		491	9.6 (7.1, 12.5)	1.24 (0.90, 1.70)	6	40	15.0 (5.7, 29.8)	1.98 (0.93, 4.23)	124	1,600	7.8 (6.5, 9.2)	118	1,560	7.6 (6.3, 9.0)	171	2,091	8.2 (7.0, 9.4)	
BSCC		26		364	7.1 (4.7, 10.3)	1.74 (1.10, 2.76)	2	31	6.5 (0.8, 21.4)	1.60 (0.41, 6.28)	50	1,220	4.1 (3.1, 5.4)	48	1,189	4.0 (3.0, 5.3)	76	1,584	4.8 (3.8, 6.0)	
BSC		6		142	4.2 (1.6, 9.0)	0.68 (0.30, 1.55)	5	101	5.0 (1.6, 11.2)	0.78 (0.32, 1.90)	56	902	6.2 (4.7, 8.0)	51	801	6.4 (4.8, 8.3)	62	1,044	5.9 (4.6, 7.5)	
BSSL		12		131	9.2 (4.8, 15.5)	1.05 (0.60, 1.84)	6	46	13.0 (4.9, 26.3)	1.51 (0.71, 3.25)	145	1,659	8.7 (7.4, 10.2)	139	1,613	8.6 (7.3, 10.1)	157	1,790	8.8 (7.5, 10.2)	
BSOS		5		52	9.6 (3.2, 21.0)	0.71 (0.30, 1.66)	5	21	23.8 (8.2, 47.2)	1.79 (0.81, 3.95)	87	638	13.6 (11.1, 16.5)	82	617	13.3 (10.7, 16.2)	92	690	13.3 (10.9, 16.1)	
Total		144		1,748	8.2 (7.0, 9.6)	1.10 (0.93, 1.30)	63	696	9.1 (7.0, 11.4)	1.23 (0.96, 1.57)	795	10,609	7.5 (7.0, 8.0)	732	9,913	7.4 (6.9, 7.9)	939	12,357	7.6 (7.1, 8.1)	
Subsequent		BSWN		156	7,614	2.0 (1.7, 2.4)	1.11 (0.94, 1.31)	64	2,756	2.3 (1.8, 3.0)	1.28 (1.00, 1.64)	986	53,539	1.8 (1.7, 2.0)	922	50,783	1.8 (1.7, 1.9)	1,142	61,153	1.9 (1.8, 2.0)
		BSCM	142	4,529	3.1 (2.6, 3.7)	1.05 (0.88, 1.24)	206	7,423	2.8 (2.4, 3.2)	0.91 (0.78, 1.05)	1,041	34,702	3.0 (2.8, 3.2)	835	27,279	3.1 (2.9, 3.3)	1,183	39,231	3.0 (2.8, 3.2)	
		BSAC	41	1,888	2.2 (1.6, 2.9)	0.91 (0.67, 1.25)	78	2,897	2.7 (2.1, 3.3)	1.15 (0.91, 1.46)	580	24,353	2.4 (2.2, 2.6)	502	21,456	2.3 (2.1, 2.6)	621	26,241	2.4 (2.2, 2.6)	
		BSM	334	10,789	3.1 (2.8, 3.4)	1.04 (0.93, 1.17)	24	947	2.5 (1.6, 3.7)	0.85 (0.57, 1.26)	1,578	52,947	3.0 (2.8, 3.1)	1,554	52,000	3.0 (2.8, 3.1)	1,912	63,736	3.0 (2.9, 3.1)	
		BSCC	113	8,537	1.3 (1.1, 1.6)	1.22 (0.99, 1.49)	8	776	1.0 (0.4, 2.0)	0.95 (0.47, 1.90)	502	46,144	1.1 (1.0, 1.2)	494	45,368	1.1 (1.0, 1.2)	615	54,681	1.1 (1.0, 1.2)	
		BSC	128	4,221	3.0 (2.5, 3.6)	0.99 (0.83, 1.19)	71	2,195	3.2 (2.5, 4.1)	1.06 (0.84, 1.35)	1,265	41,448	3.1 (2.9, 3.2)	1,194	39,253	3.0 (2.9, 3.2)	1,393	45,669	3.1 (2.9, 3.2)	
		BSSL	170	4,711	3.6 (3.1, 4.2)	1.21 (1.04, 1.41)	21	862	2.4 (1.5, 3.7)	0.81 (0.53, 1.24)	2,225	74,450	3.0 (2.9, 3.1)	2,204	73,588	3.0 (2.9, 3.1)	2,395	79,161	3.0 (2.9, 3.1)	
		BSOS	87	1,952	4.5 (3.6, 5.5)	1.19 (0.96, 1.47)	13	269	4.8 (2.6, 8.1)	1.29 (0.76, 2.20)	1,037	27,561	3.8 (3.5, 4.0)	1,024	27,292	3.8 (3.5, 4.0)	1,124	29,513	3.8 (3.6, 4.0)	
		Total	1,171	44,241	2.6 (2.5, 2.8)	1.02 (0.96, 1.08)	485	18,125	2.7 (2.4, 2.9)	1.03 (0.94, 1.13)	9,214	355,144	2.6 (2.5, 2.6)	8,729	337,019	2.6 (2.5, 2.6)	10,385	399,385	2.6 (2.6, 2.7)	
		45 to 69	Initial	BSWN	100	1,446	6.9 (5.7, 8.3)	1.40 (1.14, 1.73)	42	497	8.5 (6.2, 11.3)	1.78 (1.32, 2.42)	454	9,197	4.9 (4.5, 5.4)	412	8,700	4.7 (4.3, 5.2)	554	10,643
BSCM				66	908	7.3 (5.7, 9.2)	0.96 (0.75, 1.23)	111	1,492	7.4 (6.2, 8.9)	0.98 (0.79, 1.20)	434	5,725	7.6 (6.9, 8.3)	323	4,233	7.6 (6.8, 8.5)	500	6,633	7.5 (6.9, 8.2)
BSAC	46			477	9.6 (7.1, 12.7)	1.36 (1.02, 1.83)	28	471	5.9 (4.0, 8.5)	0.83 (0.57, 1.20)	322	4,551	7.1 (6.3, 7.9)	294	4,080	7.2 (6.4, 8.0)	368	5,028	7.3 (6.6, 8.1)	
BSM	187			1,913	9.8 (8.5, 11.2)	1.33 (1.13, 1.56)	19	191	9.9 (6.1, 15.1)	1.37 (0.88, 2.11)	513	6,972	7.4 (6.8, 8.0)	494	6,781	7.3 (6.7, 7.9)	700	8,885	7.9 (7.3, 8.5)	
BSCC	86			1,411	6.1 (4.9, 7.5)	1.57 (1.23, 2.01)	4	135	3.0 (0.8, 7.4)	0.76 (0.29, 2.02)	207	5,345	3.9 (3.4, 4.4)	203	5,210	3.9 (3.4, 4.5)	293	6,756	4.3 (3.9, 4.9)	
BSC	40			685	5.8 (4.2, 7.9)	0.89 (0.65, 1.24)	20	349	5.7 (3.5, 8.7)	0.87 (0.56, 1.35)	248	3,798	6.5 (5.8, 7.4)	228	3,449	6.6 (5.8, 7.5)	288	4,483	6.4 (5.7, 7.2)	
BSSL	67			814	8.2 (6.4, 10.3)	1.03 (0.81, 1.31)	18	215	8.4 (5.0, 12.9)	1.05 (0.67, 1.65)	84	10,092	8.0 (7.4, 8.5)	785	9,877	7.9 (7.4, 8.5)	870	10,906	8.0 (7.5, 8.5)	
BSOS	44			301	14.6 (10.8, 19.1)	1.20 (0.90, 1.60)	9	70	12.9 (6.1, 23.0)	1.06 (0.57, 1.96)	427	3,505	12.2 (11.1, 13.3)	418	3,435	12.2 (11.1, 13.3)	471	3,806	12.4 (11.3, 13.5)	
Total	636			7,955	8.0 (7.4, 8.6)	1.15 (1.06, 1.25)	251	3,420	7.3 (6.5, 8.3)	1.06 (0.94, 1.20)	3,408	49,185	6.9 (6.7, 7.2)	3,157	45,765	6.9 (6.7, 7.1)	4,044	57,140	7.1 (6.9, 7.3)	
Subsequent	BSWN			197	5,961	2.2 (1.9, 2.5)	1.13 (0.97, 1.31)	76	3,214	2.4 (1.9, 3.0)	1.23 (0.97, 1.54)	1,206	61,833	2.0 (1.8, 2.1)	1,130	58,619	1.9 (1.8, 2.0)	1,403	70,794	2.0 (1.9, 2.1)
	BSCM		174	5,518	3.2 (2.7, 3.6)	0.99 (0.85, 1.16)	260	8,784	3.0 (2.6, 3.3)	0.91 (0.80, 1.04)	1,305	41,012	3.2 (3.0, 3.4)	1,045	32,228	3.2 (3.1				


2.f, Positive predictive value

Description: The number of women with diagnosed cancer as a percentage of number of women referred to assessment.

Targets for 45–49 age group: >6% of women referred to assessment from an initial screen are diagnosed with cancer, >8% of women referred to assessment from a subsequent screen are diagnosed with cancer.

Targets for 50–69 age group: >9% of women referred to assessment from an initial or subsequent screen are diagnosed with cancer.¹⁷

Figure 55: 2.f, 50 to 69, Positive predictive value, initial and subsequent screens



For BSA overall, positive predictive values (PPV) were within the target ranges for initial and subsequent screens for each group aged 50–69 years, and within the expected ranges for women aged 45–49 years. The PPV for Māori women was higher than for non-Māori women aged 50–69 years having initial and subsequent screens, and similar to those of non-Māori for women aged 45–49 years. There was a similar pattern for Pacific women. For initial screens, some providers show a zero PPV for Pacific or Māori women but the numbers of referrals for assessment in those LPs are low and the confidence intervals are very wide. For subsequent screens, all LPs were within the target range for Pacific and Māori women aged 50–69 years.

¹⁷ The target for PPV for women aged 50–69 years is under review to determine the appropriate targets following an initial or subsequent screen.

Figure 56: 2.f, Initial, 50 to 69, Positive predictive value, by LP




Figure 57: 2.f, Subsequent, 50 to 69, Positive predictive value, by LP




Table 11: 2.f, Positive predictive value


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Māori / Non-Māori Ratio	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Cancers	Referrals	% of Referrals that were Cancers (95% CI)
45 to 49	Initial	BSWN	7	139	5.0 (2.0, 10.1)	0.68 (0.31, 1.49)	4	42	9.5 (2.7, 22.6)	1.32 (0.50, 3.52)	43	583	7.4 (5.4, 9.8)	39	541	7.2 (5.2, 9.7)	50	722	6.9 (5.2, 9.0)
		BSCM	4	51	7.8 (2.2, 18.9)	1.11 (0.40, 3.07)	10	98	10.2 (5.0, 18.0)	1.75 (0.81, 3.76)	25	355	7.0 (4.6, 10.2)	15	257	5.8 (3.3, 9.4)	29	406	7.1 (4.8, 10.1)
		BSAC	4	48	8.3 (2.3, 20.0)	0.82 (0.30, 2.24)	2	29	6.9 (0.8, 22.8)	0.66 (0.16, 2.62)	28	276	10.1 (6.8, 14.3)	26	247	10.5 (7.0, 15.0)	32	324	9.9 (6.9, 13.7)
		BSM	8	157	5.1 (2.2, 9.8)	1.01 (0.46, 2.24)	1	15	6.7 (0.2, 31.9)	1.34 (0.19, 9.34)	21	417	5.0 (3.1, 7.6)	20	402	5.0 (3.1, 7.6)	29	574	5.1 (3.4, 7.2)
		BSCC	5	67	7.5 (2.5, 16.6)	0.82 (0.31, 2.15)	1	3	33.3 (0.8, 90.6)	3.84 (0.72, 20.46)	16	176	9.1 (5.3, 14.3)	15	173	8.7 (4.9, 13.9)	21	243	8.6 (5.4, 12.9)
		BSC	5	39	12.8 (4.3, 27.4)	1.89 (0.72, 4.94)	4	19	21.1 (6.1, 45.6)	3.94 (1.36, 11.35)	14	206	6.8 (3.8, 11.1)	10	187	5.3 (2.6, 9.6)	19	245	7.8 (4.7, 11.8)
		BSSL	4	60	6.7 (1.8, 16.2)	0.91 (0.34, 2.42)	0	12	0.0 (0.0, 26.5)	0.00 (0.00, 4.25)	53	720	7.4 (5.6, 9.5)	53	708	7.5 (5.7, 9.7)	57	780	7.3 (5.6, 9.4)
		BSOS	3	42	7.1 (1.5, 19.5)	1.52 (0.47, 4.97)	0	6	0.0 (0.0, 45.9)	0.00 (0.00, 14.38)	17	362	4.7 (2.8, 7.4)	17	356	4.8 (2.8, 7.5)	20	404	5.0 (3.0, 7.5)
		Total	40	603	6.6 (4.8, 8.9)	0.95 (0.68, 1.31)	22	224	9.8 (6.3, 14.5)	1.45 (0.95, 2.20)	217	3,095	7.0 (6.1, 8.0)	195	2,871	6.8 (5.9, 7.8)	257	3,698	6.9 (6.2, 7.8)
		45 to 49	Subsequent	BSWN	8	72	11.1 (4.9, 20.7)	1.46 (0.69, 3.10)	1	15	6.7 (0.2, 31.9)	0.87 (0.13, 6.01)	26	342	7.6 (5.0, 10.9)	25	327	7.6 (5.0, 11.1)	34
BSCM	1			34	2.9 (0.1, 15.3)	0.41 (0.06, 2.92)	4	59	6.8 (1.9, 16.5)	0.92 (0.32, 2.62)	21	289	7.3 (4.6, 10.9)	17	230	7.4 (4.4, 11.6)	22	323	6.8 (4.3, 10.1)
BSAC	1			18	5.6 (0.1, 27.3)	1.03 (0.14, 7.53)	2	26	7.7 (0.9, 25.1)	1.52 (0.35, 6.66)	11	204	5.4 (2.7, 9.4)	9	178	5.1 (2.3, 9.4)	12	222	5.4 (2.8, 9.3)
BSM	3			90	3.3 (0.7, 9.4)	0.45 (0.14, 1.44)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 13.10)	28	376	7.4 (5.0, 10.6)	28	372	7.5 (5.1, 10.7)	31	466	6.7 (4.6, 9.3)
BSCC	6			34	17.6 (6.8, 34.5)	1.22 (0.53, 2.80)	1	2	50.0 (1.3, 98.7)	3.58 (0.84, 15.22)	20	138	14.5 (9.1, 21.5)	19	136	14.0 (8.6, 21.0)	26	172	15.1 (10.1, 21.4)
BSC	4			43	9.3 (2.6, 22.1)	1.28 (0.46, 3.58)	1	15	6.7 (0.2, 31.9)	0.91 (0.13, 6.37)	19	261	7.3 (4.4, 11.1)	18	246	7.3 (4.4, 11.3)	23	304	7.6 (4.9, 11.1)
BSSL	5			58	8.6 (2.9, 19.0)	0.94 (0.39, 2.25)	0	8	0.0 (0.0, 36.9)	0.00 (0.00, 5.12)	56	610	9.2 (7.0, 11.8)	56	602	9.3 (7.1, 11.9)	61	668	9.1 (7.1, 11.6)
BSOS	1			30	3.3 (0.1, 17.2)	0.54 (0.07, 3.92)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 16.48)	17	276	6.2 (3.6, 9.7)	17	272	6.3 (3.7, 9.8)	18	306	5.9 (3.5, 9.1)
Total	29			379	7.7 (5.2, 10.8)	0.97 (0.66, 1.40)	9	133	6.8 (3.1, 12.5)	0.85 (0.44, 1.61)	198	2,496	7.9 (6.9, 9.1)	189	2,363	8.0 (6.9, 9.2)	227	2,875	7.9 (6.9, 8.9)
50 to 69	Initial			BSWN	10	42	23.8 (12.1, 39.5)	1.96 (1.04, 3.69)	1	19	5.3 (0.1, 26.0)	0.42 (0.06, 2.88)	32	264	12.1 (8.4, 16.7)	31	245	12.7 (8.8, 17.5)	42
		BSCM	3	25	12.0 (2.5, 31.2)	0.83 (0.27, 2.59)	6	30	20.0 (7.7, 38.6)	1.55 (0.65, 3.74)	19	131	14.5 (9.0, 21.7)	13	101	12.9 (7.0, 21.0)	22	156	14.1 (9.1, 20.6)
		BSAC	0	8	0.0 (0.0, 36.9)	0.00 (0.00, 5.44)	3	9	33.3 (7.5, 70.1)	4.15 (1.36, 12.67)	12	121	9.9 (5.2, 16.7)	9	112	8.0 (3.7, 14.7)	12	129	9.3 (4.9, 15.7)
		BSM	16	69	23.2 (13.9, 34.9)	1.70 (0.94, 3.08)	3	10	30.0 (6.7, 65.2)	2.42 (0.85, 6.88)	20	147	13.6 (8.5, 20.2)	17	137	12.4 (7.4, 19.1)	36	216	16.7 (12.0, 22.3)
		BSCC	6	33	18.2 (7.0, 35.5)	0.90 (0.37, 2.14)	0	2	0.0 (0.0, 84.2)	0.00 (0.00, 10.17)	13	64	20.3 (11.3, 32.2)	13	62	21.0 (11.7, 33.2)	19	97	19.6 (12.2, 28.9)
		BSC	2	8	25.0 (3.2, 65.1)	1.44 (0.39, 5.30)	5	11	45.5 (16.7, 76.6)	3.77 (1.46, 9.73)	12	69	17.4 (9.3, 28.4)	7	58	12.1 (5.0, 23.3)	14	77	18.2 (10.3, 28.6)
		BSSL	0	13	0.0 (0.0, 24.7)	0.00 (0.00, 2.82)	1	7	14.3 (0.4, 57.9)	1.30 (0.20, 8.41)	19	171	11.1 (6.8, 16.8)	18	164	11.0 (6.6, 16.8)	19	184	10.3 (6.3, 15.7)
		BSOS	1	6	16.7 (0.4, 64.1)	2.58 (0.37, 18.15)	0	5	0.0 (0.0, 52.2)	0.00 (0.00, 14.95)	6	93	6.5 (2.4, 13.5)	6	88	6.8 (2.5, 14.3)	7	99	7.1 (2.9, 14.0)
		Total	38	204	18.6 (13.5, 24.7)	1.49 (1.07, 2.06)	19	93	20.4 (12.8, 30.1)	1.73 (1.12, 2.68)	133	1,060	12.5 (10.6, 14.7)	114	967	11.8 (9.8, 14.0)	171	1,264	13.5 (11.7, 15.5)
		50 to 69	Subsequent	BSWN	74	317	23.3 (18.8, 28.4)	1.41 (1.13, 1.77)	24	113	21.2 (14.1, 29.9)	1.31 (0.90, 1.90)	300	1,816	16.5 (14.8, 18.3)	276	1,703	16.2 (14.5, 18.0)	374
BSCM	48			192	25.0 (19.0, 31.7)	1.56 (1.18, 2.05)	47	263	17.9 (13.4, 23.0)	1.15 (0.85, 1.55)	203	1,266	16.0 (14.1, 18.2)	156	1,003	15.6 (13.4, 17.9)	251	1,458	17.2 (15.3, 19.3)
BSAC	23			66	34.8 (23.5, 47.6)	1.75 (1.22, 2.51)	33	119	27.7 (19.9, 36.7)	1.50 (1.08, 2.09)	153	769	19.9 (17.1, 22.9)	120	650	18.5 (15.6, 21.7)	176	835	21.1 (18.4, 24.0)
BSM	102			444	23.0 (19.1, 27.2)	1.49 (1.22, 1.82)	7	33	21.2 (9.0, 38.9)	1.39 (0.71, 2.70)	292	1,894	15.4 (13.8, 17.1)	285	1,861	15.3 (13.7, 17.0)	394	2,338	16.9 (15.4, 18.4)
BSCC	75			193	38.9 (31.9, 46.1)	1.20 (0.98, 1.47)	4	12	33.3 (9.9, 65.1)	1.03 (0.46, 2.31)	248	765	32.4 (29.1, 35.9)	244	753	32.4 (29.1, 35.9)	323	958	33.7 (30.7, 36.8)
BSC	36			166	21.7 (15.7, 28.7)	1.22 (0.90, 1.66)	20	92	21.7 (13.8, 31.6)	1.24 (0.83, 1.86)	276	1,552	17.8 (15.9, 19.8)	256	1,460	17.5 (15.6, 19.6)	312	1,718	18.2 (16.4, 20.1)
BSSL	35			208	16.8 (12.0, 22.6)	1.00 (0.73, 1.37)	7	28	25.0 (10.7, 44.9)	1.50 (0.78, 2.86)	454	2,706	16.8 (15.4, 18.2)	447	2,678	16.7 (15.3, 18.2)	489	2,914	16.8 (15.4, 18.2)
BSOS	17			105	16.2 (9.7, 24.7)	1.13 (0.71, 1.78)	4	17	23.5 (6.8, 49.9)	1.65 (0.69, 3.94)	175	1,218	14.4 (12.4, 16.5)	171	1,201	14.2 (12.3, 16.3)	192	1,323	14.5 (12.7, 16.5)
Total	410			1,691	24.2 (22.2, 26.4)	1.38 (1.26, 1.52)	146	677	21.6 (18.5, 24.9)	1.25 (1.07, 1.45)	2,101	11,986	17.5 (16.9, 18.2)	1,955	11,309	17.3 (16.6, 18.0)	2,511	13,677	18.4 (17.7, 19.0)
45 to 69	Initial			BSWN	17	181	9.4 (5.6, 14.6)	1.06 (0.64, 1.75)	5	61	8.2 (2.7, 18.1)	0.92 (0.39, 2.19)	75	847	8.9 (7.0, 11.0)	70	786	8.9 (7.0, 11.1)	92
		BSCM	7	76	9.2 (3.8, 18.1)	1.02 (0.48, 2.17)	16	128	12.5 (7.3, 19.5)	1.60 (0.90, 2.85)	44	486	9.1 (6.7, 12.0)	28	358	7.8 (5.3, 11.1)	51	562	9.1 (6.8, 11.8)
		BSAC	4	56	7.1 (2.0, 17.3)	0.71 (0.26, 1.91)	5	38	13.2 (4.4, 28.1)	1.35 (0.56, 3.24)	40	397	10.1 (7.3, 13.5)	35	359	9.7 (6.9, 13.3)	44	453	9.7 (7.1, 12.8)
		BSM	24	226	10.6 (6.9, 15.4)	1.46 (0.90, 2.36)	4	25	16.0 (4.5, 36.1)	2.33 (0.90, 6.03)	41	564	7.3 (5.3, 9.7)	37	539	6.9 (4.9, 9.3)	65	790	8.2 (6.4, 10.4)
		BSCC	11	100	11.0 (5.6, 18.8)	0.91 (0.47, 1.75)	1	5	20.0 (0.5, 71.6)	1.68 (0.28, 10.03)	29	240	12.1 (8.2, 16.9)	28	235	11.9 (8.1, 16.8)	40	340	11.8 (8.5, 15.7)
		BSC	7	47	14.9 (6.2, 28.3)	1.58 (0.73, 3.42)	9	30	30.0 (14.7, 49.4)	4.32 (2.12, 8.82)	26	275	9.5 (6.3, 13.5)	17	245	6.9 (4.1, 10.9)	33	322	10.2 (7.2, 14.1)
		BSSL	4	73	5.5 (1.5, 13.4)	0.68 (0.26, 1.80)	1	19	5.3 (0.1, 26.0)	0.65 (0.10, 4.41)	72	891	8.1 (6.4, 10.1)	71	872	8.1 (6.4, 10.2)	76	964	7.9 (6.3, 9.8)
		BSOS	4	48	8.3 (2.3, 20.0)	1.65 (0.59, 4.57)	0	11	0.0 (0.0, 28.5)	0.00 (0.00, 7.02)	23	455	5.1 (3.2, 7.5)	23	444	5.2 (3.3, 7.7)	27	503	5.4 (3.6, 7.7)
		Total	78	807	9.7 (7.7, 11.9)	1.15 (0.91, 1.45)	41	317	12.9 (9.4, 17.1)	1.61 (1.18, 2.18)	350	4,155	8.4 (7.6, 9.3)	309	3,838	8.1 (7.2, 9.0)	428	4,962	8.6 (7.9, 9.4)
		45 to 69	Subsequent	BSWN	82	389	21.1 (17.1, 25.5)	1.40 (1.12, 1.73)	25	128	19.5 (13.1, 27.5)	1.32 (0.91, 1.90)	326	2,158	15.1 (13.6, 16.7)	301	2,030	14.8 (13.3, 16.4)	408
BSCM	49			226	21.7 (16.5, 27.6)	1.51 (1.14, 1.98)	15	322	15.8 (12.0, 20.3)	1.13 (0.85, 1.50)	224	1,555	14.4 (12.7, 16.2)	173	1,233	14.0 (12.1, 16.1)	273	1,781	15.3 (13.7, 17.1)
BSAC	24			84	28.6 (19.2, 39.5)	1.70 (1.18, 2.44)	35	145	24.1 (17.4, 31.9)	1.55 (1.11, 2.15)	164	973	16.9 (14.6, 19.4)	129	828	15.6 (13.2, 18.2)	188	1,	

2.g, Benign open biopsy weight

Description: The percentage of benign open biopsies where the specimen weight is less than 30g.

Target: >90% of open biopsies which prove benign, will weigh <30g (50–69 age group only)

Figure 58: 2.g, 50 to 69, Benign open biopsy weight, percentage <30g



BSA aims to have more than 90% of open biopsies that prove to be benign weighing less than 30g. Overall, 84% of women aged 45–69 years who had a benign open biopsy had biopsies less than 30g. The target was met or within the confidence interval for most LPs, apart from BSM (80% of 85 biopsies) and BSCC (57% of 30 biopsies).

Figure 59: 2.g, 50 to 69, Benign open biopsy weight, by LP




Table 12: 2.g, Benign open biopsy weight


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Māori / Non-Māori Ratio	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Pacific / Non-Pacific Ratio	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)
45 to 49	BSWN	4	4	100.0 (39.8, 100.0)	1.07 (0.98, 1.16)	4	4	100.0 (39.8, 100.0)	1.07 (0.97, 1.19)	31	33	93.9 (79.8, 99.3)	27	29	93.1 (77.2, 99.2)	35	37	94.6 (81.8, 99.3)
	BSCM	0	0	NA (NA, NA)	NA (NA, NA)	4	4	100.0 (39.8, 100.0)	1.07 (0.94, 1.21)	19	20	95.0 (75.1, 99.9)	15	16	93.8 (69.8, 99.8)	19	20	95.0 (75.1, 99.9)
	BSAC	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	13	13	100.0 (75.3, 100.0)	12	12	100.0 (73.5, 100.0)	13	13	100.0 (75.3, 100.0)
	BSM	8	9	88.9 (51.8, 99.7)	1.16 (0.82, 1.65)	0	0	NA (NA, NA)	NA (NA, NA)	13	17	76.5 (50.1, 93.2)	13	17	76.5 (50.1, 93.2)	21	26	80.8 (60.6, 93.4)
	BSCC	3	3	100.0 (29.2, 100.0)	2.75 (1.26, 6.01)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 15.15)	4	11	36.4 (10.9, 69.2)	4	10	40.0 (12.2, 73.8)	7	14	50.0 (23.0, 77.0)
	BSC	3	3	100.0 (29.2, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 (59.0, 100.0)	7	7	100.0 (59.0, 100.0)	10	10	100.0 (69.2, 100.0)
	BSSL	1	2	50.0 (1.3, 98.7)	0.70 (0.17, 2.83)	0	0	NA (NA, NA)	NA (NA, NA)	23	32	71.9 (53.3, 86.3)	23	32	71.9 (53.3, 86.3)	24	34	70.6 (52.5, 84.9)
	BSOS	2	2	100.0 (15.8, 100.0)	1.09 (0.92, 1.29)	1	1	100.0 (2.5, 100.0)	1.10 (0.91, 1.33)	11	12	91.7 (61.5, 99.8)	10	11	90.9 (58.7, 99.8)	13	14	92.9 (66.1, 99.8)
	Total	21	23	91.3 (72.0, 98.9)	1.09 (0.95, 1.26)	10	11	90.9 (58.7, 99.8)	1.10 (0.90, 1.34)	121	145	83.4 (76.4, 89.1)	111	134	82.8 (75.4, 88.8)	142	168	84.5 (78.2, 89.6)
	50 to 69	BSWN	8	10	80.0 (44.4, 97.5)	0.94 (0.67, 1.31)	5	5	100.0 (47.8, 100.0)	1.20 (1.05, 1.37)	40	47	85.1 (71.7, 93.8)	35	42	83.3 (68.6, 93.0)	48	57
BSCM		8	9	88.9 (51.8, 99.7)	1.08 (0.81, 1.44)	7	7	100.0 (59.0, 100.0)	1.31 (1.03, 1.67)	23	28	82.1 (63.1, 93.9)	16	21	76.2 (52.8, 91.8)	31	37	83.8 (68.0, 93.8)
BSAC		2	2	100.0 (15.8, 100.0)	1.13 (0.98, 1.30)	2	2	100.0 (15.8, 100.0)	1.14 (0.98, 1.33)	23	26	88.5 (69.8, 97.6)	21	24	87.5 (67.6, 97.3)	25	28	89.3 (71.8, 97.7)
BSM		11	13	84.6 (54.6, 98.1)	1.08 (0.82, 1.43)	2	2	100.0 (15.8, 100.0)	1.29 (1.10, 1.52)	36	46	78.3 (63.6, 89.1)	34	44	77.3 (62.2, 88.5)	47	59	79.7 (67.2, 89.0)
BSCC		1	2	50.0 (1.3, 98.7)	0.78 (0.18, 3.28)	0	0	NA (NA, NA)	NA (NA, NA)	9	14	64.3 (35.1, 87.2)	9	14	64.3 (35.1, 87.2)	10	16	62.5 (35.4, 84.8)
BSC		1	2	50.0 (1.3, 98.7)	0.57 (0.14, 2.30)	3	3	100.0 (29.2, 100.0)	1.17 (0.98, 1.39)	21	24	87.5 (67.6, 97.3)	18	21	85.7 (63.7, 97.0)	22	26	84.6 (65.1, 95.6)
BSSL		1	2	50.0 (1.3, 98.7)	0.54 (0.14, 2.18)	1	1	100.0 (2.5, 100.0)	1.09 (0.99, 1.20)	35	38	92.1 (78.6, 98.3)	34	37	91.9 (78.1, 98.3)	36	40	90.0 (76.3, 97.2)
BSOS		1	2	50.0 (1.3, 98.7)	0.57 (0.14, 2.29)	1	1	100.0 (2.5, 100.0)	1.14 (0.98, 1.33)	22	25	88.0 (68.8, 97.5)	21	24	87.5 (67.6, 97.3)	23	27	85.2 (66.3, 95.8)
Total		33	42	78.6 (63.2, 89.7)	0.93 (0.79, 1.10)	21	21	100.0 (83.9, 100.0)	1.21 (1.14, 1.28)	209	248	84.3 (79.1, 88.6)	188	227	82.8 (77.3, 87.5)	242	290	83.4 (78.7, 87.5)
45 to 69		BSWN	12	14	85.7 (57.2, 98.2)	0.97 (0.77, 1.21)	9	9	100.0 (66.4, 100.0)	1.15 (1.05, 1.25)	71	80	88.8 (79.7, 94.7)	62	71	87.3 (77.3, 94.0)	83	94
	BSCM	8	9	88.9 (51.8, 99.7)	1.02 (0.79, 1.31)	11	11	100.0 (71.5, 100.0)	1.19 (1.04, 1.38)	42	48	87.5 (74.8, 95.3)	31	37	83.8 (68.0, 93.8)	50	57	87.7 (76.3, 94.9)
	BSAC	2	2	100.0 (15.8, 100.0)	1.08 (0.99, 1.19)	3	3	100.0 (29.2, 100.0)	1.09 (0.99, 1.20)	36	39	92.3 (79.1, 98.4)	33	36	91.7 (77.5, 98.2)	38	41	92.7 (80.1, 98.5)
	BSM	19	22	86.4 (65.1, 97.1)	1.11 (0.90, 1.37)	2	2	100.0 (15.8, 100.0)	1.30 (1.13, 1.49)	49	63	77.8 (65.5, 87.3)	47	61	77.0 (64.5, 86.8)	68	85	80.0 (69.9, 87.9)
	BSCC	4	5	80.0 (28.4, 99.5)	1.54 (0.86, 2.74)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.88)	13	25	52.0 (31.3, 72.2)	13	24	54.2 (32.8, 74.4)	17	30	56.7 (37.4, 74.5)
	BSC	4	5	80.0 (28.4, 99.5)	0.89 (0.56, 1.39)	3	3	100.0 (29.2, 100.0)	1.12 (0.98, 1.27)	28	31	90.3 (74.2, 98.0)	25	28	89.3 (71.8, 97.7)	32	36	88.9 (73.9, 96.9)
	BSSL	2	4	50.0 (6.8, 93.2)	0.60 (0.23, 1.62)	1	1	100.0 (2.5, 100.0)	1.21 (1.09, 1.35)	58	70	82.9 (72.0, 90.8)	57	69	82.6 (71.6, 90.7)	60	74	81.1 (70.3, 89.3)
	BSOS	3	4	75.0 (19.4, 99.4)	0.84 (0.47, 1.50)	2	2	100.0 (15.8, 100.0)	1.13 (1.00, 1.27)	33	37	89.2 (74.6, 97.0)	31	35	88.6 (73.3, 96.8)	36	41	87.8 (73.8, 95.9)
	Total	54	65	83.1 (71.7, 91.2)	0.99 (0.88, 1.11)	31	32	96.9 (83.8, 99.9)	1.17 (1.08, 1.26)	330	393	84.0 (80.0, 87.5)	299	361	82.8 (78.5, 86.6)	384	458	83.8 (80.1, 87.1)

2.h, Preoperative diagnosis rate

Description: The percentage of women who are diagnosed with breast cancer by percutaneous biopsy, prior to any surgery.

Target: >90% of screen detected cancers are diagnosed pre-operatively (50–69 age group only)

Figure 60: 2.h, 50 to 69, Preoperative diagnosis rate



All LPs met the target of >90% for the proportion of women whose screen detected cancer was diagnosed pre-operatively.

Figure 61: 2.h, 50 to 69, Preoperative diagnosis rate, by LP




Table 13: 2.h, Preoperative diagnosis rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Māori / Non-Māori Ratio	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)
45 to 49	BSWN	14	15	93.3 (68.1, 99.8)	0.99 (0.85, 1.15)	5	5	100.0 (47.8, 100.0)	1.07 (1.00, 1.14)	65	69	94.2 (85.8, 98.4)	60	64	93.8 (84.8, 98.3)	79	84	94.0 (86.7, 98.0)	
	BSCM	4	5	80.0 (28.4, 99.5)	0.82 (0.53, 1.27)	14	14	100.0 (76.8, 100.0)	1.03 (0.97, 1.10)	45	46	97.8 (88.5, 99.9)	31	32	96.9 (83.8, 99.9)	49	51	96.1 (86.5, 99.5)	
	BSAC	5	5	100.0 (47.8, 100.0)	1.11 (1.00, 1.24)	4	4	100.0 (39.8, 100.0)	1.13 (1.00, 1.27)	35	39	89.7 (75.8, 97.1)	31	35	88.6 (73.3, 96.8)	40	44	90.9 (78.3, 97.5)	
	BSM	9	11	81.8 (48.2, 97.7)	0.89 (0.67, 1.19)	1	1	100.0 (2.5, 100.0)	1.09 (1.00, 1.19)	45	49	91.8 (80.4, 97.7)	44	48	91.7 (80.0, 97.7)	54	60	90.0 (79.5, 96.2)	
	BSCC	10	11	90.9 (58.7, 99.8)	0.96 (0.79, 1.18)	2	2	100.0 (15.8, 100.0)	1.06 (0.98, 1.16)	34	36	94.4 (81.3, 99.3)	32	34	94.1 (80.3, 99.3)	44	47	93.6 (82.5, 98.7)	
	BSC	9	9	100.0 (66.4, 100.0)	1.18 (1.02, 1.36)	4	5	80.0 (28.4, 99.5)	0.93 (0.59, 1.48)	28	33	84.8 (68.1, 94.9)	24	28	85.7 (67.3, 96.0)	37	42	88.1 (74.4, 96.0)	
	BSSL	6	9	66.7 (29.9, 92.5)	0.74 (0.47, 1.18)	0	0	NA (NA, NA)	NA (NA, NA)	98	109	89.9 (82.7, 94.9)	98	109	89.9 (82.7, 94.9)	104	118	88.1 (80.9, 93.4)	
	BSOS	4	4	100.0 (39.8, 100.0)	1.10 (0.99, 1.22)	0	0	NA (NA, NA)	NA (NA, NA)	31	34	91.2 (76.3, 98.1)	31	34	91.2 (76.3, 98.1)	35	38	92.1 (78.6, 98.3)	
	Total	61	69	88.4 (78.4, 94.9)	0.96 (0.88, 1.05)	30	31	96.8 (83.3, 99.9)	1.06 (0.99, 1.14)	381	415	91.8 (88.7, 94.3)	351	384	91.4 (88.1, 94.0)	442	484	91.3 (88.5, 93.7)	
50 to 69	BSWN	82	84	97.6 (91.7, 99.7)	1.02 (0.98, 1.06)	25	25	100.0 (86.3, 100.0)	1.05 (1.02, 1.08)	317	332	95.5 (92.7, 97.4)	292	307	95.1 (92.1, 97.2)	399	416	95.9 (93.5, 97.6)	
	BSCM	51	51	100.0 (93.0, 100.0)	1.03 (1.01, 1.06)	52	53	98.1 (89.9, 100.0)	1.02 (0.97, 1.07)	215	222	96.8 (93.6, 98.7)	163	169	96.4 (92.4, 98.7)	266	273	97.4 (94.8, 99.0)	
	BSAC	21	23	91.3 (72.0, 98.9)	0.98 (0.86, 1.12)	33	36	91.7 (77.5, 98.2)	0.98 (0.88, 1.09)	154	165	93.3 (88.4, 96.6)	121	129	93.8 (88.1, 97.3)	175	188	93.1 (88.5, 96.3)	
	BSM	111	118	94.1 (88.2, 97.6)	0.98 (0.93, 1.03)	10	10	100.0 (69.2, 100.0)	1.05 (1.02, 1.07)	299	312	95.8 (93.0, 97.8)	289	302	95.7 (92.8, 97.7)	410	430	95.3 (92.9, 97.1)	
	BSCC	79	81	97.5 (91.4, 99.7)	0.99 (0.96, 1.03)	4	4	100.0 (39.8, 100.0)	1.02 (1.00, 1.04)	256	261	98.1 (95.6, 99.4)	252	257	98.1 (95.5, 99.4)	335	342	98.0 (95.8, 99.2)	
	BSC	38	38	100.0 (90.7, 100.0)	1.06 (1.03, 1.08)	25	25	100.0 (86.3, 100.0)	1.06 (1.03, 1.09)	273	288	94.8 (91.6, 97.1)	248	263	94.3 (90.8, 96.8)	311	326	95.4 (92.5, 97.4)	
	BSSL	35	35	100.0 (90.0, 100.0)	1.04 (1.02, 1.06)	7	8	87.5 (47.3, 99.7)	0.91 (0.70, 1.18)	455	473	96.2 (94.1, 97.7)	448	465	96.3 (94.2, 97.9)	490	508	96.5 (94.5, 97.9)	
	BSOS	17	18	94.4 (72.7, 99.9)	0.96 (0.86, 1.08)	4	4	100.0 (39.8, 100.0)	1.02 (1.00, 1.04)	178	181	98.3 (95.2, 99.7)	174	177	98.3 (95.1, 99.6)	195	199	98.0 (94.9, 99.4)	
	Total	434	448	96.9 (94.8, 98.3)	1.01 (0.99, 1.03)	160	165	97.0 (93.1, 99.0)	1.01 (0.98, 1.04)	2,147	2,234	96.1 (95.2, 96.9)	1,987	2,069	96.0 (95.1, 96.8)	2,581	2,682	96.2 (95.4, 96.9)	
45 to 69	BSWN	96	99	97.0 (91.4, 99.4)	1.02 (0.98, 1.06)	30	30	100.0 (88.4, 100.0)	1.05 (1.03, 1.08)	382	401	95.3 (92.7, 97.1)	352	371	94.9 (92.1, 96.9)	478	500	95.6 (93.4, 97.2)	
	BSCM	55	56	98.2 (90.4, 100.0)	1.01 (0.97, 1.05)	66	67	98.5 (92.0, 100.0)	1.02 (0.98, 1.06)	260	268	97.0 (94.2, 98.7)	194	201	96.5 (93.0, 98.6)	315	324	97.2 (94.8, 98.7)	
	BSAC	26	28	92.9 (76.5, 99.1)	1.00 (0.90, 1.12)	37	40	92.5 (79.6, 98.4)	1.00 (0.91, 1.10)	189	204	92.6 (88.2, 95.8)	152	164	92.7 (87.6, 96.2)	215	232	92.7 (88.5, 95.7)	
	BSM	120	129	93.0 (87.2, 96.8)	0.98 (0.93, 1.03)	11	11	100.0 (71.5, 100.0)	1.05 (1.03, 1.08)	344	361	95.3 (92.6, 97.2)	333	350	95.1 (92.3, 97.1)	464	490	94.7 (92.3, 96.5)	
	BSCC	89	92	96.7 (90.8, 99.3)	0.99 (0.95, 1.03)	6	6	100.0 (54.1, 100.0)	1.03 (1.01, 1.04)	290	297	97.6 (95.2, 99.0)	284	291	97.6 (95.1, 99.0)	379	389	97.4 (95.3, 98.8)	
	BSC	47	47	100.0 (92.5, 100.0)	1.07 (1.04, 1.10)	29	30	96.7 (82.8, 99.9)	1.03 (0.96, 1.11)	301	321	93.8 (90.5, 96.2)	272	291	93.5 (90.0, 96.0)	348	368	94.6 (91.7, 96.6)	
	BSSL	41	44	93.2 (81.3, 98.6)	0.98 (0.90, 1.06)	7	8	87.5 (47.3, 99.7)	0.92 (0.71, 1.20)	553	582	95.0 (92.9, 96.6)	546	574	95.1 (93.0, 96.7)	594	626	94.9 (92.9, 96.5)	
	BSOS	21	22	95.5 (77.2, 99.9)	0.98 (0.89, 1.08)	4	4	100.0 (39.8, 100.0)	1.03 (1.01, 1.05)	209	215	97.2 (94.0, 99.0)	205	211	97.2 (93.9, 98.9)	230	237	97.0 (94.0, 98.8)	
	Total	495	517	95.7 (93.6, 97.3)	1.00 (0.98, 1.02)	190	196	96.9 (93.5, 98.9)	1.02 (0.99, 1.04)	2,528	2,649	95.4 (94.6, 96.2)	2,338	2,453	95.3 (94.4, 96.1)	3,023	3,166	95.5 (94.7, 96.2)	

2.i, Specificity

Description: The number with negative screening results as a percentage of number with negative screening results plus number with false positive screening results.

Target: >93% (50–69 age group only)

Figure 62: 2.i, 50 to 69, Specificity



Among women aged 50–69 years, specificity was outside the target range of >93% for initial screens for BSA overall (90.4%), with LPs ranging from 85.7% to 93.9%. For subsequent screens, all LPs were within the target, ranging from 93.7% to 97.9%.

Specificity was around the expected range for women aged 45–49 years at 91.7% for initial screens and 95.5% for subsequent screens.

Figure 63: 2.i, Initial, 50 to 69, Specificity, by LP




Figure 64: 2.i, Subsequent, 50 to 69, Specificity, by LP




Table 14: 2.i, Specificity


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Māori / Non-Māori Ratio	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Pacific / Non-Pacific Ratio	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	
45 to 49	Initial	BSWN	1,017	1,156	88.0 (86.0, 89.8)	0.96 (0.94, 0.98)	356	398	89.4 (86.0, 92.3)	0.98 (0.94, 1.01)	6,386	6,969	91.6 (91.0, 92.3)	6,030	6,571	91.8 (91.1, 92.4)	7,403	8,125	91.1 (90.5, 91.7)
		BSCM	690	741	93.1 (91.0, 94.8)	1.01 (0.99, 1.03)	1,135	1,233	92.1 (90.4, 93.5)	1.00 (0.98, 1.02)	4,186	4,541	92.2 (91.4, 92.9)	3,051	3,308	92.2 (91.3, 93.1)	4,876	5,282	92.3 (91.6, 93.0)
		BSAC	318	366	86.9 (83.0, 90.2)	0.95 (0.91, 0.99)	343	372	92.2 (89.0, 94.7)	1.01 (0.97, 1.04)	3,097	3,373	91.8 (90.8, 92.7)	2,754	3,001	91.8 (90.7, 92.7)	3,415	3,739	91.3 (90.4, 92.2)
		BSM	1,265	1,422	89.0 (87.2, 90.5)	0.96 (0.94, 0.98)	136	151	90.1 (84.1, 94.3)	0.98 (0.93, 1.03)	4,955	5,372	92.2 (91.5, 92.9)	4,819	5,221	92.3 (91.5, 93.0)	6,220	6,794	91.6 (90.9, 92.2)
		BSCC	980	1,047	93.6 (91.9, 95.0)	0.98 (0.96, 0.99)	101	104	97.1 (91.8, 99.4)	1.02 (0.98, 1.05)	3,949	4,125	95.7 (95.1, 96.3)	3,848	4,021	95.7 (95.0, 96.3)	4,929	5,172	95.3 (94.7, 95.9)
		BSC	504	543	92.8 (90.3, 94.8)	1.00 (0.97, 1.02)	229	248	92.3 (88.3, 95.3)	0.99 (0.96, 1.03)	2,690	2,896	92.9 (91.9, 93.8)	2,461	2,648	92.9 (91.9, 93.9)	3,194	3,439	92.9 (92.0, 93.7)
		BSSL	623	683	91.2 (88.8, 93.2)	1.00 (0.97, 1.02)	157	169	92.9 (87.9, 96.3)	1.02 (0.97, 1.06)	7,713	8,433	91.5 (90.8, 92.1)	7,556	8,264	91.4 (90.8, 92.0)	8,336	9,116	91.4 (90.9, 92.0)
		BSOS	207	249	83.1 (77.9, 87.6)	0.95 (0.90, 1.01)	43	49	87.8 (75.2, 95.4)	1.00 (0.90, 1.12)	2,505	2,867	87.4 (86.1, 88.6)	2,462	2,818	87.4 (86.1, 88.6)	2,712	3,116	87.0 (85.8, 88.2)
		Total	5,604	6,207	90.3 (89.5, 91.0)	0.98 (0.97, 0.99)	2,500	2,724	91.8 (90.7, 92.8)	1.00 (0.99, 1.01)	35,481	38,576	92.0 (91.7, 92.2)	32,981	35,852	92.0 (91.7, 92.3)	41,085	44,783	91.7 (91.5, 92.0)
	Subsequent	BSWN	1,275	1,347	94.7 (93.3, 95.8)	0.99 (0.97, 1.00)	443	458	96.7 (94.7, 98.2)	1.01 (0.99, 1.03)	7,952	8,294	95.9 (95.4, 96.3)	7,509	7,836	95.8 (95.4, 96.3)	9,227	9,641	95.7 (95.3, 96.1)
		BSCM	955	989	96.6 (95.2, 97.6)	1.01 (1.00, 1.02)	1,302	1,361	95.7 (94.4, 96.7)	1.00 (0.99, 1.02)	6,021	6,310	95.4 (94.9, 95.9)	4,719	4,949	95.4 (94.7, 95.9)	6,976	7,299	95.6 (95.1, 96.0)
		BSAC	361	379	95.3 (92.6, 97.2)	1.00 (0.98, 1.02)	496	522	95.0 (92.8, 96.7)	1.00 (0.98, 1.02)	4,083	4,287	95.2 (94.6, 95.9)	3,587	3,765	95.3 (94.5, 95.9)	4,444	4,666	95.2 (94.6, 95.8)
		BSM	1,757	1,847	95.1 (94.0, 96.1)	1.00 (0.99, 1.01)	176	180	97.8 (95.4, 99.4)	1.03 (1.01, 1.05)	7,154	7,530	95.0 (94.5, 95.4)	6,978	7,350	94.9 (94.4, 95.4)	8,911	9,377	95.0 (94.6, 95.5)
		BSCC	1,485	1,519	97.8 (96.9, 98.4)	1.00 (0.99, 1.01)	129	131	98.5 (94.6, 99.8)	1.01 (0.98, 1.03)	6,618	6,756	98.0 (97.6, 98.3)	6,489	6,625	97.9 (97.6, 98.3)	8,103	8,275	97.9 (97.6, 98.2)
		BSC	714	757	94.3 (92.4, 95.9)	0.98 (0.97, 1.00)	331	346	95.7 (93.0, 97.6)	1.00 (0.97, 1.02)	6,025	6,286	95.8 (95.3, 96.3)	5,694	5,940	95.9 (95.3, 96.4)	6,739	7,043	95.7 (95.2, 96.1)
		BSSL	966	1,024	94.3 (92.7, 95.7)	0.99 (0.98, 1.01)	177	185	95.7 (91.7, 98.1)	1.01 (0.97, 1.04)	11,929	12,539	95.1 (94.7, 95.5)	11,752	12,354	95.1 (94.7, 95.5)	12,895	13,563	95.1 (94.7, 95.4)
		BSOS	381	411	92.7 (89.7, 95.0)	1.00 (0.97, 1.02)	53	57	93.0 (83.0, 98.1)	1.00 (0.93, 1.07)	3,675	3,951	93.0 (92.3, 93.8)	3,622	3,894	93.0 (92.2, 93.8)	4,056	4,362	93.1 (92.2, 93.7)
		Total	7,894	8,273	95.4 (94.9, 95.9)	1.00 (0.99, 1.00)	3,107	3,240	95.9 (95.2, 96.6)	1.00 (1.00, 1.01)	53,457	55,953	95.5 (95.4, 95.7)	50,350	52,713	95.5 (95.3, 95.7)	61,351	64,226	95.5 (95.4, 95.7)
		50 to 69	Initial	BSWN	248	290	85.5 (80.9, 89.4)	0.97 (0.92, 1.02)	80	99	80.8 (71.7, 88.0)	0.91 (0.83, 1.01)	1,964	2,228	88.2 (86.7, 89.5)	1,884	2,129	88.5 (87.1, 89.8)	2,212
BSCM	142			167	85.0 (78.7, 90.1)	0.96 (0.89, 1.02)	229	259	88.4 (83.9, 92.0)	0.99 (0.94, 1.04)	1,053	1,184	88.9 (87.0, 90.7)	824	925	89.1 (86.9, 91.0)	1,195	1,351	88.5 (86.6, 90.1)
BSAC	103			111	92.8 (86.3, 96.8)	1.03 (0.98, 1.09)	90	99	90.9 (83.4, 95.8)	1.01 (0.95, 1.08)	1,057	1,178	89.7 (87.9, 91.4)	967	1,079	89.6 (87.6, 91.4)	1,160	1,289	90.0 (88.2, 91.6)
BSM	422			491	85.9 (82.6, 88.9)	0.95 (0.91, 0.98)	30	40	75.0 (58.8, 87.3)	0.82 (0.69, 0.98)	1,453	1,600	90.8 (89.3, 92.2)	1,423	1,560	91.2 (89.7, 92.6)	1,875	2,091	89.7 (88.3, 90.9)
BSCC	331			364	90.9 (87.5, 93.7)	0.96 (0.93, 0.99)	29	31	93.5 (78.6, 99.2)	0.99 (0.90, 1.08)	1,156	1,220	94.8 (93.4, 95.9)	1,127	1,189	94.8 (93.4, 96.0)	1,487	1,584	93.9 (92.6, 95.0)
BSC	134			142	94.4 (89.2, 97.5)	1.02 (0.98, 1.07)	90	101	89.1 (81.3, 94.4)	0.96 (0.90, 1.03)	833	902	92.4 (90.4, 94.0)	743	801	92.8 (90.7, 94.5)	967	1,044	92.6 (90.9, 94.1)
BSSL	118			131	90.1 (83.6, 94.6)	1.00 (0.95, 1.06)	39	46	84.8 (71.1, 93.7)	0.94 (0.83, 1.07)	1,488	1,659	89.7 (88.1, 91.1)	1,449	1,613	89.8 (88.3, 91.3)	1,606	1,790	89.7 (88.2, 91.1)
BSOS	46			52	88.5 (76.6, 95.6)	1.04 (0.93, 1.15)	16	21	76.2 (52.8, 91.8)	0.89 (0.70, 1.13)	545	638	85.4 (82.4, 88.1)	529	617	85.7 (82.7, 88.4)	591	690	85.7 (82.8, 88.2)
Total	1,544			1,748	88.3 (86.7, 89.8)	0.98 (0.96, 1.00)	603	696	86.6 (83.9, 89.1)	0.96 (0.93, 0.99)	9,549	10,609	90.0 (89.4, 90.6)	8,946	9,913	90.2 (89.6, 90.8)	11,093	12,357	89.8 (89.2, 90.3)
Subsequent	BSWN		7,297	7,614	95.8 (95.4, 96.3)	0.99 (0.99, 1.00)	2,643	2,756	95.9 (95.1, 96.6)	0.99 (0.98, 1.00)	51,723	53,539	96.6 (96.5, 96.8)	49,080	50,783	96.6 (96.5, 96.8)	59,020	61,153	96.5 (96.4, 96.7)
	BSCM		4,337	4,529	95.8 (95.1, 96.3)	0.99 (0.99, 1.00)	7,160	7,423	96.5 (96.0, 96.9)	1.00 (1.00, 1.01)	33,436	34,702	96.4 (96.1, 96.5)	26,276	27,279	96.3 (96.1, 96.5)	37,773	39,231	96.3 (96.1, 96.5)
	BSAC		1,822	1,888	96.5 (95.6, 97.3)	1.00 (0.99, 1.00)	2,778	2,897	95.9 (95.1, 96.6)	0.99 (0.98, 1.00)	23,584	24,353	96.8 (96.6, 97.1)	20,806	21,456	97.0 (96.7, 97.2)	25,406	26,241	96.8 (96.6, 97.0)
	BSM		10,345	10,788	95.9 (95.5, 96.3)	1.00 (0.99, 1.00)	914	947	96.5 (95.1, 97.6)	1.00 (0.99, 1.01)	51,053	52,947	96.4 (96.3, 96.6)	50,139	52,000	96.4 (96.3, 96.6)	61,398	63,735	96.3 (96.2, 96.5)
	BSCC		8,344	8,537	97.7 (97.4, 98.0)	0.99 (0.99, 1.00)	764	776	98.5 (97.3, 99.2)	1.00 (0.99, 1.01)	45,379	46,144	98.3 (98.2, 98.5)	44,615	45,368	98.3 (98.2, 98.5)	53,723	54,681	98.2 (98.1, 98.4)
	BSC		4,055	4,221	96.1 (95.4, 96.6)	1.00 (0.99, 1.00)	2,103	2,195	95.8 (94.9, 96.6)	1.00 (0.99, 1.01)	39,896	41,448	96.3 (96.1, 96.5)	37,793	39,253	96.3 (96.1, 96.5)	43,951	45,669	96.2 (96.1, 96.4)
	BSSL		4,503	4,710	95.6 (95.0, 96.2)	0.99 (0.99, 1.00)	834	862	96.8 (95.3, 97.8)	1.00 (0.99, 1.02)	71,744	74,449	96.4 (96.2, 96.5)	70,910	73,587	96.4 (96.2, 96.5)	76,247	79,159	96.3 (96.2, 96.5)
	BSOS		1,846	1,950	94.7 (93.6, 95.6)	0.99 (0.98, 1.00)	252	269	93.7 (90.1, 96.3)	0.98 (0.95, 1.01)	26,343	27,561	95.6 (95.3, 95.8)	26,091	27,292	95.6 (95.3, 95.8)	28,189	29,511	95.5 (95.3, 95.8)
	Total		42,549	44,237	96.2 (96.0, 96.4)	1.00 (0.99, 1.00)	17,448	18,125	96.3 (96.0, 96.5)	1.00 (0.99, 1.00)	343,158	355,143	96.6 (96.6, 96.7)	325,710	337,018	96.6 (96.6, 96.7)	385,707	399,380	96.6 (96.5, 96.6)
	45 to 69		Initial	BSWN	1,265	1,446	87.5 (85.7, 89.1)	0.96 (0.94, 0.98)	436	497	87.7 (84.5, 90.5)	0.96 (0.93, 1.00)	8,350	9,197	90.8 (90.2, 91.4)	7,914	8,700	91.0 (90.3, 91.6)	9,615
BSCM		832		908	91.6 (89.6, 93.3)	1.00 (0.98, 1.02)	1,364	1,492	91.4 (89.9, 92.8)	1.00 (0.98, 1.02)	5,239	5,725	91.5 (90.8, 92.2)	3,875	4,233	91.5 (90.7, 92.4)	6,071	6,633	91.5 (90.8, 92.2)
BSAC		421		477	88.3 (85.0, 91.0)	0.97 (0.94, 1.00)	433	471	91.9 (89.1, 94.2)	1.01 (0.98, 1.04)	4,154	4,551	91.3 (90.4, 92.1)	3,721	4,080	91.2 (90.3, 92.1)	4,575	5,028	91.0 (90.2, 91.8)
BSM		1,687		1,913	88.2 (86.7, 89.6)	0.96 (0.94, 0.98)	166	191	86.9 (81.3, 91.3)	0.94 (0.89, 1.00)	6,408	6,972	91.9 (91.2, 92.5)	6,242	6,781	92.1 (91.4, 92.7)	8,095	8,885	91.1 (90.5, 91.7)
BSCC		1,311		1,411	92.9 (91.4, 94.2)	0.97 (0.96, 0.99)	130	135	96.3 (91.6, 98.8)	1.01 (0.97, 1.04)	5,105	5,345	95.5 (94.9, 96.0)	4,975	5,210	95.5 (94.9, 96.0)	6,416	6,756	95.0 (94.4, 95.5)
BSC		638		685	91.1 (91.0, 94.9)	1.00 (0.98, 1.03)	319	349	91.4 (88.0, 94.1)	0.98 (0.95, 1.02)	3,523	3,798	92.8 (91.9, 93.6)	3,204	3,449	92.9 (92.0, 93.7)	4,161	4,483	92.8 (92.0, 93.6)
BSSL		741		814	91.0 (88.9, 92.9)	1.00 (0.98, 1.02)	196	215	91.2 (86.5, 94.6)	1.00 (0.96, 1.04)	9,201	10,092	91.2 (90.6, 91.7)	9,005	9,877	91.2 (90.6, 91.7)	9,942	10,906	91.2 (90.6, 91.7)
BSOS		253		301	84.1 (79.4, 88.0)	0.97 (0.92, 1.02)	59	70											

2.m, Benign open biopsy rate

Description: The number of women with benign open biopsy per number of women screened.

Targets: Initial: ≤ 3.5 per 1,000 women screened. Subsequent: ≤ 1.6 per 1,000 women screened (50–69 age group only)

Figure 65: 2.m, 50 to 69, Benign open biopsy rate, total BSA



Over the two years, out of 520,481 screens 441 open biopsies were performed that turned out to be benign. For BSA overall, the benign open biopsy rate for initial screens was 2.1 per 1,000 women screened aged 45–69 years, while the rate for subsequent screens was 0.7 per 1,000 women screened. The targets were met or were within the confidence interval for each LP.

Figure 66: 2.m, Initial, 50 to 69, Benign open biopsy rate, by LP




Figure 67: 2.m, Subsequent, 50 to 69, Benign open biopsy rate, by LP




Table 15: 2.m, Benign open biopsy rate

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Māori / Non-Māori Ratio	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Pacific / Non-Pacific Ratio	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)		
45 to 49	Initial	BSWN	3	1,156	2.6 (0.5, 7.6)	0.82 (0.25, 2.74)	2	398	5.0 (0.6, 18.0)	1.65 (0.39, 7.04)	22	6,969	3.2 (2.0, 4.8)	20	6,571	3.0 (1.9, 4.7)	25	8,125	3.1 (2.0, 4.5)	
		BSCM	0	741	0.0 (0.0, 5.0)	0.00 (0.00, 4.25)	2	1,233	1.6 (0.2, 5.8)	1.07 (0.21, 5.52)	7	4,541	1.5 (0.6, 3.2)	5	3,308	1.5 (0.5, 3.5)	7	5,282	1.3 (0.5, 2.7)	
		BSAC	0	366	0.0 (0.0, 10.0)	0.00 (0.00, 10.06)	1	372	2.7 (0.1, 14.9)	2.02 (0.23, 18.00)	5	3,373	1.5 (0.5, 3.5)	4	3,001	1.3 (0.4, 3.4)	5	3,739	1.3 (0.4, 3.1)	
		BSM	7	1,422	4.9 (2.0, 10.1)	2.40 (0.93, 6.19)	0	151	0.0 (0.0, 24.1)	0.00 (0.00, 13.78)	11	5,372	2.0 (1.0, 3.7)	11	5,221	2.1 (1.1, 3.8)	18	6,794	2.6 (1.6, 4.2)	
		BSCC	1	1,047	1.0 (0.0, 5.3)	0.49 (0.06, 3.93)	1	104	9.6 (0.2, 52.4)	5.52 (0.69, 44.49)	8	4,125	1.9 (0.8, 3.8)	7	4,021	1.7 (0.7, 3.6)	9	5,172	1.7 (0.8, 3.3)	
		BSC	2	543	3.7 (0.4, 13.2)	3.56 (0.60, 21.23)	0	248	0.0 (0.0, 14.8)	0.00 (0.00, 25.84)	3	2,896	1.0 (0.2, 3.0)	3	2,648	1.0 (0.2, 3.0)	5	3,439	1.5 (0.5, 3.4)	
		BSSL	0	683	0.0 (0.0, 5.4)	0.00 (0.00, 2.37)	0	169	0.0 (0.0, 21.6)	0.00 (0.00, 9.39)	21	8,433	2.5 (1.5, 3.8)	21	8,264	2.5 (1.6, 3.9)	21	9,116	2.3 (1.4, 3.5)	
		BSOS	1	249	4.0 (0.1, 22.2)	1.15 (0.15, 8.96)	0	49	0.0 (0.0, 72.5)	0.00 (0.00, 25.66)	10	2,867	3.5 (1.7, 6.4)	10	2,818	3.5 (1.7, 6.5)	11	3,116	3.5 (1.8, 6.3)	
		Total	14	6,207	2.3 (1.2, 3.8)	1.00 (0.57, 1.76)	6	2,724	2.2 (0.8, 4.8)	0.98 (0.43, 2.23)	87	38,576	2.3 (1.8, 2.8)	81	35,852	2.3 (1.8, 2.8)	101	44,783	2.3 (1.8, 2.7)	
		Subsequent	BSWN	1	1,347	0.7 (0.0, 4.1)	0.62 (0.08, 4.80)	2	458	4.4 (0.5, 15.7)	4.28 (0.91, 20.08)	10	8,292	1.2 (0.6, 2.2)	8	7,834	1.0 (0.4, 2.0)	11	9,639	1.1 (0.6, 2.0)
	BSCM		0	989	0.0 (0.0, 3.7)	0.00 (0.00, 2.09)	2	1,361	1.5 (0.2, 5.3)	0.66 (0.15, 2.98)	13	6,308	2.1 (1.1, 3.5)	11	4,947	2.2 (1.1, 4.0)	13	7,297	1.8 (0.9, 3.0)	
	BSAC		0	379	0.0 (0.0, 9.7)	0.00 (0.00, 6.63)	0	522	0.0 (0.0, 7.0)	0.00 (0.00, 4.22)	8	4,287	1.9 (0.8, 3.7)	8	3,765	2.1 (0.9, 4.2)	8	4,666	1.7 (0.7, 3.4)	
	BSM		2	1,841	1.1 (0.1, 3.9)	1.36 (0.28, 6.75)	0	180	0.0 (0.0, 20.3)	0.00 (0.00, 34.67)	6	7,529	0.8 (0.3, 1.7)	6	7,349	0.8 (0.3, 1.8)	8	9,370	0.9 (0.4, 1.7)	
	BSCC		2	1,519	1.3 (0.2, 4.7)	Inf (1.83, 525.61)	0	131	0.0 (0.0, 27.8)	NA (1.30, 1954.75)	0	6,754	0.0 (0.0, 0.5)	0	6,623	0.0 (0.0, 0.6)	2	8,273	0.2 (0.0, 0.9)	
	BSC		1	755	1.3 (0.0, 7.4)	2.08 (0.23, 18.59)	0	345	0.0 (0.0, 10.6)	0.00 (0.00, 26.08)	4	6,285	0.6 (0.2, 1.6)	4	5,940	0.7 (0.2, 1.7)	5	7,040	0.7 (0.2, 1.7)	
	BSSL		2	1,016	2.0 (0.2, 7.1)	2.47 (0.54, 11.25)	0	183	0.0 (0.0, 20.0)	0.00 (0.00, 30.11)	10	12,535	0.8 (0.4, 1.5)	10	12,352	0.8 (0.4, 1.5)	12	13,551	0.9 (0.5, 1.5)	
	BSOS		1	406	2.5 (0.1, 13.6)	4.87 (0.44, 53.54)	1	57	17.5 (0.4, 93.9)	68.32 (4.33, 1078.78)	2	3,951	0.5 (0.1, 1.8)	1	3,894	0.3 (0.0, 1.4)	3	4,357	0.7 (0.1, 2.0)	
	Total		9	8,252	1.1 (0.5, 2.1)	1.15 (0.57, 2.33)	5	3,237	1.5 (0.5, 3.6)	1.70 (0.68, 4.26)	53	55,941	0.9 (0.7, 1.2)	48	52,704	0.9 (0.7, 1.2)	62	64,193	1.0 (0.7, 1.2)	
	50 to 69		Initial	BSWN	1	290	3.4 (0.1, 19.1)	1.92 (0.21, 17.13)	1	99	10.1 (0.3, 55.0)	7.17 (0.75, 68.30)	4	2,228	1.8 (0.5, 4.6)	3	2,129	1.4 (0.3, 4.1)	5	2,518
		BSCM		0	167	0.0 (0.0, 21.8)	0.00 (0.00, 17.16)	0	259	0.0 (0.0, 14.1)	0.00 (0.00, 8.64)	3	1,184	2.5 (0.5, 7.4)	3	925	3.2 (0.7, 9.4)	3	1,351	2.2 (0.5, 6.5)
BSAC		1		111	9.0 (0.2, 49.2)	5.31 (0.48, 58.06)	1	99	10.1 (0.3, 55.0)	10.90 (0.69, 172.92)	2	1,178	1.7 (0.2, 6.1)	1	1,079	0.9 (0.0, 5.2)	3	1,289	2.3 (0.5, 6.8)	
BSM		1		491	2.0 (0.1, 11.3)	1.09 (0.11, 10.42)	0	40	0.0 (0.0, 88.1)	0.00 (0.00, 94.38)	3	1,600	1.9 (0.4, 5.5)	3	1,560	1.9 (0.4, 5.6)	4	2,091	1.9 (0.5, 4.9)	
BSCC		0		364	0.0 (0.0, 10.1)	NA (0.09, 129.67)	0	31	0.0 (0.0, 112.2)	NA (0.94, 1403.45)	0	1,220	0.0 (0.0, 3.0)	0	1,189	0.0 (0.0, 3.1)	0	1,584	0.0 (0.0, 2.3)	
BSC		0		142	0.0 (0.0, 25.6)	NA (0.16, 245.62)	0	101	0.0 (0.0, 35.9)	NA (0.20, 304.06)	0	902	0.0 (0.0, 4.1)	0	801	0.0 (0.0, 4.6)	0	1,044	0.0 (0.0, 3.5)	
BSSL		0		131	0.0 (0.0, 27.8)	0.00 (0.00, 30.65)	0	46	0.0 (0.0, 77.1)	0.00 (0.00, 84.86)	3	1,659	1.8 (0.4, 5.3)	3	1,613	1.9 (0.4, 5.4)	3	1,790	1.7 (0.3, 4.9)	
BSOS		0		52	0.0 (0.0, 68.5)	0.00 (0.00, 29.69)	0	21	0.0 (0.0, 161.1)	0.00 (0.00, 71.10)	3	638	4.7 (1.0, 13.7)	3	617	4.9 (1.0, 14.1)	3	690	4.3 (0.9, 12.7)	
Total		3		1,748	1.7 (0.4, 5.0)	1.01 (0.30, 3.43)	2	696	2.8 (0.3, 10.3)	1.78 (0.41, 7.73)	18	10,609	1.7 (1.0, 2.7)	16	9,913	1.6 (0.9, 2.6)	21	12,357	1.7 (1.1, 2.6)	
Subsequent		BSWN		9	7,611	1.2 (0.5, 2.2)	1.67 (0.81, 3.44)	4	2,756	1.5 (0.4, 3.7)	2.17 (0.77, 6.10)	38	53,516	0.7 (0.5, 1.0)	34	50,760	0.7 (0.5, 0.9)	47	61,127	0.8 (0.6, 1.0)
		BSCM	9	4,525	2.0 (0.9, 3.8)	2.76 (1.29, 5.91)	7	7,422	0.9 (0.4, 1.9)	1.43 (0.60, 3.42)	25	34,692	0.7 (0.5, 1.1)	18	27,270	0.7 (0.4, 1.0)	34	39,217	0.9 (0.6, 1.2)	
		BSAC	1	1,888	0.5 (0.0, 2.9)	0.54 (0.07, 3.97)	1	2,897	0.3 (0.0, 1.9)	0.32 (0.04, 2.38)	24	24,353	1.0 (0.6, 1.5)	23	21,456	1.1 (0.7, 1.6)	25	26,241	1.0 (0.6, 1.4)	
		BSM	12	10,764	1.1 (0.6, 1.9)	1.44 (0.76, 2.74)	2	946	2.1 (0.3, 7.6)	2.82 (0.68, 11.65)	41	52,908	0.8 (0.6, 1.1)	39	51,962	0.8 (0.5, 1.0)	53	63,672	0.8 (0.6, 1.1)	
		BSCC	2	8,533	0.2 (0.0, 0.8)	0.83 (0.19, 3.69)	0	775	0.0 (0.0, 4.7)	0.00 (0.00, 19.20)	13	46,135	0.3 (0.1, 0.5)	13	45,360	0.3 (0.2, 0.5)	15	54,668	0.3 (0.2, 0.5)	
		BSC	2	4,211	0.5 (0.1, 1.7)	0.89 (0.21, 3.80)	3	2,192	1.4 (0.3, 4.0)	2.83 (0.84, 9.54)	22	41,415	0.5 (0.3, 0.8)	19	39,223	0.5 (0.3, 0.8)	24	45,626	0.5 (0.3, 0.8)	
		BSSL	2	4,673	0.4 (0.1, 1.5)	0.94 (0.23, 3.90)	1	857	1.2 (0.0, 6.5)	2.60 (0.36, 19.00)	34	74,426	0.5 (0.3, 0.6)	33	73,569	0.4 (0.3, 0.6)	36	79,099	0.5 (0.3, 0.6)	
		BSOS	2	1,941	1.0 (0.1, 3.7)	1.35 (0.32, 5.76)	1	267	3.7 (0.1, 20.7)	5.11 (0.69, 37.94)	21	27,557	0.8 (0.5, 1.2)	20	27,290	0.7 (0.4, 1.1)	23	29,498	0.8 (0.5, 1.2)	
		Total	39	44,146	0.9 (0.6, 1.2)	1.44 (1.02, 2.02)	19	18,112	1.0 (0.6, 1.6)	1.78 (1.11, 2.84)	218	355,002	0.6 (0.5, 0.7)	199	336,890	0.6 (0.5, 0.7)	257	399,148	0.6 (0.6, 0.7)	
		45 to 69	Initial	BSWN	4	1,446	2.8 (0.8, 7.1)	0.98 (0.34, 2.80)	3	497	6.0 (1.2, 17.5)	2.28 (0.69, 7.58)	26	9,197	2.8 (1.8, 4.1)	23	8,700	2.6 (1.7, 4.0)	30	10,643
BSCM				0	908	0.0 (0.0, 4.1)	0.00 (0.00, 2.81)	2	1,492	1.3 (0.2, 4.8)	0.71 (0.15, 3.34)	10	5,725	1.7 (0.8, 3.2)	8	4,233	1.9 (0.8, 3.7)	10	6,633	1.5 (0.7, 2.8)
BSAC	1			477	2.1 (0.1, 11.6)	1.36 (0.17, 11.05)	2	471	4.2 (0.5, 15.3)	3.47 (0.67, 17.81)	7	4,551	1.5 (0.6, 3.2)	5	4,080	1.2 (0.4, 2.9)	8	5,028	1.6 (0.7, 3.1)	
BSM	8			1,913	4.2 (1.8, 8.2)	2.08 (0.88, 4.96)	0	191	0.0 (0.0, 19.1)	0.00 (0.00, 10.70)	14	6,972	2.0 (1.1, 3.4)	14	6,781	2.1 (1.1, 3.5)	22	8,885	2.5 (1.6, 3.7)	
BSCC	1			1,411	0.7 (0.0, 3.9)	0.47 (0.06, 3.78)	1	135	7.4 (0.2, 40.6)	5.51 (0.68, 44.50)	8	5,345	1.3 (0.6, 2.9)	7	5,210	1.3 (0.5, 2.8)	9	6,756	1.3 (0.6, 2.5)	
BSC	2			685	2.9 (0.4, 10.5)	3.70 (0.62, 22.08)	0	349	0.0 (0.0, 10.5)	0.00 (0.00, 23.91)	3	3,798	0.8 (0.2, 2.3)	3	3,449	0.9 (0.2, 2.5)	5	4,483	1.1 (0.4, 2.6)	
BSSL	0			814	0.0 (0.0, 4.5)	0.00 (0.00, 2.06)	0	215	0.0 (0.0, 17.0)	0.00 (0.00, 7.63)	24	10,992	2.4 (1.5, 3.5)	24	9,877	2.4 (1.6, 3.6)	24	10,906	2.2 (1.4, 3.3)	
BSOS	1			301	3.3 (0.1, 18.4)	0.90 (0.12, 6.82)	0	70	0.0 (0.0, 51.3)	0.00 (0.00, 16.10)	13	3,505	3.7 (2.0, 6.3)	13	3,435	3.8 (2.0, 6.3)	14	3,806	3.7 (2.0, 6.2)	
Total	17			7,955	2.1 (1.2, 3.4)	1.00 (0.60, 1.67)	8	3,420	2.3 (1.0, 4.6)	1.10 (0.54, 2.27)	105	49,185	2.1 (1.7, 2.6)	97	45,765	2.1 (1.7, 2.6)	122	57,140	2.1 (1.8, 2.5)	
Subsequent	BSWN			10	8,958	1.1 (0.5, 2.1)	1.44 (0.73, 2.84)	6	3,214	1.9 (0.7, 4.1)	2.60 (1.11, 6.12)	48	61,808	0.8 (0.6, 1.0)	42	58,594	0.7 (0.5, 1.0)	58	70,766	0.8 (0.6, 1.1)
	BSCM		9	5,514	1.6 (0.7, 3.1)	1.76 (0.85, 3.64)	9	8,783	1.0 (0.5, 1.9)	1.14 (0.54, 2.40)	38	41,000	0.9 (0.7, 1.3)	29	32,217	0.9 (0.6, 1.3)	47	46,514	1.0 (0.7, 1.3)	
	BSAC		1	2,267	0.4 (0.0, 2.5)	0.40 (0.05, 2.89)	1	3,419	0.3 (0.0, 1.6)	0.24 (0.03, 1.74)	32	28,640	1.1 (0.8, 1.6)	31	25,221	1.2 (0.8, 1.7)	33	30,907	1.1 (0.7, 1.5)	


Breast Cancer Detection

3.a.1, DCIS and invasive cancer detection

Description: The number of women who have breast cancer detected, expressed as a rate per 1,000 screens.

Target: No target

Figure 68: 3.a.1, 50 to 69, breast cancer detection rates (DCIS and invasive combined), initial and subsequent screens



The total number of breast cancers detected by BSA among women aged 45–69 years was 3,166 over two years. 484 cancers were detected in women aged 45–49 years and 2,682 in women aged 50–69 years. The cancer detection rates for women aged 45–49 years were 5.7 per 1,000 initial screens and 3.5 per 1,000 subsequent screens. For women aged 50–69 years the rates were higher at 13.8 per 1,000 initial screens and 6.2 per 1,000 subsequent screens.

Māori women aged 50–69 years were more likely to have a breast cancer detected from an initial or subsequent screen than non-Māori women, with no significant differences between Māori and non-Māori rates in the 45–49 age group. This pattern was similar for Pacific and non-Māori non-Pacific women.

Figure 69: 3.a.1, Initial, 50 to 69 breast cancer detection rates (DCIS and invasive combined), by LP




Figure 70: 3.a.1, Subsequent, 50 to 69, breast cancer detection rates (DCIS and invasive combined), by LP




Table 16: 3.a.1, Breast cancer detection rates (DCIS and invasive combined)

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Pacific Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)
			45 to 49	Initial	BSWN	7	1,156	6.1 (2.4, 12.4)	0.98 (0.44, 2.18)	4	398	10.1 (2.7, 25.5)	1.69 (0.61, 4.71)	43	6,969	6.2 (4.5, 8.3)	39	6,571	5.9 (4.2, 8.1)
		BSCM	4	741	5.4 (1.5, 13.8)	0.98 (0.34, 2.81)	10	1,233	8.1 (3.9, 14.9)	1.79 (0.81, 3.97)	25	4,541	5.5 (3.8, 8.1)	15	3,308	4.5 (2.5, 7.5)	29	5,282	5.5 (3.7, 7.9)
		BSAC	4	366	10.9 (3.0, 27.7)	1.32 (0.46, 3.73)	2	372	5.4 (0.7, 19.3)	0.62 (0.15, 2.60)	28	3,373	8.3 (5.5, 12.0)	26	3,001	8.7 (5.7, 12.7)	32	3,739	8.6 (5.9, 12.1)
		BSM	8	1,422	5.6 (2.4, 11.1)	1.44 (0.64, 3.24)	1	151	6.6 (0.2, 36.3)	1.73 (0.23, 12.80)	21	5,372	3.9 (2.4, 6.0)	20	5,221	3.8 (2.3, 5.9)	29	6,794	4.3 (2.9, 6.1)
		BSCC	5	1,047	4.8 (1.6, 11.1)	1.23 (0.45, 3.35)	1	104	9.6 (0.2, 52.4)	2.58 (0.34, 19.33)	16	4,125	3.9 (2.2, 6.3)	15	4,021	3.7 (2.1, 6.1)	21	5,172	4.1 (2.5, 6.2)
		BSC	5	543	9.2 (3.0, 21.4)	1.91 (0.69, 5.27)	4	248	16.1 (4.4, 40.8)	4.27 (1.35, 13.52)	14	2,896	4.8 (2.6, 8.1)	10	2,648	3.8 (1.8, 6.9)	19	3,439	5.5 (3.3, 8.6)
		BSSL	4	683	5.9 (1.6, 14.9)	0.93 (0.34, 2.57)	0	169	0.0 (0.0, 21.6)	0.00 (0.00, 3.52)	53	8,433	6.3 (4.7, 8.2)	53	8,264	6.4 (4.8, 8.4)	57	9,116	6.3 (4.7, 8.1)
		BSOS	3	249	12.0 (2.5, 34.8)	2.03 (0.60, 6.89)	0	49	0.0 (0.0, 72.5)	0.00 (0.00, 13.94)	17	2,867	5.9 (3.5, 9.5)	17	2,818	6.0 (3.5, 9.6)	20	3,116	6.4 (3.9, 9.9)
		Total	40	6,207	6.4 (4.6, 8.8)	1.15 (0.82, 1.60)	22	2,724	8.1 (5.1, 12.2)	1.49 (0.96, 2.30)	217	38,576	5.6 (4.9, 6.4)	195	35,852	5.4 (4.7, 6.3)	257	44,783	5.7 (5.1, 6.5)
	Subsequent	BSWN	8	1,352	5.9 (2.6, 11.6)	1.90 (0.86, 4.19)	1	462	2.2 (0.1, 12.0)	0.68 (0.09, 5.03)	26	8,352	3.1 (2.0, 4.6)	25	7,890	3.2 (2.1, 4.7)	34	9,704	3.5 (2.4, 4.9)
		BSCM	1	1,002	1.0 (0.0, 5.5)	0.30 (0.04, 2.23)	4	1,366	2.9 (0.8, 7.5)	0.86 (0.29, 2.54)	21	6,333	3.3 (2.1, 5.1)	17	4,967	3.4 (2.0, 5.5)	22	7,335	3.0 (1.9, 4.5)
		BSAC	1	379	2.6 (0.1, 14.6)	1.03 (0.13, 7.94)	2	522	3.8 (0.5, 13.8)	1.60 (0.35, 7.40)	11	4,287	2.6 (1.3, 4.6)	9	3,765	2.4 (1.1, 4.5)	12	4,666	2.6 (1.3, 4.5)
		BSM	3	1,889	1.6 (0.3, 4.6)	0.43 (0.13, 1.41)	0	189	0.0 (0.0, 19.3)	0.00 (0.00, 5.51)	28	7,587	3.7 (2.5, 5.3)	28	7,398	3.8 (2.5, 5.5)	31	9,476	3.3 (2.2, 4.6)
		BSCC	6	1,538	3.9 (1.4, 8.5)	1.32 (0.53, 3.29)	1	131	7.6 (0.2, 41.8)	2.67 (0.36, 19.80)	20	6,776	3.0 (1.8, 4.6)	19	6,645	2.9 (1.7, 4.5)	26	8,314	3.1 (2.0, 4.6)
		BSC	4	782	5.1 (1.4, 13.0)	1.70 (0.58, 4.98)	1	348	2.9 (0.1, 15.9)	0.95 (0.13, 7.10)	19	6,305	3.0 (1.8, 4.7)	18	5,957	3.0 (1.8, 4.8)	23	7,087	3.2 (2.1, 4.9)
		BSSL	5	1,100	4.5 (1.5, 10.6)	1.02 (0.41, 2.55)	0	200	0.0 (0.0, 18.3)	0.00 (0.00, 4.22)	56	12,590	4.4 (3.4, 5.8)	56	12,390	4.5 (3.4, 5.9)	61	13,690	4.5 (3.4, 5.7)
		BSOS	1	429	2.3 (0.1, 12.9)	0.54 (0.07, 4.06)	0	59	0.0 (0.0, 60.6)	0.00 (0.00, 15.99)	17	3,953	4.3 (2.5, 6.9)	17	3,894	4.4 (2.5, 7.0)	18	4,382	4.1 (2.4, 6.5)
		Total	29	8,471	3.4 (2.3, 4.9)	0.97 (0.66, 1.43)	9	3,277	2.7 (1.3, 5.2)	0.77 (0.39, 1.50)	198	56,183	3.5 (3.1, 4.0)	189	52,906	3.6 (3.1, 4.1)	227	64,654	3.5 (3.1, 4.0)
50 to 69	Initial	BSWN	10	290	34.5 (16.7, 62.5)	2.40 (1.19, 4.83)	1	99	10.1 (0.3, 55.0)	0.69 (0.10, 5.03)	32	2,228	14.4 (9.8, 20.2)	31	2,129	14.6 (9.9, 20.6)	42	2,518	16.7 (12.0, 22.5)
		BSCM	3	167	18.0 (3.7, 51.6)	1.12 (0.34, 3.74)	6	259	23.2 (8.5, 49.7)	1.65 (0.63, 4.29)	19	1,184	16.0 (9.7, 24.9)	13	925	14.1 (7.5, 23.9)	22	1,351	16.3 (10.2, 24.6)
		BSAC	0	111	0.0 (0.0, 32.7)	0.00 (0.00, 3.82)	3	99	30.3 (6.3, 86.0)	3.63 (1.00, 13.20)	12	1,178	10.2 (5.3, 17.7)	9	1,079	8.3 (3.8, 15.8)	12	1,289	9.3 (4.8, 16.2)
		BSM	16	491	32.6 (18.7, 52.4)	2.61 (1.36, 4.99)	3	40	75.0 (15.7, 203.9)	6.88 (2.10, 22.55)	20	1,600	12.5 (7.7, 19.2)	17	1,560	10.9 (6.4, 17.4)	36	2,091	17.2 (12.1, 23.8)
		BSCC	6	364	16.5 (6.1, 35.5)	1.55 (0.59, 4.04)	0	31	0.0 (0.0, 112.2)	0.00 (0.00, 12.59)	13	1,220	10.7 (5.7, 18.2)	13	1,189	10.9 (5.8, 18.6)	19	1,584	12.0 (7.2, 18.7)
		BSC	2	142	14.1 (1.7, 50.0)	1.06 (0.24, 4.68)	5	101	49.5 (16.3, 111.8)	5.67 (1.83, 17.52)	12	902	13.3 (6.9, 23.1)	7	801	8.7 (3.5, 17.9)	14	1,044	13.4 (7.4, 22.4)
		BSSL	0	131	0.0 (0.0, 27.8)	0.00 (0.00, 2.71)	1	46	21.7 (0.6, 115.3)	1.95 (0.27, 14.28)	19	1,659	11.5 (6.9, 17.8)	18	1,613	11.2 (6.6, 17.6)	19	1,790	10.6 (6.4, 16.5)
		BSOS	1	52	19.2 (0.5, 102.6)	2.05 (0.25, 16.67)	0	21	0.0 (0.0, 161.1)	0.00 (0.00, 24.95)	6	638	9.4 (3.5, 20.4)	6	617	9.7 (3.6, 21.0)	7	690	10.1 (4.1, 20.8)
		Total	38	1,748	21.7 (15.4, 29.7)	1.73 (1.21, 2.48)	19	696	27.3 (16.5, 42.3)	2.37 (1.47, 3.83)	133	10,609	12.5 (10.5, 14.8)	114	9,913	11.5 (9.5, 13.8)	171	12,357	13.8 (11.9, 16.1)
	Subsequent	BSWN	74	7,652	9.7 (7.6, 12.1)	1.74 (1.35, 2.25)	24	2,775	8.6 (5.5, 12.8)	1.61 (1.06, 2.43)	300	54,052	5.6 (4.9, 6.2)	276	51,277	5.4 (4.8, 6.1)	374	61,704	6.1 (5.5, 6.7)
		BSCM	48	4,621	10.4 (7.7, 13.7)	1.79 (1.30, 2.44)	47	7,458	6.3 (4.6, 8.4)	1.11 (0.80, 1.53)	203	34,889	5.8 (5.0, 6.7)	156	27,431	5.7 (4.8, 6.6)	251	39,510	6.4 (5.6, 7.2)
		BSAC	23	1,888	12.2 (7.7, 18.2)	1.94 (1.25, 3.00)	33	2,898	11.4 (7.9, 16.0)	2.04 (1.39, 2.99)	153	24,354	6.3 (5.3, 7.4)	120	21,456	5.6 (4.6, 6.7)	176	26,242	6.7 (5.8, 7.8)
		BSM	102	11,207	9.1 (7.4, 11.0)	1.67 (1.33, 2.09)	7	986	7.1 (2.9, 14.6)	1.31 (0.62, 2.77)	292	53,611	5.4 (4.8, 6.1)	285	52,625	5.4 (4.8, 6.1)	394	64,818	6.1 (5.5, 6.7)
		BSCC	75	8,702	8.6 (6.8, 10.8)	1.62 (1.25, 2.09)	4	795	5.0 (1.4, 12.8)	0.94 (0.35, 2.52)	248	46,471	5.3 (4.7, 6.0)	244	45,676	5.3 (4.7, 6.1)	323	55,173	5.9 (5.2, 6.5)
		BSC	36	4,334	8.3 (5.8, 11.5)	1.26 (0.89, 1.78)	20	2,254	8.9 (5.4, 13.7)	1.38 (0.88, 2.17)	276	41,966	6.6 (5.8, 7.4)	256	39,712	6.4 (5.7, 7.3)	312	46,300	6.7 (6.0, 7.5)
		BSSL	35	5,138	6.8 (4.7, 9.5)	1.12 (0.80, 1.58)	7	918	7.6 (3.1, 15.6)	1.26 (0.60, 2.65)	454	74,881	6.1 (5.5, 6.6)	447	73,963	6.0 (5.5, 6.6)	489	80,019	6.1 (5.6, 6.7)
		BSOS	17	2,115	8.0 (4.7, 12.8)	1.27 (0.77, 2.08)	4	289	13.8 (3.8, 35.1)	2.21 (0.83, 5.92)	175	27,594	6.3 (5.4, 7.4)	171	27,305	6.3 (5.4, 7.3)	192	29,709	6.5 (5.6, 7.4)
		Total	410	45,657	9.0 (8.1, 9.9)	1.53 (1.38, 1.70)	146	18,373	7.9 (6.7, 9.3)	1.38 (1.17, 1.63)	2,101	357,818	5.9 (5.6, 6.1)	1,955	339,445	5.8 (5.5, 6.0)	2,511	403,475	6.2 (6.0, 6.5)
45 to 69	Initial	BSWN	17	1,446	11.8 (6.9, 18.8)	1.44 (0.85, 2.43)	5	497	10.1 (3.3, 23.3)	1.25 (0.51, 3.08)	75	9,197	8.2 (6.4, 10.2)	70	8,700	8.0 (6.3, 10.2)	92	10,643	8.6 (7.0, 10.6)
		BSCM	7	908	7.7 (3.1, 15.8)	1.00 (0.45, 2.22)	16	1,492	10.7 (6.1, 17.4)	1.62 (0.88, 2.99)	44	5,725	7.7 (5.6, 10.3)	28	4,233	6.6 (4.4, 9.5)	51	6,633	7.7 (5.7, 10.1)
		BSAC	4	477	8.4 (2.3, 21.3)	0.95 (0.34, 2.65)	5	471	10.6 (3.5, 24.6)	1.24 (0.49, 3.14)	40	4,551	8.8 (6.3, 11.9)	35	4,080	8.6 (6.0, 11.9)	44	5,028	8.8 (6.4, 11.7)
		BSM	24	1,913	12.5 (8.1, 18.6)	2.13 (1.29, 3.52)	4	191	20.9 (5.7, 52.8)	3.84 (1.38, 10.66)	41	6,972	5.9 (4.2, 8.0)	37	6,781	5.5 (3.8, 7.5)	65	8,885	7.3 (5.7, 9.3)
		BSCC	11	1,411	7.8 (3.9, 13.9)	1.44 (0.72, 2.87)	1	135	7.4 (0.2, 40.6)	1.38 (0.19, 10.06)	29	5,345	5.4 (3.6, 7.8)	28	5,210	5.4 (3.6, 7.8)	40	6,756	5.9 (4.2, 8.1)
		BSC	7	685	10.2 (4.1, 20.9)	1.49 (0.65, 3.42)	9	349	25.8 (11.9, 48.4)	5.23 (2.35, 11.65)	26	3,798	6.8 (4.5, 10.0)	17	3,449	4.9 (2.9, 7.9)	33	4,483	7.4 (5.1, 10.3)
		BSSL	4	814	4.9 (1.3, 12.5)	0.69 (0.25, 1.88)	1	215	4.7 (0.1, 25.6)	0.65 (0.09, 4.63)	72	10,092	7.1 (5.6, 9.0)	71	9,877	7.2 (5.6, 9.1)	76	10,906	7.0 (5.5, 8.7)
		BSOS	4	301	13.3 (3.6, 33.7)	2.03 (0.70, 5.82)	0	70	0.0 (0.0, 51.3)	0.00 (0.00, 8.54)	23	3,505	6.6 (4.2, 9.8)	23	3,435	6.7 (4.2, 10.0)	27	3,806	7.1 (4.7, 10.3)
		Total	78	7,955	9.8 (7.8, 12.2)	1.38 (1.08, 1.76)	41	3,420	12.0 (8.6, 16.2)	1.78 (1.28, 2.46)	350	49,185	7.1 (6.4, 7.9)	309	45,765	6.8 (6.0, 7.5)	428	57,140	7.5 (6.8, 8.2)
	Subsequent	BSWN	82	9,004	9.1 (7.2, 11.3)	1.74 (1.37, 2.22)	25												


3.a.2, Invasive breast cancer detection

Description: The number of women with diagnosed invasive cancer per number of women screened.

Targets for 45–49 age group: Initial: ≥ 3.8 per 1,000 women screened. Subsequent: ≥ 2.4 per 1,000 women screened

Targets for 50–69 age group: Initial: ≥ 6.1 per 1,000 women screened. Subsequent: ≥ 3.45 per 1,000 women screened

Figure 71: 3.a.2, 50 to 69, Invasive breast cancer detection, initial and subsequent screens



Over the two-year period, BSA detected 2,430 invasive breast cancers among women aged 45–69 years, 195 more than the previous biennium. 308 were detected from initial screens and 2,122 from subsequent screens. 324 invasive cancers were detected among women aged 45–49 years (163 from initial screens) and 2,106 among women aged 50–69 years (145 from initial screens).

Invasive breast cancer detection rates were within the target ranges for initial and subsequent screens for women in both age groups. For BSA overall, the invasive cancer detection rates for women aged 45–49 were 3.6 per 1,000 initial screens and 2.5 per 1,000 subsequent screens. For women aged 50–69 years the rates were 11.7 per 1,000 initial screens and 4.9 per 1,000 subsequent screens. Targets were met or were within the confidence interval for all LPs.

Māori women aged 45–69 were more likely than non-Māori women to have an invasive breast cancer detected from an initial screen (59% higher rate) or subsequent screen (64% higher). Pacific women aged 45–69 were also more likely to have an invasive breast cancer detected from an initial (146% higher) or subsequent screen (36% higher).

Figure 72: 3.a.2, Initial, 50 to 69, Invasive breast cancer detection, by LP




Figure 73: 3.a.2, Subsequent, 50 to 69, Invasive breast cancer detection, by LP




Table 17: 3.a.2, Invasive breast cancer detection

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)		
45 to 49	Initial	BSWN	6	1,156	5.2 (1.9, 11.3)	1.25 (0.52, 3.00)	4	398	10.1 (2.7, 25.5)	2.64 (0.92, 7.55)	29	6,969	4.2 (2.8, 6.0)	25	6,571	3.8 (2.5, 5.6)	35	8,125	4.3 (3.0, 6.0)	
		BSCM	2	741	2.7 (0.3, 9.7)	0.58 (0.14, 2.48)	10	1,233	8.1 (3.9, 14.9)	2.44 (1.04, 5.73)	21	4,541	4.6 (2.9, 7.1)	11	3,308	3.3 (1.7, 5.9)	23	5,282	4.4 (2.8, 6.5)	
		BSAC	3	366	8.2 (1.7, 23.8)	2.13 (0.61, 7.43)	2	372	5.4 (0.7, 19.3)	1.47 (0.33, 6.59)	13	3,373	3.9 (2.1, 6.6)	11	3,001	3.7 (1.8, 6.5)	16	3,739	4.3 (2.4, 6.9)	
		BSM	5	1,422	3.5 (1.1, 8.2)	1.35 (0.49, 3.74)	1	151	6.6 (0.2, 36.3)	2.66 (0.35, 20.20)	14	5,372	2.6 (1.4, 4.4)	13	5,221	2.5 (1.3, 4.3)	19	6,794	2.8 (1.7, 4.4)	
		BSCC	5	1,047	4.8 (1.6, 11.1)	1.64 (0.58, 4.65)	1	104	9.6 (0.2, 52.4)	3.52 (0.46, 26.97)	12	4,125	2.9 (1.5, 5.1)	11	4,021	2.7 (1.4, 4.9)	17	5,172	3.3 (1.9, 5.3)	
		BSC	5	543	9.2 (3.0, 21.4)	4.44 (1.36, 14.51)	2	248	8.1 (1.0, 28.8)	5.34 (0.98, 29.00)	6	2,896	2.1 (0.8, 4.5)	4	2,648	1.5 (0.4, 3.9)	11	3,439	3.2 (1.6, 5.7)	
		BSSL	1	683	1.5 (0.0, 8.1)	0.41 (0.06, 3.01)	0	169	0.0 (0.0, 21.6)	0.00 (0.00, 6.40)	30	8,433	3.6 (2.4, 5.1)	30	8,264	3.6 (2.5, 5.2)	31	9,116	3.4 (2.3, 4.8)	
		BSOS	1	249	4.0 (0.1, 22.2)	1.15 (0.15, 8.96)	0	49	0.0 (0.0, 72.5)	0.00 (0.00, 25.66)	10	2,867	3.5 (1.7, 6.4)	10	2,818	3.5 (1.7, 6.5)	11	3,116	3.5 (1.8, 6.3)	
		Total	28	6,207	4.5 (3.0, 6.5)	1.29 (0.86, 1.94)	20	2,724	7.3 (4.5, 11.3)	2.29 (1.43, 3.67)	135	38,576	3.5 (2.9, 4.1)	115	35,852	3.2 (2.6, 3.8)	163	44,783	3.6 (3.1, 4.2)	
		Subsequent	BSWN	7	1,347	5.2 (2.1, 10.7)	2.27 (0.95, 5.38)	1	458	2.2 (0.1, 12.1)	0.95 (0.13, 7.10)	19	8,292	2.3 (1.4, 3.6)	18	7,834	2.3 (1.4, 3.6)	26	9,639	2.7 (1.8, 3.9)
	BSCM		1	989	1.0 (0.0, 5.6)	0.46 (0.06, 3.46)	4	1,361	2.9 (0.8, 7.5)	1.45 (0.46, 4.63)	14	6,308	2.2 (1.2, 3.7)	10	4,947	2.0 (1.0, 3.7)	15	7,297	2.1 (1.2, 3.4)	
	BSAC		1	379	2.6 (0.1, 14.6)	1.62 (0.20, 13.10)	2	522	3.8 (0.5, 13.8)	2.89 (0.56, 14.83)	7	4,287	1.6 (0.7, 3.4)	5	3,765	1.3 (0.4, 3.1)	8	4,666	1.7 (0.7, 3.4)	
	BSM		2	1,841	1.1 (0.1, 3.9)	0.41 (0.10, 1.75)	0	180	0.0 (0.0, 20.3)	0.00 (0.00, 8.27)	20	7,529	2.7 (1.6, 4.1)	20	7,349	2.7 (1.7, 4.2)	22	9,370	2.3 (1.5, 3.6)	
	BSCC		4	1,519	2.6 (0.7, 6.7)	1.11 (0.37, 3.32)	1	131	7.6 (0.2, 41.8)	3.37 (0.45, 25.33)	16	6,754	2.4 (1.4, 3.8)	15	6,623	2.3 (1.3, 3.7)	20	8,273	2.5 (1.5, 3.7)	
	BSC		4	755	5.3 (1.4, 13.5)	2.78 (0.90, 8.58)	1	345	2.9 (0.1, 16.0)	1.57 (0.20, 12.09)	12	6,285	1.9 (1.0, 3.3)	11	5,940	1.9 (0.9, 3.3)	16	7,040	2.3 (1.3, 3.7)	
	BSSL		4	1,016	3.9 (1.1, 10.0)	1.27 (0.45, 3.53)	0	183	0.0 (0.0, 20.0)	0.00 (0.00, 6.70)	39	12,535	3.1 (2.2, 4.3)	39	12,352	3.2 (2.2, 4.3)	43	13,551	3.2 (2.3, 4.3)	
	BSOS		0	406	0.0 (0.0, 9.0)	0.00 (0.00, 3.88)	0	57	0.0 (0.0, 62.7)	0.00 (0.00, 27.22)	11	3,951	2.8 (1.4, 5.0)	11	3,894	2.8 (1.4, 5.0)	11	4,357	2.5 (1.3, 4.5)	
	Total		23	8,252	2.8 (1.8, 4.2)	1.13 (0.73, 1.76)	9	3,237	2.8 (1.3, 5.3)	1.14 (0.58, 2.23)	138	55,941	2.5 (2.1, 2.9)	129	52,704	2.4 (2.0, 2.9)	161	64,193	2.5 (2.1, 2.9)	
	50 to 69		Initial	BSWN	9	290	31.0 (14.3, 58.1)	2.47 (1.18, 5.18)	1	99	10.1 (0.3, 55.0)	0.80 (0.11, 5.80)	28	2,228	12.6 (8.4, 18.1)	27	2,129	12.7 (8.4, 18.4)	37	2,518
		BSCM		2	167	12.0 (1.5, 42.6)	0.95 (0.22, 4.10)	5	259	19.3 (6.3, 44.5)	1.79 (0.62, 5.18)	15	1,184	12.7 (7.1, 20.8)	10	925	10.8 (5.2, 19.8)	17	1,351	12.6 (7.3, 20.1)
BSAC		0		111	0.0 (0.0, 32.7)	0.00 (0.00, 3.82)	3	99	30.3 (6.3, 86.0)	3.63 (1.00, 13.20)	12	1,178	10.2 (5.3, 17.7)	9	1,079	8.3 (3.8, 15.8)	12	1,289	9.3 (4.8, 16.2)	
BSM		15		491	30.5 (17.2, 49.9)	3.06 (1.52, 6.13)	3	40	75.0 (15.7, 203.9)	9.00 (2.67, 30.35)	16	1,600	10.0 (5.7, 16.2)	13	1,560	8.3 (4.4, 14.2)	31	2,091	14.8 (10.1, 21.0)	
BSCC		6		364	16.5 (6.1, 35.5)	1.83 (0.68, 4.91)	0	31	0.0 (0.0, 112.2)	0.00 (0.00, 15.28)	11	1,220	9.0 (4.5, 16.1)	11	1,189	9.3 (4.6, 16.5)	17	1,584	10.7 (6.3, 17.1)	
BSC		2		142	14.1 (1.7, 50.0)	1.16 (0.26, 5.16)	5	101	49.5 (16.3, 111.8)	6.61 (2.05, 21.27)	11	902	12.2 (6.1, 21.7)	6	801	7.5 (2.8, 16.2)	13	1,044	12.5 (6.6, 21.2)	
BSSL		0		131	0.0 (0.0, 27.8)	0.00 (0.00, 5.05)	1	46	21.7 (0.6, 115.3)	3.51 (0.46, 26.82)	11	1,659	6.6 (3.3, 11.8)	10	1,613	6.2 (3.0, 11.4)	11	1,790	6.1 (3.1, 11.0)	
BSOS		1		52	19.2 (0.5, 102.6)	2.05 (0.25, 16.67)	0	21	0.0 (0.0, 161.1)	0.00 (0.00, 24.95)	6	638	9.4 (3.5, 20.4)	6	617	9.7 (3.6, 21.0)	7	690	10.1 (4.1, 20.8)	
Total		35		1,748	20.0 (14.0, 27.7)	1.93 (1.32, 2.81)	18	696	25.9 (15.4, 40.6)	2.79 (1.69, 4.59)	110	10,609	10.4 (8.5, 12.5)	92	9,913	9.3 (7.5, 11.4)	145	12,357	11.7 (9.9, 13.8)	
Subsequent		BSWN		64	7,612	8.4 (6.5, 10.7)	1.96 (1.49, 2.58)	20	2,756	7.3 (4.4, 11.2)	1.75 (1.11, 2.77)	230	53,518	4.3 (3.8, 4.9)	210	50,762	4.1 (3.6, 4.7)	294	61,130	4.8 (4.3, 5.4)
		BSCM	34	4,526	7.5 (5.2, 10.5)	1.66 (1.15, 2.40)	37	7,422	5.0 (3.5, 6.9)	1.13 (0.78, 1.64)	157	34,692	4.5 (3.8, 5.3)	120	27,270	4.4 (3.6, 5.3)	191	39,218	4.9 (4.2, 5.6)	
		BSAC	19	1,888	10.1 (6.1, 15.7)	2.33 (1.44, 3.80)	26	2,897	9.0 (5.9, 13.1)	2.44 (1.57, 3.79)	105	24,353	4.0 (3.5, 4.6)	79	21,456	3.7 (2.9, 4.6)	124	26,241	4.7 (3.9, 5.6)	
		BSM	84	10,766	7.8 (6.2, 9.7)	1.84 (1.44, 2.37)	4	946	4.2 (1.2, 10.8)	1.00 (0.37, 2.68)	224	52,909	4.2 (3.7, 4.8)	220	51,963	4.2 (3.7, 4.8)	308	63,675	4.8 (4.3, 5.4)	
		BSCC	66	8,535	7.7 (6.0, 9.8)	1.82 (1.38, 2.40)	3	776	3.9 (0.8, 11.3)	0.91 (0.29, 2.84)	196	46,140	4.2 (3.7, 4.9)	193	45,364	4.3 (3.7, 4.9)	262	54,675	4.8 (4.2, 5.4)	
		BSC	34	4,213	8.1 (5.6, 11.3)	1.55 (1.08, 2.22)	16	2,192	7.3 (4.2, 11.8)	1.43 (0.86, 2.38)	216	41,418	5.2 (4.5, 6.0)	200	39,226	5.1 (4.4, 5.9)	250	45,631	5.5 (4.8, 6.2)	
		BSSL	32	4,679	6.8 (4.7, 9.6)	1.47 (1.02, 2.11)	3	857	3.5 (0.7, 10.2)	0.75 (0.24, 2.33)	346	74,427	4.5 (4.2, 5.2)	343	73,570	4.7 (4.2, 5.2)	378	79,106	4.8 (4.3, 5.3)	
		BSOS	11	1,942	5.7 (2.8, 10.1)	1.09 (0.59, 2.01)	4	267	15.0 (4.1, 37.9)	2.94 (1.10, 7.89)	143	27,557	5.2 (4.4, 6.1)	139	27,290	5.1 (4.3, 6.0)	154	29,499	5.2 (4.4, 6.1)	
		Total	344	44,161	7.8 (7.0, 8.7)	1.71 (1.52, 1.92)	113	18,113	6.2 (5.1, 7.5)	1.40 (1.16, 1.69)	1,617	35,014	4.6 (4.3, 4.8)	1,504	33,901	4.5 (4.2, 4.7)	1,961	39,915	4.9 (4.7, 5.1)	
		45 to 69	Initial	BSWN	15	1,446	10.4 (5.8, 17.1)	1.67 (0.95, 2.95)	5	497	10.1 (3.3, 23.3)	1.68 (0.68, 4.20)	57	9,197	6.2 (4.7, 8.0)	52	8,700	6.0 (4.5, 7.8)	72	10,643
BSCM				4	908	4.4 (1.2, 11.2)	0.70 (0.25, 1.96)	15	1,492	10.1 (5.6, 16.5)	2.03 (1.05, 3.92)	36	5,725	6.3 (4.4, 8.7)	21	4,233	5.0 (3.1, 7.6)	40	6,633	6.0 (4.3, 8.2)
BSAC	3			477	6.3 (1.3, 18.3)	1.15 (0.35, 3.78)	5	471	10.6 (3.5, 24.6)	2.17 (0.82, 5.74)	25	4,551	5.5 (3.6, 8.1)	20	4,080	4.9 (3.0, 7.6)	28	5,028	5.6 (3.7, 8.0)	
BSM	20			1,913	10.5 (6.4, 16.1)	2.43 (1.38, 4.27)	4	191	20.9 (5.7, 52.8)	5.46 (1.93, 15.50)	30	6,972	4.3 (2.9, 6.1)	26	6,781	3.8 (2.5, 5.6)	50	8,885	5.6 (4.2, 7.4)	
BSCC	11			1,411	7.8 (3.9, 13.9)	1.81 (0.89, 3.71)	1	135	7.4 (0.2, 40.6)	1.75 (0.24, 12.92)	23	5,345	4.3 (2.7, 6.4)	22	5,210	4.2 (2.6, 6.4)	34	6,756	5.0 (3.5, 7.0)	
BSC	7			685	10.2 (4.1, 20.9)	2.28 (0.95, 5.49)	7	349	20.1 (8.1, 40.9)	6.92 (2.65, 18.06)	17	3,798	4.5 (2.6, 7.2)	10	3,449	2.9 (1.4, 5.3)	24	4,483	5.4 (3.4, 8.0)	
BSSL	1			814	1.2 (0.0, 6.8)	0.30 (0.04, 2.19)	1	215	4.7 (0.1, 25.6)	1.15 (0.16, 8.32)	41	10,092	4.1 (2.9, 5.5)	40	9,877	4.0 (2.9, 5.5)	42	10,906	3.9 (2.8, 5.2)	
BSOS	2			301	6.6 (0.8, 23.8)	1.46 (0.34, 6.30)	0	70	0.0 (0.0, 51.3)	0.00 (0.00, 12.72)	16	3,505	4.6 (2.6, 7.4)	16	3,435	4.7 (2.7, 7.6)	18	3,806	4.7 (2.8, 7.5)	
Total	63			7,955	7.9 (6.1, 10.1)	1.59 (1.21, 2.10)	38	3,420	11.1 (7.9, 15.2)	2.46 (1.74, 3.47)	245	49,185	5.0 (4.4, 5.6)	207	45,765	4.5 (3.9, 5.2)	308	57,140	5.4 (4.8, 6.0)	
Subsequent	BSWN			71	8,959	7.9 (6.2, 10.0)	1.97 (1.51, 2.56)	21	3,214	6.5 (4.0, 10.0)	1.68 (1.07, 2.62)	249	61,810	4.0 (3.5, 4.6)	228	58,596	3.9 (3.4, 4.4)	320	70,769	4.5 (4.0, 5.0)
	BSCM		35	5,515	6.3 (4.4, 8.8)	1.52 (1.06, 2.19)	41	8,783	4.7 (3.4, 6.3)	1.16 (0.81, 1.64)	171	41,000	4.2 (3.6, 4.8)	130	32,217	4.0 (3.4, 4.8)	206	46,515	4.4 (3.8, 5.1)	
	BSAC		20	2,267	8.8 (5.4, 13.6)	2.26 (1														

3.a.3, Summary of assessment outcomes

Description: See definitions for referral to assessment (2d); specificity (2l); positive prediction value(2f); detection rate of DCIS and invasive cancer (3a1).

Targets (50–69 only): Assessment: Initial: expected value <10%. Subsequent: expected value <5%; **Specificity** >93%; **Positive predictive value:** >9%; **Detection** no target.

Table 18: 3.a.3, Summary of assessment outcomes

			Māori				Pacific				Non-Māori				Non-Māori Non-Pacific				All			
			% of Women Screened Referred for Assessment	Estimated Specificity %	Positive Predictive Value %	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens
45 to 49	Initial	BSWN	12.0	88.0	5.0	6.1	10.6	89.4	9.5	10.1	8.4	91.6	7.4	6.2	8.2	91.8	7.2	5.9	8.9	91.1	6.9	6.2
		BSCM	6.9	93.1	7.8	5.4	7.9	92.1	10.2	8.1	7.8	92.2	7.0	5.5	7.8	92.2	5.8	4.5	7.7	92.3	7.1	5.5
		BSAC	13.1	86.9	8.3	10.9	7.8	92.2	6.9	5.4	8.2	91.8	10.1	8.3	8.2	91.8	10.5	8.7	8.7	91.3	9.9	8.6
		BSM	11.0	89.0	5.1	5.6	9.9	90.1	6.7	6.6	7.8	92.2	5.0	3.9	7.7	92.3	5.0	3.8	8.4	91.6	5.1	4.3
		BSCC	6.4	93.6	7.5	4.8	2.9	97.1	33.3	9.6	4.3	95.7	9.1	3.9	4.3	95.7	8.7	3.7	4.7	95.3	8.6	4.1
		BSC	7.2	92.8	12.8	9.2	7.7	92.3	21.1	16.1	7.1	92.9	6.8	4.8	7.1	92.9	5.3	3.8	7.1	92.9	7.8	5.5
		BSSL	8.8	91.2	6.7	5.9	7.1	92.9	0.0	0.0	8.5	91.5	7.4	6.3	8.6	91.4	7.5	6.4	8.6	91.4	7.3	6.3
		BSOS	16.9	83.1	7.1	12.0	12.2	87.8	0.0	0.0	12.6	87.4	4.7	5.9	12.6	87.4	4.8	6.0	13.0	87.0	5.0	6.4
	Total	9.7	90.3	6.6	6.4	8.2	91.8	9.8	8.1	8.0	92.0	7.0	5.6	8.0	92.0	6.8	5.4	8.3	91.7	6.9	5.7	
	Subsequent	BSWN	5.3	94.7	11.1	5.9	3.3	96.7	6.7	2.2	4.1	95.9	7.6	3.1	4.2	95.8	7.6	3.2	4.3	95.7	8.2	3.5
		BSCM	3.4	96.6	2.9	1.0	4.3	95.7	6.8	2.9	4.6	95.4	7.3	3.3	4.6	95.4	7.4	3.4	4.4	95.6	6.8	3.0
		BSAC	4.7	95.3	5.6	2.6	5.0	95.0	7.7	3.8	4.8	95.2	5.4	2.6	4.7	95.3	5.1	2.4	4.8	95.2	5.4	2.6
		BSM	4.9	95.1	3.3	1.6	2.2	97.8	0.0	0.0	5.0	95.0	7.4	3.7	5.1	94.9	7.5	3.8	5.0	95.0	6.7	3.3
		BSCC	2.2	97.8	17.6	3.9	1.5	98.5	50.0	7.6	2.0	98.0	14.5	3.0	2.1	97.9	14.0	2.9	2.1	97.9	15.1	3.1
BSC		5.7	94.3	9.3	5.1	4.3	95.7	6.7	2.9	4.2	95.8	7.3	3.0	4.1	95.9	7.3	3.0	4.3	95.7	7.6	3.2	
BSSL		5.7	94.3	8.6	4.5	4.3	95.7	0.0	0.0	4.9	95.1	9.2	4.4	4.9	95.1	9.3	4.5	4.9	95.1	9.1	4.5	
BSOS		7.3	92.7	3.3	2.3	7.0	93.0	0.0	0.0	7.0	93.0	6.2	4.3	7.0	93.0	6.3	4.4	7.0	93.0	5.9	4.1	
Total	4.6	95.4	7.7	3.4	4.1	95.9	6.8	2.7	4.5	95.5	7.9	3.5	4.5	95.5	8.0	3.6	4.5	95.5	7.9	3.5		
50 to 69	Initial	BSWN	12.5	87.5	9.4	34.5	12.3	87.7	8.2	10.1	9.2	90.8	8.9	14.4	9.0	91.0	8.9	14.6	9.7	90.3	8.9	16.7
		BSCM	8.4	91.6	9.2	18.0	8.6	91.4	12.5	23.2	8.5	91.5	9.1	16.0	8.5	91.5	7.8	14.1	8.5	91.5	9.1	16.3
		BSAC	11.7	88.3	7.1	0.0	8.1	91.9	13.2	30.3	8.7	91.3	10.1	10.2	8.8	91.2	9.7	8.3	9.0	91.0	9.7	9.3
		BSM	11.8	88.2	10.6	32.6	13.1	86.9	16.0	75.0	8.1	91.9	7.3	12.5	7.9	92.1	6.9	10.9	8.9	91.1	8.2	17.2
		BSCC	7.1	92.9	11.0	16.5	3.7	96.3	20.0	0.0	4.5	95.5	12.1	10.7	4.5	95.5	11.9	10.9	5.0	95.0	11.8	12.0
		BSC	6.9	93.1	14.9	14.1	8.6	91.4	30.0	49.5	7.2	92.8	9.5	13.3	7.1	92.9	6.9	8.7	7.2	92.8	10.2	13.4
		BSSL	9.0	91.0	5.5	0.0	8.8	91.2	5.3	21.7	8.8	91.2	8.1	11.5	8.8	91.2	8.1	11.2	8.8	91.2	7.9	10.6
		BSOS	15.9	84.1	8.3	19.2	15.7	84.3	0.0	0.0	13.0	87.0	5.1	9.4	12.9	87.1	5.2	9.7	13.2	86.8	5.4	10.1
	Total	10.1	89.9	9.7	21.7	9.3	90.7	12.9	27.3	8.4	91.6	8.4	12.5	8.4	91.6	8.1	11.5	8.7	91.3	8.6	13.8	
	Subsequent	BSWN	4.3	95.7	21.1	9.7	4.0	96.0	19.5	8.6	3.5	96.5	15.1	5.6	3.5	96.5	14.8	5.4	3.6	96.4	16.0	6.1
		BSCM	4.1	95.9	21.7	10.4	3.7	96.3	15.8	6.3	3.8	96.2	14.4	5.8	3.8	96.2	14.0	5.7	3.8	96.2	15.3	6.4
		BSAC	3.7	96.3	28.6	12.2	4.2	95.8	24.1	11.4	3.4	96.6	16.9	6.3	3.3	96.7	15.6	5.6	3.4	96.6	17.8	6.7
		BSM	4.2	95.8	19.7	9.1	3.3	96.7	18.9	7.1	3.8	96.2	14.1	5.4	3.8	96.2	14.0	5.4	3.8	96.2	15.2	6.1
		BSCC	2.3	97.7	35.7	8.6	1.5	98.5	35.7	5.0	1.7	98.3	29.7	5.3	1.7	98.3	29.6	5.3	1.8	98.2	30.9	5.9
BSC		4.2	95.8	19.1	8.3	4.2	95.8	19.6	8.9	3.8	96.2	16.3	6.6	3.8	96.2	16.1	6.4	3.8	96.2	16.6	6.7	
BSSL		4.6	95.4	15.0	6.8	3.4	96.6	19.4	7.6	3.8	96.2	15.4	6.1	3.8	96.2	15.3	6.0	3.9	96.1	15.4	6.1	
BSOS		5.7	94.3	13.3	8.0	6.4	93.6	19.0	13.8	4.7	95.3	12.9	6.3	4.7	95.3	12.8	6.3	4.8	95.2	12.9	6.5	
Total	3.9	96.1	21.2	9.0	3.8	96.2	19.1	7.9	3.5	96.5	15.9	5.9	3.5	96.5	15.7	5.8	3.6	96.4	16.5	6.2		


3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)

Description: The number with an invasive cancer of diameter $\leq 15\text{mm}$ as a percentage of the number with invasive cancer.

Targets for women aged 45–49 years: Initial: $>50\%$ of all invasive cancers detected will be $\leq 15\text{mm}$. Subsequent: $>50\%$ of all invasive cancers detected will be $\leq 15\text{mm}$.

Targets for women aged 50–69 years: Initial: $>50\%$ of all invasive cancers detected are $\leq 15\text{mm}$. Subsequent: $>50\%$ of all invasive cancers detected are $\leq 15\text{mm}$.

Figure 74: 3.c.p, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), initial and subsequent screens



Of 2,158 invasive cancers detected by BSA among women aged 45–69 years, 1,338 (63%) were small ($\leq 15\text{mm}$ diameter). The percentage of small cancers was lower in initial screens (53%) than in subsequent screens (64%). The targets were met or within the confidence interval for all LPs. The target of 50% or more was met for Māori, Pacific and non-Māori non-Pacific women. There were no significant differences between Māori and non-Māori in the proportion of cancers that were small. Pacific women had similar proportions of small cancers detected from initial screens as non-Māori non-Pacific women, but a lower proportion of cancers detected from subsequent screens were small (51% compared to 66%).

Figure 75: 3.c.p, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP




Figure 76: 3.c.p, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP




Table 19: 3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)
45 to 49	Initial	BSWN	1	5	20.0 (0.5, 71.6)	0.35 (0.06, 2.08)	1	4	25.0 (0.6, 80.6)	0.40 (0.07, 2.25)	16	28	57.1 (37.2, 75.5)	15	24	62.5 (40.6, 81.2)	17	33	51.5 (33.5, 69.2)
		BSCM	1	2	50.0 (1.3, 98.7)	1.06 (0.24, 4.57)	7	10	70.0 (34.8, 93.3)	3.15 (0.87, 11.42)	9	19	47.4 (24.4, 71.1)	2	9	22.2 (2.8, 60.0)	10	21	47.6 (25.7, 70.2)
		BSAC	2	3	66.7 (9.4, 99.2)	1.33 (0.50, 3.55)	1	2	50.0 (1.3, 98.7)	1.00 (0.22, 4.56)	6	12	50.0 (21.1, 78.9)	5	10	50.0 (18.7, 81.3)	8	15	53.3 (26.6, 78.7)
		BSM	2	5	40.0 (5.3, 85.3)	0.52 (0.17, 1.58)	0	0	NA (NA, NA)	NA (NA, NA)	10	13	76.9 (46.2, 95.0)	10	13	76.9 (46.2, 95.0)	12	18	66.7 (41.0, 86.7)
		BSCC	3	5	60.0 (14.7, 94.7)	2.20 (0.66, 7.32)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 24.20)	3	11	27.3 (6.0, 61.0)	3	10	30.0 (6.7, 65.2)	6	16	37.5 (15.2, 64.6)
		BSC	1	5	20.0 (0.5, 71.6)	0.30 (0.05, 1.89)	2	2	100.0 (15.8, 100.0)	2.00 (0.75, 5.33)	4	6	66.7 (22.3, 95.7)	2	4	50.0 (6.8, 93.2)	5	11	45.5 (16.7, 76.6)
		BSSL	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.87)	0	0	NA (NA, NA)	NA (NA, NA)	20	29	69.0 (49.2, 84.7)	20	29	69.0 (49.2, 84.7)	20	30	66.7 (47.2, 82.7)
		BSOS	1	1	100.0 (2.5, 100.0)	1.14 (0.88, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)	8	9	88.9 (51.8, 99.7)
		Total	11	27	40.7 (22.4, 61.2)	0.68 (0.42, 1.10)	11	19	57.9 (33.5, 79.7)	0.97 (0.64, 1.46)	75	126	59.5 (50.4, 68.2)	64	107	59.8 (49.9, 69.2)	86	153	56.2 (48.0, 64.2)
		Subsequent	BSWN	6	7	85.7 (42.1, 99.6)	1.04 (0.72, 1.51)	1	1	100.0 (2.5, 100.0)	1.23 (0.97, 1.56)	14	17	82.4 (56.6, 96.2)	13	16	81.3 (54.4, 96.0)	20	24
	BSCM		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.09)	3	4	75.0 (19.4, 99.4)	1.25 (0.58, 2.87)	9	14	64.3 (35.1, 87.2)	6	10	60.0 (26.2, 87.8)	9	15	60.0 (32.3, 83.7)
	BSAC		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.64)	1	2	50.0 (1.3, 98.7)	0.63 (0.15, 2.67)	5	7	71.4 (29.0, 96.3)	4	5	80.0 (28.4, 99.5)	5	8	62.5 (24.5, 91.5)
	BSM		1	1	100.0 (2.5, 100.0)	1.75 (1.21, 2.54)	0	0	NA (NA, NA)	NA (NA, NA)	12	21	57.1 (34.0, 78.2)	12	21	57.1 (34.0, 78.2)	13	22	59.1 (36.4, 79.3)
	BSCC		1	3	33.3 (0.8, 90.6)	0.42 (0.08, 2.11)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.04)	12	15	80.0 (50.9, 95.7)	12	14	85.7 (57.2, 98.2)	13	18	72.2 (46.5, 90.3)
	BSC		0	2	0.0 (0.0, 84.2)	0.00 (0.00, 8.33)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 15.15)	4	11	36.4 (10.9, 69.2)	4	10	40.0 (12.2, 73.8)	4	13	30.8 (9.1, 61.4)
	BSSL		3	4	75.0 (19.4, 99.4)	1.04 (0.57, 1.89)	0	0	NA (NA, NA)	NA (NA, NA)	26	36	72.2 (54.8, 85.8)	26	36	72.2 (54.8, 85.8)	29	40	72.5 (56.1, 85.4)
	BSOS		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	5	11	45.5 (16.7, 76.6)	5	11	45.5 (16.7, 76.6)	5	11	45.5 (16.7, 76.6)
	Total		11	19	57.9 (33.5, 79.7)	0.88 (0.59, 1.31)	5	9	55.6 (21.2, 86.3)	0.83 (0.46, 1.51)	87	132	65.9 (57.2, 73.9)	82	123	66.7 (57.6, 74.9)	98	151	64.9 (61.8, 72.5)
	50 to 69	Initial	BSWN	4	9	44.4 (13.7, 78.8)	0.78 (0.35, 1.73)	1	1	100.0 (2.5, 100.0)	1.80 (1.28, 2.52)	16	28	57.1 (37.2, 75.5)	15	27	55.6 (35.3, 74.5)	20	37
BSCM			0	2	0.0 (0.0, 84.2)	0.00 (0.00, 39.93)	1	5	20.0 (0.5, 71.6)	2.00 (0.15, 25.75)	2	15	13.3 (1.7, 40.5)	1	10	10.0 (0.3, 44.5)	2	17	11.8 (1.5, 36.4)
BSAC			0	0	NA (NA, NA)	NA (NA, NA)	1	3	33.3 (0.8, 90.6)	0.44 (0.09, 2.31)	7	11	63.6 (30.8, 89.1)	6	8	75.0 (34.9, 96.8)	7	11	63.6 (30.8, 89.1)
BSM			8	14	57.1 (28.9, 82.3)	0.91 (0.51, 1.65)	2	3	66.7 (9.4, 99.2)	1.08 (0.44, 2.69)	10	16	62.5 (35.4, 84.8)	8	13	61.5 (31.6, 86.1)	18	30	60.0 (40.6, 77.3)
BSCC			2	5	40.0 (5.3, 85.3)	0.93 (0.24, 3.68)	0	0	NA (NA, NA)	NA (NA, NA)	3	7	42.9 (9.9, 81.6)	3	7	42.9 (9.9, 81.6)	5	12	41.7 (15.2, 72.3)
BSC			2	2	100.0 (15.8, 100.0)	3.33 (1.29, 8.59)	2	4	50.0 (6.8, 93.2)	3.00 (0.39, 23.07)	3	10	30.0 (6.7, 65.2)	1	6	16.7 (0.4, 64.1)	5	12	41.7 (15.2, 72.3)
BSSL			0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.50 (0.94, 2.38)	7	10	70.0 (34.8, 93.3)	6	9	66.7 (29.9, 92.5)	7	10	70.0 (34.8, 93.3)
BSOS			0	1	0.0 (0.0, 97.5)	0.00 (0.00, 14.52)	0	0	NA (NA, NA)	NA (NA, NA)	3	6	50.0 (11.8, 88.2)	3	6	50.0 (11.8, 88.2)	3	7	42.9 (9.9, 81.6)
Total			16	33	48.5 (30.8, 66.5)	0.98 (0.66, 1.46)	8	17	47.1 (23.0, 72.2)	0.94 (0.55, 1.63)	51	103	49.5 (39.5, 59.5)	43	86	50.0 (39.0, 61.0)	67	136	49.3 (40.6, 58.0)
Subsequent			BSWN	42	60	70.0 (56.8, 81.2)	1.06 (0.88, 1.28)	7	20	35.0 (15.4, 59.2)	0.51 (0.28, 0.93)	148	224	66.1 (59.5, 72.2)	141	204	69.1 (62.3, 75.4)	190	284
		BSCM	18	34	52.9 (35.1, 70.2)	0.87 (0.62, 1.22)	21	36	58.3 (40.8, 74.5)	0.95 (0.69, 1.29)	95	156	60.9 (52.8, 68.6)	74	120	61.7 (52.4, 70.4)	113	190	59.5 (52.1, 66.5)
		BSAC	14	19	73.7 (48.8, 90.9)	1.10 (0.81, 1.49)	16	26	61.5 (40.6, 79.8)	0.89 (0.64, 1.25)	69	103	67.0 (57.3, 75.9)	53	77	68.8 (57.3, 78.9)	83	122	68.0 (59.0, 76.2)
		BSM	51	81	63.0 (51.5, 73.4)	0.98 (0.80, 1.18)	2	4	50.0 (6.8, 93.2)	0.77 (0.29, 2.07)	142	220	64.5 (57.8, 70.9)	140	216	64.8 (58.0, 71.2)	193	301	64.1 (58.4, 69.5)
		BSCC	29	63	46.0 (33.4, 59.1)	0.80 (0.59, 1.07)	0	2	0.0 (0.0, 84.2)	0.00 (0.00, 3.21)	111	192	57.8 (50.5, 64.9)	111	190	58.4 (51.1, 65.5)	140	255	54.9 (48.6, 61.1)
		BSC	23	34	67.6 (49.5, 82.6)	1.07 (0.83, 1.39)	5	15	33.3 (11.8, 61.6)	0.51 (0.25, 1.05)	128	203	63.1 (56.0, 69.7)	123	188	65.4 (58.2, 72.2)	151	237	63.7 (57.2, 69.8)
		BSSL	18	31	58.1 (39.1, 75.5)	0.86 (0.63, 1.17)	3	3	100.0 (29.2, 100.0)	1.48 (1.38, 1.60)	222	328	67.7 (62.3, 72.7)	219	325	67.4 (62.0, 72.5)	240	359	66.9 (61.7, 71.7)
		BSOS	6	11	54.5 (23.4, 83.3)	0.79 (0.46, 1.37)	2	4	50.0 (6.8, 93.2)	0.72 (0.27, 1.93)	96	139	69.1 (60.7, 76.6)	94	135	69.6 (61.1, 77.2)	102	150	68.0 (59.9, 75.4)
		Total	201	333	60.4 (54.9, 65.7)	0.93 (0.85, 1.03)	56	110	50.9 (41.2, 60.6)	0.78 (0.64, 0.94)	1,011	1,565	64.6 (62.2, 67.0)	955	1,455	65.6 (63.1, 68.1)	1,212	1,898	63.9 (61.6, 66.0)
45 to 69		Initial	BSWN	5	14	35.7 (12.8, 64.9)	0.63 (0.30, 1.31)	2	5	40.0 (5.3, 85.3)	0.68 (0.23, 2.04)	32	56	57.1 (43.2, 70.3)	30	51	58.8 (44.2, 72.4)	37	70
	BSCM		1	4	25.0 (0.6, 80.6)	0.77 (0.13, 4.52)	8	15	53.3 (26.6, 78.7)	3.38 (1.08, 10.57)	11	34	32.4 (17.4, 50.5)	3	19	15.8 (3.4, 39.6)	12	38	31.6 (17.5, 48.7)
	BSAC		2	3	66.7 (9.4, 99.2)	1.18 (0.49, 2.83)	2	5	40.0 (5.3, 85.3)	0.66 (0.21, 2.04)	13	23	56.5 (34.5, 76.8)	11	18	61.1 (35.7, 82.7)	15	26	57.7 (36.9, 76.6)
	BSM		10	19	52.6 (28.9, 75.6)	0.76 (0.47, 1.25)	2	3	66.7 (9.4, 99.2)	0.96 (0.42, 2.23)	20	29	69.0 (49.2, 84.7)	18	26	69.2 (48.2, 85.7)	30	48	62.5 (47.4, 76.0)
	BSCC		5	10	50.0 (18.7, 81.3)	1.50 (0.61, 3.69)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 14.44)	6	18	33.3 (13.3, 59.0)	6	17	35.3 (14.2, 61.7)	11	28	39.3 (21.5, 59.4)
	BSC		3	7	42.9 (9.9, 81.6)	0.98 (0.35, 2.72)	4	6	66.7 (22.3, 95.7)	2.22 (0.74, 6.70)	7	16	43.8 (19.8, 70.1)	3	10	30.0 (6.7, 65.2)	10	23	43.5 (23.2, 65.5)
	BSSL		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.71)	1	1	100.0 (2.5, 100.0)	1.46 (1.18, 1.81)	27	39	69.2 (52.4, 83.0)	26	38	68.4 (51.3, 82.5)	27	40	67.5 (50.9, 81.4)
	BSOS		1	2	50.0 (1.3, 98.7)	0.70 (0.17, 2.91)	0	0	NA (NA, NA)	NA (NA, NA)	10	14	71.4 (41.9, 91.6)	10	14	71.4 (41.9, 91.6)	11	16	68.8 (41.3, 89.0)
	Total		27	60	45.0 (32.1, 58.4)	0.82 (0.60, 1.11)	19	36	52.8 (35.5, 69.6)	0.95 (0.68, 1.33)	126	229	55.0 (48.3, 61.6)	107	193	55.4 (48.1, 62.6)	153	289	52.9 (47.0, 58.8)
	Subsequent		BSWN	48	67	71.6 (59.3, 82.0)	1.07 (0.90, 1.27)	8	21	38.1 (18.1, 61.6)	0.54 (0.31, 0.94)	162	241	67.2 (60.9, 73.1)	154	220	70.0 (63.5, 76.0)	210	308
		BSCM	18	35	51.4 (34.0, 68.6)	0.84 (0.60, 1.19)	24	40	60.0 (43.3, 75.1)	0.98 (0.73, 1.30)	104	170	61.2 (53.4, 68.5)	80	130	61.5 (52.6, 69.9)	122	205	59.5 (52.5, 66.3)
		BSAC	14	20	70.0 (45.7, 88.1)	1.04 (0.76, 1.43)	17	28	60.7 (40.6, 78.5)	0.87 (0.63, 1.22)	74	110	67.3 (57.7, 75.9)	57	82	69.5 (58.4, 79.2)	88	130	67.7 (58.9, 75.6)
		BSM	52	82	63.4 (52.0, 73.8)	0.99 (0.82, 1.20)	2	4	50.0 (6.8, 93.2)	0.78 (0.29, 2.09)	154	241	63.9 (57.5, 70.0)	152	237	64.1 (57.7, 70.2)	206	323	63.8 (58.3, 69.0)
		BSCC	30	66															


3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate)

Description: The number with an invasive cancer of diameter $\leq 15\text{mm}$ as a rate per 10,000 women screened.

Targets for women aged 45 to 49 years: Initial: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 19.0 per 10,000 women screened. Subsequent: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 12.0 per 10,000 women screened.

Targets for women aged 50 to 69 years: Initial: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 30.5 per 10,000 women screened. Subsequent: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 17.3 per 10,000 women screened.

Figure 77: 3.c.r, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000), initial and subsequent screens



Among women aged 45–49 years, the rate of small cancers per 10,000 women screened was on target for initial screens overall (19.5), similar for Māori women (18.5) and higher for Pacific women (41.1). The target was also met for subsequent screens overall at 15.3 per 10,000, 13.4 for Māori, 15.5 for Pacific women. The targets were met or within the confidence intervals for all LPs.

Among women aged 50–69 years, the target for initial screens was exceeded at a rate of 55.0 per 10,000 overall, twice as high for Māori (94.7) as for non-Māori (48.6), and over twice as high for Pacific women (118.0). For subsequent screens the rate of small cancers was also well within the target range at 30.6 per 10,000 overall, also higher in Māori women (46.4), but similar in Pacific (31.2) and non-Māori non-Pacific women (28.5). The targets were met by all LPs.

Figure 78: 3.c.r, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP




Figure 79: 3.c.r, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP




Table 20: 3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate)


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)
45 to 49	Initial	BSWN	1	1,149	8.7 (0.2, 48.4)	0.38 (0.05, 2.83)	1	395	25.3 (0.6, 140.2)	1.10 (0.14, 8.28)	16	6,893	23.2 (13.3, 37.7)	15	6,498	23.1 (12.9, 38.0)	17	8,042	21.1 (12.3, 35.8)
		BSCM	1	721	13.9 (0.4, 77.0)	0.70 (0.09, 5.48)	7	1,232	56.8 (22.9, 116.7)	9.31 (1.94, 44.75)	9	4,509	20.0 (9.1, 37.9)	2	3,277	6.1 (0.7, 22.0)	10	5,230	19.1 (9.2, 35.1)
		BSAC	2	364	54.9 (6.7, 197.1)	3.08 (0.62, 15.22)	1	372	26.9 (0.7, 148.9)	1.61 (0.19, 13.75)	6	3,368	17.8 (6.5, 38.7)	5	2,996	16.7 (5.4, 38.9)	8	3,732	21.4 (9.3, 42.2)
		BSM	2	1,358	14.7 (1.8, 53.1)	0.78 (0.17, 3.57)	0	141	0.0 (0.0, 258.2)	0.00 (0.00, 16.36)	10	5,313	18.8 (9.0, 34.6)	10	5,172	19.3 (9.3, 35.5)	12	6,671	18.0 (9.3, 31.4)
		BSCC	3	1,019	29.4 (6.1, 85.8)	4.01 (0.81, 19.85)	0	102	0.0 (0.0, 355.2)	0.00 (0.00, 94.57)	3	4,088	7.3 (1.5, 21.4)	3	3,986	7.5 (1.6, 22.0)	6	5,107	11.7 (4.3, 25.6)
		BSC	1	513	19.5 (0.5, 108.1)	1.36 (0.15, 12.14)	2	232	86.2 (10.5, 307.9)	11.02 (1.56, 77.88)	4	2,789	14.3 (3.9, 36.7)	2	2,557	7.8 (0.9, 28.2)	5	3,302	15.1 (4.9, 35.3)
		BSSL	0	605	0.0 (0.0, 60.8)	0.00 (0.00, 2.80)	0	156	0.0 (0.0, 233.7)	0.00 (0.00, 10.64)	20	8,354	23.9 (14.6, 37.0)	20	8,198	24.4 (14.9, 37.7)	20	8,959	22.3 (13.6, 34.5)
	BSOS	1	221	45.2 (1.1, 249.5)	1.85 (0.23, 14.93)	0	46	0.0 (0.0, 770.6)	0.00 (0.00, 42.35)	7	2,854	24.5 (9.9, 50.5)	7	2,808	24.9 (10.0, 51.3)	8	3,075	26.0 (11.2, 54.2)	
	Total	11	5,950	18.5 (9.2, 33.1)	0.94 (0.50, 1.77)	11	2,676	41.1 (20.5, 73.4)	2.28 (1.20, 4.32)	75	38,168	19.7 (15.5, 24.6)	64	35,492	18.0 (13.9, 23.0)	86	44,118	19.5 (15.6, 24.1)	
	Subsequent	BSWN	6	1,346	44.6 (16.4, 96.8)	2.64 (1.02, 6.85)	1	458	21.8 (0.6, 121.0)	1.32 (0.17, 10.03)	14	8,286	16.9 (9.2, 28.3)	13	7,828	16.6 (8.8, 28.4)	20	9,632	20.8 (12.7, 32.1)
		BSCM	0	984	0.0 (0.0, 37.4)	0.00 (0.00, 3.24)	3	1,358	22.1 (4.6, 64.4)	1.82 (0.46, 7.25)	9	6,289	14.3 (6.5, 27.1)	6	4,931	12.2 (4.5, 26.5)	9	7,273	12.4 (5.7, 23.5)
		BSAC	0	378	0.0 (0.0, 97.1)	0.00 (0.00, 12.35)	1	521	19.2 (0.5, 106.5)	1.80 (0.20, 16.10)	5	4,279	11.7 (3.8, 27.2)	4	3,758	10.6 (2.9, 27.2)	5	4,657	10.7 (3.5, 25.0)
		BSM	1	1,831	5.5 (0.1, 30.4)	0.34 (0.04, 2.63)	0	179	0.0 (0.0, 204.0)	0.00 (0.00, 14.75)	12	7,514	16.0 (8.3, 27.9)	12	7,335	16.4 (8.5, 28.6)	13	9,345	13.9 (7.4, 23.8)
		BSCC	1	1,513	6.6 (0.2, 36.8)	0.37 (0.05, 2.85)	0	131	0.0 (0.0, 277.7)	0.00 (0.00, 18.17)	12	6,746	17.8 (9.2, 31.1)	12	6,615	18.1 (9.4, 31.7)	13	8,259	15.7 (8.4, 26.9)
BSC		0	751	0.0 (0.0, 49.0)	0.00 (0.00, 12.65)	0	344	0.0 (0.0, 106.7)	0.00 (0.00, 26.10)	4	6,270	6.6 (1.7, 16.3)	4	5,926	6.7 (1.8, 17.3)	4	7,021	5.7 (1.6, 14.6)	
BSSL		3	1,014	29.6 (6.1, 86.2)	1.43 (0.43, 4.70)	0	183	0.0 (0.0, 199.6)	0.00 (0.00, 10.29)	26	12,531	20.7 (13.6, 30.4)	26	12,348	21.1 (13.8, 30.8)	29	13,545	21.4 (14.3, 30.7)	
BSOS	0	404	0.0 (0.0, 90.9)	0.00 (0.00, 10.67)	0	57	0.0 (0.0, 626.7)	0.00 (0.00, 74.53)	5	3,950	12.7 (4.1, 29.5)	5	3,893	12.8 (4.2, 29.9)	5	4,354	11.5 (3.7, 26.8)		
Total	11	8,221	13.4 (6.7, 23.9)	0.86 (0.46, 1.61)	5	3,231	15.5 (5.0, 36.1)	0.99 (0.40, 2.45)	87	55,865	15.6 (12.5, 19.2)	82	52,634	15.6 (12.4, 19.3)	98	64,086	15.3 (12.4, 18.6)		
50 to 69	Initial	BSWN	4	285	140.4 (38.4, 355.4)	1.94 (0.65, 5.75)	1	96	104.2 (2.6, 566.7)	1.47 (0.20, 10.98)	16	2,206	72.5 (41.5, 117.5)	15	2,110	71.1 (39.8, 117.0)	20	2,491	80.3 (49.1, 123.7)
		BSCM	0	165	0.0 (0.0, 221.1)	0.00 (0.00, 37.98)	1	259	38.6 (1.0, 213.2)	3.54 (0.22, 56.47)	2	1,177	17.0 (2.1, 61.2)	1	918	10.9 (0.3, 60.5)	2	1,342	14.9 (1.8, 53.7)
		BSAC	0	110	0.0 (0.0, 329.8)	0.00 (0.00, 7.39)	1	99	101.0 (2.6, 550.0)	1.81 (0.22, 14.86)	7	1,172	59.7 (24.0, 122.7)	6	1,073	55.9 (20.5, 121.3)	7	1,282	54.6 (22.0, 112.2)
		BSM	8	476	168.1 (72.8, 328.5)	2.65 (1.05, 6.67)	2	38	526.3 (64.4, 1774.9)	10.12 (2.22, 46.06)	10	1,576	63.5 (30.5, 116.4)	8	1,538	52.0 (22.5, 102.2)	18	2,052	87.7 (52.1, 138.3)
		BSCC	2	354	56.5 (6.8, 202.6)	2.27 (0.38, 13.53)	0	31	0.0 (0.0, 1121.9)	0.00 (0.00, 91.65)	3	1,205	24.9 (5.1, 72.6)	3	1,174	25.6 (5.3, 74.5)	5	1,559	32.1 (10.4, 74.7)
		BSC	2	135	148.1 (18.0, 524.9)	4.32 (0.73, 25.62)	2	95	210.5 (25.6, 739.9)	16.42 (1.50, 179.39)	3	875	34.3 (7.1, 99.9)	1	780	12.8 (0.3, 71.2)	5	1,010	49.5 (16.1, 115.1)
		BSSL	0	120	0.0 (0.0, 302.7)	0.00 (0.00, 9.52)	1	42	238.1 (6.0, 1256.6)	6.37 (0.78, 51.70)	7	1,646	42.5 (17.1, 87.4)	6	1,604	37.4 (13.7, 81.2)	7	1,766	39.6 (16.0, 81.5)
	BSOS	0	44	0.0 (0.0, 804.2)	0.00 (0.00, 34.92)	0	18	0.0 (0.0, 1853.0)	0.00 (0.00, 82.95)	3	635	47.2 (9.8, 137.4)	3	617	48.6 (10.0, 141.4)	3	679	44.2 (9.1, 128.6)	
	Total	16	1,689	94.7 (54.2, 153.4)	1.95 (1.11, 3.41)	8	678	118.0 (51.1, 231.2)	2.69 (1.27, 5.71)	51	10,492	48.6 (36.2, 63.9)	43	9,814	43.8 (31.7, 59.0)	67	12,181	55.0 (42.7, 69.8)	
	Subsequent	BSWN	42	7,587	55.4 (39.9, 74.8)	1.99 (1.41, 2.80)	7	2,740	25.5 (10.3, 52.6)	0.92 (0.43, 1.95)	148	53,214	27.8 (23.5, 32.7)	141	50,474	27.9 (23.5, 32.9)	190	60,801	31.2 (27.0, 36.0)
		BSCM	18	4,453	40.4 (24.0, 63.8)	1.47 (0.89, 2.42)	21	7,398	28.4 (17.6, 43.4)	1.04 (0.64, 1.68)	95	34,463	27.6 (22.3, 33.7)	74	27,065	27.3 (21.5, 34.3)	113	38,916	29.0 (23.9, 34.9)
		BSAC	14	1,884	74.3 (40.7, 124.4)	2.62 (1.48, 4.64)	16	2,897	55.2 (31.6, 89.5)	2.23 (1.28, 3.90)	69	24,315	28.4 (22.1, 35.9)	53	21,418	24.7 (18.5, 32.4)	83	26,199	31.7 (25.2, 39.3)
		BSM	10	10,470	48.7 (36.3, 64.0)	1.80 (1.31, 2.48)	2	918	21.8 (2.6, 78.5)	0.80 (0.20, 3.23)	142	52,445	27.1 (22.8, 31.9)	140	51,527	27.2 (22.9, 32.1)	193	62,915	30.7 (26.5, 35.3)
		BSCC	29	8,454	34.3 (23.0, 49.2)	1.42 (0.94, 2.13)	0	766	0.0 (0.0, 48.0)	0.00 (0.00, 1.99)	111	45,943	24.2 (19.9, 29.1)	111	45,177	24.6 (20.2, 29.6)	140	54,397	25.7 (21.7, 30.4)
BSC		23	4,138	55.6 (35.3, 83.3)	1.78 (1.14, 2.77)	5	2,154	23.2 (7.5, 54.1)	0.73 (0.30, 1.79)	128	40,970	31.2 (26.1, 37.1)	123	38,816	31.7 (26.3, 37.8)	151	45,108	33.5 (28.4, 39.2)	
BSSL		18	4,488	40.1 (23.8, 63.3)	1.34 (0.83, 2.16)	3	815	36.8 (7.6, 107.2)	1.23 (0.40, 3.84)	222	74,114	30.0 (26.1, 34.2)	219	73,299	29.9 (26.1, 34.1)	240	78,602	30.5 (26.8, 34.6)	
BSOS	6	1,877	32.0 (11.7, 69.4)	0.92 (0.40, 2.09)	2	261	76.6 (9.3, 274.1)	2.22 (0.55, 8.95)	96	27,506	34.9 (28.3, 42.6)	94	27,245	34.5 (27.9, 42.2)	102	29,383	34.7 (28.3, 42.1)		
Total	201	43,351	46.4 (40.2, 53.2)	1.62 (1.39, 1.88)	56	17,949	31.2 (23.6, 40.5)	1.10 (0.84, 1.43)	1,011	352,970	28.6 (26.9, 30.5)	955	335,021	28.5 (26.7, 30.4)	1,212	396,321	30.6 (28.9, 32.3)		
45 to 69	Initial	BSWN	5	1,433	34.9 (11.3, 81.2)	0.99 (0.39, 2.54)	2	491	40.7 (4.9, 146.4)	1.17 (0.28, 4.87)	32	9,089	35.2 (24.1, 49.7)	30	8,598	34.9 (23.6, 49.8)	37	10,522	35.2 (24.8, 48.4)
		BSCM	1	885	11.3 (0.3, 62.8)	0.58 (0.07, 4.52)	8	1,491	53.7 (23.2, 105.4)	7.50 (1.99, 28.23)	11	5,684	19.4 (9.7, 34.6)	3	4,193	7.2 (1.5, 20.9)	12	6,569	18.3 (9.4, 31.9)
		BSAC	2	474	42.2 (5.1, 151.6)	1.47 (0.33, 6.51)	2	471	42.5 (5.1, 152.5)	1.57 (0.35, 7.06)	13	4,539	28.6 (15.3, 48.9)	11	4,068	27.0 (13.5, 48.3)	15	5,013	29.9 (16.8, 49.3)
		BSM	10	1,832	54.6 (26.2, 100.2)	1.88 (0.88, 4.00)	2	178	112.4 (13.6, 400.0)	4.18 (0.98, 17.89)	20	6,880	29.1 (17.8, 44.9)	18	6,702	26.9 (15.9, 42.4)	30	8,712	34.4 (23.2, 49.1)
		BSCC	5	1,369	36.5 (11.9, 85.0)	3.22 (0.98, 10.53)	0	133	0.0 (0.0, 273.5)	0.00 (0.00, 32.92)	6	5,289	11.3 (4.2, 24.7)	6	5,156	11.6 (4.3, 25.3)	11	6,658	16.5 (8.3, 29.5)
		BSC	3	643	46.7 (9.6, 135.7)	2.44 (0.63, 9.39)	4	327	122.3 (33.4, 310.2)	13.57 (3.05, 60.35)	7	3,654	19.2 (7.7, 39.4)	3	3,327	9.0 (1.9, 26.3)	10	4,297	23.3 (11.2, 42.8)
		BSSL	0	719	0.0 (0.0, 51.2)	0.00 (0.00, 2.04)	1	198	50.5 (1.3, 278.2)	1.90 (0.26, 13.96)	27	9,998	27.0 (17.8, 39.3)	26	9,800	26.5 (17.3, 38.8)	27	10,717	25.2 (16.6, 36.6)
	BSOS	1	265	37.7 (1.0, 208.4)	1.32 (0.17, 10.25)	0	64	0.0 (0.0, 560.1)	0.00 (0.00, 23.88)	10	3,489	28.7 (13.8, 52.6)	10	3,425	29.2 (14.0, 53.6)	11	3,754	29.3 (14.6, 52.4)	
	Total	27	7,620	35.4 (23.4, 51.5)	1.37 (0.90, 2.07)	19	3,353	56.7 (34.1, 88.3)	2.40 (1.47, 3.90)	126	48,622	25.9 (21.6, 30.8)	107	45,269	23.6 (19.4, 28.6)	153	56,242	27.2 (23.1, 31.8)	
	Subsequent	BSWN	48	8,920	53.8 (39.7, 71.3)	2.04 (1.48, 2.81)	8	3,190	25.1 (10.8,										

3.d, Nodal involvement

Description: The inverse of the proportion of women with invasive screened detected breast cancer who do have nodal involvement. Positive sentinel nodes are included in the node positive group. Nodes identified with only isolated tumour cell (ITC) are not included.

Targets: Initial: >70%. Subsequent: >75% (50–69 years only)¹⁸

Figure 80: 3.d, 50 to 69, Nodal involvement



Among 2,431 women aged 45–69 years with invasive cancer detected by BSA, 1,942 (80%) had no nodal involvement. Of 308 women with cancer detected at their first screen 213 (69%) had no nodal involvement. Of 2,123 women with cancer detected at a subsequent screen, 1,729 (81%) had no nodal involvement.

Among women aged 45–49 years, the proportions of invasive cancers without nodal involvement were 67% of those detected at an initial screen and 80% of those detected at a subsequent screen. Among Māori women in this age group these proportions were 57% and 74% respectively, and for Pacific women they were 80% and 79%.

For women aged 50–69 years, the percentages were 71% (initial screens) and 82% (subsequent screens) with no significant differences between groups. The targets were met or were within the confidence interval for all LPs.

¹⁸ Further review is required to determine age-specific targets for women aged 45-49 years for indicator 3.d.

Figure 81: 3.d, Initial, 50 to 69, Nodal involvement, by LP




Figure 82: 3.d, Subsequent, 50 to 69, Nodal involvement, by LP




Table 21: 3.d, Nodal involvement

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Māori / Non-Māori Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	
45 to 49	Initial	BSWN	4	6	66.7 (22.3, 95.7)	1.14 (0.60, 2.16)	3	4	75.0 (19.4, 99.4)	1.34 (0.69, 2.60)	17	29	58.6 (38.9, 76.5)	14	25	56.0 (34.9, 75.6)	21	35	60.0 (42.1, 76.1)	
		BSCM	1	2	50.0 (1.3, 98.7)	0.70 (0.17, 2.87)	8	10	80.0 (44.4, 97.5)	1.26 (0.73, 2.17)	15	21	71.4 (47.8, 88.7)	7	11	63.6 (30.8, 89.1)	16	23	69.6 (47.1, 86.8)	
		BSAC	2	3	66.7 (9.4, 99.2)	0.96 (0.40, 2.32)	2	2	100.0 (15.8, 100.0)	1.57 (1.00, 2.46)	9	13	69.2 (38.6, 90.9)	7	11	63.6 (30.8, 89.1)	11	16	68.8 (41.3, 89.0)	
		BSM	2	5	40.0 (5.3, 85.3)	0.51 (0.17, 1.54)	1	1	100.0 (2.5, 100.0)	1.30 (0.96, 1.75)	11	14	78.6 (49.2, 95.3)	10	13	76.9 (46.2, 95.0)	13	19	68.4 (43.4, 87.4)	
		BSCC	3	5	60.0 (14.7, 94.7)	1.03 (0.43, 2.43)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.63)	7	12	58.3 (27.7, 84.8)	7	11	63.6 (30.8, 89.1)	10	17	58.8 (32.9, 81.6)	
		BSC	3	5	60.0 (14.7, 94.7)	0.60 (0.29, 1.23)	2	2	100.0 (15.8, 100.0)	1.00 (1.00, 1.00)	6	6	100.0 (54.1, 100.0)	4	4	100.0 (39.8, 100.0)	9	11	81.8 (48.2, 97.7)	
		BSSL	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.76)	0	0	NA (NA, NA)	NA (NA, NA)	21	30	70.0 (50.6, 85.3)	21	30	70.0 (50.6, 85.3)	21	31	67.7 (48.6, 83.3)	
		BSOS	1	1	100.0 (2.5, 100.0)	1.25 (0.92, 1.70)	0	0	NA (NA, NA)	NA (NA, NA)	8	10	80.0 (44.4, 97.5)	8	10	80.0 (44.4, 97.5)	9	11	81.8 (48.2, 97.7)	
		Total	16	28	57.1 (37.2, 75.5)	0.82 (0.58, 1.15)	16	20	80.0 (56.3, 94.3)	1.18 (0.92, 1.52)	94	135	69.6 (61.1, 77.2)	78	115	67.8 (58.5, 76.2)	110	163	67.5 (59.7, 74.6)	
		Subsequent	BSWN	6	7	85.7 (42.1, 99.6)	1.09 (0.74, 1.59)	1	1	100.0 (2.5, 100.0)	1.29 (1.00, 1.65)	15	19	78.9 (54.4, 93.9)	14	18	77.8 (52.4, 93.6)	21	26	80.8 (60.6, 93.4)
	BSCM		1	1	100.0 (2.5, 100.0)	1.27 (0.97, 1.67)	2	4	50.0 (6.8, 93.2)	0.56 (0.20, 1.51)	11	14	78.6 (49.2, 95.3)	9	10	90.0 (55.5, 99.7)	12	15	80.0 (51.9, 95.7)	
	BSAC		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.95)	2	2	100.0 (15.8, 100.0)	1.25 (0.81, 1.94)	6	7	85.7 (42.1, 99.6)	4	5	80.0 (28.4, 99.5)	6	8	75.0 (34.9, 96.8)	
	BSM		1	2	50.0 (1.3, 98.7)	0.70 (0.17, 2.87)	0	0	NA (NA, NA)	NA (NA, NA)	15	21	71.4 (47.8, 88.7)	15	21	71.4 (47.8, 88.7)	16	23	69.6 (47.1, 86.8)	
	BSCC		1	4	25.0 (0.6, 80.6)	0.31 (0.06, 1.71)	1	1	100.0 (2.5, 100.0)	1.25 (0.97, 1.61)	13	16	81.3 (54.4, 96.0)	12	15	80.0 (51.9, 95.7)	14	20	70.0 (45.7, 88.1)	
	BSC		4	4	100.0 (39.8, 100.0)	1.20 (0.93, 1.55)	1	1	100.0 (2.5, 100.0)	1.22 (0.93, 1.61)	10	12	83.3 (51.6, 97.9)	9	11	81.8 (48.2, 97.7)	14	16	87.5 (61.7, 98.4)	
	BSSL		4	4	100.0 (39.8, 100.0)	1.11 (1.00, 1.24)	0	0	NA (NA, NA)	NA (NA, NA)	35	39	89.7 (75.8, 97.1)	35	39	89.7 (75.8, 97.1)	39	43	90.7 (77.9, 97.4)	
	BSOS		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	8	11	72.7 (39.0, 94.0)	8	11	72.7 (39.0, 94.0)	8	11	72.7 (39.0, 94.0)	
	Total		17	23	73.9 (51.6, 89.8)	0.91 (0.70, 1.17)	7	9	77.8 (40.0, 97.2)	0.95 (0.67, 1.36)	113	139	81.3 (73.8, 87.4)	106	130	81.5 (73.8, 87.8)	130	162	80.2 (73.3, 86.1)	
	50 to 69		Initial	BSWN	8	9	88.9 (51.8, 99.7)	1.31 (0.93, 1.85)	1	1	100.0 (2.5, 100.0)	1.50 (1.15, 1.96)	19	28	67.9 (47.6, 84.1)	18	27	66.7 (46.0, 83.5)	27	37
		BSCM		1	2	50.0 (1.3, 98.7)	1.07 (0.24, 4.74)	4	5	80.0 (28.4, 99.5)	2.67 (0.94, 7.57)	7	15	46.7 (21.3, 73.4)	3	10	30.0 (6.7, 65.2)	8	17	47.1 (23.0, 72.2)
BSAC		0		0	NA (NA, NA)	NA (NA, NA)	1	3	33.3 (0.8, 90.6)	0.60 (0.11, 3.30)	6	12	50.0 (21.1, 78.9)	5	9	55.6 (21.2, 86.3)	6	12	50.0 (21.1, 78.9)	
BSM		12		15	80.0 (51.9, 95.7)	0.99 (0.70, 1.39)	2	3	66.7 (9.4, 99.2)	0.79 (0.34, 1.81)	13	16	81.3 (54.4, 96.0)	11	13	84.6 (54.6, 98.1)	25	31	80.6 (62.5, 92.5)	
BSCC		5		6	83.3 (35.9, 99.6)	1.02 (0.65, 1.60)	0	0	NA (NA, NA)	NA (NA, NA)	9	11	81.8 (48.2, 97.7)	9	11	81.8 (48.2, 97.7)	14	17	82.4 (56.6, 96.2)	
BSC		2		2	100.0 (15.8, 100.0)	1.38 (0.96, 1.98)	2	5	40.0 (5.3, 85.3)	0.40 (0.14, 1.17)	8	11	72.7 (39.0, 94.0)	6	6	100.0 (54.1, 100.0)	10	13	76.9 (46.2, 95.0)	
BSSL		0		0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.11 (0.90, 1.37)	10	11	90.9 (58.7, 99.8)	9	10	90.0 (55.5, 99.7)	10	11	90.9 (58.7, 99.8)	
BSOS		0		1	0.0 (0.0, 97.5)	0.00 (0.00, 14.52)	0	0	NA (NA, NA)	NA (NA, NA)	3	6	50.0 (11.8, 88.2)	3	6	50.0 (11.8, 88.2)	3	7	42.9 (9.9, 81.6)	
Total		28		35	80.0 (63.1, 91.6)	1.17 (0.95, 1.45)	11	18	61.1 (35.7, 82.7)	0.88 (0.59, 1.30)	75	110	68.2 (58.6, 76.7)	64	92	69.6 (59.1, 78.7)	103	145	71.0 (62.9, 78.3)	
Subsequent		BSWN		52	64	81.3 (69.5, 89.9)	0.97 (0.85, 1.10)	13	20	65.0 (40.8, 84.6)	0.76 (0.55, 1.05)	193	230	83.9 (78.5, 88.4)	180	210	85.7 (80.2, 90.1)	245	294	83.3 (78.6, 87.4)
		BSCM	25	34	73.5 (55.6, 87.1)	0.92 (0.74, 1.14)	28	37	75.7 (58.8, 88.2)	0.93 (0.76, 1.13)	126	157	80.3 (73.2, 86.2)	98	120	81.7 (73.6, 88.1)	151	191	79.1 (72.6, 84.6)	
		BSAC	18	19	94.7 (74.0, 99.9)	1.20 (1.04, 1.39)	23	26	88.5 (69.8, 97.6)	1.17 (0.97, 1.40)	83	105	79.0 (70.0, 86.4)	60	79	75.9 (65.0, 84.9)	101	124	81.5 (73.5, 87.9)	
		BSM	64	84	76.2 (65.7, 84.8)	0.98 (0.85, 1.13)	1	4	25.0 (0.6, 80.6)	0.32 (0.06, 1.74)	174	224	77.7 (71.7, 83.0)	173	220	78.6 (72.6, 83.9)	238	308	77.3 (72.2, 81.8)	
		BSCC	45	66	68.2 (55.6, 79.1)	0.83 (0.69, 0.99)	1	3	33.3 (0.8, 90.6)	0.40 (0.08, 2.00)	161	196	82.1 (76.1, 87.2)	160	193	82.9 (76.8, 87.9)	206	262	78.6 (73.2, 83.4)	
		BSC	27	34	79.4 (62.1, 91.3)	0.92 (0.77, 1.10)	13	16	81.3 (54.4, 96.0)	0.93 (0.73, 1.19)	187	216	86.6 (81.3, 90.8)	174	200	87.0 (81.5, 91.3)	214	250	85.6 (80.6, 89.7)	
		BSSL	27	32	84.4 (67.2, 94.7)	1.00 (0.85, 1.16)	3	3	100.0 (29.2, 100.0)	1.18 (1.13, 1.24)	293	346	84.7 (80.4, 88.3)	290	343	84.5 (80.3, 88.2)	320	378	84.7 (80.6, 88.1)	
		BSOS	10	11	90.9 (58.7, 99.8)	1.14 (0.93, 1.40)	4	4	100.0 (39.8, 100.0)	1.26 (1.16, 1.38)	114	143	79.7 (72.2, 86.0)	110	139	79.1 (71.4, 85.6)	124	154	80.5 (73.4, 86.5)	
		Total	268	344	77.9 (73.1, 82.2)	0.95 (0.89, 1.01)	86	113	76.1 (67.2, 83.6)	0.92 (0.83, 1.02)	1,331	1,617	82.3 (80.4, 84.1)	1,245	1,504	82.8 (80.8, 84.7)	1,599	1,961	81.5 (79.8, 83.2)	
		45 to 69	Initial	BSWN	12	15	80.0 (51.9, 95.7)	1.27 (0.92, 1.75)	4	5	80.0 (28.4, 99.5)	1.30 (0.80, 2.12)	36	57	63.2 (49.3, 75.6)	32	52	61.5 (47.0, 74.7)	48	72
BSCM				2	4	50.0 (6.8, 93.2)	0.82 (0.30, 2.25)	12	15	80.0 (51.9, 95.7)	1.68 (1.00, 2.81)	22	36	61.1 (43.5, 76.9)	10	21	47.6 (25.7, 70.2)	24	40	60.0 (43.3, 75.1)
BSAC	2			3	66.7 (9.4, 99.2)	1.11 (0.47, 2.63)	3	5	60.0 (14.7, 94.7)	1.00 (0.45, 2.23)	15	25	60.0 (38.7, 78.9)	12	20	60.0 (36.1, 80.9)	17	28	60.7 (40.6, 78.5)	
BSM	14			20	70.0 (45.7, 88.1)	0.88 (0.62, 1.23)	3	4	75.0 (19.4, 99.4)	0.93 (0.51, 1.69)	24	30	80.0 (61.4, 92.3)	21	26	80.8 (60.6, 93.4)	38	50	76.0 (61.8, 86.9)	
BSCC	8			11	72.7 (39.0, 94.0)	1.05 (0.67, 1.64)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.71)	16	23	69.6 (47.1, 86.8)	16	22	72.7 (49.8, 89.3)	24	34	70.6 (52.5, 84.9)	
BSC	5			7	71.4 (29.0, 96.3)	0.87 (0.52, 1.46)	4	7	57.1 (18.4, 90.1)	0.57 (0.30, 1.08)	14	17	82.4 (56.6, 96.2)	10	10	100.0 (69.2, 100.0)	19	24	79.2 (57.8, 92.9)	
BSSL	0			1	0.0 (0.0, 97.5)	0.00 (0.00, 5.18)	1	1	100.0 (2.5, 100.0)	1.33 (1.11, 1.59)	31	41	75.6 (59.7, 87.6)	30	40	75.0 (58.8, 87.3)	31	42	73.8 (58.0, 86.1)	
BSOS	1			2	50.0 (1.3, 98.7)	0.73 (0.17, 3.02)	0	0	NA (NA, NA)	NA (NA, NA)	11	16	68.8 (41.3, 89.0)	11	16	68.8 (41.3, 89.0)	12	18	66.7 (41.0, 86.7)	
Total	44			63	69.8 (57.0, 80.8)	1.01 (0.84, 1.22)	27	38	71.1 (54.1, 84.6)	1.04 (0.83, 1.29)	169	245	69.0 (62.8, 74.7)	142	207	68.6 (61.8, 74.9)	213	308	69.2 (63.7, 74.3)	
Subsequent	BSWN			58	71	81.7 (70.7, 89.9)	0.98 (0.86, 1.11)	14	21	66.7 (43.0, 85.4)	0.78 (0.58, 1.06)	208	249	83.5 (78.3, 87.9)	194	228	85.1 (79.8, 89.4)	266	320	83.1 (78.6, 87.1)
	BSCM		26	35	74.3 (56.7, 87.5)	0.93 (0.75, 1.14)	30	41	73.2 (57.1, 85.8)	0.89 (0.73, 1.09)	137	171	80.1 (73.3, 85.8)	107	130	82.3 (74.6, 88.4)	163	206	79.1 (72.9, 84.5)	
	BSAC		18	20	90.0 (68.3, 98.8)	1.13 (0.95, 1.35)	25	28	89.3 (71.8, 97.7)	1.17 (0.98, 1.40)	89	112	79.5 (70.8, 86.5)	64	84	76.2 (65.7, 84.8)	107	132	81.1 (73.3, 87.4)	
	BSM		65	86	75.6 (65.1, 84.2)	0.98 (0.85, 1.12)	1	4	25.0 (0.6, 80.6)	0.32 (0.06, 1.75)	189	245	77.1 (71.4, 8							


3.e, Ductal carcinoma in situ diagnosis

Description: The percentage of all women with screen detected cancer who are diagnosed as having ductal carcinoma in situ (DCIS) as their primary lesion.


Target: 10–25% of all cancers detected by the BSA programme are DCIS (50–69 age group only)¹⁹

Figure 83: 3.e, 45 to 49 and 50 to 69, Ductal carcinoma in situ diagnosis

45–49 years



50–69 years



Of 2,939 cancers detected by BSA among women aged 45–69 years, 695 (24%) were DCIS.

Among women aged 45–49 years the proportion of cancers detected that were DCIS was 33% overall, similar for Māori (28%). None of the 29 cancers detected among Pacific women in this age group were DCIS.

Among women aged 50–69 years the proportion was 22%. For Māori women DCIS made up a smaller proportion of screen-detected cancers at 16%. For Pacific and non-Māori non-Pacific women the proportions were similar (22% and 23% respectively). The target range was met or was within the confidence interval for all LPs.

¹⁹ Further review is required to determine age-specific targets for women aged 45-49 years for indicator 3.e.

Figure 84: 3.e, 50 to 69, Ductal carcinoma in situ diagnosis, by LP




Table 22: 3.e, Ductal carcinoma in situ diagnosis

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Māori / Non-Māori Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)
45 to 49	BSWN	2	14	14.3 (1.8, 42.8)	0.48 (0.13, 1.83)	0	5	0.0 (0.0, 52.2)	0.00 (0.00, 2.53)	19	64	29.7 (18.9, 42.4)	19	59	32.2 (20.6, 45.6)	21	78	26.9 (17.5, 38.2)	
	BSCM	2	3	66.7 (9.4, 99.2)	2.61 (1.01, 6.73)	0	13	0.0 (0.0, 24.7)	0.00 (0.00, 0.92)	11	43	25.6 (13.5, 41.2)	11	30	36.7 (19.9, 56.1)	13	46	28.3 (16.0, 43.5)	
	BSAC	1	4	25.0 (0.6, 80.6)	0.57 (0.10, 3.25)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 2.12)	17	39	43.6 (27.8, 60.4)	17	35	48.6 (31.4, 66.0)	18	43	41.9 (27.0, 57.9)	
	BSM	4	10	40.0 (12.2, 73.8)	1.20 (0.51, 2.85)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 12.27)	15	45	33.3 (20.0, 49.0)	15	44	34.1 (20.5, 49.9)	19	55	34.5 (22.2, 48.6)	
	BSCC	1	9	11.1 (0.3, 48.2)	0.54 (0.08, 3.84)	0	2	0.0 (0.0, 84.2)	0.00 (0.00, 11.10)	7	34	20.6 (8.7, 37.9)	7	32	21.9 (9.3, 40.0)	8	43	18.6 (8.4, 33.4)	
	BSC	0	9	0.0 (0.0, 33.6)	0.00 (0.00, 1.42)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 2.79)	11	32	34.4 (18.6, 53.2)	11	28	39.3 (21.5, 59.4)	11	41	26.8 (14.2, 42.9)	
	BSSL	4	8	50.0 (15.7, 84.3)	1.28 (0.61, 2.66)	0	0	NA (NA, NA)	NA (NA, NA)	40	102	39.2 (29.7, 49.4)	40	102	39.2 (29.7, 49.4)	44	110	40.0 (30.8, 49.8)	
	BSOS	3	4	75.0 (19.4, 99.4)	1.90 (0.94, 3.86)	0	0	NA (NA, NA)	NA (NA, NA)	13	33	39.4 (22.9, 57.9)	13	33	39.4 (22.9, 57.9)	16	37	43.2 (27.1, 60.5)	
	Total	17	61	27.9 (17.1, 40.8)	0.82 (0.54, 1.26)	0	29	0.0 (0.0, 11.9)	0.00 (0.00, 0.35)	133	392	33.9 (29.3, 38.9)	133	363	36.6 (31.7, 41.8)	150	453	33.1 (28.8, 37.7)	
50 to 69	BSWN	11	78	14.1 (7.3, 23.8)	0.58 (0.33, 1.04)	4	21	19.0 (5.4, 41.9)	0.77 (0.31, 1.91)	72	297	24.2 (19.5, 29.5)	68	276	24.6 (19.7, 30.2)	83	375	22.1 (18.0, 26.7)	
	BSCM	15	50	30.0 (17.9, 44.6)	1.32 (0.81, 2.16)	11	51	21.6 (11.3, 35.3)	0.94 (0.52, 1.70)	47	207	22.7 (17.2, 29.0)	36	156	23.1 (16.7, 30.5)	62	257	24.1 (19.0, 29.8)	
	BSAC	3	20	15.0 (3.2, 37.9)	0.52 (0.18, 1.53)	7	34	20.6 (8.7, 37.9)	0.67 (0.33, 1.36)	45	157	28.7 (21.7, 36.4)	38	123	30.9 (22.9, 39.9)	48	177	27.1 (20.7, 34.3)	
	BSM	17	109	15.6 (9.4, 23.8)	0.67 (0.41, 1.08)	3	9	33.3 (7.5, 70.1)	1.45 (0.56, 3.74)	67	287	23.3 (18.6, 28.7)	64	278	23.0 (18.2, 28.4)	84	396	21.2 (17.3, 25.6)	
	BSCC	8	77	10.4 (4.6, 19.4)	0.54 (0.27, 1.09)	1	4	25.0 (0.6, 80.6)	1.31 (0.23, 7.27)	46	239	19.2 (14.4, 24.8)	45	235	19.1 (14.3, 24.8)	54	316	17.1 (13.1, 21.7)	
	BSC	2	36	5.6 (0.7, 18.7)	0.26 (0.07, 1.04)	4	25	16.0 (4.5, 36.1)	0.74 (0.29, 1.88)	57	271	21.0 (16.3, 26.4)	53	246	21.5 (16.6, 27.2)	59	307	19.2 (15.0, 24.1)	
	BSSL	3	31	9.7 (2.0, 25.8)	0.37 (0.12, 1.10)	4	8	50.0 (15.7, 84.3)	1.95 (0.96, 3.97)	115	441	26.1 (22.0, 30.4)	111	433	25.6 (21.6, 30.0)	118	472	25.0 (21.2, 29.2)	
	BSOS	6	16	37.5 (15.2, 64.6)	2.06 (1.01, 4.17)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 5.24)	31	170	18.2 (12.7, 24.9)	31	166	18.7 (13.1, 25.4)	37	186	19.9 (14.4, 26.4)	
	Total	65	417	15.6 (12.2, 19.4)	0.67 (0.53, 0.85)	34	156	21.8 (15.6, 29.1)	0.94 (0.69, 1.27)	480	2,069	23.2 (21.4, 25.1)	446	1,913	23.3 (21.4, 25.3)	545	2,486	21.9 (20.3, 23.6)	
45 to 69	BSWN	13	92	14.1 (7.7, 23.0)	0.56 (0.33, 0.96)	4	26	15.4 (4.4, 34.9)	0.59 (0.24, 1.49)	91	361	25.2 (20.8, 30.0)	87	335	26.0 (21.4, 31.0)	104	453	23.0 (19.2, 27.1)	
	BSCM	17	53	32.1 (19.9, 46.3)	1.38 (0.88, 2.17)	11	64	17.2 (8.9, 28.7)	0.68 (0.38, 1.23)	58	250	23.2 (18.1, 28.9)	47	186	25.3 (19.2, 32.1)	75	303	24.8 (20.0, 30.0)	
	BSAC	4	24	16.7 (4.7, 37.4)	0.53 (0.21, 1.32)	7	38	18.4 (7.7, 34.3)	0.53 (0.26, 1.07)	62	196	31.6 (25.2, 38.6)	55	158	34.8 (27.4, 42.8)	66	220	30.0 (24.0, 36.5)	
	BSM	21	119	17.6 (11.3, 25.7)	0.71 (0.46, 1.10)	3	10	30.0 (6.7, 65.2)	1.22 (0.47, 3.21)	82	332	24.7 (20.2, 29.7)	79	322	24.5 (19.9, 29.6)	103	451	22.8 (19.0, 27.0)	
	BSCC	9	86	10.5 (4.9, 18.9)	0.54 (0.28, 1.05)	1	6	16.7 (0.4, 64.1)	0.86 (0.14, 5.21)	53	273	19.4 (14.9, 24.6)	52	267	19.5 (14.9, 24.7)	62	359	17.3 (13.5, 21.6)	
	BSC	2	45	4.4 (0.5, 15.1)	0.20 (0.05, 0.78)	4	29	13.8 (3.9, 31.7)	0.59 (0.23, 1.50)	68	303	22.4 (17.9, 27.6)	64	274	23.4 (18.5, 28.8)	70	348	20.1 (16.0, 24.7)	
	BSSL	7	39	17.9 (7.5, 33.5)	0.63 (0.32, 1.25)	4	8	50.0 (15.7, 84.3)	1.77 (0.87, 3.59)	155	543	28.5 (24.8, 32.5)	151	535	28.2 (24.4, 32.2)	162	582	27.8 (24.2, 31.7)	
	BSOS	9	20	45.0 (23.1, 68.5)	2.08 (1.20, 3.60)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 4.35)	44	203	21.7 (16.2, 28.0)	44	199	22.1 (16.5, 28.5)	53	223	23.8 (18.3, 29.9)	
	Total	82	478	17.2 (13.9, 20.8)	0.69 (0.56, 0.85)	34	185	18.4 (13.1, 24.7)	0.72 (0.53, 0.99)	613	2,461	24.9 (23.2, 26.7)	579	2,276	25.4 (23.7, 27.3)	695	2,939	23.6 (22.1, 25.2)	

Treatment: Early detection of DCIS or invasive breast cancer

3.a.2.t, Detection of invasive breast cancer, women screened during the 4 years to December 2020

Table 23: 3.a.2.t, Detection of invasive cancer, women screened during the 4 years to December 2020

		Māori				Pacific				Non-Māori				Non-Māori Non-Pacific				All	
		Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Pacific Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	
		45 to 49	Initial	BSWN	11	2,423	4.5 (2.3, 8.1)	1.10 (0.58, 2.08)	5	826	6.1 (2.0, 14.1)	1.51 (0.60, 3.75)	60	14,504	4.1 (3.2, 5.3)	55	13,678	4.0 (3.0, 5.2)	71
		BSCM	9	1,706	5.3 (2.4, 10.0)	1.33 (0.65, 2.73)	16	2,765	5.8 (3.3, 9.4)	1.75 (0.94, 3.27)	41	10,316	4.0 (2.9, 5.4)	25	7,551	3.3 (2.1, 4.9)	50	12,022	4.2 (3.1, 5.5)
		BSAC	4	742	5.4 (1.5, 13.7)	1.49 (0.53, 4.21)	5	936	5.3 (1.7, 12.4)	1.57 (0.60, 4.08)	30	8,267	3.6 (2.4, 5.2)	25	7,331	3.4 (2.2, 5.0)	34	9,009	3.8 (2.6, 5.3)
		BSM	13	3,221	4.0 (2.2, 6.9)	1.32 (0.70, 2.49)	1	335	3.0 (0.1, 16.5)	0.98 (0.14, 7.12)	37	12,137	3.0 (2.1, 4.2)	36	11,802	3.1 (2.1, 4.2)	50	15,358	3.3 (2.4, 4.3)
		BSCC	17	2,377	7.2 (4.2, 11.4)	1.77 (1.00, 3.14)	3	225	13.3 (2.8, 38.5)	3.50 (1.08, 11.32)	37	9,156	4.0 (2.8, 5.6)	34	8,931	3.8 (2.6, 5.3)	54	11,533	4.7 (3.5, 6.1)
		BSC	9	1,153	7.8 (3.6, 14.8)	2.48 (1.16, 5.30)	2	570	3.5 (0.4, 12.6)	1.13 (0.27, 4.76)	25	7,943	3.1 (2.0, 4.7)	23	7,373	3.1 (2.0, 4.7)	34	9,096	3.7 (2.6, 5.2)
		BSSL	3	1,339	2.2 (0.5, 6.5)	0.58 (0.18, 1.84)	2	308	6.5 (0.8, 23.3)	1.70 (0.42, 6.92)	67	17,337	3.9 (3.0, 4.9)	65	17,029	3.8 (2.9, 4.9)	70	18,676	3.7 (2.9, 4.7)
		BSOS	3	548	5.5 (1.1, 15.9)	1.82 (0.54, 6.16)	1	88	11.4 (0.3, 61.7)	3.94 (0.53, 29.29)	18	5,994	3.0 (1.8, 4.7)	17	5,896	2.9 (1.7, 4.6)	21	6,532	3.2 (2.0, 4.8)
		Total	69	13,509	5.1 (4.0, 6.5)	1.39 (1.07, 1.80)	35	6,953	5.8 (4.0, 8.0)	1.64 (1.16, 2.33)	315	85,644	3.7 (3.3, 4.1)	280	79,591	3.5 (3.1, 4.0)	384	99,153	3.9 (3.5, 4.3)
	Subsequent	BSWN	13	2,751	4.7 (2.5, 8.1)	1.58 (0.86, 2.89)	1	957	1.0 (0.0, 5.8)	0.34 (0.05, 2.43)	53	17,688	3.0 (2.2, 3.9)	52	16,731	3.1 (2.3, 4.1)	66	20,439	3.2 (2.5, 4.1)
		BSCM	6	1,985	3.0 (1.1, 6.6)	1.17 (0.49, 2.77)	9	2,951	3.0 (1.4, 5.8)	1.24 (0.58, 2.64)	35	13,511	2.6 (1.8, 3.6)	26	10,560	2.5 (1.6, 3.6)	41	15,496	2.6 (1.9, 3.6)
		BSAC	1	845	1.2 (0.0, 6.6)	0.48 (0.07, 3.50)	6	1,180	5.1 (1.9, 11.0)	2.36 (0.95, 5.86)	26	10,458	2.5 (1.6, 3.6)	20	9,278	2.2 (1.3, 3.3)	27	11,303	2.4 (1.6, 3.5)
		BSM	10	3,500	2.9 (1.4, 5.2)	1.20 (0.60, 2.41)	0	337	0.0 (0.0, 10.9)	0.00 (0.00, 4.72)	37	15,520	2.4 (1.7, 3.3)	37	15,183	2.4 (1.7, 3.4)	47	19,020	2.5 (1.8, 3.3)
		BSCC	8	2,949	2.7 (1.2, 5.3)	1.10 (0.51, 2.38)	2	261	7.7 (0.9, 27.4)	3.24 (0.78, 13.48)	33	13,378	2.5 (1.7, 3.5)	31	13,117	2.4 (1.6, 3.4)	41	16,327	2.5 (1.8, 3.4)
		BSC	10	1,517	6.6 (3.2, 12.1)	4.01 (1.89, 8.51)	2	697	2.9 (0.3, 10.3)	1.83 (0.43, 7.82)	21	12,784	1.6 (1.0, 2.5)	19	12,087	1.6 (0.9, 2.5)	31	14,301	2.2 (1.5, 3.1)
		BSSL	7	1,982	3.5 (1.4, 7.3)	1.34 (0.62, 2.91)	0	339	0.0 (0.0, 10.8)	0.00 (0.00, 4.18)	69	26,141	2.6 (2.1, 3.3)	69	25,802	2.7 (2.1, 3.4)	76	28,123	2.7 (2.1, 3.4)
		BSOS	1	788	1.3 (0.0, 7.1)	0.46 (0.06, 3.36)	0	115	0.0 (0.0, 31.6)	0.00 (0.00, 12.29)	23	8,240	2.8 (1.8, 4.2)	23	8,125	2.8 (1.8, 4.2)	24	9,028	2.7 (1.7, 4.0)
		Total	56	16,317	3.4 (2.6, 4.5)	1.36 (1.02, 1.81)	20	6,837	2.9 (1.8, 4.5)	1.17 (0.74, 1.84)	297	117,720	2.5 (2.2, 2.8)	277	110,883	2.5 (2.2, 2.8)	353	134,037	2.6 (2.4, 2.9)
50 to 69	Initial	BSWN	15	552	27.2 (15.3, 44.4)	2.99 (1.67, 5.36)	1	219	4.6 (0.1, 25.2)	0.49 (0.07, 3.55)	42	4,622	9.1 (6.6, 12.3)	41	4,403	9.3 (6.7, 12.6)	57	5,174	11.0 (8.4, 14.2)
		BSCM	4	363	11.0 (3.0, 28.0)	1.10 (0.39, 3.09)	8	673	11.9 (5.1, 23.3)	1.25 (0.56, 2.78)	31	3,088	10.0 (6.8, 14.2)	23	2,415	9.5 (6.0, 14.3)	35	3,451	10.1 (7.1, 14.1)
		BSAC	0	209	0.0 (0.0, 17.5)	0.00 (0.00, 2.55)	3	257	11.7 (2.4, 33.7)	1.63 (0.48, 5.51)	2	2,777	7.6 (4.7, 11.5)	18	2,520	7.1 (4.2, 11.3)	21	2,986	7.0 (4.4, 10.7)
		BSM	22	1,082	20.3 (12.8, 30.6)	2.08 (1.23, 3.52)	4	102	39.2 (10.8, 97.4)	4.38 (1.58, 12.16)	36	3,679	9.8 (6.9, 13.5)	32	3,577	8.9 (6.1, 12.6)	58	4,761	12.2 (9.3, 15.7)
		BSCC	19	789	24.1 (14.6, 37.4)	3.17 (1.70, 5.91)	0	87	0.0 (0.0, 41.5)	0.00 (0.00, 5.92)	20	2,632	7.6 (4.6, 11.7)	20	2,545	7.9 (4.8, 12.1)	39	3,421	11.4 (8.1, 15.6)
		BSC	5	310	16.1 (5.3, 37.2)	1.65 (0.63, 4.1)	6	199	30.2 (11.1, 64.5)	3.83 (1.53, 9.59)	23	2,356	8.9 (6.2, 14.6)	17	2,157	7.9 (4.6, 12.6)	28	2,666	10.5 (7.0, 15.1)
		BSSL	3	229	13.1 (2.7, 37.8)	2.01 (0.60, 6.72)	1	94	10.6 (0.3, 57.9)	1.67 (0.23, 12.32)	20	3,072	6.5 (4.0, 10.0)	19	2,978	6.4 (3.8, 9.9)	23	3,301	7.0 (4.4, 10.4)
		BSOS	1	113	8.8 (0.2, 48.3)	1.03 (0.13, 7.90)	0	36	0.0 (0.0, 97.4)	0.00 (0.00, 13.77)	11	1,280	8.6 (4.3, 15.3)	11	1,244	8.8 (4.4, 15.8)	12	1,393	8.6 (4.5, 15.0)
		Total	69	3,647	18.9 (14.7, 23.9)	2.18 (1.66, 2.86)	23	1,667	13.8 (8.8, 20.6)	1.60 (1.08, 2.56)	204	23,506	8.7 (7.5, 9.9)	181	21,839	8.3 (7.1, 9.6)	273	27,153	10.1 (8.9, 11.3)
	Subsequent	BSWN	125	15,248	8.2 (6.8, 9.8)	1.81 (1.49, 2.20)	33	5,554	5.9 (4.1, 8.3)	1.33 (0.94, 1.90)	495	109,208	4.5 (4.1, 4.9)	462	103,654	4.5 (4.1, 4.9)	620	124,456	5.0 (4.6, 5.4)
		BSCM	64	9,099	7.0 (5.4, 9.0)	1.64 (1.25, 2.15)	79	15,314	5.2 (4.1, 6.4)	1.27 (0.99, 1.64)	307	71,576	4.3 (3.8, 4.8)	228	56,262	4.1 (3.5, 4.6)	371	80,675	4.6 (4.1, 5.1)
		BSAC	34	3,996	8.5 (5.9, 11.9)	2.00 (1.40, 2.85)	46	6,374	7.2 (5.3, 9.6)	1.85 (1.35, 2.55)	244	57,207	4.3 (3.7, 4.8)	198	50,833	3.9 (3.4, 4.5)	278	61,203	4.5 (4.0, 5.1)
		BSM	179	20,885	8.6 (7.4, 9.9)	1.86 (1.56, 2.20)	6	1,811	3.3 (1.2, 7.2)	0.71 (0.32, 1.59)	493	106,776	4.6 (4.2, 5.0)	487	104,965	4.6 (4.2, 5.1)	672	127,661	5.3 (4.9, 5.7)
		BSCC	114	16,788	6.8 (5.6, 8.2)	1.53 (1.24, 1.88)	10	1,489	6.7 (3.2, 12.3)	1.53 (0.82, 2.85)	411	92,547	4.4 (4.0, 4.9)	401	91,058	4.4 (4.0, 4.9)	525	109,335	4.8 (4.4, 5.2)
		BSC	58	8,088	7.2 (5.4, 9.3)	1.48 (1.12, 1.95)	24	4,250	5.6 (3.6, 8.4)	1.18 (0.78, 1.77)	394	81,218	4.9 (4.4, 5.4)	370	76,968	4.8 (4.3, 5.3)	452	89,306	5.1 (4.6, 5.5)
		BSSL	61	8,764	7.0 (5.3, 8.9)	1.58 (1.22, 2.03)	6	1,557	3.9 (1.4, 8.4)	0.87 (0.39, 1.95)	656	148,924	4.4 (4.1, 4.8)	650	147,367	4.4 (4.1, 4.8)	717	157,688	4.5 (4.2, 4.9)
		BSOS	19	3,618	5.3 (3.2, 8.2)	1.02 (0.64, 1.62)	6	468	12.8 (4.7, 27.7)	2.52 (1.13, 5.63)	289	56,143	5.1 (4.6, 5.8)	283	55,675	5.1 (4.5, 5.7)	308	59,761	5.2 (4.6, 5.8)
		Total	654	86,486	7.6 (7.0, 8.2)	1.66 (1.53, 1.81)	210	36,817	5.7 (5.0, 6.5)	1.27 (1.11, 1.46)	3,289	723,599	4.5 (4.4, 4.7)	3,079	686,782	4.5 (4.3, 4.6)	3,943	810,085	4.9 (4.7, 5.0)
45 to 69	Initial	BSWN	26	2,975	8.7 (5.7, 12.8)	1.64 (1.07, 2.52)	6	1,045	5.7 (2.1, 12.5)	1.08 (0.47, 2.46)	102	19,126	5.3 (4.4, 6.5)	96	18,081	5.3 (4.3, 6.5)	128	22,101	5.8 (4.8, 6.9)
		BSCM	13	2,069	6.3 (3.3, 10.7)	1.17 (0.65, 2.11)	24	3,438	7.0 (4.5, 10.4)	1.45 (0.89, 2.36)	72	13,404	5.4 (4.2, 6.8)	48	9,966	4.8 (3.6, 6.4)	85	15,473	5.5 (4.4, 6.8)
		BSAC	4	951	4.2 (1.1, 10.7)	0.91 (0.33, 2.52)	8	1,193	6.7 (2.9, 13.2)	1.54 (0.72, 3.26)	51	11,044	4.6 (3.4, 6.1)	43	9,851	4.4 (3.2, 5.9)	55	11,995	4.6 (3.5, 6.0)
		BSM	35	4,303	8.1 (5.7, 11.3)	1.76 (1.18, 2.63)	5	437	11.4 (3.7, 26.5)	2.59 (1.05, 6.38)	73	15,816	4.6 (3.6, 5.8)	68	15,379	4.4 (3.4, 5.6)	108	20,119	5.4 (4.4, 6.5)
		BSCC	36	3,166	11.4 (8.0, 15.7)	2.35 (1.55, 3.56)	3	312	9.6 (2.0, 27.8)	2.04 (0.84, 6.50)	57	11,788	4.8 (3.7, 6.3)	54	11,476	4.7 (3.5, 6.1)	93	14,954	6.2 (5.0, 7.6)
		BSC	14	1,463	9.6 (5.2, 16.0)	2.05 (1.14, 3.71)	8	769	10.4 (4.5, 20.4)	2.48 (1.16, 5.28)	48	10,399	4.7 (3.4, 6.2)	40	9,530	4.2 (3.0, 5.7)	62	11,762	5.3 (4.0, 6.8)
		BSSL	6	1,968	3.8 (1.4, 8.3)	0.90 (0.39, 2.05)	3	402	7.5 (1.5, 21.7)	1.78 (0.56, 5.60)	87	20,409	4.3 (3.4, 5.3)	84	20,007	4.2 (3.4, 5.2)	93	21,977	4.2 (3.4, 5.2)
		BSOS	4	661	6.1 (1.7, 15.4)	1.52 (0.54, 4.30)	1	124	8.1 (0.2, 44.1)	2.06 (0.28, 14.99)	29	7,264	4.0 (2.7, 5.7)	28	7,140	3.9 (2.6, 5.7)	33	7,925	4.2 (2.9, 5.8)
		Total	138	17,156	8.0 (6.8, 9.5)	1.69 (1.40, 2.04)	58	7,720	7.5 (5.7, 9.7)	1.65 (1.26, 2.17)	519	109,150	4.8 (4.4, 5.2)	461	101,430	4.5 (4.1, 5.0)	657	126,306	5.2 (4.8, 5.6)
	Subsequent	BSWN	138	17,999	7.7 (6.4, 9.1)	1.78 (1.47, 2.14)	34	6,511	5.2 (3.6, 7.3)	1.22 (0.86, 1.73)	548	126,896	4.3 (4.0, 4.7)	514	120,385	4.3 (3.9, 4.7)	686	144,895	4.7 (4.4, 5.1)
		BSCM	70	11,084	6.3 (4.9, 8.0)														

3.a.3.t, Treatment Data Completeness, women screened during the 4 years to December 2020

Description: Lead Providers have 9 months to complete Staging and Surgery data entry for women referred to treatment. Lead Providers have 6 months to complete Endocrine, Radiotherapy, and Chemotherapy data entry for women referred to treatment. The 't' in the indicator id marks it as a treatment indicator.

Target: ≥ 90%

Table 24: 3.a.3.t, Treatment Data Completeness, women screened during the 4 years to December 2020

			Staging Data Target Met	Staging Data Collected	Surgery Data Target Met	Surgery Data Collected	Endocrine Data Target Met	Endocrine Data Collected	Radiotherapy Data Target Met	Radiotherapy Data Collected	Chemotherapy Data Target Met	Chemotherapy Data Collected	
45 - 49	BSWN		0.52	1.00	1.00	1.00	0.84	1.00	0.82	1.00	0.85	1.00	
	BSCM		0.94	1.00	1.00	1.00	0.92	1.00	0.98	1.00	0.98	1.00	
	BSAC		0.81	1.00	1.00	1.00	0.93	1.00	0.95	1.00	0.91	1.00	
	BSM		0.50	1.00	0.90	1.00	0.55	0.98	0.60	0.98	0.64	0.98	
	BSCC		0.72	1.00	0.91	1.00	0.78	1.00	0.76	1.00	0.86	1.00	
	BSC		0.74	1.00	1.00	1.00	0.89	1.00	0.79	1.00	0.96	1.00	
	BSSL		0.90	1.00	0.99	1.00	0.89	1.00	0.88	1.00	0.99	1.00	
	BSOS		0.83	1.00	1.00	1.00	0.93	1.00	0.88	1.00	0.98	1.00	
	50 - 69	BSWN		0.49	1.00	0.99	1.00	0.84	1.00	0.73	1.00	0.87	1.00
		BSCM		0.97	1.00	0.99	1.00	0.98	1.00	0.94	1.00	0.98	1.00
		BSAC		0.85	1.00	0.99	1.00	0.97	1.00	0.94	1.00	0.97	1.00
		BSM		0.56	0.99	0.94	1.00	0.60	0.98	0.60	0.98	0.64	0.98
		BSCC		0.74	1.00	0.95	1.00	0.83	1.00	0.83	1.00	0.89	1.00
		BSC		0.75	1.00	0.99	1.00	0.93	1.00	0.88	1.00	0.95	1.00
BSSL			0.93	1.00	0.99	1.00	0.91	1.00	0.90	1.00	1.00	1.00	
BSOS			0.89	1.00	1.00	1.00	0.99	1.00	0.98	1.00	1.00	1.00	

3.c.p.t, Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2020

Table 25: 3.c.p.t Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2020

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
			Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)		
45 to 49	Initial	BSWN	3	10	30.0 (6.7, 65.2)	0.55 (0.21, 1.46)	1	5	20.0 (0.5, 71.6)	0.35 (0.06, 2.02)	30	55	54.5 (40.6, 68.0)	29	50	58.0 (43.2, 71.8)	33	65	50.8 (38.1, 63.4)		
		BSCM	4	8	50.0 (15.7, 84.3)	1.54 (0.67, 3.55)	7	16	43.8 (19.8, 70.1)	1.84 (0.71, 4.73)	12	37	32.4 (18.0, 49.8)	5	21	23.8 (8.2, 47.2)	16	45	35.6 (21.9, 51.2)		
		BSAC	3	4	75.0 (19.4, 99.4)	1.45 (0.74, 2.83)	2	5	40.0 (5.3, 85.3)	0.73 (0.23, 2.29)	14	27	51.9 (31.9, 71.3)	12	22	54.5 (32.2, 75.6)	17	31	54.8 (36.0, 72.7)		
		BSM	8	13	61.5 (31.6, 86.1)	0.88 (0.54, 1.43)	0	0	NA (NA, NA)	NA (NA, NA)	23	33	69.7 (51.3, 84.4)	23	33	69.7 (51.3, 84.4)	31	46	67.4 (52.0, 80.5)		
		BSCC	7	16	43.8 (19.8, 70.1)	0.78 (0.42, 1.47)	1	3	33.3 (0.8, 90.6)	0.57 (0.11, 2.92)	19	34	55.9 (37.9, 72.8)	18	31	58.1 (39.1, 75.5)	26	50	52.0 (37.4, 66.3)		
		BSC	2	9	22.2 (2.8, 60.0)	0.37 (0.10, 1.29)	2	2	100.0 (15.8, 100.0)	1.75 (1.21, 2.54)	14	23	60.9 (38.5, 80.3)	12	21	57.1 (34.0, 78.2)	16	32	50.0 (31.9, 68.1)		
		BSSL	1	3	33.3 (0.8, 90.6)	0.50 (0.10, 2.52)	1	2	50.0 (1.3, 98.7)	0.75 (0.18, 3.03)	41	62	66.1 (53.0, 77.7)	40	60	66.7 (53.3, 78.3)	42	65	64.6 (51.8, 76.1)		
		BSOS	2	3	66.7 (9.4, 99.2)	0.97 (0.41, 2.31)	1	1	100.0 (2.5, 100.0)	1.50 (1.05, 2.15)	11	16	68.8 (41.3, 89.0)	10	15	66.7 (38.4, 88.2)	13	19	68.4 (43.4, 87.4)		
		Total	30	66	45.5 (33.1, 58.2)	0.80 (0.60, 1.05)	15	34	44.1 (27.2, 62.1)	0.75 (0.51, 1.11)	164	287	57.1 (51.2, 62.9)	149	253	58.9 (52.6, 65.0)	194	353	55.0 (49.6, 60.2)		
		45 to 49	Subsequent	BSWN	10	13	76.9 (46.2, 95.0)	1.10 (0.78, 1.56)	1	1	100.0 (2.5, 100.0)	1.44 (1.20, 1.74)	35	50	70.0 (55.4, 82.1)	34	49	69.4 (54.6, 81.7)	45	63	71.4 (58.7, 82.1)
				BSCM	1	6	16.7 (0.4, 64.1)	0.33 (0.05, 2.06)	4	9	44.4 (13.7, 78.8)	0.86 (0.38, 1.94)	17	34	50.0 (32.4, 67.6)	13	25	52.0 (31.3, 72.2)	18	40	45.0 (29.3, 61.5)
				BSAC	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.82)	2	6	33.3 (4.3, 77.7)	0.40 (0.13, 1.26)	17	24	70.8 (48.9, 87.4)	15	18	83.3 (58.6, 96.4)	17	25	68.0 (46.5, 85.1)
				BSM	4	9	44.4 (13.7, 78.8)	0.70 (0.33, 1.52)	0	0	NA (NA, NA)	NA (NA, NA)	24	38	63.2 (46.0, 78.2)	24	38	63.2 (46.0, 78.2)	28	47	59.6 (44.3, 73.6)
				BSCC	2	7	28.6 (3.7, 71.0)	0.40 (0.12, 1.31)	1	2	50.0 (1.3, 98.7)	0.68 (0.17, 2.77)	23	32	71.9 (53.3, 86.3)	22	30	73.3 (54.1, 87.7)	25	39	64.1 (47.2, 78.8)
BSC	2			8	25.0 (3.2, 65.1)	0.48 (0.13, 1.70)	1	2	50.0 (1.3, 98.7)	0.94 (0.22, 4.05)	10	19	52.9 (28.9, 75.6)	9	17	52.9 (27.8, 77.0)	12	27	44.4 (25.5, 64.7)		
BSSL	5			7	71.4 (29.0, 96.3)	1.05 (0.64, 1.72)	0	0	NA (NA, NA)	NA (NA, NA)	43	63	68.3 (55.3, 79.4)	43	63	68.3 (55.3, 79.4)	48	70	68.6 (56.4, 79.1)		
BSOS	0			1	0.0 (0.0, 97.5)	0.00 (0.00, 7.92)	0	0	NA (NA, NA)	NA (NA, NA)	12	22	54.5 (32.2, 75.6)	12	22	54.5 (32.2, 75.6)	12	23	52.2 (30.6, 73.2)		
Total	24			52	46.2 (32.1, 60.5)	0.72 (0.53, 0.98)	9	20	45.0 (27.1, 68.5)	0.69 (0.42, 1.12)	181	282	64.2 (58.3, 69.8)	172	262	65.6 (59.6, 71.4)	205	334	61.4 (52.9, 66.6)		
50 to 69	Initial			BSWN	6	14	42.9 (17.7, 71.1)	0.75 (0.39, 1.45)	1	1	100.0 (2.5, 100.0)	1.78 (1.36, 2.34)	24	42	57.1 (41.0, 72.3)	23	41	56.1 (39.7, 71.5)	30	56	53.6 (39.7, 67.0)
				BSCM	1	4	25.0 (0.6, 80.6)	1.07 (0.17, 6.59)	2	7	28.6 (3.7, 71.0)	1.31 (0.32, 5.36)	7	30	23.3 (9.9, 42.3)	5	23	21.7 (7.5, 43.7)	8	34	23.5 (10.7, 41.2)
				BSAC	0	0	NA (NA, NA)	NA (NA, NA)	1	3	33.3 (0.8, 90.6)	0.44 (0.09, 2.21)	14	20	70.0 (45.7, 88.1)	13	17	76.5 (50.1, 93.2)	14	20	70.0 (45.7, 88.1)
				BSM	12	21	57.1 (34.0, 78.2)	1.08 (0.67, 1.75)	3	4	75.0 (19.4, 99.4)	1.50 (0.77, 2.91)	19	36	52.8 (35.5, 69.6)	16	32	50.0 (31.9, 68.1)	31	57	54.4 (40.7, 67.6)
				BSCC	8	17	47.1 (23.0, 72.2)	0.94 (0.47, 1.90)	0	0	NA (NA, NA)	NA (NA, NA)	8	16	50.0 (24.7, 75.3)	8	16	50.0 (24.7, 75.3)	16	33	48.5 (30.8, 66.5)
		BSC	4	4	100.0 (99.8, 100.0)	2.00 (1.32, 3.04)	3	5	60.0 (14.7, 94.7)	1.28 (0.33, 3.06)	11	22	50.0 (28.2, 71.8)	8	17	47.1 (23.0, 72.2)	15	26	57.7 (36.9, 76.6)		
		BSSL	2	3	66.7 (9.4, 99.2)	0.91 (0.39, 2.10)	1	1	100.0 (2.5, 100.0)	1.39 (1.04, 1.84)	14	19	73.7 (48.8, 90.9)	13	18	72.2 (46.5, 90.3)	16	22	72.7 (49.8, 89.3)		
		BSOS	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 8.49)	0	0	NA (NA, NA)	NA (NA, NA)	6	10	60.0 (26.2, 87.8)	6	10	60.0 (26.2, 87.8)	6	11	54.5 (23.4, 83.3)		
		Total	33	64	51.6 (38.7, 64.2)	0.98 (0.74, 1.28)	11	21	52.4 (45.6, 74.3)	0.99 (0.64, 1.52)	103	195	52.9 (45.6, 60.8)	92	174	62.1 (54.9, 69.5)	136	259	54.5 (46.2, 58.7)		
		50 to 69	Subsequent	BSWN	79	117	67.5 (58.2, 75.9)	1.00 (0.86, 1.15)	12	33	36.4 (20.4, 54.9)	0.52 (0.33, 0.82)	325	479	67.8 (63.5, 72.0)	313	446	70.2 (65.7, 74.4)	404	596	67.8 (63.9, 71.5)
				BSCM	31	64	48.4 (35.8, 61.3)	0.83 (0.63, 1.08)	43	78	55.1 (43.4, 66.4)	0.92 (0.74, 1.16)	176	301	58.5 (52.7, 64.1)	133	223	59.6 (52.9, 66.1)	207	365	56.7 (51.5, 61.9)
				BSAC	23	34	67.6 (49.5, 82.6)	1.01 (0.79, 1.29)	31	46	67.4 (52.0, 80.5)	1.01 (0.60, 1.26)	157	234	67.1 (60.7, 73.1)	126	188	67.0 (59.8, 73.7)	180	268	67.2 (61.2, 72.8)
				BSM	119	174	68.4 (60.9, 75.2)	1.01 (0.90, 1.14)	2	5	40.0 (5.3, 85.3)	0.59 (0.20, 1.73)	326	483	67.5 (63.1, 71.7)	324	478	67.8 (63.4, 72.0)	445	657	67.7 (64.0, 71.3)
				BSCC	56	110	50.9 (41.2, 60.6)	0.91 (0.74, 1.11)	1	8	12.5 (0.3, 52.7)	0.22 (0.04, 1.37)	224	399	56.1 (51.1, 61.1)	223	391	57.0 (52.0, 62.0)	280	509	55.0 (50.6, 59.4)
BSC	34			58	58.6 (44.9, 71.4)	0.91 (0.72, 1.15)	8	23	34.8 (16.4, 57.3)	0.53 (0.30, 0.92)	242	376	64.4 (59.3, 69.2)	234	353	66.3 (61.1, 71.2)	276	434	63.6 (58.9, 68.1)		
BSSL	33			59	55.9 (42.4, 68.8)	0.81 (0.64, 1.02)	5	6	83.3 (35.9, 99.6)	1.21 (0.84, 1.74)	436	632	69.0 (65.2, 72.6)	431	626	68.8 (65.1, 72.5)	469	691	67.9 (64.2, 71.3)		
BSOS	11			19	57.9 (33.5, 79.7)	0.86 (0.58, 1.27)	3	6	50.0 (11.8, 88.2)	0.74 (0.33, 1.64)	188	278	67.6 (61.8, 73.1)	185	272	68.0 (62.1, 73.5)	199	297	67.0 (61.3, 72.3)		
Total	386			635	60.8 (56.9, 64.6)	0.93 (0.87, 1.00)	105	205	51.2 (44.2, 58.2)	0.77 (0.68, 0.89)	2,074	3,182	65.2 (63.5, 66.8)	1,969	2,977	66.1 (64.4, 67.8)	2,460	3,817	64.4 (62.9, 66.0)		
45 to 69	Initial			BSWN	9	24	37.5 (18.8, 59.4)	0.67 (0.39, 1.16)	2	6	33.3 (4.3, 77.7)	0.58 (0.19, 1.83)	54	97	55.7 (45.2, 65.8)	52	91	57.1 (46.3, 67.5)	63	121	52.1 (42.8, 61.2)
				BSCM	5	12	41.7 (15.2, 72.3)	1.47 (0.68, 3.17)	9	23	39.1 (19.7, 61.5)	1.72 (0.82, 3.63)	19	67	28.4 (18.0, 40.7)	10	44	22.7 (11.5, 37.8)	24	79	30.4 (20.5, 41.8)
				BSAC	3	4	75.0 (19.4, 99.4)	1.26 (0.68, 2.32)	3	8	37.5 (8.5, 75.5)	0.59 (0.23, 1.48)	28	47	59.6 (44.3, 73.6)	25	39	64.1 (47.2, 78.8)	31	51	60.8 (46.1, 74.2)
				BSM	20	34	58.8 (40.7, 75.4)	0.97 (0.69, 1.36)	3	4	75.0 (19.4, 99.4)	1.25 (0.69, 2.28)	42	69	60.9 (48.4, 72.4)	39	65	60.0 (47.1, 72.0)	62	103	60.2 (50.1, 69.7)
				BSCC	15	33	45.5 (28.1, 63.6)	0.84 (0.54, 1.32)	1	3	33.3 (0.8, 90.6)	0.60 (0.12, 3.05)	27	50	54.0 (39.3, 68.2)	26	47	55.3 (40.1, 69.8)	42	83	50.6 (39.4, 61.8)
		BSC	6	13	46.2 (19.2, 74.9)	0.83 (0.44, 1.58)	5	7	71.4 (29.0, 96.3)	1.36 (0.78, 2.37)	25	45	55.6 (40.0, 70.4)	20	38	52.6 (35.8, 69.0)	31	58	53.4 (39.9, 66.7)		
		BSSL	3	6	50.0 (11.8, 88.2)	0.74 (0.33, 1.66)	2	3	66.7 (9.4, 99.2)	0.98 (0.43, 2.22)	55	81	67.9 (56.6, 77.8)	53	78	67.9 (56.4, 78.1)	58	87	66.7 (55.7, 76.4)		
		BSOS	2	4	50.0 (6.8, 93.2)	0.77 (0.28, 2.12)	1	1	100.0 (2.5, 100.0)	1.56 (1.17, 2.10)	17	26	65.4 (44.3, 82.8)	16	25	64.0 (42.5, 82.0)	19	30	63.3 (43.9, 80.1)		
		Total	63	130	48.5 (39.6, 57.4)	0.88 (0.72, 1.06)	26	55	47.3 (33.7, 61.2)	0.84 (0.63, 1.12)	267	482	55.4 (50.8, 59.9)	241	427	56.4 (51.6, 61.2)	330	612	53.9 (49.9, 57.9)		
		45 to 69	Subsequent	BSWN	89	130	68.5 (59.7, 76.3)	1.01 (0.88, 1.15)	13	34	38.2 (22.2, 56.4)	0.55 (0.35, 0.84)	360	529	68.1 (63.9, 72.0)	347	495	70.1 (65.9, 74.1)	449	659	68.1 (64.4, 71.7)
				BSCM	32	70	45.7 (33.7, 58.1)	0.79 (0.60, 1.04)	47	87	54.0 (43.0, 64.8)	0.92 (0.74, 1.14)	193	335	57.6 (52.1, 63.0)	146	248	58.9 (52.5, 65.1)	225	405	55.6 (50.6, 60.5)
				BSAC	23	35	65.7 (47.8, 80.9)	0.97 (0.76, 1.26)	33	52	63.5 (49.0, 76.4)	0.93 (0.74, 1.16)	174	258	67.4 (61.4,						

3.c.r.t, Detection of invasive breast cancer less than or equal to 15mm (rate), women screened during the 4 years to December 2020

Table 26: 3.c.r.t Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000 screens), women screened during the 4 years to December 2020

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)
			45 to 49	Initial	BSWN	3	2,397	12.5 (2.6, 36.5)	0.60 (0.18, 1.95)	1	804	12.4 (0.3, 69.1)	0.58 (0.08, 4.23)	30	14,267	21.0 (14.2, 30.0)	29	13,463	21.5 (14.4, 30.9)
		BSCM	4	1,663	24.1 (6.6, 61.5)	2.03 (0.65, 6.27)	7	2,731	25.6 (10.3, 52.7)	3.78 (1.20, 11.90)	12	10,107	11.9 (6.1, 20.7)	5	7,376	6.8 (2.2, 15.8)	16	11,770	13.6 (7.8, 22.1)
		BSAC	3	733	40.9 (8.4, 119.1)	2.38 (0.68, 8.25)	2	924	21.6 (2.6, 78.0)	1.30 (0.29, 5.80)	14	8,127	17.2 (9.4, 28.9)	12	7,203	16.7 (8.6, 29.1)	17	8,860	19.2 (11.2, 30.7)
		BSM	8	3,125	25.6 (11.1, 50.4)	1.33 (0.60, 2.98)	0	325	0.0 (0.0, 112.9)	0.00 (0.00, 6.24)	23	11,976	19.2 (12.2, 28.8)	23	11,651	19.7 (12.5, 29.6)	31	15,101	20.5 (14.0, 29.1)
		BSCC	7	2,323	30.1 (12.1, 62.0)	1.43 (0.60, 3.38)	1	223	44.8 (1.1, 247.3)	2.18 (0.29, 16.28)	19	8,984	21.1 (12.7, 33.0)	18	8,761	20.5 (12.2, 32.5)	26	11,307	23.0 (15.0, 33.7)
		BSC	2	1,086	18.4 (2.2, 66.4)	1.03 (0.23, 4.51)	2	533	37.5 (4.5, 134.9)	2.27 (0.51, 10.13)	14	7,800	17.9 (9.8, 30.1)	12	7,267	16.5 (8.5, 28.8)	16	8,886	18.0 (10.3, 29.2)
		BSSL	1	1,245	8.0 (0.2, 44.7)	0.34 (0.05, 2.44)	1	294	34.0 (0.9, 188.0)	1.43 (0.20, 10.38)	41	17,132	23.9 (17.2, 32.5)	40	16,838	23.8 (17.0, 32.3)	42	18,377	22.9 (16.5, 30.9)
		BSOS	2	512	39.1 (4.7, 140.4)	2.11 (0.47, 9.49)	1	85	117.6 (3.0, 638.1)	6.89 (0.89, 53.19)	11	5,938	18.5 (9.3, 33.1)	10	5,853	17.1 (8.2, 31.4)	13	6,450	20.2 (10.7, 34.4)
		Total	30	13,084	22.9 (15.5, 32.7)	1.18 (0.80, 1.74)	15	5,919	25.3 (14.2, 41.8)	1.33 (0.79, 2.27)	164	84,331	19.4 (16.6, 22.7)	149	78,412	19.0 (16.1, 22.3)	194	97,415	19.9 (17.2, 22.9)
	Subsequent	BSWN	10	2,749	36.4 (17.5, 66.8)	1.84 (0.91, 3.70)	1	957	10.4 (0.3, 58.1)	0.51 (0.07, 3.75)	35	17,670	19.8 (13.8, 27.5)	34	16,713	20.3 (14.1, 28.4)	45	20,419	22.0 (16.1, 29.5)
		BSCM	1	1,974	5.1 (0.1, 28.2)	0.40 (0.05, 3.01)	4	2,942	13.6 (3.7, 34.8)	1.10 (0.36, 3.37)	17	13,470	12.6 (7.4, 20.2)	13	10,528	12.3 (6.6, 21.1)	18	15,444	11.7 (6.9, 18.4)
		BSAC	0	840	0.0 (0.0, 43.8)	0.00 (0.00, 3.00)	2	1,176	17.0 (2.1, 61.3)	1.05 (0.24, 4.58)	17	10,416	16.3 (9.5, 26.1)	15	9,240	16.2 (9.1, 26.8)	17	11,256	15.1 (8.8, 24.2)
		BSM	4	3,485	11.5 (3.1, 29.4)	0.74 (0.26, 2.13)	0	336	0.0 (0.0, 109.2)	0.00 (0.00, 7.49)	24	15,491	15.5 (9.9, 23.0)	24	15,155	15.8 (10.1, 23.6)	28	18,976	14.8 (9.8, 21.3)
		BSCC	2	2,941	6.8 (0.8, 24.5)	0.40 (0.09, 1.68)	1	261	38.3 (1.0, 211.6)	2.28 (0.31, 16.87)	23	13,367	17.2 (10.9, 25.8)	22	13,106	16.8 (10.5, 25.4)	25	16,308	15.3 (9.9, 22.6)
		BSC	2	1,508	13.3 (1.6, 47.8)	1.69 (0.37, 7.72)	1	696	14.4 (0.4, 79.8)	1.93 (0.24, 15.8)	10	12,765	7.8 (3.8, 14.4)	9	12,069	7.5 (3.4, 14.2)	12	14,273	8.4 (4.3, 14.7)
		BSSL	5	1,978	25.3 (8.2, 58.9)	1.54 (0.61, 3.87)	0	339	0.0 (0.0, 108.2)	0.00 (0.00, 6.81)	43	26,126	16.5 (11.9, 22.2)	43	25,787	16.7 (12.1, 22.5)	48	28,104	17.1 (12.6, 22.6)
		BSOS	0	784	0.0 (0.0, 46.9)	0.00 (0.00, 3.78)	0	115	0.0 (0.0, 315.7)	0.00 (0.00, 25.40)	12	8,230	14.6 (7.5, 25.5)	12	8,115	14.8 (7.6, 25.8)	12	9,014	13.3 (6.9, 23.2)
		Total	24	16,259	14.8 (9.5, 22.0)	0.96 (0.63, 1.47)	9	6,822	13.2 (6.0, 25.0)	0.85 (0.43, 1.66)	181	117,535	15.4 (13.2, 17.8)	172	110,713	15.5 (13.3, 18.0)	205	133,794	15.3 (13.3, 17.6)
50 to 69	Initial	BSWN	6	541	110.9 (40.8, 239.8)	2.11 (0.86, 5.13)	1	215	46.5 (1.2, 256.4)	0.88 (0.12, 6.47)	24	4,558	52.7 (33.8, 78.2)	23	4,343	53.0 (33.6, 79.4)	30	5,099	58.8 (39.7, 83.9)
		BSCM	1	360	27.8 (0.7, 153.8)	1.20 (0.15, 9.70)	2	662	30.2 (3.7, 108.7)	1.42 (0.28, 7.32)	7	3,017	23.2 (9.3, 47.7)	5	2,355	21.2 (6.9, 49.5)	8	3,377	23.7 (10.2, 46.6)
		BSAC	0	200	0.0 (0.0, 182.8)	0.00 (0.00, 4.12)	1	257	38.9 (1.0, 214.9)	0.74 (0.10, 5.63)	14	2,730	51.3 (28.1, 85.9)	13	2,473	52.6 (28.0, 89.7)	14	2,930	47.8 (26.1, 80.0)
		BSM	12	1,058	113.4 (58.7, 197.3)	2.17 (1.05, 4.45)	3	98	306.1 (63.6, 868.6)	6.75 (2.00, 22.80)	19	3,628	52.4 (31.6, 81.7)	16	3,530	45.3 (25.9, 73.5)	31	4,686	66.2 (45.0, 93.8)
		BSCC	8	772	103.6 (44.8, 203.2)	3.34 (1.26, 8.87)	0	85	0.0 (0.0, 424.7)	0.00 (0.00, 17.19)	8	2,579	31.0 (13.4, 61.0)	8	2,494	32.1 (13.9, 63.1)	16	3,351	47.7 (27.3, 77.4)
		BSC	4	285	140.4 (38.4, 355.4)	2.95 (0.95, 9.21)	3	184	163.0 (33.8, 469.1)	4.34 (1.16, 16.22)	11	2,313	47.6 (23.8, 84.9)	8	2,129	37.6 (16.2, 73.9)	15	2,598	57.7 (32.3, 95.0)
		BSSL	2	218	91.7 (11.1, 327.5)	2.00 (0.46, 8.73)	1	88	113.6 (2.9, 616.9)	2.59 (0.34, 19.57)	14	3,049	45.9 (25.1, 76.9)	13	2,961	43.9 (23.4, 75.0)	16	3,267	49.0 (28.0, 79.4)
		BSOS	0	105	0.0 (0.0, 345.2)	0.00 (0.00, 10.27)	0	33	0.0 (0.0, 1057.6)	0.00 (0.00, 31.81)	6	1,269	47.3 (17.4, 102.6)	6	1,236	48.5 (17.8, 105.4)	6	1,374	43.7 (16.0, 94.8)
		Total	33	3,539	93.2 (64.3, 130.7)	2.10 (1.42, 3.10)	11	1,622	67.8 (33.9, 121.0)	1.59 (0.85, 2.96)	103	23,143	44.5 (36.3, 54.0)	92	21,521	42.7 (34.5, 52.4)	136	26,682	51.0 (42.8, 60.3)
	Subsequent	BSWN	79	15,174	52.1 (41.2, 64.8)	1.74 (1.36, 2.22)	12	5,491	21.9 (1.3, 38.1)	0.72 (0.40, 1.28)	325	108,323	30.0 (26.8, 33.4)	313	102,832	30.4 (27.2, 34.0)	404	123,497	32.7 (29.6, 36.1)
		BSCM	31	8,975	34.5 (23.5, 49.0)	1.39 (0.95, 2.03)	43	15,186	28.3 (20.5, 38.1)	1.18 (0.84, 1.67)	176	70,716	24.9 (21.4, 28.8)	133	55,530	24.0 (20.1, 28.4)	207	79,691	26.0 (22.6, 29.8)
		BSAC	23	3,956	58.1 (36.9, 87.1)	2.09 (1.35, 3.23)	31	6,301	49.2 (33.5, 69.8)	1.96 (1.32, 2.90)	157	56,435	27.8 (23.6, 32.5)	126	50,134	25.1 (20.9, 29.9)	180	60,391	29.8 (25.6, 34.5)
		BSM	119	20,458	58.2 (48.2, 69.6)	1.89 (1.53, 2.33)	2	1,777	11.3 (1.4, 40.6)	0.36 (0.09, 1.45)	326	105,826	30.8 (27.6, 34.3)	324	104,049	31.1 (27.8, 34.7)	445	126,284	35.2 (32.0, 38.7)
		BSCC	56	16,636	33.7 (25.4, 43.7)	1.38 (1.03, 1.85)	1	1,473	6.8 (0.2, 37.8)	0.28 (0.04, 1.96)	224	91,897	24.4 (21.3, 27.8)	223	90,424	24.7 (21.5, 28.1)	280	108,533	25.8 (22.9, 29.0)
		BSC	34	7,939	42.8 (29.7, 59.8)	1.43 (1.00, 2.04)	8	4,164	19.2 (8.3, 37.8)	0.63 (0.31, 1.27)	242	80,608	30.0 (26.4, 34.0)	234	76,444	30.6 (26.8, 34.8)	276	88,547	31.2 (27.6, 35.1)
		BSSL	33	8,523	38.7 (26.7, 54.3)	1.32 (0.92, 1.87)	5	1,508	33.2 (10.8, 77.2)	1.13 (0.47, 2.72)	436	148,163	29.4 (26.7, 32.3)	431	146,655	29.4 (26.7, 32.3)	469	156,686	29.9 (27.3, 32.8)
		BSOS	11	3,540	31.1 (15.5, 55.5)	0.92 (0.50, 1.69)	3	458	65.5 (13.5, 190.2)	1.96 (0.63, 6.11)	188	55,801	33.7 (29.1, 38.9)	185	55,343	33.4 (28.8, 38.6)	199	59,341	33.5 (29.0, 38.5)
		Total	386	85,201	45.3 (40.9, 50.0)	1.57 (1.41, 1.75)	105	36,358	28.9 (23.6, 34.9)	1.00 (0.82, 1.22)	2,074	717,769	28.9 (27.7, 30.2)	1,969	681,411	28.9 (27.6, 30.2)	2,460	802,970	30.6 (29.4, 31.9)
45 to 69	Initial	BSWN	9	2,936	30.7 (14.0, 58.1)	1.07 (0.53, 2.16)	2	1,019	19.6 (2.4, 70.7)	0.70 (0.16, 2.75)	54	18,796	28.7 (21.6, 37.5)	52	17,677	29.3 (21.9, 38.3)	63	21,732	29.0 (22.3, 37.1)
		BSCM	5	2,020	24.8 (8.0, 57.7)	1.71 (0.64, 4.57)	9	3,390	26.5 (12.1, 50.3)	2.58 (1.05, 6.34)	19	13,103	14.5 (8.7, 22.6)	10	9,713	10.3 (4.9, 18.9)	24	15,123	15.9 (10.2, 23.6)
		BSAC	3	933	32.2 (6.6, 93.7)	1.25 (0.38, 4.09)	3	1,181	25.4 (5.2, 74.1)	0.98 (0.30, 3.25)	28	10,844	25.8 (17.2, 37.3)	25	9,663	25.9 (16.7, 38.2)	31	11,777	26.3 (17.9, 37.3)
		BSM	20	4,177	47.9 (29.3, 73.9)	1.78 (1.04, 3.02)	3	422	71.1 (14.7, 206.3)	2.76 (0.86, 8.91)	15	15,585	26.9 (19.4, 36.4)	39	15,163	25.7 (18.3, 35.1)	62	19,762	31.4 (24.1, 40.2)
		BSCC	15	3,089	48.6 (27.2, 80.0)	2.08 (1.11, 3.90)	1	308	32.5 (0.8, 179.6)	1.40 (0.19, 10.31)	27	11,548	23.4 (15.4, 34.0)	26	11,240	23.1 (15.1, 33.9)	42	14,637	28.7 (20.7, 38.8)
		BSC	6	1,362	44.1 (16.2, 95.6)	1.78 (0.73, 4.33)	5	714	10.0 (2.8, 162.7)	3.29 (1.24, 8.73)	25	10,100	24.8 (16.0, 36.5)	20	9,386	21.3 (13.0, 32.9)	31	11,462	27.0 (18.4, 38.4)
		BSSL	3	1,455	20.6 (4.3, 60.1)	0.76 (0.24, 2.41)	2	382	52.4 (6.3, 187.8)	1.96 (0.48, 7.99)	55	20,169	27.3 (20.5, 35.5)	53	19,787	26.8 (20.1, 35.0)	58	21,624	26.8 (20.4, 34.7)
		BSOS	2	616	32.5 (3.9, 116.8)	1.38 (0.32,													

3.d.t, Nodal involvement, women screened during the 4 years to December 2020

Table 27: 3.d.t, Nodal involvement, women screened during the 4 years to December 2020

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Māori / Non-Māori Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)
45 to 49	Initial	BSWN	8	11	72.7 (39.0, 94.0)	1.21 (0.80, 1.84)	3	5	60.0 (14.7, 94.7)	1.00 (0.47, 2.11)	36	60	60.0 (46.5, 72.4)	33	55	60.0 (45.9, 73.0)	44	71	62.0 (49.7, 73.2)
		BSCM	5	9	55.6 (21.2, 86.3)	0.74 (0.40, 1.35)	12	16	75.0 (47.6, 92.7)	0.99 (0.69, 1.41)	31	41	75.6 (59.7, 87.6)	19	25	76.0 (54.9, 90.6)	36	50	72.0 (57.5, 83.8)
		BSAC	3	4	75.0 (19.4, 99.4)	1.13 (0.60, 2.09)	4	5	80.0 (28.4, 99.5)	1.25 (0.74, 2.12)	20	30	66.7 (47.2, 82.7)	16	25	64.0 (42.5, 82.0)	23	34	67.6 (49.5, 82.6)
		BSM	7	13	53.8 (25.1, 80.8)	0.80 (0.46, 1.38)	1	1	100.0 (2.5, 100.0)	1.50 (1.19, 1.89)	25	37	67.6 (50.2, 82.0)	24	36	66.7 (49.0, 81.4)	32	50	64.0 (49.2, 77.1)
		BSCC	10	17	58.8 (32.9, 81.6)	0.95 (0.59, 1.51)	2	3	66.7 (9.4, 99.2)	1.08 (0.47, 2.51)	23	37	62.2 (44.8, 77.5)	21	34	61.8 (43.6, 77.8)	33	54	61.1 (46.9, 74.1)
		BSC	6	9	66.7 (29.9, 92.5)	0.76 (0.47, 1.23)	2	2	100.0 (15.8, 100.0)	1.15 (0.98, 1.35)	22	25	88.0 (68.8, 97.5)	20	23	87.0 (66.4, 97.2)	28	34	82.4 (65.5, 93.2)
		BSSL	1	3	33.3 (0.8, 90.6)	0.50 (0.10, 2.48)	0	2	0.0 (0.0, 94.2)	0.00 (0.00, 2.78)	45	67	67.2 (54.6, 78.2)	45	65	69.2 (56.6, 80.1)	46	70	65.7 (53.4, 76.7)
		BSOS	2	3	66.7 (9.4, 99.2)	0.86 (0.37, 1.98)	1	1	100.0 (2.5, 100.0)	1.31 (1.00, 1.70)	14	18	77.8 (52.4, 93.6)	13	17	76.5 (50.1, 93.2)	16	21	76.2 (52.8, 91.8)
		Total	42	69	60.9 (48.4, 72.4)	0.89 (0.72, 1.09)	25	35	71.4 (53.7, 85.4)	1.05 (0.84, 1.31)	216	315	68.6 (63.1, 73.7)	191	280	68.2 (62.4, 73.6)	258	384	67.2 (62.2, 71.9)
		Subsequent	BSWN	11	13	84.6 (54.6, 98.1)	1.28 (0.95, 1.73)	1	1	100.0 (2.5, 100.0)	1.53 (1.25, 1.86)	35	53	66.0 (51.7, 78.5)	34	52	65.4 (50.9, 78.0)	46	66
	BSCM		3	6	50.0 (11.8, 88.2)	0.76 (0.33, 1.75)	3	9	33.3 (7.5, 70.1)	0.43 (0.17, 1.12)	23	35	65.7 (47.8, 80.9)	20	26	76.9 (56.4, 91.0)	26	41	63.4 (46.9, 77.9)
	BSAC		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 4.75)	5	6	83.3 (35.9, 99.6)	0.98 (0.66, 1.47)	22	26	84.6 (65.1, 95.6)	17	20	85.0 (62.1, 96.8)	22	27	81.5 (61.9, 93.7)
	BSM		7	10	70.0 (34.8, 93.3)	0.86 (0.56, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	31	38	81.6 (65.7, 92.3)	31	38	81.6 (65.7, 92.3)	38	48	79.2 (65.0, 89.5)
	BSCC		3	8	37.5 (8.5, 75.5)	0.44 (0.18, 1.09)	2	2	100.0 (15.8, 100.0)	1.19 (1.02, 1.39)	28	33	84.8 (68.1, 94.9)	26	31	83.9 (66.3, 94.5)	31	41	75.6 (59.7, 87.6)
	BSC		5	10	50.0 (18.7, 81.3)	0.70 (0.36, 1.38)	2	2	100.0 (15.8, 100.0)	1.46 (1.08, 1.98)	15	21	71.4 (47.8, 88.7)	13	19	68.4 (43.4, 87.4)	20	31	64.5 (45.4, 80.8)
	BSSL		6	7	85.7 (42.1, 99.6)	1.08 (0.78, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	55	69	79.7 (68.3, 88.4)	55	69	79.7 (68.3, 88.4)	61	76	80.3 (69.5, 88.5)
	BSOS		1	1	100.0 (2.5, 100.0)	1.28 (1.03, 1.58)	0	0	NA (NA, NA)	NA (NA, NA)	18	23	78.3 (56.3, 92.5)	18	23	78.3 (56.3, 92.5)	19	24	79.2 (57.8, 92.9)
	Total		36	56	64.3 (50.4, 76.6)	0.84 (0.69, 1.04)	13	20	65.0 (40.8, 84.6)	0.84 (0.61, 1.17)	227	298	76.2 (70.9, 80.9)	214	278	77.0 (71.6, 81.8)	263	354	74.3 (69.4, 78.8)
	50 to 69		Initial	BSWN	12	15	80.0 (51.9, 95.7)	1.08 (0.79, 1.48)	1	1	100.0 (2.5, 100.0)	1.37 (1.14, 1.65)	31	42	73.8 (58.0, 86.1)	30	41	73.2 (57.1, 85.8)	43
BSCM		3		4	75.0 (19.4, 99.4)	1.22 (0.65, 2.30)	5	8	62.5 (24.5, 91.5)	1.03 (0.55, 1.93)	19	31	61.3 (42.2, 78.2)	14	23	60.9 (38.5, 80.3)	22	35	62.9 (44.9, 78.5)
BSAC		0		0	NA (NA, NA)	NA (NA, NA)	1	3	33.3 (0.8, 90.6)	0.67 (0.13, 3.53)	10	21	47.6 (25.7, 70.2)	9	18	50.0 (26.0, 74.0)	10	21	47.6 (25.7, 70.2)
BSM		18		22	81.8 (59.7, 94.8)	1.13 (0.85, 1.50)	3	4	75.0 (19.4, 99.4)	1.04 (0.57, 1.91)	26	36	72.2 (54.8, 85.8)	23	32	71.9 (53.3, 86.3)	44	58	75.9 (62.8, 86.1)
BSCC		15		19	78.9 (54.4, 93.9)	1.05 (0.75, 1.48)	0	0	NA (NA, NA)	NA (NA, NA)	15	20	75.0 (50.9, 91.3)	15	20	75.0 (50.9, 91.3)	30	39	76.9 (60.7, 88.9)
BSC		4		5	80.0 (28.4, 99.5)	0.97 (0.60, 1.56)	3	6	50.0 (11.8, 88.2)	0.53 (0.24, 1.19)	19	23	82.6 (61.2, 95.0)	16	17	94.1 (71.3, 99.9)	23	28	82.1 (63.1, 93.9)
BSSL		2		3	66.7 (9.4, 99.2)	0.70 (0.31, 1.57)	1	1	100.0 (2.5, 100.0)	1.06 (0.95, 1.17)	19	20	95.0 (75.1, 99.9)	18	19	94.7 (74.0, 99.9)	21	23	91.3 (72.0, 98.9)
BSOS		0		1	0.0 (0.0, 97.5)	0.00 (0.00, 7.63)	0	0	NA (NA, NA)	NA (NA, NA)	7	11	63.6 (30.8, 89.1)	7	11	63.6 (30.8, 89.1)	7	12	58.3 (27.7, 84.8)
Total		54		69	78.3 (66.7, 87.3)	1.09 (0.94, 1.27)	14	23	60.9 (38.5, 80.3)	0.84 (0.59, 1.17)	146	204	71.6 (64.8, 77.6)	132	181	72.9 (65.8, 79.3)	200	273	73.3 (67.6, 78.4)
Subsequent		BSWN		101	125	80.8 (72.8, 87.3)	0.97 (0.88, 1.07)	22	33	66.7 (48.2, 82.0)	0.79 (0.62, 1.01)	412	495	83.2 (79.6, 86.4)	390	462	84.4 (80.8, 87.6)	513	620
		BSCM	50	64	78.1 (66.0, 87.5)	0.97 (0.84, 1.11)	63	79	79.7 (69.2, 88.0)	0.98 (0.86, 1.12)	248	307	80.8 (75.9, 85.0)	185	228	81.1 (75.4, 86.0)	298	371	80.3 (75.9, 84.2)
		BSAC	29	34	85.3 (68.9, 95.0)	1.11 (0.95, 1.29)	39	46	84.8 (71.1, 93.7)	1.13 (0.97, 1.30)	188	244	77.0 (71.3, 82.2)	147	248	75.3 (68.6, 81.1)	217	278	78.1 (72.7, 82.8)
		BSM	128	179	71.5 (64.3, 78.0)	0.88 (0.80, 0.98)	3	6	50.0 (11.8, 88.2)	0.62 (0.28, 1.37)	399	493	80.9 (77.2, 84.3)	396	487	81.3 (77.6, 84.7)	527	672	78.4 (75.1, 81.5)
		BSCC	77	114	67.5 (58.1, 76.0)	0.87 (0.76, 1.00)	5	10	50.0 (18.7, 81.3)	0.64 (0.34, 1.19)	319	411	77.6 (73.3, 81.6)	314	401	78.3 (73.9, 82.2)	396	525	75.4 (71.5, 79.1)
		BSC	46	58	79.3 (66.6, 88.8)	0.97 (0.84, 1.11)	19	24	79.2 (57.8, 92.9)	0.97 (0.78, 1.19)	323	395	81.8 (77.6, 85.5)	304	371	81.9 (77.6, 85.7)	369	453	81.5 (77.6, 84.9)
		BSSL	52	61	85.2 (73.8, 93.0)	1.04 (0.93, 1.16)	6	6	100.0 (54.1, 100.0)	1.22 (1.18, 1.26)	539	656	82.2 (79.0, 85.0)	533	650	82.0 (78.8, 84.9)	591	717	82.4 (79.4, 85.1)
		BSOS	18	19	94.7 (74.0, 99.9)	1.21 (1.07, 1.36)	5	6	83.3 (35.9, 99.6)	1.06 (0.74, 1.53)	227	289	78.5 (73.4, 83.1)	222	283	78.4 (73.2, 83.1)	245	308	79.5 (74.6, 83.9)
		Total	501	654	76.6 (73.2, 79.8)	0.95 (0.91, 0.99)	162	210	77.1 (70.9, 82.6)	0.95 (0.88, 1.03)	2,655	3,290	80.7 (79.3, 82.0)	2,493	3,080	80.9 (79.5, 82.3)	3,156	3,944	80.0 (78.7, 81.3)
		45 to 69	Initial	BSWN	20	26	76.9 (56.4, 91.0)	1.17 (0.91, 1.51)	4	6	66.7 (22.3, 95.7)	1.02 (0.57, 1.82)	67	102	65.7 (55.6, 74.8)	63	96	65.6 (55.2, 75.0)	87
BSCM	8			13	61.5 (31.6, 86.1)	0.89 (0.56, 1.40)	17	24	70.8 (48.9, 87.4)	1.03 (0.75, 1.42)	50	72	69.4 (57.5, 79.8)	33	48	68.8 (53.7, 81.3)	58	85	68.2 (57.2, 77.9)
BSAC	3			4	75.0 (19.4, 99.4)	1.28 (0.69, 2.35)	5	8	62.5 (24.5, 91.5)	1.08 (0.59, 1.95)	30	51	58.8 (44.2, 72.4)	25	43	58.1 (42.1, 73.0)	33	55	60.0 (45.9, 73.0)
BSM	25			35	71.4 (53.7, 85.4)	1.02 (0.79, 1.32)	4	5	80.0 (28.4, 99.5)	1.16 (0.73, 1.84)	51	73	69.9 (58.0, 80.1)	47	68	69.1 (56.7, 79.8)	76	108	70.4 (60.8, 78.0)
BSCC	25			36	69.4 (51.9, 83.7)	1.04 (0.78, 1.38)	2	3	66.7 (9.4, 99.2)	1.00 (0.44, 2.27)	38	57	66.7 (52.9, 78.6)	36	54	66.7 (52.5, 78.9)	63	93	67.7 (57.3, 77.1)
BSC	10			14	71.4 (41.9, 91.6)	0.84 (0.59, 1.19)	5	8	62.5 (24.5, 91.5)	0.69 (0.40, 1.20)	41	48	85.4 (72.2, 93.9)	36	40	90.0 (76.3, 97.2)	51	62	82.3 (70.5, 90.8)
BSSL	3			6	50.0 (11.8, 88.2)	0.68 (0.30, 1.53)	1	3	33.3 (0.8, 90.6)	0.44 (0.09, 2.21)	64	87	73.6 (63.0, 82.4)	63	84	75.0 (64.4, 83.8)	67	93	72.0 (61.8, 80.9)
BSOS	2			4	50.0 (6.8, 93.2)	0.69 (0.25, 1.89)	1	1	100.0 (2.5, 100.0)	1.40 (1.11, 1.77)	21	29	72.4 (52.8, 87.3)	20	28	71.4 (51.3, 86.8)	23	33	69.7 (51.3, 84.4)
Total	96			138	69.6 (61.2, 77.1)	1.00 (0.88, 1.13)	39	58	67.2 (53.7, 79.0)	0.96 (0.79, 1.16)	362	519	69.7 (65.6, 73.7)	323	461	70.1 (65.7, 74.2)	458	657	69.7 (66.0, 73.2)
Subsequent	BSWN			112	138	81.2 (73.6, 87.3)	1.00 (0.91, 1.09)	23	34	67.6 (49.5, 82.6)	0.82 (0.65, 1.04)	447	548	81.6 (78.1, 84.7)	424	514	82.5 (78.9, 85.7)	559	686
	BSCM		53	70	75.7 (64.0, 85.2)	0.96 (0.83, 1.10)	66	88	75.0 (64.6, 83.6)	0.93 (0.81, 1.06)	211	342	79.2 (74.5, 83.4)	205	254	80.7 (75.3, 85.4)	324	412	78.6 (74.4, 82.5)
	BSAC		29	35	82.9 (66.4, 93.4)	1.07 (0.91, 1.25)	44	52	84.6 (71.9, 93.1)	1.11 (0.97, 1.27)	210	270	77.8 (7						

3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2020

Table 28: 3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2020


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Māori / Non-Māori Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)
45 to 49	BSWN	6	27	22.2 (8.6, 42.3)	0.81 (0.38, 1.71)	2	8	25.0 (3.2, 65.1)	0.90 (0.26, 3.08)	40	145	27.6 (20.5, 35.6)	38	137	27.7 (20.4, 36.0)	46	172	26.7 (20.3, 34.0)	
	BSCM	2	14	14.3 (1.8, 42.8)	0.45 (0.12, 1.67)	8	32	25.0 (11.5, 43.4)	0.72 (0.37, 1.42)	34	107	31.8 (23.1, 41.5)	26	75	34.7 (24.0, 46.5)	36	121	29.8 (21.8, 38.7)	
	BSAC	3	7	42.9 (9.9, 81.6)	1.10 (0.45, 2.69)	2	12	16.7 (2.1, 48.4)	0.39 (0.11, 1.43)	35	90	38.9 (28.8, 49.7)	33	78	42.3 (31.2, 54.0)	38	97	39.2 (29.4, 49.6)	
	BSM	11	33	33.3 (18.0, 51.8)	1.19 (0.67, 2.13)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 14.02)	26	93	28.0 (19.1, 38.2)	26	92	28.3 (19.4, 38.6)	37	126	29.4 (21.6, 38.1)	
	BSCC	4	27	14.8 (4.2, 33.7)	0.64 (0.24, 1.69)	1	6	16.7 (0.4, 64.1)	0.70 (0.11, 4.36)	21	90	23.3 (15.1, 33.4)	20	84	23.8 (15.2, 34.3)	25	117	21.4 (14.3, 29.9)	
	BSC	1	17	5.9 (0.1, 28.7)	0.18 (0.03, 1.23)	1	6	16.7 (0.4, 64.1)	0.49 (0.08, 3.00)	24	73	32.9 (22.3, 44.9)	23	67	34.3 (23.2, 46.9)	25	90	27.8 (18.9, 38.2)	
	BSSL	6	15	40.0 (16.3, 67.7)	1.13 (0.59, 2.16)	0	2	0.0 (0.0, 84.2)	0.00 (0.00, 5.30)	69	195	35.4 (28.7, 42.5)	69	193	35.8 (29.0, 43.0)	75	210	35.7 (29.2, 42.6)	
	BSOS	4	7	57.1 (18.4, 90.1)	1.39 (0.68, 2.81)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 9.45)	26	63	41.3 (29.0, 54.4)	26	62	41.9 (29.5, 55.2)	30	70	42.9 (31.1, 55.3)	
	Total	37	147	25.2 (18.4, 33.0)	0.78 (0.58, 1.05)	14	68	20.6 (11.7, 32.1)	0.62 (0.39, 1.00)	275	856	32.1 (29.0, 35.4)	261	788	33.1 (29.8, 36.5)	312	1,003	31.1 (28.3, 34.1)	
50 to 69	BSWN	24	153	15.7 (10.3, 22.4)	0.63 (0.43, 0.93)	14	42	33.3 (19.6, 49.5)	1.38 (0.88, 2.16)	156	628	24.8 (21.5, 28.4)	142	586	24.2 (20.8, 27.9)	180	781	23.0 (20.1, 26.2)	
	BSCM	22	86	25.6 (16.8, 36.1)	1.01 (0.68, 1.50)	24	103	23.3 (15.5, 32.7)	0.90 (0.60, 1.33)	105	415	25.3 (21.2, 29.8)	81	312	26.0 (21.2, 31.2)	127	501	25.3 (21.6, 29.4)	
	BSAC	8	38	21.1 (9.6, 37.3)	0.76 (0.40, 1.43)	11	56	19.6 (10.2, 32.4)	0.67 (0.38, 1.17)	97	349	27.8 (23.2, 32.8)	86	293	29.4 (24.2, 34.9)	105	387	27.1 (22.8, 31.9)	
	BSM	37	230	16.1 (11.6, 21.5)	0.77 (0.55, 1.07)	5	15	33.3 (11.8, 61.6)	1.62 (0.78, 3.37)	130	623	20.9 (17.7, 24.3)	125	608	20.6 (17.4, 24.0)	167	853	19.6 (17.0, 22.4)	
	BSCC	16	142	11.3 (6.6, 17.7)	0.55 (0.34, 0.91)	1	10	10.0 (0.3, 44.5)	0.49 (0.07, 3.15)	101	497	20.3 (16.9, 24.1)	100	487	20.5 (17.0, 24.4)	117	639	18.3 (15.4, 21.5)	
	BSC	5	65	7.7 (2.5, 17.0)	0.37 (0.15, 0.87)	4	34	11.8 (3.3, 27.5)	0.54 (0.21, 1.39)	105	501	21.0 (17.5, 24.8)	101	467	21.6 (18.0, 25.6)	110	566	19.4 (16.3, 22.9)	
	BSSL	9	65	13.8 (6.5, 24.7)	0.53 (0.29, 0.98)	5	12	41.7 (15.2, 72.3)	1.61 (0.82, 3.18)	221	847	26.1 (23.2, 29.2)	216	835	25.9 (22.9, 29.0)	230	912	25.2 (22.4, 28.2)	
	BSOS	8	26	30.8 (14.3, 51.8)	1.39 (0.76, 2.55)	1	7	14.3 (0.4, 57.9)	0.64 (0.10, 3.97)	82	370	22.2 (18.0, 26.7)	81	363	22.3 (18.1, 27.0)	90	396	22.7 (18.7, 27.2)	
	Total	129	805	16.0 (13.6, 18.7)	0.68 (0.57, 0.80)	65	279	23.3 (18.5, 28.7)	0.99 (0.79, 1.23)	997	4,230	23.6 (22.3, 24.9)	932	3,951	23.6 (22.3, 24.9)	1,126	5,035	22.4 (21.2, 23.5)	
45 to 69	BSWN	30	180	16.7 (11.5, 22.9)	0.66 (0.46, 0.93)	16	50	32.0 (19.5, 46.7)	1.29 (0.84, 1.96)	196	773	25.4 (22.3, 28.6)	180	723	24.9 (21.8, 28.2)	226	953	23.7 (21.0, 26.5)	
	BSCM	24	100	24.0 (16.0, 33.6)	0.90 (0.62, 1.31)	32	135	23.7 (16.8, 31.8)	0.86 (0.61, 1.21)	139	522	26.6 (22.9, 30.6)	107	387	27.6 (23.2, 32.4)	163	622	26.2 (22.8, 29.8)	
	BSAC	11	45	24.4 (12.9, 39.5)	0.81 (0.48, 1.39)	13	68	19.1 (10.6, 30.5)	0.60 (0.36, 0.99)	132	439	30.1 (25.8, 34.6)	119	371	32.1 (27.4, 37.1)	143	484	29.5 (25.5, 33.8)	
	BSM	48	263	18.3 (13.8, 23.5)	0.84 (0.63, 1.12)	5	16	31.3 (11.0, 58.7)	1.45 (0.69, 3.04)	156	716	21.8 (18.8, 25.0)	151	700	21.6 (18.6, 24.8)	204	979	20.8 (18.3, 23.5)	
	BSCC	20	169	11.8 (7.4, 17.7)	0.57 (0.37, 0.89)	2	16	12.5 (1.6, 38.3)	0.60 (0.16, 2.20)	122	587	20.8 (17.6, 24.3)	120	571	21.0 (17.7, 24.6)	142	756	18.8 (16.1, 21.8)	
	BSC	6	82	7.3 (2.7, 15.2)	0.33 (0.15, 0.71)	5	40	12.5 (4.2, 26.8)	0.54 (0.23, 1.24)	129	574	22.5 (19.1, 26.1)	124	534	23.2 (19.7, 27.0)	135	656	20.6 (17.5, 23.9)	
	BSSL	15	80	18.8 (10.9, 29.0)	0.67 (0.42, 1.07)	5	14	35.7 (12.8, 64.9)	1.29 (0.63, 2.62)	290	1,042	27.8 (25.1, 30.7)	285	1,028	27.7 (25.0, 30.6)	305	1,122	27.2 (24.6, 29.9)	
	BSOS	12	33	36.4 (20.4, 54.9)	1.46 (0.90, 2.36)	1	8	12.5 (0.3, 52.7)	0.50 (0.08, 3.13)	108	433	24.9 (20.9, 29.3)	107	425	25.2 (21.1, 29.6)	120	466	25.8 (21.8, 30.0)	
	Total	166	952	17.4 (15.1, 20.0)	0.70 (0.60, 0.81)	79	347	22.8 (18.5, 27.5)	0.90 (0.74, 1.10)	1,272	5,086	25.0 (23.8, 26.2)	1,193	4,739	25.2 (23.9, 26.4)	1,438	6,038	23.8 (22.7, 24.9)	

4.a.1.t, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to December 2020


Description: The proportion of women with invasive breast cancers less than or equal to 30mm who have sentinel node biopsy as their first axillary procedure. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 85: 4.a.1.t, 45 to 49 and 50 to 69, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020



45 to 49 years



50 to 69 years

Among women aged 45–69 years whose invasive breast cancer was detected during the four years to 30 June 2020, 84% had a sentinel node biopsy as their first axillary procedure. For Māori and Pacific women, the proportions were 80% each, with 85% for non-Māori non-Pacific women.

(Note the trend graphs above and below present data for 2-year time periods to 31 December 2020, while the table presents data for a 4-year period to 31 December 2020).

Figure 86: 4.a.1.t, 50 to 69, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020, by LP



Table 29: 4.a.1.t, Women with invasive breast cancers ≤30mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2020


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Māori / Non-Māori Ratio	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Pacific / Non-Pacific Ratio	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure
45 to 49	BSWN	16	20	80.0 (56.3, 94.3)	1.06 (0.83, 1.36)	5	5	100.0 (47.8, 100.0)	1.35 (1.20, 1.52)	74	98	75.5 (65.8, 83.6)	69	93	74.2 (64.1, 82.7)	90	118	76.3 (67.6, 83.6)
	BSCM	9	11	81.8 (48.2, 97.7)	1.08 (0.79, 1.48)	12	19	63.2 (38.4, 83.7)	0.77 (0.53, 1.12)	44	58	75.9 (62.8, 86.1)	32	39	82.1 (66.5, 92.5)	53	69	76.8 (65.1, 86.1)
	BSAC	4	4	100.0 (39.8, 100.0)	1.19 (1.05, 1.34)	8	9	88.9 (51.8, 99.7)	1.07 (0.82, 1.40)	42	50	84.0 (70.9, 92.8)	34	41	82.9 (67.9, 92.8)	46	54	85.2 (72.9, 93.4)
	BSM	14	21	66.7 (43.0, 85.4)	0.80 (0.58, 1.09)	0	0	NA (NA, NA)	NA (NA, NA)	57	68	83.8 (72.9, 91.6)	57	68	83.8 (72.9, 91.6)	71	89	79.8 (69.9, 87.6)
	BSCC	13	19	68.4 (43.4, 87.4)	0.79 (0.57, 1.09)	3	4	75.0 (19.4, 99.4)	0.86 (0.48, 1.52)	52	60	86.7 (75.4, 94.1)	49	56	87.5 (75.9, 94.8)	65	79	82.3 (72.1, 90.0)
	BSC	12	15	80.0 (51.9, 95.7)	0.80 (0.62, 1.03)	3	3	100.0 (29.2, 100.0)	1.00 (1.00, 1.00)	35	35	100.0 (90.0, 100.0)	32	32	100.0 (89.1, 100.0)	47	50	94.0 (83.5, 98.7)
	BSSL	4	7	57.1 (18.4, 90.1)	0.73 (0.38, 1.40)	1	2	50.0 (1.3, 98.7)	0.64 (0.16, 2.55)	96	123	78.0 (69.7, 85.0)	95	121	78.5 (70.1, 85.5)	100	130	76.9 (68.7, 83.9)
	BSOS	3	3	100.0 (29.2, 100.0)	1.35 (1.11, 1.64)	1	1	100.0 (2.5, 100.0)	1.36 (1.11, 1.66)	26	35	74.3 (56.7, 87.5)	25	34	73.5 (55.6, 87.1)	29	38	76.3 (59.8, 88.6)
	Total	75	100	75.0 (65.3, 83.1)	0.93 (0.82, 1.05)	33	43	76.7 (61.4, 88.2)	0.95 (0.80, 1.12)	426	527	80.8 (77.2, 84.1)	393	484	81.2 (77.4, 84.6)	501	627	79.9 (76.6, 83.0)
50 to 69	BSWN	92	128	71.9 (63.2, 79.5)	0.89 (0.79, 0.99)	24	29	82.8 (64.2, 94.2)	1.02 (0.86, 1.21)	405	499	81.2 (77.5, 84.5)	381	470	81.1 (77.2, 84.5)	497	627	79.3 (75.9, 82.4)
	BSCM	49	64	76.6 (64.3, 86.2)	0.95 (0.82, 1.10)	58	74	78.4 (67.3, 87.1)	0.96 (0.84, 1.10)	241	298	80.9 (75.9, 85.2)	183	224	81.7 (76.0, 86.5)	290	362	80.1 (75.6, 84.1)
	BSAC	27	31	87.1 (70.2, 96.4)	1.01 (0.87, 1.16)	39	44	88.6 (75.4, 96.2)	1.03 (0.91, 1.16)	214	247	86.6 (81.8, 90.6)	175	203	86.2 (80.7, 90.6)	241	278	86.7 (82.1, 90.5)
	BSM	155	185	83.8 (77.7, 88.8)	0.98 (0.91, 1.05)	5	10	50.0 (18.7, 81.3)	0.58 (0.31, 1.07)	428	498	85.9 (82.6, 88.9)	423	488	86.7 (83.3, 89.6)	583	683	85.4 (82.5, 87.9)
	BSCC	83	113	73.5 (64.3, 81.3)	0.85 (0.76, 0.96)	5	8	62.5 (24.5, 91.5)	0.72 (0.42, 1.23)	325	376	86.4 (82.6, 89.7)	320	368	87.0 (83.1, 90.2)	408	489	83.4 (79.8, 86.6)
	BSC	53	58	91.4 (81.0, 97.1)	1.03 (0.94, 1.12)	24	26	92.3 (74.9, 99.1)	1.04 (0.93, 1.17)	341	383	89.0 (85.5, 92.0)	317	357	88.8 (85.1, 91.9)	394	441	89.3 (86.1, 92.1)
	BSSL	53	57	93.0 (83.0, 98.1)	1.10 (1.02, 1.19)	6	7	85.7 (42.1, 99.6)	1.02 (0.75, 1.38)	530	628	84.4 (81.3, 87.1)	524	621	84.4 (81.3, 87.1)	583	685	85.1 (82.2, 87.7)
	BSOS	14	17	82.4 (56.6, 96.2)	0.95 (0.76, 1.20)	4	6	66.7 (22.3, 95.7)	0.77 (0.44, 1.36)	239	277	86.3 (81.7, 90.1)	235	271	86.7 (82.1, 90.5)	253	294	86.1 (81.6, 89.8)
	Total	526	653	80.6 (77.3, 83.5)	0.95 (0.91, 0.99)	165	204	80.9 (74.8, 86.0)	0.95 (0.89, 1.02)	2,723	3,206	84.9 (83.6, 86.2)	2,558	3,002	85.2 (83.9, 86.5)	3,249	3,859	84.2 (83.0, 85.3)
45 to 69	BSWN	108	148	73.0 (65.1, 79.9)	0.91 (0.82, 1.01)	29	34	85.3 (68.9, 95.0)	1.07 (0.92, 1.23)	479	597	80.2 (76.8, 83.4)	450	563	79.9 (76.4, 83.2)	587	745	78.8 (75.7, 81.7)
	BSCM	58	75	77.3 (66.2, 86.2)	0.97 (0.85, 1.10)	70	93	75.3 (65.2, 83.6)	0.92 (0.81, 1.05)	285	356	80.1 (75.5, 84.1)	215	263	81.7 (76.5, 86.2)	343	431	79.6 (75.5, 83.3)
	BSAC	31	35	88.6 (73.3, 96.8)	1.03 (0.91, 1.17)	47	53	88.7 (77.0, 95.7)	1.04 (0.93, 1.16)	256	297	86.2 (81.7, 89.9)	209	244	85.7 (80.6, 89.8)	287	332	86.4 (82.3, 89.9)
	BSM	169	206	82.0 (76.1, 87.0)	0.96 (0.89, 1.03)	5	10	50.0 (18.7, 81.3)	0.58 (0.31, 1.08)	485	566	85.7 (82.5, 88.5)	480	556	86.3 (83.2, 89.1)	654	772	84.7 (82.0, 87.2)
	BSCC	96	132	72.7 (64.3, 80.1)	0.84 (0.75, 0.94)	8	12	66.7 (34.9, 90.1)	0.77 (0.51, 1.15)	377	436	86.5 (82.9, 89.5)	369	424	87.0 (83.5, 90.1)	473	568	83.3 (79.9, 86.3)
	BSC	65	73	89.0 (79.5, 95.1)	0.99 (0.91, 1.08)	27	29	93.1 (77.2, 99.2)	1.04 (0.94, 1.15)	376	418	90.0 (86.7, 92.7)	349	389	89.7 (86.3, 92.6)	441	491	89.8 (86.8, 92.3)
	BSSL	57	64	89.1 (78.8, 95.5)	1.07 (0.97, 1.17)	7	9	77.8 (40.0, 97.2)	0.93 (0.66, 1.32)	626	751	83.4 (80.5, 86.0)	619	742	83.4 (80.5, 86.0)	683	815	83.8 (81.1, 86.3)
	BSOS	17	20	85.0 (62.1, 96.8)	1.00 (0.83, 1.21)	5	7	71.4 (29.0, 96.3)	0.84 (0.52, 1.34)	265	312	84.9 (80.5, 88.7)	260	305	85.2 (80.8, 89.0)	282	332	84.9 (80.6, 88.6)
	Total	601	753	79.8 (76.8, 82.6)	0.95 (0.91, 0.98)	198	247	80.2 (74.6, 84.9)	0.95 (0.89, 1.01)	3,149	3,733	84.4 (83.2, 85.5)	2,951	3,486	84.7 (83.4, 85.8)	3,750	4,486	83.6 (82.5, 84.7)

4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020

Description: The percentage of women with invasive cancer who have a single excisional breast treatment procedure. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 87: 4.b.t, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020



Among women aged 45–69 years whose invasive breast cancer was detected during the 4 years to December 2020, 86% had a single excisional breast treatment procedure, with little variation between LP regions, but slightly higher in BSWN (90%) and BSCM (92%).

Figure 88: 4.b.t, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020, by LP




Table 30: 4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2020


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Māori / Non-Māori Ratio	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)
45 to 49	BSWN	23	24	95.8 (78.9, 99.9)	1.17 (1.03, 1.31)	5	6	83.3 (35.9, 99.6)	1.02 (0.70, 1.47)	92	112	82.1 (73.8, 88.7)	87	106	82.1 (73.4, 88.8)	115	136	84.6 (77.4, 90.2)
	BSCM	14	15	93.3 (68.1, 99.8)	1.01 (0.87, 1.18)	21	24	87.5 (67.6, 97.3)	0.93 (0.79, 1.10)	69	75	92.0 (83.4, 97.0)	48	51	94.1 (83.8, 98.8)	83	90	92.2 (84.6, 96.8)
	BSAC	4	5	80.0 (28.4, 99.5)	0.88 (0.56, 1.38)	10	11	90.9 (58.7, 99.8)	1.00 (0.81, 1.24)	49	54	90.7 (79.7, 96.9)	39	43	90.7 (77.9, 97.4)	53	59	89.8 (79.2, 96.2)
	BSM	17	22	77.3 (54.6, 92.2)	0.97 (0.75, 1.25)	1	1	100.0 (2.5, 100.0)	1.26 (1.12, 1.42)	58	73	79.5 (68.4, 88.0)	57	72	79.2 (68.0, 87.8)	75	95	78.9 (69.4, 86.6)
	BSCC	20	25	80.0 (59.3, 93.2)	1.01 (0.80, 1.27)	4	4	100.0 (39.8, 100.0)	1.29 (1.13, 1.47)	53	67	79.1 (67.4, 88.1)	49	63	77.8 (65.5, 87.3)	73	92	79.3 (69.6, 87.1)
	BSC	15	19	78.9 (54.4, 93.9)	1.04 (0.78, 1.38)	4	4	100.0 (39.8, 100.0)	1.36 (1.13, 1.62)	35	46	76.1 (61.2, 87.4)	31	42	73.8 (58.0, 86.1)	50	65	76.9 (64.8, 86.5)
	BSSL	7	8	87.5 (47.3, 99.7)	1.03 (0.78, 1.35)	2	2	100.0 (15.8, 100.0)	1.18 (1.09, 1.27)	108	127	85.0 (77.6, 90.7)	106	125	84.8 (77.3, 90.6)	115	135	85.2 (78.1, 90.7)
	BSOS	3	4	75.0 (19.4, 99.4)	0.85 (0.48, 1.52)	1	1	100.0 (2.5, 100.0)	1.14 (1.02, 1.28)	36	41	87.8 (73.8, 95.9)	35	40	87.5 (73.2, 95.8)	39	45	86.7 (73.2, 94.9)
	Total	103	122	84.4 (76.8, 90.4)	1.01 (0.92, 1.09)	48	53	90.6 (79.3, 96.9)	1.09 (0.99, 1.19)	500	595	84.0 (80.8, 86.9)	452	542	83.4 (80.0, 86.4)	603	717	84.1 (81.2, 86.7)
50 to 69	BSWN	120	130	92.3 (86.3, 96.2)	1.02 (0.96, 1.08)	32	33	97.0 (84.2, 99.9)	1.07 (1.00, 1.15)	479	528	90.7 (87.9, 93.1)	447	495	90.3 (87.3, 92.8)	599	658	91.0 (88.6, 93.1)
	BSCM	57	64	89.1 (78.8, 95.5)	0.97 (0.88, 1.06)	73	82	89.0 (80.2, 94.9)	0.96 (0.88, 1.04)	297	323	92.0 (88.4, 94.7)	224	241	92.9 (88.9, 95.8)	354	387	91.5 (88.2, 94.1)
	BSAC	29	31	93.5 (78.6, 99.2)	1.09 (0.98, 1.21)	40	49	81.6 (68.0, 91.2)	0.94 (0.81, 1.08)	225	261	86.2 (81.4, 90.1)	185	212	87.3 (82.0, 91.4)	254	292	87.0 (82.6, 90.6)
	BSM	170	199	85.4 (79.7, 90.0)	1.06 (0.98, 1.14)	8	10	80.0 (44.4, 97.5)	0.99 (0.72, 1.35)	424	525	80.8 (77.1, 84.0)	416	515	80.8 (77.1, 84.1)	594	724	82.0 (79.1, 84.8)
	BSCC	111	130	85.4 (78.1, 91.0)	0.96 (0.89, 1.04)	8	10	80.0 (44.4, 97.5)	0.90 (0.66, 1.23)	374	422	88.6 (85.2, 91.5)	366	412	88.8 (85.4, 91.7)	485	552	87.9 (84.8, 90.5)
	BSC	47	61	77.0 (64.5, 86.8)	0.90 (0.78, 1.04)	24	29	82.8 (64.2, 94.2)	0.96 (0.81, 1.14)	352	411	85.6 (81.9, 88.9)	328	382	85.9 (82.0, 89.2)	399	472	84.5 (81.0, 87.7)
	BSSL	57	64	89.1 (78.8, 95.5)	1.05 (0.95, 1.15)	7	7	100.0 (59.0, 100.0)	1.18 (1.14, 1.22)	556	653	85.1 (82.2, 87.8)	549	646	85.0 (82.0, 87.7)	613	717	85.5 (82.7, 88.0)
	BSOS	15	20	75.0 (50.9, 91.3)	0.87 (0.67, 1.12)	6	6	100.0 (54.1, 100.0)	1.16 (1.11, 1.21)	260	300	86.7 (82.3, 90.3)	254	294	86.4 (81.9, 90.1)	275	320	85.9 (81.6, 89.6)
	Total	606	699	86.7 (84.0, 89.1)	1.00 (0.97, 1.03)	198	226	87.6 (82.6, 91.6)	1.01 (0.96, 1.06)	2,967	3,423	86.7 (85.5, 87.8)	2,769	3,197	86.6 (85.4, 87.8)	3,573	4,122	86.7 (85.6, 87.7)
45 to 69	BSWN	143	154	92.9 (87.6, 96.4)	1.04 (0.99, 1.10)	37	39	94.9 (82.7, 99.4)	1.07 (0.99, 1.16)	571	640	89.2 (86.6, 91.5)	534	601	88.9 (86.1, 91.3)	714	794	89.9 (87.6, 91.9)
	BSCM	71	79	89.9 (81.0, 95.5)	0.98 (0.90, 1.06)	94	106	88.7 (81.1, 94.0)	0.95 (0.88, 1.03)	366	398	92.0 (88.8, 94.4)	272	292	93.2 (89.6, 95.8)	437	477	91.6 (88.8, 93.9)
	BSAC	33	36	91.7 (77.5, 98.2)	1.05 (0.95, 1.17)	50	60	83.3 (71.5, 91.7)	0.95 (0.84, 1.07)	274	315	87.0 (82.8, 90.5)	224	255	87.8 (83.2, 91.6)	307	351	87.5 (83.5, 90.7)
	BSM	187	221	84.6 (79.2, 89.1)	1.05 (0.98, 1.12)	9	11	81.8 (48.2, 97.7)	1.02 (0.77, 1.34)	482	598	80.6 (77.2, 83.7)	473	587	80.6 (77.1, 83.7)	669	819	81.7 (78.9, 84.3)
	BSCC	131	155	84.5 (77.8, 89.8)	0.97 (0.90, 1.04)	12	14	85.7 (57.2, 98.2)	0.98 (0.79, 1.22)	427	489	87.3 (84.0, 90.1)	415	475	87.4 (84.0, 90.2)	558	644	86.6 (83.8, 89.2)
	BSC	62	80	77.5 (66.8, 86.1)	0.92 (0.81, 1.04)	28	33	84.8 (68.1, 94.9)	1.00 (0.86, 1.16)	387	457	84.7 (81.0, 87.9)	359	424	84.7 (80.9, 88.0)	449	537	83.6 (80.2, 86.6)
	BSSL	64	72	88.9 (79.3, 95.1)	1.04 (0.96, 1.14)	9	9	100.0 (66.4, 100.0)	1.18 (1.14, 1.21)	664	780	85.1 (82.4, 87.6)	655	771	85.0 (82.2, 87.4)	728	852	85.4 (82.9, 87.7)
	BSOS	18	24	75.0 (53.3, 90.2)	0.86 (0.68, 1.09)	7	7	100.0 (59.0, 100.0)	1.16 (1.11, 1.21)	296	341	86.8 (82.7, 90.2)	289	334	86.5 (82.4, 90.0)	314	365	86.0 (82.0, 89.4)
	Total	709	821	86.4 (83.8, 88.6)	1.00 (0.97, 1.03)	246	279	88.2 (83.8, 91.7)	1.02 (0.98, 1.07)	3,467	4,018	86.3 (85.2, 87.3)	3,221	3,739	86.1 (85.0, 87.2)	4,176	4,839	86.3 (85.3, 87.3)

4.e.t, DCIS having breast conserving surgery, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed with pure DCIS of pathological diameter $\leq 20\text{mm}$ who have breast conserving surgery (BCS). The 't' in the indicator id marks it as a treatment indicator.

Target: $>50\%$ of screen-detected DCIS $\leq 20\text{mm}$ are treated by BCS.

Figure 89: 4.e.t, 50 to 69, DCIS $\leq 20\text{mm}$ having breast conserving surgery, women screened during the 4 years to December 2020



The majority (87%) of women aged 45–69 years who were diagnosed with DCIS with a diameter 20mm or less had breast conserving surgery. The proportions were over 80% in most LPs apart from BSCM (70%).

Figure 90: 4.e.t, 50 to 69, DCIS ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020, by LP




Table 31: 4.e.t, DCIS ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	Māori / Non-Māori Ratio	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)
45 to 49	BSWN	1	1	100.0 (2.5, 100.0)	1.05 (0.95, 1.16)	1	1	100.0 (2.5, 100.0)	1.05 (0.95, 1.16)	20	21	95.2 (76.2, 99.9)	19	20	95.0 (75.1, 99.9)	21	22	95.5 (77.2, 99.9)
	BSCM	0	0	NA (NA, NA)	NA (NA, NA)	2	3	66.7 (9.4, 99.2)	0.82 (0.36, 1.89)	15	19	78.9 (54.4, 93.9)	13	16	81.3 (54.4, 96.0)	15	19	78.9 (54.4, 93.9)
	BSAC	1	1	100.0 (2.5, 100.0)	1.08 (0.93, 1.27)	0	0	NA (NA, NA)	NA (NA, NA)	12	13	92.3 (64.0, 99.8)	12	13	92.3 (64.0, 99.8)	13	14	92.9 (66.1, 99.8)
	BSM	5	5	100.0 (47.8, 100.0)	1.33 (1.00, 1.77)	0	0	NA (NA, NA)	NA (NA, NA)	12	16	75.0 (47.6, 92.7)	12	16	75.0 (47.6, 92.7)	17	21	81.0 (58.1, 94.6)
	BSCC	3	3	100.0 (29.2, 100.0)	1.15 (0.95, 1.41)	1	1	100.0 (2.5, 100.0)	1.17 (0.94, 1.45)	13	15	86.7 (59.5, 98.3)	12	14	85.7 (57.2, 98.2)	16	18	88.9 (65.3, 98.6)
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	10	10	100.0 (69.2, 100.0)	10	10	100.0 (69.2, 100.0)	10	10	100.0 (69.2, 100.0)
	BSSL	3	3	100.0 (29.2, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	30	30	100.0 (88.4, 100.0)	30	30	100.0 (88.4, 100.0)	33	33	100.0 (89.4, 100.0)
	BSOS	3	3	100.0 (29.2, 100.0)	1.10 (0.91, 1.33)	0	0	NA (NA, NA)	NA (NA, NA)	10	11	90.9 (58.7, 99.8)	10	11	90.9 (58.7, 99.8)	13	14	92.9 (66.1, 99.8)
	Total	16	16	100.0 (79.4, 100.0)	1.11 (1.05, 1.17)	4	5	80.0 (28.4, 99.5)	0.88 (0.57, 1.37)	122	135	90.4 (84.1, 94.8)	118	130	90.8 (84.4, 95.1)	138	151	91.4 (85.7, 95.3)
50 to 69	BSWN	15	17	88.2 (63.6, 98.5)	1.05 (0.86, 1.27)	7	7	100.0 (59.0, 100.0)	1.20 (1.09, 1.32)	81	96	84.4 (75.5, 91.0)	74	89	83.1 (73.7, 90.2)	96	113	85.0 (77.0, 91.0)
	BSCM	10	14	71.4 (41.9, 91.6)	1.02 (0.70, 1.48)	11	13	84.6 (54.6, 98.1)	1.28 (0.94, 1.76)	40	57	70.2 (56.6, 81.6)	29	44	65.9 (50.1, 79.5)	50	71	70.4 (58.4, 80.7)
	BSAC	3	4	75.0 (19.4, 99.4)	0.88 (0.49, 1.57)	4	5	80.0 (28.4, 99.5)	0.93 (0.59, 1.47)	35	41	85.4 (70.8, 94.4)	31	36	86.1 (70.5, 95.3)	38	45	84.4 (70.5, 93.5)
	BSM	18	19	94.7 (74.0, 99.9)	0.99 (0.88, 1.11)	1	1	100.0 (2.5, 100.0)	1.04 (0.99, 1.09)	72	75	96.0 (88.8, 99.2)	71	74	95.9 (88.6, 99.2)	90	94	95.7 (89.5, 98.8)
	BSCC	8	8	100.0 (63.1, 100.0)	1.30 (1.12, 1.51)	0	0	NA (NA, NA)	NA (NA, NA)	40	52	76.9 (63.2, 87.5)	40	52	76.9 (63.2, 87.5)	48	60	80.0 (67.7, 89.2)
	BSC	4	4	100.0 (39.8, 100.0)	1.07 (0.99, 1.16)	1	1	100.0 (2.5, 100.0)	1.07 (0.99, 1.16)	43	46	93.5 (82.1, 98.6)	42	45	93.3 (81.7, 98.6)	47	50	94.0 (83.5, 98.7)
	BSSL	6	6	100.0 (54.1, 100.0)	1.09 (1.03, 1.16)	3	3	100.0 (29.2, 100.0)	1.10 (1.04, 1.16)	106	116	91.4 (84.7, 95.8)	103	113	91.2 (84.3, 95.7)	112	122	91.8 (85.4, 96.0)
	BSOS	4	4	100.0 (39.8, 100.0)	1.19 (1.05, 1.36)	1	1	100.0 (2.5, 100.0)	1.20 (1.05, 1.37)	36	43	83.7 (69.3, 93.2)	35	42	83.3 (68.6, 93.0)	40	47	85.1 (71.7, 93.8)
	Total	68	76	89.5 (80.3, 95.3)	1.04 (0.95, 1.13)	28	31	90.3 (74.2, 98.0)	1.05 (0.93, 1.19)	453	526	86.1 (82.9, 89.0)	425	495	85.9 (82.5, 88.8)	521	602	86.5 (83.6, 89.2)
45 to 69	BSWN	16	18	88.9 (65.3, 98.6)	1.03 (0.86, 1.23)	8	8	100.0 (63.1, 100.0)	1.17 (1.08, 1.27)	101	117	86.3 (78.7, 92.0)	93	109	85.3 (77.3, 91.4)	117	135	86.7 (79.7, 91.9)
	BSCM	10	14	71.4 (41.9, 91.6)	0.99 (0.69, 1.41)	13	16	81.3 (54.4, 96.0)	1.16 (0.87, 1.55)	55	76	72.4 (60.9, 82.0)	42	60	70.0 (56.8, 81.2)	65	90	72.2 (61.8, 81.1)
	BSAC	4	5	80.0 (28.4, 99.5)	0.92 (0.59, 1.44)	4	5	80.0 (28.4, 99.5)	0.91 (0.58, 1.43)	47	54	87.0 (75.1, 94.6)	43	49	87.8 (75.2, 95.4)	51	59	86.4 (75.0, 94.0)
	BSM	23	24	95.8 (78.9, 99.9)	1.04 (0.94, 1.15)	1	1	100.0 (2.5, 100.0)	1.08 (1.02, 1.15)	84	91	92.3 (84.8, 96.9)	83	90	92.2 (84.6, 96.8)	107	115	93.0 (86.8, 96.9)
	BSCC	11	11	100.0 (71.5, 100.0)	1.26 (1.12, 1.43)	1	1	100.0 (2.5, 100.0)	1.27 (1.12, 1.44)	53	67	79.1 (67.4, 88.1)	52	66	78.8 (67.0, 87.9)	64	78	82.1 (71.7, 89.8)
	BSC	4	4	100.0 (39.8, 100.0)	1.06 (0.99, 1.12)	1	1	100.0 (2.5, 100.0)	1.06 (0.99, 1.13)	53	56	94.6 (85.1, 98.9)	52	55	94.5 (84.9, 98.9)	57	60	95.0 (86.1, 99.0)
	BSSL	9	9	100.0 (66.4, 100.0)	1.07 (1.03, 1.12)	3	3	100.0 (29.2, 100.0)	1.08 (1.03, 1.12)	136	146	93.2 (87.8, 96.7)	133	143	93.0 (87.5, 96.6)	145	155	93.5 (88.5, 96.9)
	BSOS	7	7	100.0 (59.0, 100.0)	1.17 (1.05, 1.31)	1	1	100.0 (2.5, 100.0)	1.18 (1.05, 1.32)	46	54	85.2 (72.9, 93.4)	45	53	84.9 (72.4, 93.3)	53	61	86.9 (75.8, 94.2)
	Total	84	92	91.3 (83.6, 96.2)	1.05 (0.98, 1.12)	32	36	88.9 (73.9, 96.9)	1.02 (0.91, 1.15)	575	661	87.0 (84.2, 89.5)	543	625	86.9 (84.0, 89.4)	659	753	87.5 (84.9, 89.8)

4.f.t, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed with invasive cancer, without a DCIS component, of pathological diameter $\leq 20\text{mm}$ who have breast conserving surgery (BCS). The 't' in the indicator id marks it as a treatment indicator.

Target: $>50\%$ of screen-detected invasive cancers $\leq 20\text{mm}$ are treated by BCS

Figure 91: 4.f.t, 50 to 69, Invasive cancers $\leq 20\text{mm}$ having breast conserving surgery, women screened during the 4 years to December 2020



Most women aged 45–69 years who were diagnosed with invasive breast cancer with a diameter 20mm or less had breast conserving surgery (86%). The proportions were over 75% for all LPs.

Figure 92: 4.f.t, 50 to 69, Invasive cancers ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020, by LP




Table 32: 4.f.t, Invasive cancers ≤20mm having breast conserving surgery, women screened during the 4 years to December 2020


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)
45 to 49	BSWN	2	2	100.0 (15.8, 100.0)	1.14 (0.88, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)	9	10	90.0 (55.5, 99.7)
	BSCM	0	0	NA (NA, NA)	NA (NA, NA)	1	2	50.0 (1.3, 98.7)	0.67 (0.15, 2.98)	4	6	66.7 (22.3, 95.7)	3	4	75.0 (19.4, 99.4)	4	6	66.7 (22.3, 95.7)
	BSAC	1	1	100.0 (2.5, 100.0)	1.50 (0.67, 3.34)	0	0	NA (NA, NA)	NA (NA, NA)	2	3	66.7 (9.4, 99.2)	2	3	66.7 (9.4, 99.2)	3	4	75.0 (19.4, 99.4)
	BSM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	9	10	90.0 (55.5, 99.7)	9	10	90.0 (55.5, 99.7)	9	10	90.0 (55.5, 99.7)
	BSCC	2	2	100.0 (15.8, 100.0)	1.40 (0.88, 2.24)	2	2	100.0 (15.8, 100.0)	1.67 (0.81, 3.41)	5	7	71.4 (29.0, 96.3)	3	5	60.0 (14.7, 94.7)	7	9	77.8 (40.0, 97.2)
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (15.8, 100.0)	1.00 (1.00, 1.00)	6	6	100.0 (54.1, 100.0)	4	4	100.0 (39.8, 100.0)	6	6	100.0 (54.1, 100.0)
	BSSL	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	3	100.0 (29.2, 100.0)	3	3	100.0 (29.2, 100.0)	3	3	100.0 (29.2, 100.0)
	BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	5	5	100.0 (47.8, 100.0)	5	5	100.0 (47.8, 100.0)	5	5	100.0 (47.8, 100.0)
	Total	5	5	100.0 (47.8, 100.0)	1.17 (1.04, 1.32)	5	6	83.3 (35.9, 99.6)	0.97 (0.67, 1.42)	41	48	85.4 (72.2, 93.9)	36	42	85.7 (71.5, 94.6)	46	53	86.8 (74.7, 94.5)
50 to 69	BSWN	34	38	89.5 (75.2, 97.1)	1.07 (0.93, 1.23)	4	4	100.0 (39.8, 100.0)	1.21 (1.10, 1.32)	86	103	83.5 (74.9, 90.1)	82	99	82.8 (73.9, 89.7)	120	141	85.1 (78.1, 90.5)
	BSCM	7	8	87.5 (47.3, 99.7)	1.00 (0.75, 1.34)	4	4	100.0 (39.8, 100.0)	1.17 (1.02, 1.34)	34	39	87.2 (72.6, 95.7)	30	35	85.7 (69.7, 95.2)	41	47	87.2 (74.3, 95.2)
	BSAC	5	5	100.0 (47.8, 100.0)	1.13 (1.02, 1.25)	6	8	75.0 (34.9, 96.8)	0.83 (0.55, 1.25)	45	51	88.2 (76.1, 95.6)	39	43	90.7 (77.9, 97.4)	50	56	89.3 (78.1, 96.0)
	BSM	28	33	84.8 (68.1, 94.9)	0.93 (0.79, 1.09)	2	2	100.0 (15.8, 100.0)	1.10 (1.03, 1.17)	85	93	91.4 (83.8, 96.2)	83	91	91.2 (83.4, 96.1)	113	126	89.7 (83.0, 94.4)
	BSCC	14	21	66.7 (43.0, 85.4)	0.82 (0.60, 1.13)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 4.63)	64	79	81.0 (70.6, 89.0)	64	78	82.1 (71.7, 89.8)	78	100	78.0 (68.6, 85.7)
	BSC	8	10	80.0 (44.4, 97.5)	0.88 (0.64, 1.22)	2	2	100.0 (15.8, 100.0)	1.11 (1.01, 1.21)	48	53	90.6 (79.3, 96.9)	46	51	90.2 (78.6, 96.7)	56	63	88.9 (78.4, 95.4)
	BSSL	11	12	91.7 (61.5, 99.8)	1.11 (0.91, 1.36)	2	2	100.0 (15.8, 100.0)	1.22 (1.09, 1.36)	57	69	82.6 (71.6, 90.7)	55	67	82.1 (70.8, 90.4)	68	81	84.0 (74.1, 91.2)
	BSOS	4	4	100.0 (39.8, 100.0)	1.15 (1.04, 1.27)	2	2	100.0 (15.8, 100.0)	1.15 (1.04, 1.28)	48	55	87.3 (75.5, 94.7)	46	53	86.8 (74.7, 94.5)	52	59	88.1 (77.1, 95.1)
	Total	111	131	84.7 (77.4, 90.4)	0.98 (0.91, 1.06)	22	25	88.0 (68.8, 97.5)	1.02 (0.88, 1.19)	467	542	86.2 (83.0, 89.0)	445	517	86.1 (82.8, 88.9)	578	673	85.9 (83.0, 88.4)
45 to 69	BSWN	36	40	90.0 (76.3, 97.2)	1.07 (0.94, 1.23)	4	4	100.0 (39.8, 100.0)	1.20 (1.10, 1.31)	93	111	83.8 (75.6, 90.1)	89	107	83.2 (74.7, 89.7)	129	151	85.4 (78.8, 90.6)
	BSCM	7	8	87.5 (47.3, 99.7)	1.04 (0.78, 1.39)	5	6	83.3 (35.9, 99.6)	0.99 (0.67, 1.44)	38	45	84.4 (70.5, 93.5)	33	39	84.6 (69.5, 94.1)	45	53	84.9 (72.4, 93.3)
	BSAC	6	6	100.0 (54.1, 100.0)	1.15 (1.04, 1.27)	6	8	75.0 (34.9, 96.8)	0.84 (0.56, 1.27)	47	54	87.0 (75.1, 94.6)	41	46	89.1 (76.4, 96.4)	53	60	88.3 (77.4, 95.2)
	BSM	28	33	84.8 (68.1, 94.9)	0.93 (0.80, 1.09)	2	2	100.0 (15.8, 100.0)	1.10 (1.03, 1.17)	94	103	91.3 (84.1, 95.9)	92	101	91.1 (83.8, 95.8)	122	136	89.7 (83.3, 94.3)
	BSCC	16	23	69.6 (47.1, 86.8)	0.87 (0.65, 1.16)	2	3	66.7 (9.4, 99.2)	0.83 (0.37, 1.85)	69	86	80.2 (70.2, 88.0)	67	83	80.7 (70.6, 88.6)	85	109	78.0 (69.0, 85.4)
	BSC	8	10	80.0 (44.4, 97.5)	0.87 (0.64, 1.20)	4	4	100.0 (39.8, 100.0)	1.10 (1.01, 1.20)	54	59	91.5 (81.3, 97.2)	50	55	90.9 (80.0, 97.0)	62	69	89.9 (80.2, 95.8)
	BSSL	11	12	91.7 (61.5, 99.8)	1.10 (0.90, 1.34)	2	2	100.0 (15.8, 100.0)	1.21 (1.08, 1.34)	60	72	83.3 (72.7, 91.1)	58	70	82.9 (72.0, 90.8)	71	84	84.5 (75.0, 91.5)
	BSOS	4	4	100.0 (39.8, 100.0)	1.13 (1.03, 1.24)	2	2	100.0 (15.8, 100.0)	1.14 (1.03, 1.25)	53	60	88.3 (77.4, 95.2)	51	58	87.9 (76.7, 95.0)	57	64	89.1 (78.8, 95.5)
	Total	116	136	85.3 (78.2, 90.8)	0.99 (0.92, 1.07)	27	31	87.1 (70.2, 96.4)	1.01 (0.88, 1.16)	508	590	86.1 (83.0, 88.8)	481	559	86.0 (82.9, 88.8)	624	726	86.0 (83.2, 88.4)

4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed with invasive cancer, who have breast conserving surgery (BCS) who go on to have radiotherapy. The 't' in the indicator id marks it as a treatment indicator.

Target: ≥95%

Figure 93: 4.g.t, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020



Among women aged 45–69 years, 89% of women who were diagnosed with invasive breast cancer and had breast conserving surgery went on to have radiotherapy. The target of 95% or more was met or was within the confidence interval in two LPs (BSC, BSOS) and lowest in BSAL/BSAC (82%) and BSM (81%). Māori women were slightly less likely than non-Māori to have radiotherapy (84% compared to 90%).

Figure 94: 4.g.t, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020, by LP




Table 33: 4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2020


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Invasive Cancers Having Bcs Who Have Radiothera PY	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers Having Bcs Who Have Radiothera PY	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers Having Bcs Who Have Radiothera PY	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Invasive Cancers Having Bcs Who Have Radiothera PY	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Invasive Cancers Having Bcs Who Have Radiothera PY	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)
45 to 49	BSWN	17	19	89.5 (66.9, 98.7)	1.06 (0.88, 1.27)	2	3	66.7 (9.4, 99.2)	0.78 (0.35, 1.75)	55	65	84.6 (73.5, 92.4)	53	62	85.5 (74.2, 93.1)	72	84	85.7 (76.4, 92.4)
	BSCM	8	9	88.9 (51.8, 99.7)	0.99 (0.76, 1.28)	7	10	70.0 (34.8, 93.3)	0.70 (0.47, 1.05)	27	30	90.0 (73.5, 97.9)	20	20	100.0 (83.2, 100.0)	35	39	89.7 (75.8, 97.1)
	BSAC	1	2	50.0 (1.3, 98.7)	0.54 (0.13, 2.15)	6	6	100.0 (54.1, 100.0)	1.10 (0.96, 1.24)	27	29	93.1 (77.2, 99.2)	21	23	91.3 (72.0, 98.9)	28	31	90.3 (74.2, 98.0)
	BSM	15	16	93.8 (69.8, 99.8)	1.21 (1.00, 1.46)	1	1	100.0 (2.5, 100.0)	1.30 (1.12, 1.49)	45	58	77.6 (64.7, 87.5)	44	57	77.2 (64.2, 87.3)	60	74	81.1 (70.3, 89.3)
	BSCC	10	10	100.0 (69.2, 100.0)	1.05 (0.98, 1.12)	3	3	100.0 (29.2, 100.0)	1.05 (0.98, 1.13)	41	43	95.3 (84.2, 99.4)	38	40	95.0 (83.1, 99.4)	51	53	96.2 (87.0, 99.5)
	BSC	11	11	100.0 (71.5, 100.0)	1.03 (0.97, 1.11)	3	3	100.0 (29.2, 100.0)	1.04 (0.96, 1.12)	29	30	96.7 (82.8, 99.9)	26	27	96.3 (81.0, 99.9)	40	41	97.6 (87.1, 99.9)
	BSSL	5	5	100.0 (47.8, 100.0)	1.09 (1.02, 1.18)	0	0	NA (NA, NA)	NA (NA, NA)	64	70	91.4 (82.3, 96.8)	64	70	91.4 (82.3, 96.8)	69	75	92.0 (83.4, 97.0)
	BSOS	3	3	100.0 (29.2, 100.0)	1.00 (1.00, 1.00)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	24	24	100.0 (85.8, 100.0)	23	23	100.0 (85.2, 100.0)	27	27	100.0 (87.2, 100.0)
	Total	70	75	93.3 (85.1, 97.8)	1.04 (0.97, 1.12)	23	27	85.2 (66.3, 95.8)	0.95 (0.81, 1.12)	312	349	89.4 (85.7, 92.4)	289	322	89.8 (85.9, 92.8)	382	424	90.1 (86.8, 92.8)
50 to 69	BSWN	79	89	88.8 (80.3, 94.5)	0.98 (0.91, 1.06)	19	23	82.6 (61.2, 95.0)	0.91 (0.75, 1.10)	322	356	90.4 (86.9, 93.3)	303	333	91.0 (87.4, 93.8)	401	445	90.1 (87.0, 92.7)
	BSCM	35	43	81.4 (66.6, 91.6)	0.92 (0.79, 1.07)	39	46	84.8 (71.1, 93.7)	0.94 (0.83, 1.08)	171	193	88.6 (83.3, 92.7)	132	147	89.8 (83.7, 94.2)	206	236	87.3 (82.4, 91.3)
	BSAC	16	25	64.0 (42.5, 82.0)	0.77 (0.57, 1.04)	29	33	87.9 (71.8, 96.6)	1.07 (0.93, 1.24)	157	189	83.1 (76.9, 88.1)	128	156	82.1 (75.1, 87.7)	173	214	80.8 (74.9, 85.9)
	BSM	114	152	75.0 (67.3, 81.7)	0.91 (0.82, 1.00)	4	6	66.7 (22.3, 95.7)	0.80 (0.46, 1.42)	351	424	82.8 (78.8, 86.3)	347	418	83.0 (79.1, 86.5)	465	576	80.7 (77.3, 83.9)
	BSCC	70	82	85.4 (75.8, 92.2)	0.91 (0.83, 1.00)	4	4	100.0 (39.8, 100.0)	1.07 (1.04, 1.10)	275	294	93.5 (90.1, 96.1)	271	290	93.4 (90.0, 96.0)	345	376	91.8 (88.5, 94.3)
	BSC	46	48	95.8 (85.7, 99.5)	1.02 (0.96, 1.09)	23	24	95.8 (78.9, 99.9)	1.02 (0.94, 1.12)	314	335	93.7 (90.6, 96.1)	291	311	93.6 (90.2, 96.0)	360	383	94.0 (91.1, 96.2)
	BSSL	34	37	91.9 (78.1, 98.3)	1.00 (0.90, 1.10)	4	4	100.0 (39.8, 100.0)	1.08 (1.05, 1.11)	410	444	92.3 (89.5, 94.6)	406	440	92.3 (89.4, 94.6)	444	481	92.3 (89.6, 94.5)
	BSOS	14	16	87.5 (61.7, 98.4)	0.94 (0.78, 1.14)	4	4	100.0 (39.8, 100.0)	1.08 (1.04, 1.12)	183	197	92.9 (88.4, 96.1)	179	193	92.7 (88.1, 96.0)	197	213	92.5 (88.1, 95.6)
	Total	408	492	82.9 (79.3, 86.1)	0.92 (0.89, 0.96)	126	144	87.5 (81.0, 92.4)	0.97 (0.91, 1.04)	2,183	2,432	89.8 (88.5, 90.9)	2,057	2,288	89.9 (88.6, 91.1)	2,591	2,924	88.6 (87.4, 89.7)
45 to 69	BSWN	96	108	88.9 (81.4, 94.1)	0.99 (0.92, 1.07)	21	26	80.8 (60.6, 93.4)	0.90 (0.74, 1.08)	377	421	89.5 (86.2, 92.3)	356	395	90.1 (86.8, 92.9)	473	529	89.4 (86.5, 91.9)
	BSCM	43	52	82.7 (69.7, 91.8)	0.93 (0.82, 1.06)	46	56	82.1 (69.6, 91.1)	0.90 (0.79, 1.03)	198	223	88.8 (83.9, 92.6)	152	167	91.0 (85.6, 94.9)	241	275	87.6 (83.2, 91.3)
	BSAC	17	27	63.0 (42.4, 80.6)	0.75 (0.56, 1.00)	35	39	89.7 (75.8, 97.1)	1.08 (0.95, 1.22)	184	218	84.4 (78.9, 89.0)	149	179	83.2 (76.9, 88.4)	201	245	82.0 (76.7, 86.6)
	BSM	129	168	76.8 (69.7, 82.9)	0.94 (0.85, 1.03)	5	7	71.4 (29.0, 96.3)	0.87 (0.54, 1.39)	396	482	82.2 (78.4, 85.5)	391	475	82.3 (78.6, 85.6)	525	650	80.8 (77.5, 83.7)
	BSCC	80	92	87.0 (78.3, 93.1)	0.93 (0.85, 1.01)	7	7	100.0 (59.0, 100.0)	1.07 (1.04, 1.10)	316	337	93.8 (90.6, 96.1)	309	330	93.6 (90.4, 96.0)	396	429	92.3 (89.4, 94.6)
	BSC	57	59	96.6 (88.3, 99.6)	1.03 (0.97, 1.09)	26	27	96.3 (81.0, 99.9)	1.03 (0.95, 1.11)	343	365	94.0 (91.0, 96.2)	317	338	93.8 (90.7, 96.1)	400	424	94.3 (91.7, 96.3)
	BSSL	39	42	92.9 (80.5, 98.5)	1.01 (0.92, 1.10)	4	4	100.0 (39.8, 100.0)	1.09 (1.06, 1.11)	474	514	92.2 (89.6, 94.4)	470	510	92.2 (89.5, 94.3)	513	556	92.3 (89.7, 94.3)
	BSOS	17	19	89.5 (66.9, 98.7)	0.96 (0.82, 1.12)	5	5	100.0 (47.8, 100.0)	1.07 (1.03, 1.11)	207	221	93.7 (89.6, 96.5)	202	216	93.5 (89.4, 96.4)	224	240	93.3 (89.4, 96.1)
	Total	478	567	84.3 (81.0, 87.2)	0.94 (0.91, 0.98)	149	171	87.1 (81.2, 91.8)	0.97 (0.91, 1.03)	2,495	2,781	89.7 (88.5, 90.8)	2,346	2,610	89.9 (88.7, 91.0)	2,973	3,348	88.8 (87.7, 89.8)

4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed solely with DCIS, who have Breast Conserving Surgery (BCS), who go on to have radiotherapy. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 95: 4.h.t, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2020



Among women aged 45–69 who were diagnosed with DCIS and had breast conserving surgery, 58% went on to have radiotherapy, lowest in BSOS (49%) and highest in BSM (68%). There were no significant differences in the proportions of Māori, Pacific or non-Māori non-Pacific women who had radiotherapy.

Figure 96: 4.h.t, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2020, by LP



Table 34: 4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2020

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	Māori / Non-Māori Ratio	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	Pacific / Non-Māori Pacific Ratio	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)
45 to 49	BSWN	3	4	75.0 (19.4, 99.4)	1.39 (0.70, 2.72)	1	2	50.0 (1.3, 98.7)	0.92 (0.22, 3.86)	13	24	54.2 (32.8, 74.4)	12	22	54.5 (32.2, 75.6)	16	28	57.1 (37.2, 75.5)
	BSCM	1	1	100.0 (2.5, 100.0)	1.55 (1.09, 2.19)	1	2	50.0 (1.3, 98.7)	0.75 (0.18, 3.14)	11	17	64.7 (38.3, 85.8)	10	15	66.7 (38.4, 88.2)	12	18	66.7 (41.0, 86.7)
	BSAC	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 9.63)	1	1	100.0 (2.5, 100.0)	2.25 (1.34, 3.77)	9	19	47.4 (24.4, 71.1)	8	18	44.4 (21.5, 69.2)	9	20	45.0 (23.1, 68.5)
	BSM	5	6	83.3 (35.9, 99.6)	1.22 (0.76, 1.95)	0	0	NA (NA, NA)	NA (NA, NA)	13	19	68.4 (43.4, 87.4)	13	19	68.4 (43.4, 87.4)	18	25	72.0 (50.6, 87.9)
	BSCC	2	3	66.7 (9.4, 99.2)	1.24 (0.48, 3.19)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 8.33)	7	13	53.8 (25.1, 80.8)	7	12	58.3 (27.7, 84.8)	9	16	56.3 (29.9, 80.2)
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	10	16	62.5 (35.4, 84.8)	10	16	62.5 (35.4, 84.8)	10	16	62.5 (35.4, 84.8)
	BSSL	3	5	60.0 (14.7, 94.7)	0.91 (0.43, 1.93)	0	0	NA (NA, NA)	NA (NA, NA)	27	41	65.9 (49.4, 79.9)	27	41	65.9 (49.4, 79.9)	30	46	65.2 (49.8, 78.6)
	BSOS	1	3	33.3 (0.8, 90.6)	0.93 (0.16, 5.36)	0	0	NA (NA, NA)	NA (NA, NA)	5	14	35.7 (12.8, 64.9)	5	14	35.7 (12.8, 64.9)	6	17	35.3 (14.2, 61.7)
	Total	15	23	65.2 (42.7, 83.6)	1.12 (0.81, 1.55)	3	6	50.0 (11.8, 88.2)	0.85 (0.38, 1.92)	95	163	58.3 (50.3, 65.9)	92	157	58.6 (50.5, 66.4)	110	186	59.1 (51.7, 66.3)
	50 to 69	BSWN	9	16	56.3 (29.9, 80.2)	0.96 (0.60, 1.52)	5	9	55.6 (21.2, 86.3)	0.94 (0.51, 1.73)	60	102	58.8 (48.6, 68.5)	55	93	59.1 (48.5, 69.2)	69	118
BSCM		5	11	45.5 (16.7, 76.6)	0.80 (0.41, 1.59)	7	12	58.3 (27.7, 84.8)	1.04 (0.60, 1.78)	34	60	56.7 (43.2, 69.4)	27	48	56.3 (41.2, 70.5)	39	71	54.9 (42.7, 66.8)
BSAC		3	5	60.0 (14.7, 94.7)	1.10 (0.52, 2.34)	3	8	37.5 (8.5, 75.5)	0.65 (0.26, 1.65)	30	55	54.5 (40.6, 68.0)	27	47	57.4 (42.2, 71.7)	33	60	55.0 (41.6, 67.9)
BSM		22	32	68.8 (50.0, 83.9)	1.03 (0.79, 1.35)	4	5	80.0 (28.4, 99.5)	1.21 (0.77, 1.92)	72	108	66.7 (56.9, 75.4)	68	103	66.0 (56.0, 75.1)	94	140	67.1 (58.7, 74.8)
BSCC		6	11	54.5 (23.4, 83.3)	0.96 (0.54, 1.74)	0	0	NA (NA, NA)	NA (NA, NA)	30	53	56.6 (42.3, 70.2)	30	53	56.6 (42.3, 70.2)	36	64	56.3 (43.3, 68.6)
BSC		2	5	40.0 (5.3, 85.3)	0.69 (0.23, 2.05)	1	3	33.3 (0.8, 90.6)	0.57 (0.11, 2.83)	47	81	58.0 (46.5, 68.9)	46	78	59.0 (47.3, 70.0)	49	86	57.0 (45.8, 67.6)
BSSL		5	9	55.6 (21.2, 86.3)	1.05 (0.57, 1.92)	2	5	40.0 (5.3, 85.3)	0.75 (0.25, 2.22)	81	153	52.9 (44.7, 61.1)	79	148	53.4 (45.0, 61.6)	86	162	53.1 (45.1, 61.0)
BSOS		2	6	33.3 (4.3, 77.7)	0.62 (0.19, 1.96)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.10)	33	61	54.1 (40.8, 66.9)	33	60	55.0 (41.6, 67.9)	35	67	52.2 (39.7, 64.6)
Total		54	95	56.8 (46.3, 67.0)	0.99 (0.82, 1.19)	22	43	51.2 (35.5, 66.7)	0.88 (0.66, 1.19)	387	673	57.5 (53.7, 61.3)	365	630	57.9 (54.0, 61.8)	441	768	57.4 (53.8, 60.9)
45 to 69		BSWN	12	20	60.0 (36.1, 80.9)	1.04 (0.70, 1.53)	6	11	54.5 (23.4, 83.3)	0.94 (0.53, 1.64)	73	126	57.9 (48.8, 66.7)	67	115	58.3 (48.7, 67.4)	85	146
	BSCM	6	12	50.0 (21.1, 78.9)	0.86 (0.47, 1.55)	8	14	57.1 (28.9, 82.3)	0.97 (0.59, 1.60)	45	77	58.4 (46.6, 69.6)	37	63	58.7 (45.6, 71.0)	51	89	57.3 (46.4, 67.7)
	BSAC	3	6	50.0 (11.8, 88.2)	0.95 (0.41, 2.17)	4	9	44.4 (13.7, 78.8)	0.83 (0.38, 1.77)	39	74	52.7 (40.7, 64.4)	35	65	53.8 (41.0, 66.3)	42	80	52.5 (41.0, 63.8)
	BSM	27	38	71.1 (54.1, 84.6)	1.06 (0.84, 1.34)	4	5	80.0 (28.4, 99.5)	1.21 (0.76, 1.90)	85	127	66.9 (58.0, 75.0)	81	122	66.4 (57.3, 74.7)	112	165	67.9 (60.2, 74.9)
	BSCC	8	14	57.1 (28.9, 82.3)	1.02 (0.62, 1.68)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 6.82)	37	66	56.1 (43.3, 68.3)	37	65	56.9 (44.0, 69.2)	45	80	56.3 (44.7, 67.3)
	BSC	2	5	40.0 (5.3, 85.3)	0.68 (0.23, 2.02)	1	3	33.3 (0.8, 90.6)	0.56 (0.11, 2.80)	57	97	58.8 (48.3, 68.7)	56	94	59.6 (49.0, 69.6)	59	102	57.8 (47.7, 67.6)
	BSSL	8	14	57.1 (28.9, 82.3)	1.03 (0.64, 1.64)	2	5	40.0 (5.3, 85.3)	0.71 (0.24, 2.10)	108	194	55.7 (48.4, 62.8)	106	189	56.1 (48.7, 63.3)	116	208	55.8 (48.7, 62.6)
	BSOS	3	9	33.3 (7.5, 70.1)	0.66 (0.25, 1.70)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.54)	38	75	50.7 (38.9, 62.4)	38	74	51.4 (39.4, 63.1)	41	84	48.8 (37.7, 60.0)
	Total	69	118	58.5 (49.0, 67.5)	1.01 (0.86, 1.19)	25	49	51.0 (36.3, 65.6)	0.88 (0.66, 1.16)	482	836	57.7 (54.2, 61.0)	457	787	58.1 (54.5, 61.5)	551	954	57.8 (54.6, 60.9)

4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed with invasive cancer who have chemotherapy, reported by disease character groups. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Among women aged 45–69 years who were diagnosed with invasive cancer, 92% of those whose cancer was node positive and ER and PR negative had chemotherapy, as did 67% of those with node negative, high risk, and ER and PR negative cancer, 51% of those who were node positive, either ER or PR positive, and 17% of those who were node negative, high risk, and ER or PR positive.

Table 35: 4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2020

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	
45 to 49	Group 1: Node positive, and ER and PR negative	BSWN	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	4	75.0 (19.4, 99.4)	3	4	75.0 (19.4, 99.4)	3	4	75.0 (19.4, 99.4)
		BSCM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSAC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSCC	2	2	100.0 (15.8, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (15.8, 100.0)	2	2	100.0 (15.8, 100.0)	4	4	100.0 (15.8, 100.0)
		BSC	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1	1	100.0 (2.5, 100.0)	2	2	100.0 (15.8, 100.0)
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	3	3	100.0 (29.2, 100.0)	2	2	100.0 (15.8, 100.0)	3	3	100.0 (29.2, 100.0)
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1	1	100.0 (2.5, 100.0)	1	1	100.0 (2.5, 100.0)
		Total	3	3	100.0 (29.2, 100.0)	1.10 (0.91, 1.33)	1	1	100.0 (2.5, 100.0)	1.11 (0.90, 1.37)	10	11	90.9 (58.7, 99.8)	9	10	90.0 (55.5, 99.7)	13	14	92.9 (66.1, 99.8)
		Group 2: Node negative, high risk, and ER and PR negative	BSWN	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.40 (0.88, 2.24)	6	8	75.0 (34.9, 96.8)	5	7	71.4 (29.0, 96.3)	6	8
	BSCM		0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	2	2	100.0 (15.8, 100.0)	1	1	100.0 (2.5, 100.0)	2	2	100.0 (15.8, 100.0)
	BSAC		0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	3	3	100.0 (29.2, 100.0)	2	2	100.0 (15.8, 100.0)	3	3	100.0 (29.2, 100.0)
	BSM		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	2	4	50.0 (6.8, 93.2)	2	4	50.0 (6.8, 93.2)	2	4	50.0 (6.8, 93.2)
	BSCC		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
	BSC		3	3	100.0 (29.2, 100.0)	1.33 (0.76, 2.35)	1	1	100.0 (2.5, 100.0)	1.50 (0.67, 3.34)	3	4	75.0 (19.4, 99.4)	2	3	66.7 (9.4, 99.2)	6	7	85.7 (42.1, 99.6)
	BSSL		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)
	BSOS		0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (15.8, 100.0)	2	2	100.0 (15.8, 100.0)	2	2	100.0 (15.8, 100.0)
	Total		3	3	100.0 (29.2, 100.0)	1.24 (1.04, 1.47)	4	4	100.0 (39.8, 100.0)	1.29 (1.05, 1.57)	25	31	80.6 (62.5, 92.5)	21	27	77.8 (57.7, 91.4)	28	34	82.4 (65.5, 93.2)
	Group 3: Node positive, either ER or PR positive		BSWN	4	5	80.0 (28.4, 99.5)	1.14 (0.70, 1.85)	1	2	50.0 (1.3, 98.7)	0.70 (0.17, 2.84)	26	37	70.3 (53.0, 84.1)	25	35	71.4 (53.7, 85.4)	30	42
		BSCM	4	7	57.1 (18.4, 90.1)	0.95 (0.46, 1.99)	5	10	50.0 (18.7, 81.3)	0.71 (0.34, 1.50)	12	20	60.0 (36.1, 80.9)	7	10	70.0 (34.8, 93.3)	16	27	59.3 (38.8, 77.6)
		BSAC	2	2	100.0 (15.8, 100.0)	1.08 (0.93, 1.27)	2	2	100.0 (15.8, 100.0)	1.10 (0.91, 1.33)	12	13	92.3 (64.0, 99.8)	10	11	90.9 (58.7, 99.8)	14	15	93.3 (68.1, 99.8)
		BSM	6	9	66.7 (29.9, 92.5)	1.81 (0.86, 3.82)	0	0	NA (NA, NA)	NA (NA, NA)	7	19	36.8 (16.3, 61.6)	7	19	36.8 (16.3, 61.6)	13	28	46.4 (27.5, 66.1)
		BSCC	7	10	70.0 (34.8, 93.3)	0.97 (0.59, 1.59)	1	1	100.0 (2.5, 100.0)	1.42 (1.04, 1.93)	13	18	72.2 (46.5, 90.3)	12	17	70.6 (44.0, 89.7)	20	28	71.4 (51.3, 86.8)
		BSC	5	7	71.4 (29.0, 96.3)	1.14 (0.56, 2.33)	0	0	NA (NA, NA)	NA (NA, NA)	5	8	62.5 (24.5, 91.5)	5	8	62.5 (24.5, 91.5)	10	15	66.7 (38.4, 88.2)
		BSSL	3	3	100.0 (29.2, 100.0)	1.65 (1.25, 2.17)	1	1	100.0 (2.5, 100.0)	1.68 (1.26, 2.24)	20	33	60.6 (42.1, 77.1)	19	32	59.4 (40.6, 76.3)	23	36	63.9 (46.2, 79.2)
		BSOS	1	1	100.0 (2.5, 100.0)	1.40 (0.88, 2.24)	0	0	NA (NA, NA)	NA (NA, NA)	5	7	71.4 (29.0, 96.3)	5	7	71.4 (29.0, 96.3)	6	8	75.0 (34.9, 96.8)
		Total	32	44	72.7 (57.2, 85.0)	1.13 (0.91, 1.40)	10	16	62.5 (35.4, 84.8)	0.97 (0.65, 1.44)	100	155	64.5 (56.4, 72.0)	90	139	64.7 (56.2, 72.7)	132	199	66.3 (59.3, 72.9)
		Group 4: Node negative, high risk, either ER or PR positive	BSWN	2	13	15.4 (1.9, 45.4)	0.67 (0.17, 2.70)	1	3	33.3 (0.8, 90.6)	1.50 (0.27, 8.32)	9	39	23.1 (11.1, 39.3)	8	36	22.2 (10.1, 39.2)	11	52
	BSCM		2	5	40.0 (5.3, 85.3)	0.89 (0.29, 2.74)	1	9	11.1 (0.3, 48.2)	0.20 (0.03, 1.32)	18	40	45.0 (29.3, 61.5)	17	31	54.8 (36.0, 72.7)	20	45	44.4 (29.6, 60.0)
	BSAC		0	1	0.0 (0.0, 97.5)	0.00 (0.00, 11.16)	2	5	40.0 (5.3, 85.3)	1.02 (0.31, 3.35)	11	28	39.3 (21.5, 59.4)	9	23	39.1 (19.7, 61.5)	11	29	37.9 (20.7, 57.7)
	BSM		1	12	8.3 (0.2, 38.5)	0.34 (0.05, 2.47)	1	1	100.0 (2.5, 100.0)	4.57 (2.38, 8.80)	8	35	24.2 (11.1, 42.3)	7	32	21.9 (9.3, 40.0)	9	45	20.0 (9.6, 34.6)
	BSCC		5	9	55.6 (21.2, 86.3)	1.98 (0.88, 4.42)	2	4	50.0 (6.8, 93.2)	2.00 (0.62, 6.45)	9	32	28.1 (13.7, 46.7)	7	28	25.0 (10.7, 44.9)	14	41	34.1 (20.1, 50.6)
	BSC		2	7	28.6 (3.7, 71.0)	1.20 (0.30, 4.86)	0	3	0.0 (0.0, 70.8)	0.00 (0.00, 6.55)	5	21	23.8 (8.2, 47.2)	5	18	27.8 (9.7, 53.5)	7	28	25.0 (10.7, 44.9)
	BSSL		0	5	0.0 (0.0, 52.2)	0.00 (0.00, 2.82)	0	0	NA (NA, NA)	NA (NA, NA)	18	62	29.0 (18.2, 41.9)	18	62	29.0 (18.2, 41.9)	18	67	26.9 (16.8, 39.1)
	BSOS		0	3	0.0 (0.0, 70.8)	0.00 (0.00, 7.64)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 22.08)	6	27	22.2 (8.6, 42.3)	6	26	23.1 (9.0, 43.6)	6	30	20.0 (7.7, 38.6)
	Total		12	55	21.8 (11.8, 35.0)	0.73 (0.43, 1.25)	7	26	26.9 (11.6, 47.8)	0.90 (0.46, 1.73)	84	282	29.8 (24.5, 35.5)	77	256	30.1 (24.5, 36.1)	96	337	28.5 (23.7, 33.6)

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	
50 to 69	Group 1: Node positive, and ER and PR negative	BSWN	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 (59.0, 100.0)	7	7	100.0 (59.0, 100.0)	8	8	100.0 (63.1, 100.0)
		BSCM	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (15.8, 100.0)	1.20 (0.84, 1.72)	7	8	87.5 (47.3, 99.7)	5	6	83.3 (35.9, 99.6)	7	8	87.5 (47.3, 99.7)
		BSAC	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	4	4	100.0 (39.8, 100.0)	3	3	100.0 (29.2, 100.0)	4	4	100.0 (39.8, 100.0)
		BSM	4	5	80.0 (28.4, 99.5)	0.96 (0.55, 1.69)	0	0	NA (NA, NA)	NA (NA, NA)	5	6	83.3 (35.9, 99.6)	5	6	83.3 (35.9, 99.6)	9	11	81.8 (48.2, 97.7)
		BSCC	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	11	11	100.0 (71.5, 100.0)	11	11	100.0 (71.5, 100.0)	14	15	93.3 (68.1, 99.8)
		BSC	1	2	50.0 (1.3, 98.7)	0.50 (0.12, 2.00)	0	0	NA (NA, NA)	NA (NA, NA)	9	9	100.0 (66.4, 100.0)	9	9	100.0 (66.4, 100.0)	10	11	90.9 (58.7, 99.8)
		BSSL	1	1	100.0 (2.5, 100.0)	1.14 (0.95, 1.38)	0	0	NA (NA, NA)	NA (NA, NA)	14	16	87.5 (61.7, 98.4)	14	16	87.5 (61.7, 98.4)	15	17	88.2 (63.6, 98.5)
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	8	8	100.0 (63.1, 100.0)	8	8	100.0 (63.1, 100.0)	8	8	100.0 (63.1, 100.0)
		Total	10	13	76.9 (46.2, 95.0)	0.82 (0.60, 1.11)	3	3	100.0 (29.2, 100.0)	1.07 (1.00, 1.13)	65	69	94.2 (85.8, 98.4)	62	66	93.9 (85.2, 98.3)	75	82	91.5 (83.2, 96.5)
	Group 2: Node negative, high risk, and ER and PR negative	BSWN	2	4	50.0 (6.8, 93.2)	0.62 (0.23, 1.68)	2	2	100.0 (15.8, 100.0)	1.26 (1.06, 1.49)	29	36	80.6 (64.0, 91.8)	27	34	79.4 (62.1, 91.3)	31	40	77.5 (61.5, 89.2)
		BSCM	2	2	100.0 (15.8, 100.0)	1.47 (1.10, 1.95)	3	3	100.0 (29.2, 100.0)	1.58 (1.12, 2.23)	15	22	68.2 (45.1, 86.1)	12	19	63.2 (38.4, 83.7)	17	24	70.8 (48.9, 87.4)
		BSAC	1	1	100.0 (2.5, 100.0)	1.33 (0.96, 1.85)	2	2	100.0 (15.8, 100.0)	1.43 (0.95, 2.14)	9	12	75.0 (42.8, 94.5)	7	10	70.0 (34.8, 93.3)	10	13	76.9 (46.2, 95.0)
		BSM	3	8	37.5 (8.5, 75.5)	0.70 (0.27, 1.83)	0	0	NA (NA, NA)	NA (NA, NA)	15	28	53.6 (33.9, 72.5)	15	28	53.6 (33.9, 72.5)	18	36	50.0 (32.9, 67.1)
		BSCC	3	6	50.0 (11.8, 88.2)	0.70 (0.31, 1.60)	1	1	100.0 (2.5, 100.0)	1.42 (1.14, 1.76)	25	35	71.4 (53.7, 85.4)	24	34	70.6 (52.5, 84.9)	28	41	68.3 (51.9, 81.9)
		BSC	1	5	20.0 (0.5, 71.6)	0.30 (0.05, 1.73)	1	1	100.0 (2.5, 100.0)	1.50 (1.19, 1.89)	25	37	67.6 (50.2, 82.0)	24	36	66.7 (49.0, 81.4)	26	42	61.9 (45.6, 76.4)
		BSSL	2	3	66.7 (9.4, 99.2)	1.00 (0.44, 2.28)	1	2	50.0 (1.3, 98.7)	0.74 (0.18, 3.01)	32	48	66.7 (51.6, 79.6)	31	46	67.4 (52.0, 80.5)	34	51	66.7 (52.1, 79.2)
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 8.03)	10	19	52.6 (28.9, 75.6)	10	18	55.6 (30.8, 78.5)	10	19	52.6 (28.9, 75.6)
		Total	14	29	48.3 (29.4, 67.5)	0.72 (0.49, 1.05)	10	12	83.3 (51.6, 97.9)	1.25 (0.95, 1.64)	160	237	67.5 (61.1, 73.4)	150	225	66.7 (60.1, 72.8)	174	266	65.4 (59.4, 71.1)
	Group 3: Node positive, either ER or PR positive	BSWN	14	25	56.0 (34.9, 75.6)	1.22 (0.80, 1.84)	6	11	54.5 (23.4, 83.3)	1.22 (0.67, 2.21)	40	87	46.0 (35.2, 57.0)	34	76	44.7 (33.3, 56.6)	54	112	48.2 (38.7, 57.9)
		BSCM	9	15	60.0 (32.3, 83.7)	1.08 (0.68, 1.73)	8	17	47.1 (23.0, 72.2)	0.80 (0.46, 1.40)	35	63	55.6 (42.5, 68.1)	27	46	58.7 (43.2, 73.0)	44	78	56.4 (44.7, 67.6)
		BSAC	3	7	42.9 (9.9, 81.6)	0.83 (0.34, 2.02)	4	8	50.0 (15.7, 84.3)	0.96 (0.46, 2.02)	31	60	51.7 (38.4, 64.8)	27	52	51.9 (37.6, 66.0)	34	67	50.7 (38.2, 63.2)
		BSM	18	50	36.0 (22.9, 50.8)	0.85 (0.55, 1.32)	1	4	25.0 (0.6, 80.6)	0.58 (0.10, 3.23)	41	97	42.3 (32.3, 52.7)	40	93	43.0 (32.8, 53.7)	59	147	40.1 (32.1, 48.5)
		BSCC	16	36	44.4 (27.9, 61.9)	1.03 (0.66, 1.59)	4	5	80.0 (28.4, 99.5)	1.95 (1.17, 3.26)	36	83	43.4 (32.5, 54.7)	32	78	41.0 (30.0, 52.7)	52	119	43.7 (34.6, 53.1)
		BSC	2	11	18.2 (2.3, 51.8)	0.38 (0.10, 1.35)	2	7	28.6 (3.7, 71.0)	0.56 (0.17, 1.86)	30	62	48.4 (35.5, 61.4)	28	55	50.9 (37.1, 64.6)	32	73	43.8 (32.2, 55.9)
		BSSL	5	9	55.6 (21.2, 86.3)	1.15 (0.62, 2.12)	0	0	NA (NA, NA)	NA (NA, NA)	49	101	48.5 (38.4, 58.7)	49	101	48.5 (38.4, 58.7)	54	110	49.1 (39.4, 58.8)
		BSOS	2	2	100.0 (15.8, 100.0)	1.87 (1.47, 2.38)	1	1	100.0 (2.5, 100.0)	1.90 (1.49, 2.43)	31	58	53.4 (39.9, 66.7)	30	57	52.6 (39.0, 66.0)	33	60	55.0 (41.6, 67.9)
		Total	69	155	44.5 (36.5, 52.7)	0.93 (0.76, 1.13)	26	53	49.1 (35.1, 63.2)	1.03 (0.77, 1.37)	293	611	48.0 (43.9, 52.0)	267	558	47.8 (43.6, 52.1)	362	766	47.3 (43.7, 50.9)
	Group 4: Node negative, high risk, either ER or PR positive	BSWN	13	75	17.3 (9.6, 27.8)	0.91 (0.52, 1.59)	3	12	25.0 (5.5, 57.2)	1.33 (0.48, 3.68)	46	241	19.1 (14.3, 24.6)	43	229	18.8 (13.9, 24.4)	59	316	18.7 (14.5, 23.4)
		BSCM	6	36	16.7 (6.4, 32.8)	0.87 (0.39, 1.92)	10	51	19.6 (9.8, 33.1)	1.03 (0.53, 2.02)	32	167	19.2 (13.5, 26.0)	22	116	19.0 (12.3, 27.3)	38	203	18.7 (13.6, 24.8)
		BSAC	2	19	10.5 (1.3, 33.1)	0.55 (0.14, 2.14)	4	30	13.3 (3.8, 30.7)	0.65 (0.24, 1.73)	27	142	19.0 (12.9, 26.4)	23	112	20.5 (13.5, 29.2)	29	161	18.0 (12.4, 24.8)
		BSM	13	105	12.4 (6.8, 20.2)	1.30 (0.70, 2.42)	1	5	20.0 (0.5, 71.6)	2.15 (0.36, 12.86)	28	295	9.5 (6.4, 13.4)	27	290	9.3 (6.2, 13.3)	41	400	10.3 (7.5, 13.6)
		BSCC	10	52	19.2 (9.6, 32.5)	1.32 (0.69, 2.50)	2	3	66.7 (9.4, 99.2)	4.80 (2.02, 11.41)	32	219	14.6 (10.2, 20.0)	30	216	13.9 (9.6, 19.2)	42	271	15.5 (11.4, 20.4)
		BSC	4	35	11.4 (3.2, 26.7)	0.73 (0.28, 1.93)	7	18	38.9 (17.3, 64.3)	2.87 (1.45, 5.67)	33	210	15.7 (11.1, 21.4)	26	192	13.5 (9.0, 19.2)	37	245	15.1 (10.9, 20.2)
		BSSL	6	38	15.8 (6.0, 31.3)	1.15 (0.53, 2.50)	2	4	50.0 (6.8, 93.2)	3.75 (1.35, 10.38)	46	334	13.8 (10.3, 17.9)	44	330	13.3 (9.9, 17.5)	52	372	14.0 (10.6, 17.9)
		BSOS	2	11	18.2 (2.3, 51.8)	1.05 (0.28, 3.86)	0	4	0.0 (0.0, 60.2)	0.00 (0.00, 5.57)	24	138	17.4 (11.5, 24.8)	24	134	17.9 (11.8, 25.5)	26	149	17.4 (11.7, 24.5)
		Total	56	371	15.1 (11.6, 19.1)	0.98 (0.75, 1.28)	29	127	22.8 (15.9, 31.1)	1.55 (1.10, 2.17)	268	1,746	15.3 (13.7, 17.1)	239	1,619	14.8 (13.1, 16.6)	324	2,117	15.3 (13.8, 16.9)

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	
45 to 69	Group 1: Node positive, and ER and PR negative	BSWN	1	1	100.0 (20.65, 100)	1.10 (0.91, 1.33)	0	0	NA NA	NA NA	10	11	90.9 (62.3, 98.4)	10	11	90.9 (62.3, 98.4)	11	12	91.7 (64.6, 98.5)
		BSCM	0	0	NA NA	NA NA	2	2	100.0 (34.2, 100)	1.14 (1.14, 1.63)	7	8	87.5 (52.9, 97.8)	5	6	83.3 (43.6, 97)	7	8	87.5 (52.9, 97.8)
		BSAC	0	0	NA NA	NA NA	1	1	100.0 (20.7, 100)	1.00 (1, 1)	4	4	100.0 (51, 100)	3	3	100.0 (43.9, 100)	4	4	100.0 (51, 100)
		B5M	4	5	80.0 (37.55, 96.38)	0.96 (0.55, 1.69)	0	0	NA NA	NA NA	5	6	83.3 (43.6, 97)	5	6	83.3 (43.6, 97)	9	11	81.8 (52.3, 94.9)
		B5CC	5	6	83.3 (43.65, 96.99)	0.83 (0.58, 1.19)	0	0	NA NA	NA NA	13	13	100.0 (77.2, 100)	13	13	100.0 (77.2, 100)	18	19	94.7 (75.4, 99.1)
		B5C	2	3	66.7 (20.77, 93.85)	0.67 (0.3, 1.48)	0	0	NA NA	NA NA	10	10	100.0 (72.2, 100)	10	10	100.0 (72.2, 100)	12	13	92.3 (66.7, 98.6)
		B55L	1	1	100.0 (20.65, 100)	1.12 (0.96, 1.3)	1	1	100.0 (20.7, 100)	1.11 (1.11, 1.31)	17	19	89.5 (68.6, 97.1)	16	18	88.9 (67.2, 96.9)	18	20	90.0 (69.9, 97.2)
		B5OS	0	0	NA NA	NA NA	0	0	NA NA	NA NA	9	9	100.0 (70.1, 100)	9	9	100.0 (70.1, 100)	9	9	100.0 (70.1, 100)
	Total	13	16	81.3 (56.99, 93.41)	0.87 (0.68, 1.1)	4	4	100.0 (51, 100)	1.09 (1.09, 1.16)	75	80	93.8 (86.2, 97.3)	71	76	93.4 (85.5, 97.2)	88	96	91.7 (84.4, 95.7)	
	Group 2: Node negative, high risk, and ER and PR negative	BSWN	2	4	50.0 (15, 85)	0.63 (0.23, 1.69)	3	3	100.0 (43.9, 100)	1.30 (1.3, 1.53)	35	44	79.5 (65.5, 88.8)	32	41	78.0 (63.3, 88)	37	48	77.1 (63.5, 86.7)
		BSCM	2	2	100.0 (34.24, 100)	1.41 (1.09, 1.82)	4	4	100.0 (51, 100)	1.37 (1.37, 1.89)	17	24	70.8 (50.8, 85.1)	13	20	65.0 (43.3, 81.9)	19	26	73.1 (53.9, 86.3)
		BSAC	1	1	100.0 (20.65, 100)	1.25 (0.97, 1.61)	3	3	100.0 (43.9, 100)	1.23 (1.23, 1.71)	12	15	80.0 (54.8, 93)	9	12	75.0 (46.8, 91.1)	13	16	81.3 (57, 93.4)
		B5M	3	8	37.5 (13.68, 69.43)	0.71 (0.27, 1.83)	0	0	NA NA	NA NA	17	32	53.1 (36.4, 69.1)	17	32	53.1 (36.4, 69.1)	20	40	50.0 (35.2, 64.8)
		B5CC	3	6	50.0 (18.76, 81.24)	0.70 (0.31, 1.6)	1	1	100.0 (20.7, 100)	1.46 (1.46, 1.82)	25	35	71.4 (54.9, 83.7)	24	34	70.6 (53.8, 83.2)	28	41	68.3 (53, 80.4)
		B5C	4	8	50.0 (21.52, 78.48)	0.73 (0.36, 1.51)	2	2	100.0 (34.2, 100)	1.53 (1.53, 1.91)	28	41	68.3 (53, 80.4)	26	39	66.7 (51, 79.4)	32	49	65.3 (51.3, 77.1)
		B55L	2	3	66.7 (20.77, 93.85)	0.96 (0.42, 2.17)	1	2	50.0 (9.5, 90.5)	0.72 (0.18, 2.91)	39	56	69.6 (56.7, 80.1)	38	54	70.4 (57.2, 80.9)	41	59	69.5 (56.9, 79.7)
B5OS		0	0	NA NA	NA NA	0	1	0.0 (0, 79.3)	0.00 NA	12	21	57.1 (36.5, 75.5)	12	20	60.0 (38.7, 78.1)	12	21	57.1 (36.5, 75.5)	
Total	17	32	53.1 (36.45, 69.13)	0.77 (0.55, 1.08)	14	16	87.5 (64, 96.5)	1.30 (1.08, 1.59)	185	268	69.0 (63.3, 74.3)	171	252	67.9 (61.9, 73.3)	202	300	67.3 (61.8, 72.4)		
Group 3: Node positive either ER or PR positive	BSWN	18	30	60.0 (42.32, 75.41)	1.13 (0.81, 1.58)	7	13	53.8 (29.1, 76.8)	0.99 (0.6, 1.68)	66	124	53.2 (44.5, 61.8)	59	111	53.2 (43.9, 62.2)	84	154	54.5 (46.7, 62.2)	
	BSCM	13	22	59.1 (38.73, 76.74)	1.04 (0.7, 1.55)	13	27	48.1 (30.7, 66)	0.84 (0.57, 1.31)	47	83	56.6 (45.9, 66.8)	34	56	60.7 (47.6, 72.4)	60	105	57.1 (47.6, 66.2)	
	BSAC	5	9	55.6 (26.67, 81.12)	0.94 (0.51, 1.74)	6	10	60.0 (31.3, 83.2)	1.03 (0.62, 1.77)	43	73	58.9 (47.4, 69.5)	37	63	58.7 (46.4, 70)	48	82	58.5 (47.7, 68.6)	
	B5M	24	59	40.7 (29.09, 53.41)	0.98 (0.67, 1.43)	1	4	25.0 (4.6, 69.9)	0.61 (0.11, 3.36)	48	116	41.4 (32.8, 50.5)	47	112	42.0 (33.2, 51.2)	72	175	41.1 (34.1, 48.5)	
	B5CC	23	46	50.0 (36.12, 63.88)	1.03 (0.72, 1.47)	5	6	83.3 (43.6, 97)	1.70 (1.19, 2.58)	49	101	48.5 (39, 58.1)	44	95	46.3 (36.6, 56.3)	72	147	49.0 (41, 57)	
	B5C	7	18	38.9 (20.31, 61.38)	0.78 (0.42, 1.45)	2	7	28.6 (8.2, 64.1)	0.60 (0.19, 1.98)	35	70	50.0 (38.6, 61.4)	33	63	52.4 (40.3, 64.2)	42	88	47.7 (37.6, 58)	
	B55L	8	12	66.7 (39.06, 86.19)	1.29 (0.84, 2)	1	1	100.0 (20.7, 100)	1.90 (1.9, 2.24)	69	134	51.5 (43.1, 59.8)	68	133	51.1 (42.7, 59.5)	77	146	52.7 (44.7, 60.7)	
	B5OS	3	3	100.0 (43.85, 100)	1.81 (1.45, 2.25)	1	1	100.0 (20.7, 100)	1.74 (1.74, 2.18)	36	65	55.4 (43.3, 66.8)	35	64	54.7 (42.6, 66.3)	39	68	57.4 (45.5, 68.4)	
Total	101	199	50.8 (43.86, 57.62)	0.99 (0.85, 1.15)	36	69	52.2 (40.6, 63.5)	1.02 (0.81, 1.29)	393	766	51.3 (47.8, 54.8)	357	697	51.2 (47.5, 54.9)	494	965	51.2 (48, 54.3)		
Group 4: Node negative, high risk, either ER or PR positive	BSWN	15	88	17.0 (10.61, 26.24)	0.87 (0.52, 1.46)	4	15	26.7 (10.9, 52)	1.40 (0.61, 3.36)	55	280	19.6 (15.4, 24.7)	51	265	19.2 (15, 24.4)	70	368	19.0 (15.3, 23.3)	
	BSCM	8	41	19.5 (10.23, 34.01)	0.81 (0.41, 1.57)	11	60	18.3 (10.6, 29.9)	0.78 (0.46, 1.43)	50	207	24.2 (18.8, 30.4)	39	147	26.5 (20.1, 34.2)	58	248	23.4 (18.5, 29)	
	BSAC	2	20	10.0 (2.79, 30.1)	0.45 (0.12, 1.72)	6	35	17.1 (8.1, 32.7)	0.81 (0.39, 1.79)	38	170	22.4 (16.7, 29.2)	32	135	23.7 (17.3, 31.5)	40	190	21.1 (15.9, 27.4)	
	B5M	14	117	12.0 (7.26, 19.09)	1.09 (0.61, 1.95)	2	6	33.3 (9.7, 70)	2.97 (0.96, 9.61)	36	328	11.0 (8, 14.8)	34	322	10.6 (7.7, 14.4)	50	445	11.2 (8.6, 14.5)	
	B5CC	15	61	24.6 (15.51, 36.68)	1.51 (0.89, 2.53)	4	7	57.1 (25, 84.2)	3.18 (1.68, 6.46)	41	251	16.3 (12.3, 21.4)	37	244	15.2 (11.2, 20.2)	56	312	17.9 (14.1, 22.6)	
	B5C	6	42	14.3 (6.72, 27.84)	0.87 (0.39, 1.92)	7	21	33.3 (17.2, 54.6)	2.07 (1.13, 4.11)	38	231	16.5 (12.2, 21.8)	31	210	14.8 (10.6, 20.2)	44	273	16.1 (12.2, 20.9)	
	B55L	6	43	14.0 (6.56, 27.26)	0.86 (0.4, 1.87)	2	4	50.0 (15, 85)	3.14 (1.18, 8.58)	64	396	16.2 (12.9, 20.1)	62	392	15.8 (12.5, 19.8)	70	439	15.9 (12.8, 19.7)	
	B5OS	2	14	14.3 (4.01, 39.94)	0.79 (0.21, 2.95)	0	5	0.0 (0, 43.4)	0.00 NA	30	165	18.2 (13, 24.8)	30	160	18.8 (13.5, 25.5)	32	179	17.9 (13, 24.1)	
Total	68	426	16.0 (12.79, 19.74)	0.92 (0.73, 1.17)	36	153	23.5 (17.5, 30.8)	1.37 (1.03, 1.86)	352	2,028	17.4 (15.8, 19.1)	316	1,875	16.9 (15.2, 18.6)	420	2,454	17.1 (15.7, 18.7)		

4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2020

Description: The percentage of women diagnosed with invasive cancer who have endocrine therapy reported by disease character group. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Among women aged 45–69 years who were diagnosed with invasive breast cancer during the four years to December 2020, 92% of those who were node positive and either ER or PR positive had endocrine therapy, as did 73% of those who were node negative, high risk, and either ER or PR positive, and 43% who were node negative, low risk, and either ER or PR positive.

Table 36: 4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2020

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	
45 to 49	Group 1: Node positive, either ER or PR positive	BSWN	4	5	80.0 (28.4, 99.5)	0.87 (0.56, 1.36)	2	2	100.0 (15.8, 100.0)	1.09 (0.99, 1.21)	34	37	91.9 (78.1, 98.3)	32	35	91.4 (76.9, 98.2)	38	42	90.5 (77.4, 97.3)	
		BSCM	7	7	100.0 (59.0, 100.0)	1.06 (0.95, 1.17)	8	9	88.9 (51.8, 99.7)	0.89 (0.71, 1.12)	18	19	94.7 (74.0, 99.9)	10	10	100.0 (69.2, 100.0)	25	26	96.2 (80.4, 99.9)	
		BSAC	2	2	100.0 (15.8, 100.0)	1.08 (0.93, 1.27)	2	2	100.0 (15.8, 100.0)	1.10 (0.91, 1.33)	12	13	92.3 (64.0, 99.8)	10	11	90.9 (58.7, 99.8)	14	15	93.3 (68.1, 99.8)	
		BSM	8	9	88.9 (51.8, 99.7)	0.99 (0.75, 1.31)	0	0	NA (NA, NA)	NA (NA, NA)	17	19	89.5 (66.9, 98.7)	17	19	89.5 (66.9, 98.7)	25	28	89.3 (71.8, 97.7)	
		BSCC	10	10	100.0 (69.2, 100.0)	1.06 (0.95, 1.18)	1	1	100.0 (2.5, 100.0)	1.06 (0.94, 1.20)	17	18	94.4 (72.7, 99.9)	16	17	94.1 (71.3, 99.9)	27	28	96.4 (81.7, 99.9)	
		BSC	7	7	100.0 (59.0, 100.0)	1.14 (0.88, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)	14	15	93.3 (68.1, 99.8)	
		BSSL	2	3	66.7 (9.4, 99.2)	0.76 (0.34, 1.71)	1	1	100.0 (2.5, 100.0)	1.14 (1.00, 1.30)	29	33	87.9 (71.8, 96.6)	28	32	87.5 (71.0, 96.5)	31	36	86.1 (70.5, 95.3)	
		BSOS	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 (59.0, 100.0)	7	7	100.0 (59.0, 100.0)	8	8	100.0 (63.1, 100.0)	
		Total	41	44	93.2 (81.3, 98.6)	1.02 (0.93, 1.12)	14	15	93.3 (68.1, 99.8)	1.02 (0.88, 1.18)	141	154	91.4 (86.0, 95.4)	127	139	91.4 (85.4, 95.5)	182	198	91.0 (82.2, 95.3)	
		Group 2: Node negative, high risk, either ER or PR positive	BSWN	9	13	69.2 (38.6, 90.9)	0.90 (0.60, 1.34)	3	3	100.0 (29.2, 100.0)	1.33 (1.10, 1.61)	30	39	76.9 (60.7, 88.9)	27	36	75.0 (57.8, 87.9)	39	52	75.0 (61.1, 86.0)
	BSCM		5	5	100.0 (47.8, 100.0)	1.25 (1.07, 1.46)	6	9	66.7 (29.9, 92.5)	0.80 (0.49, 1.29)	32	40	80.0 (64.4, 90.9)	26	31	83.9 (66.3, 94.5)	37	45	82.2 (67.9, 92.0)	
	BSAC		1	1	100.0 (2.5, 100.0)	1.40 (1.11, 1.77)	4	5	80.0 (28.4, 99.5)	1.15 (0.69, 1.93)	20	28	71.4 (51.3, 86.8)	16	23	69.6 (47.1, 86.8)	21	29	72.4 (52.8, 87.3)	
	BSM		12	12	100.0 (73.5, 100.0)	1.07 (0.98, 1.16)	1	1	100.0 (2.5, 100.0)	1.07 (0.97, 1.17)	31	33	93.9 (79.8, 99.3)	30	32	93.8 (79.2, 99.2)	43	45	95.6 (84.9, 99.5)	
	BSCC		9	9	100.0 (66.4, 100.0)	1.23 (1.04, 1.45)	2	4	50.0 (6.8, 93.2)	0.58 (0.22, 2.57)	26	32	81.3 (63.6, 92.8)	24	28	85.7 (67.3, 96.0)	35	41	85.4 (70.8, 94.4)	
	BSC		7	7	100.0 (59.0, 100.0)	1.11 (0.96, 1.27)	3	3	100.0 (29.2, 100.0)	1.13 (0.95, 1.32)	19	21	90.5 (69.6, 98.8)	16	18	88.9 (65.3, 98.6)	26	28	92.9 (76.5, 99.1)	
	BSSL		3	5	60.0 (14.7, 94.7)	0.89 (0.42, 1.85)	0	0	NA (NA, NA)	NA (NA, NA)	42	62	67.7 (54.7, 79.1)	42	62	67.7 (54.7, 79.1)	45	67	67.2 (54.6, 78.2)	
	BSOS		1	3	33.3 (0.8, 90.6)	0.47 (0.09, 2.39)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 5.57)	19	27	70.4 (49.8, 86.2)	19	26	73.1 (52.2, 88.4)	20	30	66.7 (47.2, 82.7)	
	Total		47	55	85.5 (73.3, 93.5)	1.10 (0.97, 1.25)	19	26	73.1 (52.2, 88.4)	0.94 (0.73, 1.19)	219	282	77.7 (72.3, 82.4)	200	256	78.1 (72.6, 83.0)	266	337	78.9 (74.2, 83.2)	
	Group 3: Node negative, low risk, either ER or PR positive		BSWN	2	6	33.3 (4.3, 77.7)	0.67 (0.20, 2.21)	0	0	NA (NA, NA)	NA (NA, NA)	12	24	50.0 (29.1, 70.9)	12	24	50.0 (29.1, 70.9)	14	30	46.7 (28.3, 65.7)
		BSCM	1	3	33.3 (0.8, 90.6)	4.33 (0.37, 51.29)	0	5	0.0 (0.0, 52.2)	0.00 (0.00, 62.40)	1	13	7.7 (0.2, 36.0)	1	8	12.5 (0.3, 52.7)	2	16	12.5 (1.6, 38.3)	
		BSAC	1	2	50.0 (1.3, 98.7)	2.00 (0.37, 10.92)	2	3	66.7 (9.4, 99.2)	6.00 (0.80, 44.95)	3	12	25.0 (5.5, 57.2)	1	9	11.1 (0.3, 48.2)	4	14	28.6 (8.4, 58.1)	
		BSM	1	1	100.0 (2.5, 100.0)	1.19 (0.98, 1.44)	0	0	NA (NA, NA)	NA (NA, NA)	16	19	84.2 (60.4, 96.6)	16	19	84.2 (60.4, 96.6)	17	20	85.0 (62.1, 96.8)	
		BSCC	3	4	75.0 (19.4, 99.4)	4.50 (1.39, 14.61)	0	0	NA (NA, NA)	NA (NA, NA)	3	18	16.7 (3.6, 41.4)	3	18	16.7 (3.6, 41.4)	6	22	27.3 (10.7, 50.2)	
		BSC	1	1	100.0 (2.5, 100.0)	1.09 (0.92, 1.29)	0	0	NA (NA, NA)	NA (NA, NA)	11	12	91.7 (61.5, 99.8)	11	12	91.7 (61.5, 99.8)	12	13	92.3 (64.0, 99.8)	
		BSSL	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 25.10)	0	0	NA (NA, NA)	NA (NA, NA)	5	23	21.7 (7.5, 43.7)	5	23	21.7 (7.5, 43.7)	5	24	20.8 (7.1, 42.2)	
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	4	0.0 (0.0, 60.2)	0	4	0.0 (0.0, 60.2)	0	4	0.0 (0.0, 60.2)	
		Total	9	18	50.0 (26.0, 74.0)	1.23 (0.74, 2.04)	2	8	25.0 (3.2, 65.1)	0.60 (0.18, 2.02)	51	125	40.8 (32.1, 49.9)	49	117	41.9 (32.8, 51.4)	60	143	42.0 (33.8, 50.5)	
		50 to 69	Group 1: Node positive, either ER or PR positive	BSWN	25	25	100.0 (86.3, 100.0)	1.13 (1.05, 1.22)	9	11	81.8 (48.2, 97.7)	0.91 (0.69, 1.22)	77	87	88.5 (79.9, 94.3)	68	76	89.5 (80.3, 95.3)	102	112
	BSCM			14	15	93.3 (68.1, 99.8)	0.98 (0.85, 1.13)	15	17	88.2 (63.6, 98.5)	0.90 (0.75, 1.08)	60	63	95.2 (86.7, 99.0)	45	46	97.8 (88.5, 99.9)	74	78	94.9 (87.4, 98.6)
	BSAC			5	7	71.4 (29.0, 96.3)	0.86 (0.53, 1.39)	8	8	100.0 (63.1, 100.0)	1.24 (1.08, 1.41)	50	60	83.3 (71.5, 91.7)	42	52	80.8 (67.5, 90.4)	55	67	82.1 (70.8, 90.4)
BSM	46			50	92.0 (80.8, 97.8)	1.00 (0.91, 1.11)	2	4	50.0 (6.8, 93.2)	0.53 (0.20, 1.43)	89	97	91.8 (84.4, 96.4)	87	93	93.5 (86.5, 97.6)	135	147	91.8 (86.2, 95.7)	
BSCC	32			36	88.9 (73.9, 96.9)	0.90 (0.80, 1.01)	5	5	100.0 (47.8, 100.0)	1.01 (0.99, 1.04)	82	83	98.8 (93.5, 100.0)	77	78	98.7 (93.1, 100.0)	114	119	95.8 (90.5, 98.6)	
BSC	11			11	100.0 (71.5, 100.0)	1.05 (0.99, 1.11)	7	7	100.0 (59.0, 100.0)	1.06 (0.99, 1.13)	59	62	95.2 (86.5, 99.0)	52	55	94.5 (84.9, 98.9)	70	73	95.9 (88.5, 99.1)	
BSSL	8			9	88.9 (51.8, 99.7)	1.01 (0.79, 1.28)	0	0	NA (NA, NA)	NA (NA, NA)	89	101	88.1 (80.2, 93.7)	89	101	88.1 (80.2, 93.7)	97	110	88.2 (80.6, 93.6)	
BSOS	1			2	50.0 (1.3, 98.7)	0.53 (0.13, 2.11)	1	1	100.0 (2.5, 100.0)	1.06 (0.99, 1.12)	55	58	94.8 (85.6, 98.9)	54	57	94.7 (85.4, 98.9)	56	60	93.3 (83.8, 98.2)	
Total	142			155	91.6 (86.1, 95.5)	1.00 (0.95, 1.05)	47	53	88.7 (77.0, 95.7)	0.96 (0.87, 1.06)	561	611	91.8 (89.4, 93.9)	514	558	92.1 (89.6, 94.2)	703	766	91.8 (89.6, 93.6)	
Group 2: Node negative, high risk, either ER or PR positive	BSWN			41	75	54.7 (42.7, 66.2)	0.80 (0.64, 1.00)	12	12	100.0 (73.5, 100.0)	1.50 (1.37, 1.64)	165	241	68.5 (62.2, 74.3)	153	229	66.8 (60.3, 72.9)	206	316	65.2 (59.7, 70.4)
	BSCM		29	36	80.6 (64.0, 91.8)	1.13 (0.94, 1.36)	37	51	72.5 (58.3, 84.1)	1.03 (0.84, 1.26)	119	167	71.3 (63.8, 78.0)	82	116	70.7 (61.5, 78.8)	148	203	72.9 (66.2, 78.9)	
	BSAC		10	19	52.6 (28.9, 75.6)	0.91 (0.58, 1.43)	19	30	63.3 (43.9, 80.1)	1.13 (0.82, 1.55)	82	142	57.7 (49.2, 66.0)	63	112	56.3 (46.6, 65.6)	92	161	57.1 (49.1, 64.9)	
	BSM		93	105	88.6 (80.9, 94.0)	1.03 (0.94, 1.11)	5	5	100.0 (47.8, 100.0)	1.16 (1.11, 1.22)	255	295	86.4 (82.0, 90.1)	250	290	86.2 (81.7, 90.0)	348	400	87.0 (83.3, 90.1)	
	BSCC		44	52	84.6 (71.9, 93.1)	1.10 (0.96, 1.26)	3	3	100.0 (29.2, 100.0)	1.31 (1.22, 1.41)	168	219	76.7 (70.5, 82.1)	165	216	76.4 (70.2, 81.9)	212	271	78.2 (72.8, 83.0)	
	BSC		35	35	100.0 (90.0, 100.0)	1.12 (1.07, 1.17)	17	18	94.4 (72.7, 99.9)	1.06 (0.94, 1.20)	188	210	89.5 (84.6, 93.3)	171	192	89.1 (83.8, 93.1)	223	245	91.0 (86.7, 94.3)	
	BSSL		27	38	71.1 (54.1, 84.6)	1.26 (1.00, 1.57)	1	4	25.0 (0.6, 80.6)	0.44 (0.08, 2.40)	189	334	56.6 (51.1, 62.0)	188	330	57.0 (51.4, 62.4)	216	372	58.1 (52.9, 63.1)	
	BSOS		7	11	63.6 (30.8, 89.1)	1.11 (0.69, 1.78)	1	4	50.0 (6.8, 93.2)	0.87 (0.32, 2.34)	79	138	57.2 (48.5, 65.6)	77	134	57.5 (48.6, 66.0)	86	149	57.7 (49.4, 65.8)	
	Total		286	371	77.1 (72.5, 81.3)	1.08 (1.01, 1.15)	96	127	75.6 (67.2, 82.8)	1.07 (0.96, 1.18)	1,245	1,746	71.3 (69.1, 73.4)	1,149	1,619	71.0 (68.7, 73.2)	1,531	2,117	72.3 (70.4, 74.2)	
	Group 3: Node negative, low risk, either ER or PR positive		BSWN	5	32	15.6 (5.3, 32.8)	0.63 (0.27, 1.49)	3	9	33.3 (7.5, 70.1)	1.38 (0.52, 3.64)	37	150	24.7 (18.0, 32.4)	34	141	24.1 (17.3, 32.0)	42	182	23.1 (17.2, 29.9)
BSCM			1	12	8.3 (0.2, 38.5)	0.93 (0.12, 7.06)	0	13	0.0 (0.0, 24.7)	0.00 (0.00, 3.53)	6	67	9.0 (3.4, 18.5)	6	54	11.1 (4.2, 22.6)	7	79	8.9 (3.6, 17.4)	
BSAC			1	8	12.5 (0.3, 52.7)	1.41 (0.18, 11.01)	1	8	12.5 (0.3, 52.7)	1.54 (0.18, 12.98)	4	45	8.9 (2.5, 21.2)	3	37	8.1 (1.7, 21.9)	5	53	9.4 (3.1, 20.7)	
BSM			25	32	78.1 (60.0, 90.7)	0.94 (0.77, 1.15)	1	1	100.0 (2.5,											

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	
45 to 69	Group 1: Node positive, either ER or PR positive	BSWN	29	30	96.7 (82.8, 99.9)	1.08 (0.99, 1.18)	11	13	84.6 (54.6, 98.1)	0.94 (0.74, 1.19)	111	124	89.5 (82.7, 94.3)	100	111	90.1 (83.0, 94.9)	140	154	90.9 (85.2, 94.9)
		BSCM	21	22	95.5 (77.2, 99.9)	1.00 (0.91, 1.11)	23	26	88.5 (69.8, 97.6)	0.90 (0.78, 1.04)	78	82	95.1 (88.0, 98.7)	55	56	98.2 (90.4, 100.0)	99	104	95.2 (89.1, 98.4)
		BSAC	7	9	77.8 (40.0, 97.2)	0.92 (0.64, 1.32)	10	10	100.0 (69.2, 100.0)	1.21 (1.08, 1.36)	62	73	84.9 (74.6, 92.2)	52	63	82.5 (70.9, 90.9)	69	82	84.1 (74.4, 91.3)
		BSM	54	59	91.5 (81.3, 97.2)	1.00 (0.91, 1.10)	2	4	50.0 (6.8, 93.2)	0.54 (0.20, 1.44)	106	116	91.4 (84.7, 95.8)	104	112	92.9 (86.4, 96.9)	160	175	91.4 (86.3, 95.1)
		BSCC	42	46	91.3 (79.2, 97.6)	0.93 (0.85, 1.02)	6	6	100.0 (54.1, 100.0)	1.02 (0.99, 1.05)	99	101	98.0 (93.0, 99.8)	93	95	97.9 (92.6, 99.7)	141	147	95.9 (91.3, 98.5)
		BSC	18	18	100.0 (81.5, 100.0)	1.06 (1.00, 1.12)	7	7	100.0 (59.0, 100.0)	1.07 (1.00, 1.14)	66	70	94.3 (86.0, 98.4)	59	63	93.7 (84.5, 98.2)	84	88	95.5 (88.8, 98.7)
		BSSL	10	12	83.3 (51.6, 97.9)	0.95 (0.73, 1.23)	1	1	100.0 (2.5, 100.0)	1.14 (1.07, 1.21)	118	134	88.1 (81.3, 93.0)	117	133	88.0 (81.2, 93.0)	128	146	87.7 (81.2, 92.5)
		BSOS	2	3	66.7 (9.4, 99.2)	0.70 (0.31, 1.56)	1	1	100.0 (2.5, 100.0)	1.05 (0.99, 1.11)	62	65	95.4 (87.1, 99.0)	61	64	95.3 (86.9, 99.0)	64	68	94.1 (85.6, 98.4)
		Total	183	199	92.0 (87.3, 95.3)	1.00 (0.96, 1.05)	61	68	89.7 (79.9, 95.8)	0.98 (0.90, 1.06)	702	765	91.8 (89.6, 93.6)	641	697	92.0 (89.7, 93.9)	885	964	91.8 (89.9, 93.5)
	Group 2: Node negative, high risk, either ER or PR positive	BSWN	50	88	56.8 (45.8, 67.3)	0.82 (0.67, 0.99)	15	15	100.0 (78.2, 100.0)	1.47 (1.35, 1.60)	195	280	69.6 (63.9, 75.0)	180	265	67.9 (61.9, 73.5)	245	368	66.6 (61.5, 71.4)
		BSCM	34	41	82.9 (67.9, 92.8)	1.14 (0.97, 1.34)	43	60	71.7 (58.6, 82.5)	0.98 (0.81, 1.18)	151	207	72.9 (66.4, 78.9)	108	147	73.5 (65.6, 80.4)	185	248	74.6 (68.7, 79.9)
		BSAC	11	20	55.0 (31.5, 76.9)	0.92 (0.60, 1.39)	23	35	65.7 (47.8, 80.9)	1.12 (0.85, 1.48)	102	170	60.0 (52.2, 67.4)	79	135	58.5 (49.7, 66.9)	113	190	59.5 (52.1, 66.5)
		BSM	105	117	89.7 (82.8, 94.6)	1.03 (0.96, 1.11)	6	6	100.0 (54.1, 100.0)	1.15 (1.10, 1.20)	286	328	87.2 (83.1, 90.6)	280	322	87.0 (82.8, 90.4)	391	445	87.9 (84.5, 90.8)
		BSCC	53	61	86.9 (75.8, 94.2)	1.12 (1.00, 1.26)	5	7	71.4 (29.0, 96.3)	0.92 (0.57, 1.48)	194	251	77.3 (71.6, 82.3)	189	244	77.5 (71.7, 82.5)	247	312	79.2 (74.2, 83.5)
		BSC	42	42	100.0 (91.6, 100.0)	1.12 (1.07, 1.17)	20	21	95.2 (76.2, 99.9)	1.07 (0.96, 1.19)	207	231	89.6 (84.9, 93.2)	187	210	89.0 (84.0, 92.9)	249	273	91.2 (87.2, 94.3)
		BSSL	30	43	69.8 (53.9, 82.8)	1.20 (0.97, 1.48)	1	4	25.0 (0.6, 80.6)	0.43 (0.08, 2.33)	231	396	58.3 (53.3, 63.2)	230	392	58.7 (53.6, 63.6)	261	439	59.5 (54.7, 64.1)
		BSOS	8	14	57.1 (28.9, 82.3)	0.96 (0.60, 1.54)	2	5	40.0 (5.3, 85.3)	0.67 (0.23, 1.97)	98	165	59.4 (51.5, 67.0)	96	160	60.0 (52.0, 67.7)	106	179	59.2 (51.6, 66.5)
		Total	333	426	78.2 (73.9, 82.0)	1.08 (1.02, 1.15)	115	153	75.2 (67.5, 81.8)	1.05 (0.95, 1.15)	1,464	2,028	72.2 (70.2, 74.1)	1,349	1,875	71.9 (69.9, 74.0)	1,797	2,454	73.2 (71.4, 75.0)
	Group 3: Node negative, low risk, either ER or PR positive	BSWN	7	38	18.4 (7.7, 34.3)	0.65 (0.32, 1.33)	3	9	33.3 (7.5, 70.1)	1.20 (0.46, 3.11)	49	174	28.2 (21.6, 35.5)	46	165	27.9 (21.2, 35.4)	56	212	26.4 (20.6, 32.9)
		BSCM	2	15	13.3 (1.7, 40.5)	1.52 (0.35, 6.64)	0	18	0.0 (0.0, 18.5)	0.00 (0.00, 2.39)	7	80	8.8 (3.6, 17.2)	7	62	11.3 (4.7, 21.9)	9	95	9.5 (4.4, 17.2)
		BSAC	2	10	20.0 (2.5, 55.6)	1.63 (0.39, 6.74)	3	11	27.3 (6.0, 61.0)	3.14 (0.82, 12.03)	7	57	12.3 (5.1, 23.7)	4	46	8.7 (2.4, 20.8)	9	67	13.4 (6.3, 24.0)
		BSM	26	33	78.8 (61.1, 91.0)	0.94 (0.78, 1.15)	1	1	100.0 (2.5, 100.0)	1.20 (1.11, 1.30)	101	121	83.5 (75.6, 89.6)	100	120	83.3 (75.4, 89.5)	127	154	82.5 (75.5, 88.1)
		BSCC	20	32	62.5 (43.7, 78.9)	1.33 (0.95, 1.87)	1	1	100.0 (2.5, 100.0)	2.15 (1.74, 2.66)	47	100	47.0 (36.9, 57.2)	46	99	46.5 (36.4, 56.8)	67	132	50.8 (41.9, 59.6)
		BSC	10	11	90.9 (58.7, 99.8)	1.10 (0.89, 1.34)	4	4	100.0 (39.8, 100.0)	1.21 (1.11, 1.33)	88	106	83.0 (74.5, 89.6)	84	102	82.4 (73.6, 89.2)	98	117	83.8 (75.8, 89.9)
		BSSL	7	13	53.8 (25.1, 80.8)	1.51 (0.88, 2.59)	1	1	100.0 (2.5, 100.0)	2.83 (2.32, 3.44)	65	182	35.7 (28.8, 43.1)	64	181	35.4 (28.4, 42.8)	72	195	36.9 (30.1, 44.1)
		BSOS	3	5	60.0 (14.7, 94.7)	2.70 (1.19, 6.15)	0	0	NA (NA, NA)	NA (NA, NA)	18	81	22.2 (13.7, 32.8)	18	81	22.2 (13.7, 32.8)	21	86	24.4 (15.8, 34.9)
		Total	77	157	49.0 (41.0, 57.1)	1.16 (0.97, 1.38)	13	45	28.9 (16.4, 44.3)	0.67 (0.42, 1.07)	382	901	42.4 (39.1, 45.7)	369	856	43.1 (39.8, 46.5)	459	1,058	43.4 (40.4, 46.4)


Timeliness

5.a, Time taken for provision of screening results

Description: The time since screening that it takes for a woman to be sent the results of her mammogram.

Target: ≥ 90% notified within 10 working days.

Figure 97: 5.a, Time taken for provision of screening results, 50 to 69 years, total BSA



Overall, BSA met the target of 90% or more of women receiving their screening results within 10 working days at 93%.

BreastScreen Midland showed a 6% increase from 79% to 85%. BreastScreen Central remained just under target at 87%. All other LPs were within the target range with three LPs over 98%.

Figure 98: 5.a, Time taken for provision of screening results, by LP




Table 37: 5.a, Time taken for provision of screening results


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Māori / Non-Māori Ratio	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)
45 to 49	BSWN		2,405	2,482	96.9 (96.1, 97.5)	0.98 (0.98, 0.99)	835	845	98.8 (97.8, 99.4)	1.00 (0.99, 1.01)	14,874	15,092	98.6 (98.4, 98.7)	14,039	14,247	98.5 (98.3, 98.7)	17,279	17,574	98.3 (98.1, 98.5)
	BSCM		1,650	1,685	97.9 (97.1, 98.5)	1.00 (1.00, 1.01)	2,512	2,585	97.2 (96.5, 97.8)	1.00 (0.99, 1.00)	10,490	10,751	97.6 (97.3, 97.9)	7,978	8,166	97.7 (97.3, 98.0)	12,140	12,436	97.6 (97.3, 97.9)
	BSAC		733	742	98.8 (97.7, 99.4)	1.00 (0.99, 1.01)	886	892	99.3 (98.5, 99.8)	1.01 (1.00, 1.01)	7,556	7,642	98.9 (98.6, 99.1)	6,670	6,750	98.8 (98.5, 99.1)	8,289	8,384	98.9 (98.6, 99.1)
	BSM		2,632	3,114	84.5 (83.2, 85.8)	0.99 (0.98, 1.01)	254	315	80.6 (75.8, 84.9)	0.95 (0.90, 1.00)	10,867	12,755	85.2 (84.6, 85.8)	10,613	12,440	85.3 (84.7, 85.9)	13,499	15,869	85.1 (84.5, 85.6)
	BSCC		2,381	2,500	95.2 (94.3, 96.0)	0.99 (0.98, 1.00)	217	229	94.8 (91.0, 97.3)	0.99 (0.95, 1.01)	10,385	10,795	96.2 (95.8, 96.6)	10,168	10,566	96.2 (95.9, 96.6)	12,766	13,295	96.0 (95.7, 96.3)
	BSC		1,049	1,240	84.6 (82.5, 86.6)	1.00 (0.97, 1.02)	468	568	82.4 (79.0, 85.4)	0.97 (0.93, 1.01)	7,621	8,976	84.9 (84.1, 85.6)	7,153	8,408	85.1 (84.3, 85.8)	8,670	10,216	84.9 (84.2, 85.6)
	BSSL		1,384	1,537	90.0 (88.4, 91.5)	0.99 (0.97, 1.01)	289	323	89.5 (85.6, 92.6)	0.98 (0.95, 1.02)	18,945	20,839	90.9 (90.5, 91.3)	18,656	20,516	90.9 (90.5, 91.3)	20,329	22,376	90.9 (90.5, 91.2)
	BSOS		530	593	89.4 (86.6, 91.7)	1.00 (0.97, 1.03)	89	96	92.7 (85.6, 97.0)	1.04 (0.98, 1.10)	6,088	6,797	89.6 (88.8, 90.3)	5,999	6,701	89.5 (88.8, 90.2)	6,618	7,390	89.6 (88.8, 90.2)
	Total		12,764	13,893	91.9 (91.4, 92.3)	0.99 (0.99, 1.00)	5,550	5,853	94.8 (94.2, 95.4)	1.02 (1.02, 1.03)	86,826	93,647	92.7 (92.5, 92.9)	81,276	87,794	92.6 (92.4, 92.7)	99,590	107,540	92.6 (92.4, 92.8)
	50 to 69	BSWN		7,771	7,876	98.7 (98.4, 98.9)	1.00 (0.99, 1.00)	2,807	2,838	98.9 (98.5, 99.3)	1.00 (0.99, 1.00)	54,928	55,426	99.1 (99.0, 99.2)	52,121	52,588	99.1 (99.0, 99.2)	62,699	63,302
BSCM			4,519	4,617	97.9 (97.4, 98.3)	1.00 (0.99, 1.00)	7,530	7,658	98.3 (98.0, 98.6)	1.00 (1.00, 1.00)	35,047	35,641	98.3 (98.2, 98.5)	27,517	27,983	98.3 (98.2, 98.5)	39,566	40,258	98.3 (98.1, 98.4)
BSAC			1,973	1,994	98.9 (98.4, 99.3)	1.01 (1.00, 1.01)	2,964	2,996	98.9 (98.5, 99.3)	1.01 (1.00, 1.01)	25,050	25,490	98.3 (98.1, 98.4)	22,086	22,494	98.2 (98.0, 98.4)	27,023	27,484	98.3 (98.2, 98.5)
BSM			9,130	10,950	83.4 (82.7, 84.1)	0.98 (0.97, 0.99)	772	956	80.8 (78.1, 83.2)	0.95 (0.92, 0.98)	45,996	54,026	85.0 (84.7, 85.3)	45,164	53,070	85.1 (84.8, 85.4)	55,066	64,976	84.7 (84.5, 85.0)
BSCC			8,454	8,812	95.9 (95.5, 96.3)	0.99 (0.98, 0.99)	770	797	96.6 (95.1, 97.8)	1.00 (0.98, 1.01)	45,744	47,158	97.0 (96.8, 97.2)	44,974	46,361	97.0 (96.8, 97.2)	54,198	55,970	96.8 (96.7, 97.0)
BSC			3,711	4,273	86.8 (85.8, 87.8)	1.00 (0.99, 1.01)	1,929	2,250	85.7 (84.2, 87.2)	0.99 (0.97, 1.00)	36,362	41,859	86.9 (86.5, 87.2)	34,433	39,609	86.9 (86.6, 87.3)	40,073	46,132	86.9 (86.6, 87.2)
BSSL			4,290	4,609	93.1 (92.3, 93.8)	1.01 (1.00, 1.02)	787	857	91.8 (89.8, 93.6)	1.00 (0.97, 1.01)	69,966	75,778	92.3 (92.1, 92.5)	69,179	74,921	92.3 (92.1, 92.5)	74,256	80,387	92.4 (92.2, 92.6)
BSOS			1,776	1,920	92.5 (91.2, 93.6)	1.00 (0.98, 1.01)	250	279	89.6 (85.4, 92.9)	0.97 (0.93, 1.01)	26,077	28,146	92.6 (92.3, 93.0)	25,827	27,867	92.7 (92.4, 93.0)	27,853	30,066	92.6 (92.3, 92.9)
Total			41,624	45,051	92.4 (92.1, 92.6)	0.99 (0.99, 0.99)	17,809	18,631	95.6 (95.3, 95.9)	1.03 (1.02, 1.03)	339,110	363,524	93.3 (93.2, 93.4)	321,301	344,893	93.2 (93.1, 93.2)	380,734	408,575	93.2 (93.1, 93.3)
45 to 69		BSWN		10,176	10,358	98.2 (98.0, 98.5)	0.99 (0.99, 0.99)	3,642	3,683	98.9 (98.5, 99.2)	1.00 (0.99, 1.00)	69,802	70,518	99.0 (98.9, 99.1)	66,160	66,835	99.0 (98.9, 99.1)	79,978	80,876
	BSCM		6,169	6,302	97.9 (97.5, 98.2)	1.00 (0.99, 1.00)	10,042	10,243	98.0 (97.8, 98.3)	1.00 (0.99, 1.00)	45,537	46,392	98.2 (98.0, 98.3)	35,495	36,149	98.2 (98.0, 98.3)	51,706	52,694	98.1 (98.0, 98.2)
	BSAC		2,706	2,736	98.9 (98.4, 99.3)	1.01 (1.00, 1.01)	3,850	3,888	99.0 (98.7, 99.3)	1.01 (1.00, 1.01)	32,606	33,132	98.4 (98.3, 98.5)	28,756	29,244	98.3 (98.2, 98.5)	35,312	35,868	98.4 (98.3, 98.6)
	BSM		11,762	14,064	83.6 (83.0, 84.2)	0.98 (0.97, 0.99)	1,026	1,271	80.7 (78.4, 82.9)	0.95 (0.92, 0.97)	56,803	66,781	85.1 (84.8, 85.3)	55,777	65,510	85.1 (84.9, 85.4)	68,565	80,845	84.8 (84.6, 85.1)
	BSCC		10,835	11,312	95.8 (95.4, 96.1)	0.99 (0.98, 0.99)	987	1,026	96.2 (94.8, 97.3)	0.99 (0.98, 1.00)	56,129	57,953	96.9 (96.7, 97.0)	55,142	56,927	96.9 (96.7, 97.0)	66,964	69,265	96.7 (96.5, 96.8)
	BSC		4,760	5,513	86.3 (85.4, 87.2)	1.00 (0.99, 1.01)	2,397	2,818	85.1 (83.7, 86.4)	0.98 (0.97, 1.00)	43,983	50,835	86.5 (86.2, 86.8)	41,586	48,017	86.6 (86.3, 86.9)	48,743	56,348	86.5 (86.2, 86.8)
	BSSL		5,674	6,146	92.3 (91.6, 93.0)	1.00 (1.00, 1.01)	1,076	1,180	91.2 (89.4, 92.7)	0.99 (0.97, 1.01)	88,911	96,617	92.0 (91.9, 92.2)	87,835	95,437	92.0 (91.9, 92.2)	94,585	102,763	92.0 (91.9, 92.2)
	BSOS		2,306	2,513	91.8 (90.6, 92.8)	1.00 (0.98, 1.01)	339	375	90.4 (87.0, 93.2)	0.98 (0.95, 1.01)	32,165	34,943	92.0 (91.8, 92.3)	31,826	34,568	92.1 (91.8, 92.4)	34,471	37,456	92.0 (91.8, 92.3)
	Total		54,388	58,944	92.3 (92.1, 92.5)	0.99 (0.99, 0.99)	23,359	24,484	95.4 (95.1, 95.7)	1.03 (1.02, 1.03)	425,936	457,171	93.2 (93.1, 93.2)	402,577	432,687	93.0 (93.0, 93.1)	480,324	516,115	93.1 (93.0, 93.1)

5.b, Time taken from screening visit to first offer of an assessment

Description: The time between screening and the earliest appointment date the woman is offered for assessment. In some cases this date may not coincide with the actual date of assessment due to the fact that many women arrange for a time that suits them better.

Target: 90% offered an assessment appointment within 15 working days.

Figure 99: 5.b, 50 to 69, Time taken from screening visit to first offer of an assessment



The overall proportion of women offered an assessment within 15 working days of their screen was 83%. Two LPS (BSAC and BSC) met the target of 90% or more. Most other LPS showed small declines, although BSCC increased to 71%.

Figure 100: 5.b, 50 to 69, Time taken from screening visit to first offer of an assessment, by LP




Table 38: 5.b, Time taken from screening visit to first offer of an assessment


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Māori / Non-Māori Ratio	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)
45 to 49	BSWN	170	211	80.6 (74.6, 85.7)	0.93 (0.86, 0.99)	51	57	89.5 (78.5, 96.0)	1.03 (0.94, 1.13)	795	915	86.9 (84.5, 89.0)	744	858	86.7 (84.3, 88.9)	965	1,126	85.7 (83.5, 87.7)
	BSCM	66	84	78.6 (68.3, 86.8)	0.91 (0.81, 1.02)	127	156	81.4 (74.4, 87.2)	0.93 (0.85, 1.01)	552	640	86.3 (83.3, 88.8)	425	484	87.8 (84.6, 90.6)	618	724	85.4 (82.6, 87.9)
	BSAC	65	65	100.0 (94.5, 100.0)	1.01 (1.00, 1.02)	53	54	98.1 (90.1, 100.0)	0.99 (0.95, 1.03)	474	478	99.2 (97.9, 99.8)	421	424	99.3 (97.9, 99.9)	539	543	99.3 (98.1, 99.8)
	BSM	169	230	73.5 (67.3, 79.1)	0.97 (0.89, 1.06)	13	18	72.2 (46.5, 90.3)	0.95 (0.71, 1.27)	591	781	75.7 (72.5, 78.6)	578	763	75.8 (72.6, 78.8)	760	1,011	75.2 (72.4, 77.8)
	BSCC	68	101	67.3 (57.3, 76.3)	0.99 (0.84, 1.15)	3	5	60.0 (14.7, 94.7)	0.88 (0.43, 1.80)	214	313	68.4 (62.9, 73.5)	211	308	68.5 (63.0, 73.7)	282	414	68.1 (63.4, 72.6)
	BSC	66	75	88.0 (78.4, 94.4)	0.96 (0.88, 1.05)	26	33	78.8 (61.1, 91.0)	0.85 (0.71, 1.02)	419	457	91.7 (88.8, 94.0)	393	424	92.7 (89.8, 95.0)	485	532	91.2 (88.4, 93.4)
	BSSL	84	104	80.8 (71.9, 87.8)	0.92 (0.83, 1.01)	14	18	77.8 (52.4, 93.6)	0.88 (0.69, 1.13)	1,159	1,317	88.0 (86.1, 89.7)	1,145	1,299	88.1 (86.3, 89.9)	1,243	1,421	87.5 (85.6, 89.2)
	BSOS	45	61	73.8 (60.9, 84.2)	1.01 (0.86, 1.18)	6	9	66.7 (29.9, 92.5)	0.91 (0.57, 1.45)	464	634	73.2 (69.6, 76.6)	458	625	73.3 (69.6, 76.7)	509	695	73.2 (69.8, 76.5)
	Total	733	931	78.7 (76.0, 81.3)	0.93 (0.90, 0.97)	293	350	83.7 (79.4, 87.4)	0.99 (0.95, 1.04)	4,668	5,535	84.3 (83.4, 85.3)	4,375	5,185	84.4 (83.4, 85.4)	5,401	6,466	83.5 (82.6, 84.4)
50 to 69	BSWN	302	356	84.8 (80.7, 88.4)	0.97 (0.93, 1.02)	110	129	85.3 (78.0, 90.9)	0.97 (0.90, 1.05)	1,792	2,048	87.5 (86.0, 88.9)	1,682	1,919	87.6 (86.1, 89.1)	2,094	2,404	87.1 (85.7, 88.4)
	BSCM	159	211	75.4 (69.0, 81.0)	0.89 (0.82, 0.96)	225	291	77.3 (72.1, 82.0)	0.89 (0.84, 0.95)	1,170	1,383	84.6 (82.6, 86.5)	945	1,092	86.5 (84.4, 88.5)	1,329	1,594	83.4 (81.5, 85.2)
	BSAC	72	74	97.3 (90.6, 99.7)	0.99 (0.95, 1.03)	126	128	98.4 (94.5, 99.8)	1.00 (0.98, 1.03)	874	889	98.3 (97.2, 99.1)	748	761	98.3 (97.1, 99.1)	946	963	98.2 (97.2, 99.0)
	BSM	355	485	73.2 (69.0, 77.1)	1.00 (0.94, 1.06)	30	42	71.4 (55.4, 84.3)	0.97 (0.80, 1.18)	1,474	2,007	73.4 (71.5, 75.4)	1,444	1,965	73.5 (71.5, 75.4)	1,829	2,492	73.4 (71.6, 75.1)
	BSCC	153	223	68.6 (62.1, 74.6)	0.94 (0.85, 1.04)	11	14	78.6 (49.2, 95.3)	1.08 (0.82, 1.42)	603	826	73.0 (69.8, 76.0)	592	812	72.9 (69.7, 75.9)	756	1,049	72.1 (69.2, 74.8)
	BSC	149	170	87.6 (81.7, 92.2)	0.96 (0.90, 1.02)	95	101	94.1 (87.5, 97.8)	1.03 (0.98, 1.08)	1,453	1,588	91.5 (90.0, 92.8)	1,358	1,487	91.3 (89.8, 92.7)	1,602	1,758	91.1 (89.7, 92.4)
	BSSL	166	194	85.6 (79.8, 90.2)	1.00 (0.94, 1.06)	27	34	79.4 (62.1, 91.3)	0.93 (0.78, 1.10)	2,451	2,856	85.8 (84.5, 87.1)	2,424	2,822	85.9 (84.6, 87.2)	2,617	3,050	85.8 (84.5, 87.0)
	BSOS	70	103	68.0 (58.0, 76.8)	0.98 (0.85, 1.12)	10	20	50.0 (27.2, 72.8)	0.72 (0.46, 1.11)	908	1,304	69.6 (67.1, 72.1)	898	1,284	69.9 (67.3, 72.4)	978	1,407	69.5 (67.0, 71.9)
	Total	1,426	1,816	78.5 (76.6, 80.4)	0.95 (0.92, 0.97)	634	759	83.5 (80.7, 86.1)	1.01 (0.97, 1.04)	10,725	12,901	83.1 (82.5, 83.8)	10,091	12,142	83.1 (82.4, 83.8)	12,151	14,717	82.6 (81.9, 83.2)
45 to 69	BSWN	472	567	83.2 (79.9, 86.2)	0.95 (0.92, 0.99)	161	186	86.6 (80.8, 91.1)	0.99 (0.94, 1.05)	2,587	2,963	87.3 (86.1, 88.5)	2,426	2,777	87.4 (86.1, 88.6)	3,059	3,530	86.7 (85.5, 87.8)
	BSCM	225	295	76.3 (71.0, 81.0)	0.90 (0.84, 0.96)	352	447	78.7 (74.7, 82.5)	0.91 (0.86, 0.95)	1,722	2,023	85.1 (83.5, 86.6)	1,370	1,576	86.9 (85.2, 88.6)	1,947	2,318	84.0 (82.4, 85.5)
	BSAC	137	139	98.6 (94.9, 99.8)	1.00 (0.98, 1.02)	179	182	98.4 (95.3, 99.7)	1.00 (0.98, 1.02)	1,348	1,367	98.6 (97.8, 99.2)	1,169	1,185	98.6 (97.8, 99.2)	1,485	1,506	98.6 (97.9, 99.1)
	BSM	524	715	73.3 (69.9, 76.5)	0.99 (0.94, 1.04)	43	60	71.7 (58.6, 82.5)	0.97 (0.82, 1.14)	2,065	2,788	74.1 (72.4, 75.7)	2,022	2,728	74.1 (72.4, 75.8)	2,589	3,503	73.9 (72.4, 75.4)
	BSCC	221	324	68.2 (62.8, 73.2)	0.95 (0.88, 1.03)	14	19	73.7 (48.8, 90.9)	1.03 (0.78, 1.35)	817	1,139	71.7 (69.0, 74.3)	803	1,120	71.7 (69.0, 74.3)	1,038	1,463	71.0 (68.5, 73.3)
	BSC	215	245	87.8 (83.0, 91.6)	0.96 (0.91, 1.01)	121	134	90.3 (84.0, 94.7)	0.99 (0.93, 1.04)	1,872	2,045	91.5 (90.2, 92.7)	1,751	1,911	91.6 (90.3, 92.8)	2,087	2,290	91.1 (89.9, 92.3)
	BSSL	250	298	83.9 (79.2, 87.9)	0.97 (0.92, 1.02)	41	52	78.8 (65.3, 88.9)	0.91 (0.79, 1.05)	3,610	4,173	86.5 (85.4, 87.5)	3,569	4,121	86.6 (85.5, 87.6)	3,860	4,471	86.3 (85.3, 87.3)
	BSOS	115	164	70.1 (62.5, 77.0)	0.99 (0.89, 1.10)	16	29	55.2 (35.7, 73.6)	0.78 (0.56, 1.08)	1,372	1,938	70.8 (68.7, 72.8)	1,356	1,909	71.0 (68.9, 73.1)	1,487	2,102	70.7 (68.7, 72.7)
	Total	2,159	2,747	78.6 (77.0, 80.1)	0.94 (0.92, 0.96)	927	1,109	83.6 (81.3, 85.7)	1.00 (0.97, 1.03)	15,393	18,436	83.5 (83.0, 84.0)	14,466	17,327	83.5 (82.9, 84.0)	17,552	21,183	82.9 (82.3, 83.4)

5.c.1, Women receiving a needle biopsy within 5 working days of assessment

Description: The number of needle biopsies performed within 5 working days of assessment as a percentage of total number of needle biopsies.

Target: $\geq 90\%$

Figure 101: 5.c.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, total BSA



All LPs achieved the target of 90% or more receiving a needle biopsy within 5 working days of assessment, with all achieving over 95%.

Figure 102: 5.c.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, by LP




Table 39: 5.c.1, Women receiving a needle biopsy within 5 working days of assessment


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Māori / Non-Māori Ratio	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Pacific / Non-Pacific Ratio	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)
45 to 49	BSWN	69	69	100.0 (94.8, 100.0)	1.00 (1.00, 1.00)	30	30	100.0 (88.4, 100.0)	1.00 (1.00, 1.00)	333	333	100.0 (98.9, 100.0)	303	303	100.0 (98.8, 100.0)	402	402	100.0 (99.1, 100.0)
	BSCM	32	33	97.0 (84.2, 99.9)	0.98 (0.92, 1.04)	76	76	100.0 (95.3, 100.0)	1.02 (1.00, 1.03)	266	269	98.9 (96.8, 99.8)	190	193	98.4 (95.5, 99.7)	298	302	98.7 (96.6, 99.6)
	BSAC	25	27	92.6 (75.7, 99.1)	0.96 (0.86, 1.07)	23	23	100.0 (85.2, 100.0)	1.04 (1.01, 1.07)	174	180	96.7 (92.9, 98.8)	151	157	96.2 (91.9, 98.6)	199	207	96.1 (92.5, 98.3)
	BSM	92	94	97.9 (92.5, 99.7)	1.03 (0.98, 1.07)	6	6	100.0 (54.1, 100.0)	1.05 (1.02, 1.08)	210	220	95.5 (91.8, 97.8)	204	214	95.3 (91.6, 97.7)	302	314	96.2 (93.4, 98.0)
	BSCC	42	43	97.7 (87.7, 99.9)	0.98 (0.93, 1.02)	3	3	100.0 (29.2, 100.0)	1.00 (1.00, 1.00)	102	102	100.0 (96.4, 100.0)	99	99	100.0 (96.3, 100.0)	144	145	99.3 (96.2, 100.0)
	BSC	19	19	100.0 (82.4, 100.0)	1.00 (1.00, 1.00)	7	7	100.0 (59.0, 100.0)	1.00 (1.00, 1.00)	80	80	100.0 (95.5, 100.0)	73	73	100.0 (95.1, 100.0)	99	99	100.0 (96.3, 100.0)
	BSSL	40	42	95.2 (83.8, 99.4)	0.98 (0.91, 1.05)	4	4	100.0 (39.8, 100.0)	1.03 (1.01, 1.05)	416	428	97.2 (95.2, 98.5)	412	424	97.2 (95.1, 98.5)	456	470	97.0 (95.1, 98.4)
	BSOS	20	21	95.2 (76.2, 99.9)	0.99 (0.89, 1.09)	2	2	100.0 (15.8, 100.0)	1.04 (1.00, 1.07)	146	151	96.7 (92.4, 98.9)	144	149	96.6 (92.3, 98.9)	166	172	96.5 (92.6, 98.7)
	Total	339	348	97.4 (95.1, 98.8)	0.99 (0.98, 1.01)	151	151	100.0 (97.6, 100.0)	1.02 (1.01, 1.03)	1,727	1,763	98.0 (97.2, 98.6)	1,576	1,612	97.8 (96.9, 98.4)	2,066	2,111	97.9 (97.2, 98.4)
50 to 69	BSWN	143	147	97.3 (93.2, 99.3)	1.00 (0.97, 1.02)	47	47	100.0 (92.5, 100.0)	1.03 (1.01, 1.04)	688	704	97.7 (96.3, 98.7)	641	657	97.6 (96.1, 98.6)	831	851	97.6 (96.4, 98.6)
	BSCM	118	122	96.7 (91.8, 99.1)	0.98 (0.94, 1.01)	127	129	98.4 (94.5, 99.8)	0.99 (0.97, 1.01)	543	548	99.1 (97.9, 99.7)	416	419	99.3 (97.9, 99.9)	661	670	98.7 (97.5, 99.4)
	BSAC	36	36	100.0 (90.3, 100.0)	1.07 (1.04, 1.09)	54	59	91.5 (81.3, 97.2)	0.97 (0.89, 1.05)	310	330	93.9 (90.8, 96.3)	256	271	94.5 (91.0, 96.9)	346	366	94.5 (91.7, 96.6)
	BSM	203	216	94.0 (89.9, 96.8)	0.96 (0.93, 1.00)	19	20	95.0 (75.1, 99.9)	0.97 (0.88, 1.08)	653	670	97.5 (96.0, 98.5)	634	650	97.5 (96.0, 98.6)	856	886	96.6 (95.2, 97.7)
	BSCC	122	125	97.6 (93.1, 99.5)	0.98 (0.95, 1.01)	5	5	100.0 (47.8, 100.0)	1.01 (1.00, 1.01)	407	409	99.5 (98.2, 99.9)	402	404	99.5 (98.2, 99.9)	529	534	99.1 (97.8, 99.7)
	BSC	48	50	96.0 (86.3, 99.5)	0.96 (0.91, 1.02)	39	39	100.0 (91.0, 100.0)	1.00 (1.00, 1.00)	403	403	100.0 (99.1, 100.0)	364	364	100.0 (99.0, 100.0)	451	453	99.6 (98.4, 99.9)
	BSSL	75	77	97.4 (90.9, 99.7)	1.01 (0.97, 1.05)	15	15	100.0 (78.2, 100.0)	1.03 (1.02, 1.05)	889	919	96.7 (95.4, 97.8)	874	904	96.7 (95.3, 97.8)	964	996	96.8 (95.5, 97.8)
	BSOS	33	33	100.0 (89.4, 100.0)	1.02 (1.00, 1.03)	8	9	88.9 (51.8, 99.7)	0.90 (0.72, 1.14)	352	358	98.3 (96.4, 99.4)	344	349	98.6 (96.7, 99.5)	385	391	98.5 (96.7, 99.4)
	Total	778	806	96.5 (95.0, 97.7)	0.99 (0.97, 1.00)	314	323	97.2 (94.8, 98.7)	0.99 (0.97, 1.01)	4,245	4,341	97.8 (97.3, 98.2)	3,931	4,018	97.8 (97.3, 98.3)	5,023	5,147	97.6 (97.1, 98.0)
45 to 69	BSWN	212	216	98.1 (95.3, 99.5)	1.00 (0.98, 1.02)	77	77	100.0 (95.3, 100.0)	1.02 (1.01, 1.02)	1,021	1,037	98.5 (97.5, 99.1)	944	960	98.3 (97.3, 99.0)	1,233	1,253	98.4 (97.5, 99.0)
	BSCM	150	155	96.8 (92.6, 98.9)	0.98 (0.95, 1.01)	203	205	99.0 (96.5, 99.9)	1.00 (0.98, 1.02)	809	817	99.0 (98.1, 99.6)	606	612	99.0 (97.9, 99.6)	959	972	98.7 (97.7, 99.3)
	BSAC	61	63	96.8 (89.0, 99.6)	1.02 (0.97, 1.07)	77	82	93.9 (86.3, 98.0)	0.99 (0.93, 1.05)	484	510	94.9 (92.6, 96.6)	407	428	95.1 (92.6, 96.9)	545	573	95.1 (93.0, 96.7)
	BSM	295	310	95.2 (92.1, 97.3)	0.98 (0.95, 1.01)	25	26	96.2 (80.4, 99.9)	0.99 (0.92, 1.07)	863	890	97.0 (95.6, 98.0)	838	864	97.0 (95.6, 98.0)	1,158	1,200	96.5 (95.3, 97.5)
	BSCC	164	168	97.6 (94.0, 99.3)	0.98 (0.96, 1.00)	8	8	100.0 (63.1, 100.0)	1.00 (1.00, 1.01)	509	511	99.6 (98.6, 100.0)	501	503	99.6 (98.6, 100.0)	673	679	99.1 (98.1, 99.7)
	BSC	67	69	97.1 (89.9, 99.6)	0.97 (0.93, 1.01)	46	46	100.0 (92.3, 100.0)	1.00 (1.00, 1.00)	483	483	100.0 (99.2, 100.0)	437	437	100.0 (99.2, 100.0)	550	552	99.6 (98.7, 100.0)
	BSSL	115	119	96.6 (91.6, 99.1)	1.00 (0.96, 1.03)	19	19	100.0 (82.4, 100.0)	1.03 (1.02, 1.04)	1,305	1,347	96.9 (95.8, 97.7)	1,286	1,328	96.8 (95.7, 97.7)	1,420	1,466	96.9 (95.8, 97.7)
	BSOS	53	54	98.1 (90.1, 100.0)	1.00 (0.96, 1.04)	10	11	90.9 (58.7, 99.8)	0.93 (0.77, 1.12)	498	509	97.8 (96.2, 98.9)	488	498	98.0 (96.3, 99.0)	551	563	97.9 (96.3, 98.9)
	Total	1,117	1,154	96.8 (95.6, 97.7)	0.99 (0.98, 1.00)	465	474	98.1 (96.4, 99.1)	1.00 (0.99, 1.02)	5,972	6,104	97.8 (97.4, 98.2)	5,507	5,630	97.8 (97.4, 98.2)	7,089	7,258	97.7 (97.3, 98.0)

5.c.2, Women having an open biopsy procedure within 20 working days

Description: The number of open biopsies (level 3 assessments) within 20 working days of notification of the need for this operation as a percentage of total number of open biopsies (Date of final diagnostic biopsy minus date of notification to woman of 1st and 2nd level assessment results).

Target: $\geq 90\%$

Figure 103: 5.c.2, 50 to 69, Women having an open biopsy procedure within 20 working days



Of 607 women aged 45–69 years who had an open biopsy, 52% had their biopsy within 20 working days, lower for Māori women at 42% and similar for Pacific women at 47%.

The LPs with the highest proportions of open biopsies received within 20 working days were BSAL/BSAC (90%) and BSSL (82%). The lowest proportions of biopsies performed within 20 working days were in BSCC (20% of 40 open biopsies), and BSCM (21% of 66 open biopsies).

Figure 104: 5.c.2, 50 to 69, Women having an open biopsy procedure within 20 working days, by LP



Table 40: 5.c.2, Women having an open biopsy procedure within 20 working days


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Open Biopsies Within 20 Working Days of Notificatio	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Māori / Non-Māori Ratio	Open Biopsies Within 20 Working Days of Notificatio	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Open Biopsies Within 20 Working Days of Notificatio	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Open Biopsies Within 20 Working Days of Notificatio	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Open Biopsies Within 20 Working Days of Notificatio	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)
45 to 49	BSWN	1	6	16.7 (0.4, 64.1)	0.32 (0.05, 1.95)	2	5	40.0 (5.3, 85.3)	0.74 (0.24, 2.26)	23	44	52.3 (36.7, 67.5)	21	39	53.8 (37.2, 69.9)	24	50	48.0 (33.7, 62.6)
	BSCM	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 31.81)	2	4	50.0 (6.8, 93.2)	4.25 (0.83, 21.68)	4	21	19.0 (5.4, 41.9)	2	17	11.8 (1.5, 36.4)	4	22	18.2 (5.2, 40.3)
	BSAC	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (2.5, 100.0)	1.00 (1.00, 1.00)	17	17	100.0 (80.5, 100.0)	16	16	100.0 (79.4, 100.0)	17	17	100.0 (80.5, 100.0)
	BSM	5	11	45.5 (16.7, 76.6)	1.19 (0.51, 2.78)	0	0	NA (NA, NA)	NA (NA, NA)	8	21	38.1 (18.1, 61.6)	8	21	38.1 (18.1, 61.6)	13	32	40.6 (23.7, 59.4)
	BSCC	0	3	0.0 (0.0, 70.8)	0.00 (0.00, 6.56)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 18.18)	4	13	30.8 (9.1, 61.4)	4	12	33.3 (9.9, 65.1)	4	16	25.0 (7.3, 52.4)
	BSC	1	3	33.3 (0.8, 90.6)	0.80 (0.14, 4.53)	1	1	100.0 (2.5, 100.0)	2.75 (1.26, 6.01)	5	12	41.7 (15.2, 72.3)	4	11	36.4 (10.9, 69.2)	6	15	40.0 (16.3, 67.7)
	BSSL	5	5	100.0 (47.8, 100.0)	1.34 (1.13, 1.60)	0	0	NA (NA, NA)	NA (NA, NA)	32	43	74.4 (58.8, 86.5)	32	43	74.4 (58.8, 86.5)	37	48	77.1 (62.7, 88.0)
	BSOS	1	2	50.0 (1.3, 98.7)	0.75 (0.18, 3.17)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 6.44)	8	12	66.7 (34.9, 90.1)	8	11	72.7 (39.0, 94.0)	9	14	64.3 (35.1, 87.2)
	Total	13	31	41.9 (24.5, 60.9)	0.76 (0.49, 1.17)	6	13	46.2 (19.2, 74.9)	0.83 (0.45, 1.51)	101	183	55.2 (47.7, 62.5)	95	170	55.9 (48.1, 63.5)	114	214	53.3 (46.3, 60.1)
50 to 69	BSWN	4	13	30.8 (9.1, 61.4)	0.65 (0.28, 1.51)	3	5	60.0 (14.7, 94.7)	1.29 (0.60, 2.75)	37	78	47.4 (36.0, 59.1)	34	73	46.6 (34.8, 58.6)	41	91	45.1 (34.6, 55.8)
	BSCM	2	9	22.2 (2.8, 60.0)	0.97 (0.25, 3.81)	0	8	0.0 (0.0, 36.9)	0.00 (0.00, 1.98)	8	35	22.9 (10.4, 40.1)	8	27	29.6 (13.8, 50.2)	10	44	22.7 (11.5, 37.8)
	BSAC	4	4	100.0 (39.8, 100.0)	1.19 (1.04, 1.38)	4	5	80.0 (28.4, 99.5)	0.95 (0.60, 1.51)	31	37	83.8 (68.0, 93.8)	27	32	84.4 (67.2, 94.7)	35	41	85.4 (70.8, 94.4)
	BSM	12	21	57.1 (34.0, 78.2)	0.93 (0.61, 1.42)	2	2	100.0 (15.8, 100.0)	1.67 (1.34, 2.07)	35	57	61.4 (47.6, 74.0)	33	55	60.0 (45.9, 73.0)	47	78	60.3 (48.5, 71.2)
	BSCC	0	5	0.0 (0.0, 52.2)	0.00 (0.00, 5.76)	0	0	NA (NA, NA)	NA (NA, NA)	4	19	21.1 (6.1, 45.6)	4	19	21.1 (6.1, 45.6)	4	24	16.7 (4.7, 37.4)
	BSC	0	2	0.0 (0.0, 84.2)	0.00 (0.00, 5.73)	1	3	33.3 (0.8, 90.6)	0.90 (0.17, 4.71)	14	38	36.8 (21.8, 54.0)	13	35	37.1 (21.5, 55.1)	14	40	35.0 (20.6, 51.7)
	BSSL	1	2	50.0 (1.3, 98.7)	0.58 (0.14, 2.31)	2	2	100.0 (15.8, 100.0)	1.16 (1.04, 1.29)	46	53	86.8 (74.7, 94.5)	44	51	86.3 (73.7, 94.3)	47	55	85.5 (73.3, 93.5)
	BSOS	1	2	50.0 (1.3, 98.7)	1.80 (0.37, 8.68)	0	0	NA (NA, NA)	NA (NA, NA)	5	18	27.8 (9.7, 53.5)	5	18	27.8 (9.7, 53.5)	6	20	30.0 (11.9, 54.3)
	Total	24	58	41.4 (28.6, 55.1)	0.77 (0.56, 1.06)	12	25	48.0 (27.8, 68.7)	0.89 (0.58, 1.35)	180	335	53.7 (48.2, 59.2)	168	310	54.2 (48.5, 59.8)	204	393	51.9 (46.8, 56.9)
45 to 69	BSWN	5	19	26.3 (9.1, 51.2)	0.54 (0.25, 1.16)	5	10	50.0 (18.7, 81.3)	1.02 (0.53, 1.95)	60	122	49.2 (40.0, 58.4)	55	112	49.1 (39.5, 58.7)	65	141	46.1 (37.7, 54.7)
	BSCM	2	10	20.0 (2.5, 55.6)	0.93 (0.24, 3.55)	2	12	16.7 (2.1, 48.4)	0.73 (0.18, 2.91)	12	56	21.4 (11.6, 34.4)	10	44	22.7 (11.5, 37.8)	14	66	21.2 (12.1, 33.0)
	BSAC	4	4	100.0 (39.8, 100.0)	1.13 (1.02, 1.24)	5	6	83.3 (35.9, 99.6)	0.93 (0.64, 1.35)	48	54	88.9 (77.4, 95.8)	43	48	89.6 (77.3, 96.5)	52	58	89.7 (78.8, 96.1)
	BSM	17	32	53.1 (34.7, 70.9)	0.96 (0.66, 1.41)	2	2	100.0 (15.8, 100.0)	1.85 (1.51, 2.28)	43	78	55.1 (43.4, 66.4)	41	76	53.9 (42.1, 65.5)	60	110	54.5 (44.8, 64.1)
	BSCC	0	8	0.0 (0.0, 36.9)	0.00 (0.00, 2.34)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 18.16)	8	32	25.0 (11.5, 43.4)	8	31	25.8 (11.9, 44.6)	8	40	20.0 (9.1, 35.6)
	BSC	1	5	20.0 (0.5, 71.6)	0.53 (0.09, 3.15)	2	4	50.0 (6.8, 93.2)	1.35 (0.47, 3.87)	19	50	38.0 (24.7, 52.8)	17	46	37.0 (23.2, 52.5)	20	55	36.4 (23.8, 50.4)
	BSSL	6	7	85.7 (42.1, 99.6)	1.06 (0.77, 1.45)	2	2	100.0 (15.8, 100.0)	1.24 (1.12, 1.36)	78	96	81.3 (72.0, 88.5)	76	94	80.9 (71.4, 88.2)	84	103	81.6 (72.7, 88.5)
	BSOS	2	4	50.0 (6.8, 93.2)	1.15 (0.40, 3.34)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 9.52)	13	30	43.3 (25.5, 62.6)	13	29	44.8 (26.4, 64.3)	15	34	44.1 (27.2, 62.1)
	Total	37	89	41.6 (31.2, 52.5)	0.77 (0.59, 0.99)	18	38	47.4 (31.0, 64.2)	0.87 (0.61, 1.22)	281	518	54.2 (49.8, 58.6)	263	480	54.8 (50.2, 59.3)	318	607	52.4 (48.3, 56.4)

5.d, Time taken from final diagnostic biopsy to reporting assessment results

Description: The time taken from the final biopsy procedure to reporting the diagnosis to the women.

Target: Results reported to at least 90% of women within five working days²⁰ of final diagnostic biopsy.

Figure 105: 5.d, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results



The proportion of BSA women aged 45–69 years who received the results of their final diagnostic biopsy within five working days was 84%, similar for Māori (83%) and Pacific women (85%).

LPs ranged from 66% (BSOS) to 91% (BSWN) for total women.

²⁰ In March 2022, BSA Action and Advisory Group approved a change to NPQS Element 3.2.7: Target for this indicator. The new target is that: $\geq 90\%$ of women receive their result within seven working days of their final percutaneous needle biopsy. The new target will be introduced in the next annual report for period ending June 2022.

Figure 106: 5.d, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results, by LP




Table 41: 5.d, Time taken from final diagnostic biopsy to reporting assessment results


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Māori / Non-Māori Ratio	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)
45 to 49	BSWN	58	68	85.3 (74.6, 92.7)	0.93 (0.83, 1.03)	28	30	93.3 (77.9, 99.2)	1.01 (0.92, 1.12)	307	333	92.2 (88.8, 94.8)	279	303	92.1 (88.4, 94.9)	365	401	91.0 (87.8, 93.6)
	BSCM	30	33	90.9 (75.7, 98.1)	0.98 (0.87, 1.09)	69	76	90.8 (81.9, 96.2)	0.97 (0.89, 1.05)	250	269	92.9 (89.2, 95.7)	181	193	93.8 (89.4, 96.7)	280	302	92.7 (89.2, 95.4)
	BSAC	24	27	88.9 (70.8, 97.6)	1.05 (0.91, 1.22)	20	23	87.0 (66.4, 97.2)	1.03 (0.87, 1.23)	152	180	84.4 (78.3, 89.4)	132	157	84.1 (77.4, 89.4)	176	207	85.0 (79.4, 89.6)
	BSM	73	92	79.3 (69.6, 87.1)	1.01 (0.89, 1.14)	4	6	66.7 (22.3, 95.7)	0.84 (0.48, 1.49)	173	220	78.6 (72.6, 83.9)	169	214	79.0 (72.9, 84.2)	246	312	78.8 (73.9, 83.2)
	BSCC	32	43	74.4 (58.8, 86.5)	0.85 (0.70, 1.03)	3	3	100.0 (29.2, 100.0)	1.15 (1.07, 1.24)	89	102	87.3 (79.2, 93.0)	86	99	86.9 (78.6, 92.8)	121	145	83.4 (76.4, 89.1)
	BSC	14	19	73.7 (48.8, 90.9)	0.89 (0.67, 1.19)	5	7	71.4 (29.0, 96.3)	0.86 (0.53, 1.38)	66	80	82.5 (72.4, 90.1)	61	73	83.6 (73.0, 91.2)	80	99	80.8 (71.7, 88.0)
	BSSL	36	42	85.7 (71.5, 94.6)	1.04 (0.91, 1.19)	4	4	100.0 (39.8, 100.0)	1.22 (1.16, 1.27)	353	428	82.5 (78.5, 86.0)	349	424	82.3 (78.3, 85.8)	389	470	82.8 (79.0, 86.1)
	BSOS	12	21	57.1 (34.0, 78.2)	0.88 (0.60, 1.30)	2	2	100.0 (15.8, 100.0)	1.55 (1.38, 1.75)	98	151	64.9 (56.7, 72.5)	96	149	64.4 (56.2, 72.1)	110	172	64.0 (56.3, 71.1)
	Total	279	345	80.9 (76.3, 84.9)	0.96 (0.91, 1.01)	135	151	89.4 (83.4, 93.8)	1.07 (1.00, 1.13)	1,488	1,763	84.4 (82.6, 86.1)	1,353	1,612	83.9 (82.0, 85.7)	1,767	2,108	83.8 (82.2, 85.4)
50 to 69	BSWN	134	148	90.5 (84.6, 94.7)	0.99 (0.94, 1.05)	42	46	91.3 (79.2, 97.6)	1.00 (0.91, 1.09)	641	701	91.4 (89.1, 93.4)	599	655	91.5 (89.0, 93.5)	775	849	91.3 (89.2, 93.1)
	BSCM	108	122	88.5 (81.5, 93.6)	1.00 (0.93, 1.07)	106	129	82.2 (74.5, 88.3)	0.91 (0.83, 0.99)	485	548	88.5 (85.5, 91.1)	379	419	90.5 (87.2, 93.1)	593	670	88.5 (85.8, 90.8)
	BSAC	30	36	83.3 (67.2, 93.6)	1.00 (0.86, 1.17)	50	59	84.7 (73.0, 92.8)	1.03 (0.91, 1.16)	274	330	83.0 (78.5, 86.9)	224	271	82.7 (77.6, 87.0)	304	366	83.1 (78.8, 86.8)
	BSM	162	216	75.0 (68.7, 80.6)	0.94 (0.86, 1.02)	15	20	75.0 (50.9, 91.3)	0.93 (0.72, 1.21)	536	668	80.2 (77.0, 83.2)	521	648	80.4 (77.1, 83.4)	698	884	79.0 (76.1, 81.6)
	BSCC	103	124	83.1 (75.3, 89.2)	0.91 (0.83, 0.99)	5	5	100.0 (47.8, 100.0)	1.09 (1.06, 1.12)	375	409	91.7 (88.6, 94.2)	370	404	91.6 (88.4, 94.1)	478	533	89.7 (86.8, 92.1)
	BSC	46	50	92.0 (80.8, 97.8)	1.10 (1.01, 1.21)	29	39	74.4 (57.9, 87.0)	0.88 (0.73, 1.07)	336	403	83.4 (79.4, 86.9)	307	364	84.3 (80.2, 87.9)	382	453	84.3 (80.6, 87.6)
	BSSL	67	77	87.0 (77.4, 93.6)	1.08 (0.98, 1.18)	11	15	73.3 (44.9, 92.2)	0.91 (0.67, 1.23)	741	919	80.6 (77.9, 83.1)	730	904	80.8 (78.0, 83.3)	808	996	81.1 (78.6, 83.5)
	BSOS	24	33	72.7 (54.5, 86.7)	1.09 (0.87, 1.35)	7	9	77.8 (40.0, 97.2)	1.17 (0.81, 1.67)	240	358	67.0 (61.9, 71.9)	233	349	66.8 (61.6, 71.7)	264	391	67.5 (62.6, 72.1)
	Total	674	806	83.6 (80.9, 86.1)	1.00 (0.97, 1.03)	265	322	82.3 (77.7, 86.3)	0.98 (0.93, 1.03)	3,628	4,336	83.7 (82.5, 84.8)	3,363	4,014	83.8 (82.6, 84.9)	4,302	5,142	83.7 (82.6, 84.7)
45 to 69	BSWN	192	216	88.9 (83.9, 92.7)	0.97 (0.92, 1.02)	70	76	92.1 (83.6, 97.0)	1.01 (0.94, 1.08)	948	1,034	91.7 (89.8, 93.3)	878	958	91.6 (89.7, 93.3)	1,140	1,250	91.2 (89.5, 92.7)
	BSCM	138	155	89.0 (83.0, 93.5)	0.99 (0.93, 1.05)	175	205	85.4 (79.8, 89.9)	0.93 (0.88, 0.99)	735	817	90.0 (87.7, 91.9)	560	612	91.5 (89.0, 93.6)	873	972	89.8 (87.7, 91.6)
	BSAC	54	63	85.7 (74.6, 93.3)	1.03 (0.92, 1.14)	70	82	85.4 (75.8, 92.2)	1.03 (0.93, 1.13)	426	510	83.5 (80.0, 86.6)	356	428	83.2 (79.3, 86.6)	480	573	83.8 (80.5, 86.7)
	BSM	235	308	76.3 (71.1, 80.9)	0.96 (0.89, 1.02)	19	26	73.1 (52.2, 88.4)	0.91 (0.72, 1.16)	709	888	79.8 (77.1, 82.4)	690	862	80.0 (77.2, 82.7)	944	1,196	78.9 (76.5, 81.2)
	BSCC	135	167	80.8 (74.0, 86.5)	0.89 (0.82, 0.96)	8	8	100.0 (63.1, 100.0)	1.10 (1.07, 1.13)	464	511	90.8 (88.0, 93.2)	456	503	90.7 (87.8, 93.1)	599	678	88.3 (85.7, 90.7)
	BSC	60	69	87.0 (76.7, 93.9)	1.05 (0.95, 1.15)	34	46	73.9 (58.9, 85.7)	0.88 (0.74, 1.05)	402	483	83.2 (79.6, 86.5)	368	437	84.2 (80.4, 87.5)	462	552	83.7 (80.3, 86.7)
	BSSL	103	119	86.6 (79.1, 92.1)	1.07 (0.99, 1.15)	15	19	78.9 (54.4, 93.9)	0.97 (0.77, 1.23)	1,094	1,347	81.2 (79.0, 83.3)	1,079	1,328	81.3 (79.0, 83.3)	1,197	1,466	81.7 (79.6, 83.6)
	BSOS	36	54	66.7 (52.5, 78.9)	1.00 (0.82, 1.22)	9	11	81.8 (48.2, 97.7)	1.24 (0.93, 1.65)	338	509	66.4 (62.1, 70.5)	329	498	66.1 (61.7, 70.2)	374	563	66.4 (62.4, 70.3)
	Total	953	1,151	82.8 (80.5, 84.9)	0.99 (0.96, 1.02)	400	473	84.6 (81.0, 87.7)	1.01 (0.97, 1.05)	5,116	6,099	83.9 (82.9, 84.8)	4,716	5,626	83.8 (82.8, 84.8)	6,069	7,250	83.7 (82.8, 84.6)

5.e.t, First surgical treatment, women screened during the 4 years to December 2020

Description: The time from when a woman receives her final diagnostic results to the date of her first surgical treatment. The 't' in the indicator id marks it as a treatment indicator.

Target: 90% of women should normally receive their first surgical treatment within 31 calendar days of receiving their final diagnostic results.

Figure 107: 5.e.t, 50 to 69, First surgical treatment, women screened during the 4 years to December 2020



For total BSA women aged 45–69 years whose cancer was detected during the 4 years to 31 December 2020, around half (54%) received their first surgical treatment within 31 calendar days of receiving their final diagnostic results. The proportions were 48% for Māori, 50% for Pacific and 55% for non-Māori, non-Pacific women.

The proportions of women receiving timely surgical treatment within LPs ranged from 42% (BSCC) to 61% (BSM).

When the proportions of women receiving their first surgical treatment within 31 calendar days were calculated, the overall percentage was the same (54%) as was the proportion of non-Māori non-Pacific women but the proportions of Māori (50%), Pacific (54%) were slightly higher.

Figure 5.e.t.3, 50 to 69, First surgical treatment, women screened during the 4 years to December 2020



Table 42: 5.e.t, First surgical treatment, women screened during the 4 years to December 2020

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		First Surgical Treatment Within 31 Calendar Days	Number Having Surgery	% Receiving First Surgery Within 31 Calendar Days (95% CI)	Māori / Non-Māori Ratio	First Surgical Treatment Within 31 Calendar Days	Number Having Surgery	% Receiving First Surgery Within 31 Calendar Days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	First Surgical Treatment Within 31 Calendar Days	Number Having Surgery	% Receiving First Surgery Within 31 Calendar Days (95% CI)	First Surgical Treatment Within 31 Calendar Days	Number Having Surgery	% Receiving First Surgery Within 31 Calendar Days (95% CI)	First Surgical Treatment Within 31 Calendar Days	Number Having Surgery	% Receiving First Surgery Within 31 Calendar Days (95% CI)
45 to 49	BSWN	14	30	46.7 (28.3, 65.7)	0.82 (0.54, 1.23)	6	8	75.0 (34.9, 96.8)	1.34 (0.87, 2.04)	88	154	57.1 (48.9, 65.1)	82	146	56.2 (47.7, 64.4)	102	184	55.4 (47.9, 62.7)
	BSCM	7	17	41.2 (18.4, 67.1)	0.73 (0.40, 1.32)	16	32	50.0 (31.9, 68.1)	0.84 (0.57, 1.25)	61	108	56.5 (46.6, 66.0)	45	76	59.2 (47.3, 70.4)	68	125	54.4 (45.3, 63.3)
	BSAC	3	8	37.5 (8.5, 75.5)	0.75 (0.30, 1.88)	6	13	46.2 (19.2, 74.9)	0.91 (0.49, 1.71)	46	92	50.0 (39.4, 60.6)	40	79	50.6 (39.1, 62.1)	49	100	49.0 (38.9, 59.2)
	BSM	18	34	52.9 (35.1, 70.2)	1.10 (0.76, 1.60)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 7.90)	49	102	48.0 (38.0, 58.2)	49	101	48.5 (38.4, 58.7)	67	136	49.3 (40.6, 58.0)
	BSCC	9	29	31.0 (15.3, 50.8)	0.67 (0.37, 1.21)	1	5	20.0 (0.5, 71.6)	0.42 (0.07, 2.46)	41	89	46.1 (35.4, 57.0)	40	84	47.6 (36.6, 58.8)	50	118	42.4 (33.3, 51.8)
	BSC	8	20	40.0 (19.1, 63.9)	0.69 (0.39, 1.22)	4	6	66.7 (22.3, 95.7)	1.16 (0.64, 2.12)	43	74	58.1 (46.1, 69.5)	39	68	57.4 (44.8, 69.3)	51	94	54.3 (43.7, 64.6)
	BSSL	11	15	73.3 (44.9, 92.2)	1.67 (1.19, 2.36)	1	2	50.0 (1.3, 98.7)	1.14 (0.28, 4.61)	89	203	43.8 (36.9, 51.0)	88	201	43.8 (36.8, 50.9)	100	218	45.9 (39.1, 52.7)
	BSOS	5	8	62.5 (24.5, 91.5)	1.47 (0.80, 2.70)	0	1	0.0 (0.0, 97.5)	0.00 (0.00, 9.15)	28	66	42.4 (30.3, 55.2)	28	65	43.1 (30.8, 56.0)	33	74	44.6 (33.0, 56.6)
	Total	75	161	46.6 (38.7, 54.6)	0.93 (0.78, 1.11)	34	68	50.0 (37.6, 62.4)	1.00 (0.78, 1.28)	445	888	50.1 (46.8, 53.5)	411	820	50.1 (46.6, 53.6)	520	1,049	49.6 (46.5, 52.6)
50 to 69	BSWN	57	155	36.8 (29.2, 44.9)	0.57 (0.46, 0.71)	24	45	53.3 (37.9, 68.3)	0.82 (0.62, 1.08)	444	688	64.5 (60.8, 68.1)	420	643	65.3 (61.5, 69.0)	501	843	59.4 (56.0, 62.8)
	BSCM	58	86	67.4 (56.5, 77.2)	1.11 (0.94, 1.31)	58	106	54.7 (44.8, 64.4)	0.88 (0.72, 1.06)	268	442	60.6 (55.9, 65.2)	210	336	62.5 (57.1, 67.7)	326	528	61.7 (57.4, 65.9)
	BSAC	20	42	47.6 (32.0, 63.6)	0.93 (0.67, 1.30)	28	61	45.9 (33.1, 59.2)	0.88 (0.66, 1.18)	187	365	51.2 (46.0, 56.5)	159	304	52.3 (46.5, 58.0)	207	407	50.9 (45.9, 55.8)
	BSM	144	242	59.5 (53.0, 65.7)	0.94 (0.83, 1.05)	10	16	62.5 (35.4, 84.8)	0.98 (0.67, 1.44)	427	671	63.6 (59.9, 67.3)	417	655	63.7 (59.8, 67.4)	571	913	62.5 (59.3, 65.7)
	BSCC	42	146	28.8 (21.6, 36.8)	0.63 (0.48, 0.83)	4	11	36.4 (10.9, 69.2)	0.80 (0.36, 1.75)	243	534	45.5 (41.2, 49.8)	239	523	45.7 (41.4, 50.1)	285	680	41.9 (38.2, 45.7)
	BSC	33	68	48.5 (36.2, 61.0)	0.89 (0.68, 1.14)	12	31	38.7 (21.9, 57.8)	0.69 (0.44, 1.09)	288	525	54.9 (50.5, 59.2)	276	494	55.9 (51.4, 60.3)	321	593	54.1 (50.0, 58.2)
	BSSL	34	74	45.9 (34.3, 57.9)	0.91 (0.71, 1.18)	7	12	58.3 (27.7, 84.8)	1.16 (0.72, 1.88)	447	889	50.3 (46.9, 53.6)	440	877	50.2 (46.8, 53.5)	481	963	49.9 (46.7, 53.2)
	BSOS	13	27	48.1 (28.7, 68.1)	0.94 (0.63, 1.41)	2	7	28.6 (3.7, 71.0)	0.56 (0.17, 1.80)	196	384	51.0 (45.9, 56.1)	194	377	51.5 (46.3, 56.6)	209	411	50.9 (45.9, 55.8)
	Total	401	840	47.7 (44.3, 51.2)	0.86 (0.80, 0.93)	145	289	50.2 (44.3, 56.1)	0.90 (0.80, 1.01)	2,500	4,498	55.6 (54.1, 57.0)	2,355	4,209	56.0 (54.4, 57.5)	2,901	5,338	54.3 (53.0, 55.7)
45 to 69	BSWN	71	185	38.4 (31.3, 45.8)	0.61 (0.50, 0.73)	30	53	56.6 (42.3, 70.2)	0.89 (0.70, 1.13)	532	842	63.2 (59.8, 66.4)	502	789	63.6 (60.2, 67.0)	603	1,027	58.7 (55.6, 61.7)
	BSCM	65	103	63.1 (53.0, 72.4)	1.06 (0.90, 1.24)	74	138	53.6 (44.9, 62.1)	0.87 (0.73, 1.03)	329	550	59.8 (55.6, 63.9)	255	412	61.9 (57.0, 66.6)	394	653	60.3 (56.5, 64.1)
	BSAC	23	50	46.0 (31.8, 60.7)	0.90 (0.66, 1.23)	34	74	45.9 (34.3, 57.9)	0.88 (0.68, 1.15)	233	457	51.0 (46.3, 55.7)	199	383	52.0 (46.8, 57.1)	256	507	50.5 (46.1, 54.9)
	BSM	162	276	58.7 (52.6, 64.6)	0.95 (0.85, 1.07)	10	17	58.8 (32.9, 81.6)	0.95 (0.64, 1.43)	476	773	61.6 (58.0, 65.0)	466	756	61.6 (58.1, 65.1)	638	1,049	60.8 (57.8, 63.8)
	BSCC	51	175	29.1 (22.5, 36.5)	0.64 (0.50, 0.82)	5	16	31.3 (11.0, 58.7)	0.68 (0.33, 1.41)	284	623	45.6 (41.6, 49.6)	279	607	46.0 (41.9, 50.0)	335	798	42.0 (38.5, 45.5)
	BSC	41	88	46.6 (35.9, 57.5)	0.84 (0.67, 1.07)	16	37	43.2 (27.1, 60.5)	0.77 (0.53, 1.12)	331	599	55.3 (51.2, 59.3)	315	562	56.0 (51.8, 60.2)	372	687	54.1 (50.3, 57.9)
	BSSL	45	89	50.6 (39.8, 61.3)	1.03 (0.83, 1.28)	8	14	57.1 (28.9, 82.3)	1.17 (0.74, 1.84)	536	1,092	49.1 (46.1, 52.1)	528	1,078	49.0 (46.0, 52.0)	581	1,181	49.2 (46.3, 52.1)
	BSOS	18	35	51.4 (34.0, 68.6)	1.03 (0.74, 1.44)	2	8	25.0 (3.2, 65.1)	0.50 (0.15, 1.66)	224	450	49.8 (45.1, 54.5)	222	442	50.2 (45.5, 55.0)	242	485	49.9 (45.4, 54.4)
	Total	476	1,001	47.6 (44.4, 50.7)	0.87 (0.81, 0.93)	179	357	50.1 (44.8, 55.4)	0.91 (0.82, 1.01)	2,945	5,386	54.7 (53.3, 56.0)	2,766	5,029	55.0 (53.6, 56.4)	3,421	6,387	53.6 (52.3, 54.8)

Appendices

Technical notes

Indicator targets

Targets have been set for the majority of indicators. This report includes different targets for women aged 45–49 and 50–69 for breast cancer detection (3.a.2, 3.c.r). For biennial coverage and routine rescreens within 27 months the targets now apply to women aged 45–69 years and 45–67 years respectively. Targets for assessment rates after initial screens (<10%) and subsequent screens (<5%) now apply to women aged 45–49 and 50–69 years.

Targets for positive predictive values have been set for women aged 45–49 years (>6% for initial screens and >8% for subsequent screens). Further work is required to develop appropriate targets for positive predictive values for women aged 50–69 years following an initial and a subsequent screen (currently >9% for initial and subsequent screens).

Further review is required to determine age-specific targets for women aged 45-49 years for indicators 3.d nodal involvement and 3.e Ductal carcinoma in situ diagnosis.

Changes to indicator targets

The target for Indicator 5.e: the time from when a woman receives her final diagnostic results to the date of her first surgical treatment has changed from 20 working days to 31 calendar days.

Data source and extraction date

The screening and treatment data used in this report were extracted by the National Screening Unit from the national BreastScreen Aotearoa database during June 2022. This report presents data for the period January 2017 to June 2021 for all BreastScreen Aotearoa screening and assessment indicators, and data for women screened between June 2016 to December 2020 for all treatment indicators (treatment indicators are identified by a 't' at the end of the indicator code)

Ethnicity

For both women screened and, in the denominator, women have been prioritised to a single ethnicity using the following priority order: Māori, Pacific, Other. This means that if a woman chooses more than one category, and one of these is Māori, she is counted as Māori.

Confidence intervals

A confidence interval is a range of values that describes the uncertainty surrounding an estimate. Confidence intervals are one way to represent how 'good' an estimate is; the larger a confidence interval, the more caution is required when using the estimate. When presenting percentages this report uses 95% confidence intervals calculated using the exact binomial method. When presenting ratios this report uses 95% confidence intervals calculated using the exact binomial, Poisson, and Monte Carlo methods.

Population projections

The denominators used for calculating coverage were derived from projected resident populations provided by Statistics New Zealand. The projections are based on the 2013 New Zealand Census (2019 update), assuming medium fertility, medium mortality, medium inter-ethnic mobility, and medium migration assumptions. The projections used for calculating coverage for the latest reporting period are provided in Table 44.

Table 43: Mid-year population projections, 2020 update of the 2018 Census by ethnicity, Lead Provider, and 5-year age group

		BSWN	BSCM	BSAC	BSM	BSCC	BSC	BSSL	BSOS	Total
Māori	45-49	4,020	2,750	1,230	6,390	4,780	2,280	2,400	1,000	24,850
	50-54	3,690	2,640	1,170	5,850	4,420	2,050	2,290	1,000	23,110
	55-59	3,660	2,340	1,120	5,810	4,290	1,860	2,000	910	21,990
	60-64	2,980	1,670	840	4,680	3,430	1,480	1,500	610	17,190
	65-69	2,090	1,220	610	3,420	2,540	950	1,020	450	12,300
Pacific	45-49	1,440	3,770	1,600	610	445	1,155	530	190	9,740
	50-54	1,460	3,730	1,790	550	415	1,150	505	180	9,780
	55-59	1,260	3,150	1,510	420	395	945	430	120	8,230
	60-64	950	2,240	1,200	360	290	770	295	100	6,205
	65-69	720	1,610	910	280	210	610	215	60	4,615
Non-Māori	45-49	24,630	16,550	15,480	20,570	15,295	16,705	26,640	10,250	146,120
	50-54	24,620	16,360	14,620	20,770	15,735	15,970	26,520	10,330	144,925
	55-59	24,230	15,570	13,880	21,620	17,245	15,575	27,345	11,000	146,465
	60-64	21,860	13,080	11,660	20,740	16,405	13,580	24,685	10,250	132,260
	65-69	18,530	10,730	9,630	19,520	15,015	11,480	21,835	8,780	115,520
Non-Māori Non-Pacific	45-49	23,190	12,780	13,880	19,960	14,850	15,550	26,110	10,060	136,380
	50-54	23,160	12,630	12,830	20,220	15,320	14,820	26,015	10,150	135,145
	55-59	22,970	12,420	12,370	21,200	16,850	14,630	26,915	10,880	138,235
	60-64	20,910	10,840	10,460	20,380	16,115	12,810	24,390	10,150	126,055
	65-69	17,810	9,120	8,720	19,240	14,805	10,870	21,620	8,720	110,905
All	45-49	28,650	19,300	16,710	26,960	20,075	18,985	29,040	11,250	170,970
	50-54	28,310	19,000	15,790	26,620	20,155	18,020	28,810	11,330	168,035
	55-59	27,890	17,910	15,000	27,430	21,535	17,435	29,345	11,910	168,455
	60-64	24,840	14,750	12,500	25,420	19,835	15,060	26,185	10,860	149,450
	65-69	20,620	11,950	10,240	22,940	17,555	12,430	22,855	9,230	127,820